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UNIVERSITY OF SOUTHAMPTON 
ABSTRACT 
FACULTY OF MEDICINE 
Clinical and Experimental Sciences 
Doctor of Philosophy 
A STUDY OF THE ROLE OF MICRORNAS IN INFLAMMATORY BOWEL DISEASE: THE 
EFFECT OF MIR-31 DYSREGULATION IN THE EXPRESSION OF TSLP IN ULCERATIVE 
COLITIS 
By Andrew Claridge 
Our current understanding suggests that Inflammatory Bowel Disease (IBD) is an 
immunological mediated disease triggered by unknown environmental factors in 
those who are genetically susceptible.  MicroRNAs (miRNAs) are a class of small 
non  coding  RNAs  that  play  a  critical  role  in  many  immunological  pathways  by 
regulating  gene  expression.  To  date  over  70  miRNAs  have  been  identified  as 
having a differential expression in IBD although their roles remain unknown. 
Using microarray and RT-qPCR we have identified the differential expression of 7 
miRNAs; miR-31, -146b, -194, -200b, -223, -375 and -422a, in the sigmoid mucosa of 
treatment naïve Ulcerative Colitis. Of these, the expressions of miR-31 and -223 
are also increased in mucosal lymphocytes and the CD4
+CD25
intermediate subfamily. 
Using  in  silico  analysis,  thymic  stromal  lymphopoietin  (TSLP)  is  identified  as  a 
target for 4 of the 7 miRNAs; miR-31, -223, -194 and -422a. TSLP has been shown to 
be  increased  in  T
H2  mediated  disorders  of  the  lung  and  skin  and  implicated  in 
epithelial  barrier  homeostasis  and  lymphocyte  function  in  response  to  luminal 
flora.  Here  we  show  for  the  first  time  the  expression  of  TSLP  by  healthy 
lymphocytes  and  a  decreased  expression  in  mucosal  biopsies  and  mucosal 
lymphocytes in active UC. In addition, using a human lymphocyte cell model we 
demonstrate an increased expression of miR-31 in stimulated lymphocytes which 
is inversely related to a decreased expression of TSLP mRNA and an even larger Abstract   
ii 
effect on the expression of TSLP protein in the same cells. Selective inhibition of 
miR-31 prevents the decrease in TSLP in stimulated lymphocytes. 
The  increased  expression  of  miR-31  in  UC  actively  decreases  the  expression  of 
TSLP,  a  factor  associated  with  epithelial  homeostasis  and  less  destructive 
inflammation.  Manipulation  of  the  miR-31  /  TSLP  pathway  offers  a  potential 
therapeutic strategy for UC.     Table of contents 
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Terminology 
For clarity, certain words used in this document have the following definitions  
Antigen  A substance which stimulates the production of an antibody. 
Pathogen  A microorganism that causes disease. 
Inflammatory 
Bowel Disease / 
IBD 
A collective term for UC and Crohn’s disease, which does not 
include any other cause of inflammation of the intestine. 
Active UC / 
Crohn’s / IBD 
Macroscopic inflammation at the site of the biopsy. 
Inactive UC / 
Crohn’s / IBD 
No macroscopic inflammation within any part of the intestine 
seen during the endoscopy, but the patient has an established 
diagnosis of either UC or Crohn’s. 
Unaffected UC / 
Crohn’s / IBD 
The biopsy is taken from a site where there is no macroscopic 
inflammation, but there is  inflammation in other parts of the 
intestine. 
RT-PCR  Reverse Transcription - PCR. Not to be confused with real time – 
PCR which is also often abbreviated to RT-PCR in the literature. 
miRNA seed 
region 
The consecutive 7-8 nucleotide sequence starting at the 1
st or 
2
nd base of the 5’ end of a miRNA. 
Candidate 
miRNAs 
The  7  miRNAs  identified  by  microarray  to  be  differentially 
expressed  in  active  sigmoid  UC  compared  with  healthy 
controls. Candidate miRNA are miR-31, miR-146b, miR-194, miR-
200b, miR-223, miR-375, miR-422a. 
Colitis  Colitis is an umbrella term which means “inflammation of the 
colon”.  Colitis  has  many  distinct  forms  and  manifestations 
depending  on  the  aetiological  factors,  i.e.  infection,  toxin, 
microscopic  colitis  and  radiation  colitis.  IBD  is  a  distinct 
category of colitis which includes, in this thesis, only UC and 
Crohn’s disease. In the wider literature, IBD and colitis are often 
used interchangeably, especially in the literature that review or 
report IBD. In this thesis the term “colitis” is used in reference 
to non UC and non Crohn’s disease forms of inflammation of 
the colon. 
Relative 
expression / fold 
change 
Differential  expression  (2
-∆∆CT)  of  mRNA  or  miRNA  after 
normalising to a house keeper gene and comparing against 
control. 
Treatment naive  No medical treatment for IBD for  6 months  
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1.1  Inflammatory Bowel Disease 
1.1.1  Introduction 
Crohn’s disease (Crohn’s) and Ulcerative Colitis (UC) are the two major types of 
chronic  idiopathic  Inflammatory  Bowel  Disease  (IBD).  Together  UC  and  Crohn’s 
affect approximately 1 in 250 people in the UK, and have a wide ranging and often 
devastating  impact  on  health  and  quality  of  life  (Ghosh  and  Mitchell,  2007, 
Claridge, 2010). It is a disease of the young and for  many inflicts a lifetime of 
relapsing and remitting activity (Solberg et al., 2007). 
Rare before the 1940’s the incidence of IBD rose steadily until the 1980’s, for UC it 
then reached a plateau, but for Crohn’s the incidence has continued to rise slowly. 
In the UK the current prevalence for UC is 243 per 100,000 and for Crohn’s 145 per 
100,000 (Rubin et al., 2000). The financial burden of IBD is increasing and likely to 
grow  exponentially  with  the  adoption  of  more  sophisticated  investigative 
techniques and modern management regimes. Current estimates place the cost to 
the NHS of between 500 and 700 million pounds per year, although the added cost 
to the individual, including indirect and non-medical costs may be as much as 2 to 
3 times this amount (Bassi et al., 2004, Stark R. et al., 2006). 
Predominantly a disease of northern Europeans, there are an estimated 2.2 million 
people with IBD across Europe (Loftus, 2004). The global impact of IBD is less well 
known and is still considered to be a rare illness in Africa, South America and the 
Far East; however, over recent decades the incidence in these areas is increasing, 
trebling in the last 10 years. Although the prevalence elsewhere is still well below 
that of northern Europe, IBD is now a recognised and growing problem worldwide 
(Ahuja and Tandon, 2010). 
Historical  data  suggests  that  in  the  untreated  patient  the  short  term  mortality 
from an acute attack of IBD is similar to that of a Myocardial Infarction, and the 
longer term  mortality is  much greater.  Acute myocardial  infarction treated  with 
placebo has a 35 day mortality of 11.8% (ISIS-2, 1988) and a 1 year mortality of 
18.6% (Baigent et al., 1998), compared with 9.9% at 42 days and 23.7% at 9 months 
for severe UC. In addition to the 1 in 4 people who have died as a result of their Chapter 1. Introduction 
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initial attack of UC another half remain symptomatic after 9 months (Truelove and 
Witts, 1955). 
In the early 1950s a steroid, cortisone, was introduced for the treatment of UC and 
reduced  the  mortality  rate  from  23.7%  to  7%  and  increased  symptom  free 
remission to almost 50% at 9 months (Truelove and Witts, 1955). The treatment of 
Crohn’s  with  steroids  followed  shortly  afterwards,  although  it  took  another  20 
years  for  a  randomised  controlled  trial  to  demonstrate  a  definitive  benefit 
(Summers et al., 1979). 
Over the years many medical and non-medical treatments have been introduced 
for  IBD,  however  the  success  has  been  variable  and  many  difficulties  remain. 
Traditional treatments are unsatisfactory; often any potential benefits are offset 
by unacceptable side effects, and newer biological treatments, such as anti-TNF 
therapies, are only effective in up to 60% of patients in the short term (Rutgeerts 
et al., 2005), and  over time  loose efficacy as patients  develop tolerance or side 
effects (Zabana et al., 2010). 
Given the impact of IBD on patients, their families and society as a whole, there is 
considerable interest to understand the aetiology of IBD with a view to developing 
new therapies. 
1.1.2  Classification, definition and diagnosis 
The term “Inflammatory Bowel Disease”, is an accepted collective term for UC and 
Crohn’s, and used throughout this thesis  with  this definition. The term is often 
preceded by the word idiopathic to distinguish the diseases from other forms of 
inflammatory bowel disease such as those caused by infection, toxin or ischemia. 
All of which can often be indistinguishable from IBD. 
Idiopathic  ulceration  of  the  colon  later to  be  coined  Ulcerative  Colitis  was  first 
described  in  1859  by  Wilks  and  Moxon  (cited  by  Asakura  et al.,  2007).  Isolated 
inflammation of the terminal ileum as a separate entity and not caused by TB, was 
first described in 1913 by Dalziel (Dalziel, 1913), although in 1932 this pattern of 
disease  was  given  the  name  Crohn’s  after  Burrill  Crohn,  Ginzburg,  and 
Oppenheimer gained notoriety for describing a case series of idiopathic regional     Chapter 1. Introduction 
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ileitis associated with intestinal stenosis and fistulae (Crohn et al., 1932). Despite 
these relatively recent histories, case reports of illnesses, likely to be IBD, go back 
many centuries
1, and illnesses with striking similarity to IBD are described back to 
antiquity. 
The classical differenc e  between  UC  and  Crohn’s  is  the  disease  distribution, 
although  microscopic  appearance,  macroscopic  appearance,  the  depth  of 
inflammation  seen  by  imaging  or  surgery,  strictures,  fistulae  and  extra-luminal 
features  are  often  used  in  combination  to  help  distinguish  between  the  two. 
However,  there  are  no  findings  which  can  definitively  differentiate  UC  from 
Crohn’s, and the significant overlap in clinical phenotype, investigative findings, 
and disease progression result in  10-15% of patients having  their  disease  label 
changed  within  a  year  of  diagnosis  and  approximately  5%  of  patients  being 
labelled as “IBD, type unclassified” in the longer term. 
To complicate things further the differences and overlap of the clinical phenotype 
and  investigative  findings  of  both  UC  and  Crohn’s  are  dependent  on  the 
population in question. For example the age of onset or disease distribution in 
Asian  compared  with  Western  populations  is  reviewed  by  Ahuja  and  Tandon 
(2010), the disease distribution can be altered by treatment; e.g. the skip lesions or 
rectal sparing classically associated with Crohn’s are often found in partially or 
locally  treated  UC  respectively.  There  are  also  disease  variants  in  which  the 
classical features of one disease are a feature of the other, for example, terminal 
ileitis is seen in up to 1 in 5 patients who have undergone resection for extensive 
UC but can also be found in association with distal disease only  (Haskell et al., 
2005). 
Other difficulties of interpretation are the differing classification criteria between 
observers  and  different  causative  and  propagating  factors  between  population 
groups.  All  of  the  above  complicate  the  interpretation  of  studies  which  rarely 
define  their  population  groups  in  terms  of  race,  disease  definition  or  disease 
phenotype. 
                                              
1 The first description of CD is attributed to an Italian physician Giovanni Battista Morgagni in 1769, 
when  he  investigated  and  diagnosed  a  man  with  a  chronic,  debilitating  illness  and  diarrhoea. 
(Article Source: http://EzineArticles.com/409008, accessed 2.9.11) Chapter 1. Introduction 
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Despite  the  diagnostic  problems  our  increased  understanding  of  the  disease 
process  has  enabled  us  to  increasingly  use  new  biological  characteristics 
including;  biochemistry,  immunology  and  genetic  variations  to  differentiate 
patients  into  UC  or  Crohn’s.  Differentiating  disease  and  defining  phenotype  is 
critical in planning and predicting the response to treatment, and the challenge 
reflects the complex interplay between aetiological and propagating factors. 
1.1.3  Ulcerative Colitis 
1.1.3.1  Introduction 
The age at which Ulcerative Colitis presents has a bimodal distribution; the peak 
age  of  presentation  is  between  15  and  25  years  of  age  with  a  second  peak 
between  50  and  60  years  of  age.  The  classical  presentation  includes  diarrhoea 
often with visible blood, perhaps some weight loss and occasional abdominal pain. 
Ulcerative Colitis is characterised by diffuse mucosal inflammation of the colon, 
without involving the ileum. The inflammation of treatment naïve UC is not patchy 
unlike the pattern in Crohn’s. The three most clinically relevant characteristics of 
UC are; disease extent (which in the case of UC correlates to phenotype), clinical 
symptoms and endoscopic appearance. 
1.1.3.2  Phenotype 
Prognosis  and  treatment  outcomes  are  closely  related  to  phenotype  which  is 
generally accepted as being characterised by the disease extent, i.e. the length of 
colonic mucosa affected, beginning from the rectum, which is diffusely inflamed. 
This is the most easily measured variable and most commonly used clinically. 
 
Maximal extent of inflammation observed at colonoscopy 
Proctitis  E1 
Left-sided - extending to splenic flexure  E2 
More extensive disease  E3 
Table  1.  Definition  of  UC  according  to  the  Montreal  classification 
(Silverberg et al., 2005).     Chapter 1. Introduction 
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Disease extent is classified using the Montreal classification, Table 1 (Silverberg et 
al.,  2005).  Disease  extent  has  significant  implications  for  a  variety  of  variables 
including  lifetime  risk  of  developing  Colorectal  cancer,  optimising  the  use  of 
topical treatments,  response to treatment,  risk of  requiring  colectomy and  long 
term morbidity (Farmer et al., 1993, Biancone et al., 2008). 
There are some less common variants of UC, for example those patients who also 
suffer  from  UC  associated  Primary  Sclerosing  Cholangitis  (PSC),  and  /  or  other 
extra intestinal manifestations in which IBD may be part of a syndrome rather than 
a distinct disease in itself (Evans and Pardi, 2007). These phenotypic variants are 
most  likely  to  represent  different  disease  aetiologies  and  are  therefore  not 
included or considered further. 
1.1.3.3  Clinical activity in UC 
There is no internationally agreed system of defining clinical disease activity in 
UC, the method used is often dependent on the context in which activity is being 
calculated (Travis et al., 2011). Of the numerous activity indexes which are used, 
both  the  Food  and  Drug  Administration  (USA)  and  the  British  Society  of 
Gastroenterology  (UK)  currently  recommend  disease  activity  assessment  using 
either the  Truelove and  Witts clinical activity index,  Table  2, or the  Mayo  score 
disease activity index known as DAI, Table 3. 
 
Activity  Criteria 
Severe  ≥6 motions a day with macroscopic blood in stools. 
 
And ≥ 1 of the following; 
 
Fever (mean evening temperature >37.5 ˚C), or a temperature of ≥37.8 ˚C on ≥ 
2 days out of 4.  
Tachycardia (pulse >90bpm) 
Anaemia (Hb ≤75% normal) 
E.S.R. ≥ 30mm/hr 
Moderately severe  Intermediate between severe and mild. 
mild  ≤4 motions a day with no more than small amounts of macroscopic blood in 
stools. No fever. No tachycardia. Anaemia not severe. E.S.R. ≤30 
Table  2.  The  Truelove  and  Witts  clinical  activity  index  for  UC 
(Truelove and Witts, 1955). Chapter 1. Introduction 
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The Mayo score disease activity index (DAI) 
Stool frequency 
0= normal no. of stools for this patient 
1= 1-2 stools more than usual 
2= 3-4 stools more than usual 
3= 5 or more stools than normal 
Rectal bleeding
1 
0= no blood seen 
1= streaks of blood with stool less than half the time 
2= obvious blood with stool most of the time 
3= blood alone passed 
Scope findings 
0= normal or inactive disease 
1= mild disease (erythema, decreased vascular pattern, mild friability) 
2= moderate disease (marked erythema, absent vascular pattern, friability, erosions) 
3= severe disease (spontaneous bleeding, ulceration) 
Physicians global assessment
2 
0= normal (no symptoms of colitis, patient feels well, and scope score = 0) 
1= mild disease (mild symptoms, scope score is mild) 
2= moderate disease (more serious abnormalities and scope score and symptom scores of 1 or 2) 
3=  severe  disease  (symptom  and  scope  scores  of  3  and  patient  requires  steroids  and  /  or 
hospitalisation) 
1The most severe bleeding of the day 
2The PGA acknowledges 3 criteria, the patient’s daily record of abdominal discomfort and general sense of 
well being, and other observations, such as physician’s findings and the patient’s performance status. 
Table 3. Mayo score disease activity index (DAI) for UC (Schroeder et 
al., 1987). 
Cortisone was the new wonder drug for many inflammatory conditions just after 
the 2nd World War
2. The first randomised controlled trial of cortisone in IBD was 
published by Truelove and Witts  (1955)  who also introduced the first disease 
activity index the “Truelove and Witts clinical activity index”, which is still widely 
used today, The index was developed to identify those patients with high acute 
mortality and those requiring colectomy. Its ability to identify severe disease is 
well validated; however it is limited in its ability to discriminate mild or moderate 
disease or changes in activity over time and therefore many other indices have 
been  used, or  proposed,  which  incorporate numerous other prognostic  markers 
(Caprilli et al., 2007, Cooney et al., 2007). Despite its short comings the Truelove 
and Witts activity index is still the most widely utilised clinical activity index in the 
setting of severe UC. 
                                              
2The advent of modern medicine were exemplified in “Bigger Than Life” (1956), a movie classic starring 
James Mason and Walter Matthau that tells the story of a small town school teacher whose life is saved 
from the  rapidly  fatal  effects  of  polyarteritis  nodosa,  by  the  prescription  of  an “experimental”  new 
drug, cortisone..     Chapter 1. Introduction 
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1.1.3.4  Endoscopic activity index 
Endoscopic  activity  is  now  gaining  favour  as  the  most  important  factor  in  the 
prediction  of  disease  activity  and  treatment  outcome,  and  is  becoming  a  more 
commonly  used  activity  marker  in  clinical  practice.  Endoscopic  activity  is  also 
widely used as a disease activity marker and endpoint in many important trials. 
 
Table  4.  A  comparison  of  the  3  most  commonly  used  endoscopic 
scoring algorithms. 
There are over 9 widely used scoring systems for endoscopic activity in UC, the 
most widely used are the Baron scoring system introduced by Baron et al. (1964) 
from which many adaptations have been developed including the modified Baron 
score, otherwise known as the Feagan score (Feagan et al., 2005), and the Mayo 
score taken from the endoscopic section of the Mayo activity index, Table 4. 
Although  endoscopic  activity  is  rapidly  gaining  favour  over  clinical  activity 
indexes as the desired end point for both clinical treatment as well as trials there 
are a number of recognised drawbacks. The first is the substantial inter-observer 
variation in the endoscopic assessment of severity. Bernhardt et al (2009) reported 
  Baron Score 
(Baron et al., 1964) 
Modified Baron / 
Feagan Score 
(Feagan et al., 2005) 
Mayo score 
(Schroeder et al., 1987) 
0 
Normal  matt  mucosa,  ramifying 
vascular  pattern  clearly  visible,  no 
spontaneous bleeding, no bleeding to 
light touch 
Normal  smooth  glistening 
mucosa  with  vascular 
pattern visible, not friable 
normal or inactive disease 
 
1 
Abnormal,  but  non-haemorrhagic 
appearance between 0 and 2 
Granular  mucosa,  vascular 
pattern  not  visible,  not 
friable, hyperaemia 
mild  disease  (erythema, 
decreased vascular pattern, 
mild friability) 
 
2 
Moderately haemorrhagic, bleeding to 
light  touch,  but  no  spontaneous 
bleeding seen ahead of the instrument 
on initial inspection 
As  1,  with  a  friable 
mucosa,  but  not 
spontaneously bleeding 
moderate  disease  (marked 
erythema,  absent  vascular 
pattern, friability, erosions) 
3 
Severely  haemorrhagic,  spontaneous 
bleeding seen ahead of instrument at 
initial  inspection  and  bleed  to  light 
touch 
As  2,  but  mucosa 
spontaneously bleeding 
severe  disease 
(spontaneous  bleeding, 
ulceration) 
4 
  As  3,  but  clear  ulceration, 
denuded mucosa 
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that for severe colitis there is only 76% concordance between endoscopists, and 
only 47% concordance for moderate inflammation. The second is the difficulty in 
comparing different indexes, clinical indexes tend to give trials a more favourable 
outcome and have therefore been favoured historically in pharmaceutical studies. 
Clinical indexes cannot be compared with endoscopic indexes because symptoms 
correlate poorly with endoscopic (and biochemical) activity. 
1.1.4  Crohn’s Disease 
1.1.4.1  Introduction 
Crohn’s disease most commonly presents in early adulthood and is characterised 
by  a  transmural  and  granulomatous  patchy  inflammation  of  any  part  of  the 
gastrointestinal  tract  (GI  tract).  Crohn’s  disease  phenotype  can  be  more  clearly 
subdivided  than  UC,  mainly  due  to  the  clear  distinctions  between  different 
anatomical  distributions  and  the  complications  that  ensue.  In  Crohn’s 
approximately  30%  of  patients  present  with  endoscopic  and  /  or  radiological 
evidence  for  ileal  disease,  45%  with  involvement  of  both  the  ileum  and  colon, 
largely localised to the terminal ileum and IC valve, and 26% present with isolated 
colonic inflammation (Truelove and Pena, 1976). 
The  most  common  presenting  symptom  is  diarrhoea,  seldom  associated  with 
blood.  Abdominal  pain  and  weight  loss  are  also  commonly  seen,  and  are  more 
frequent  complaints  than  in  UC.  Extra  intestinal  manifestations  are  also  more 
common place mainly involving the joints, skin and eyes. 
The  cardinal  difference  between  UC  and  Crohn’s  is  the  depth  of  inflammatory 
involvement.  Due  to  transmural  inflammation  seen  in  Crohn’s,  penetrating 
(fistulae) and strictures are frequently encountered, and when present, drastically 
alter the disease impact, treatment and disease course. 
1.1.4.2  Phenotype 
An  initial  consensus  meeting  in  Rome  1991  identified;  age  of  onset,  disease 
location and behaviour as the three main phenotypic characteristics that affected 
disease  prognosis  and  treatment outcome  in  Crohn’s.  Reviewed  in  Vienna  1998     Chapter 1. Introduction 
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(Gasche et al., 2000) and updated in Montreal 2005 (Silverberg et al., 2005), the 
simplified  Montreal  classification  is  now  used  to  define  phenotype  in  Crohn’s, 
Table 5. 
 
Age of onset  location  Behaviour 
<16 years  (A1)  Ileal   (L1)  Non-stricturing   
17-40 years  (A2)  Colonic  (L2)  Non penetrating   (B1) 
>40 years  (A3)  Ileocolonic  (L3)  Stricturing  (B2) 
        Penetrating  (B3) 
        Perianal disease  + p 
Table  5.  Definition  of  Crohn's  disease  phenotype  according  to  the 
Montreal classification (Silverberg et al., 2005). 
Like  UC the  distribution  of  phenotypes  differs  between  population  groups,  and 
again may reflect different aetiological and propagating factors. 
1.1.4.3  Clinical activity in Crohn’s disease 
In clinical practice Crohn’s activity is graded as mild, moderate or severe. The 2006 
European  Crohn’s  and  Colitis  Organisation  guidance  definitions  are  outlined  in 
Table 6, and although helpful in clinical situations are subjective and are subject 
to large inter-observer variation. 
 
Mild  Moderate  Severe 
Equivalent to a CDAI of 150–220 
Ambulatory, eating and 
drinking. 
<10% weight loss. 
No features of obstruction, 
fever, dehydration, abdominal 
mass, or tenderness.  
CRP usually increased above the 
upper limit of normal 
Equivalent to a CDAI of 220–450 
Intermittent vomiting, or weight 
loss >10%. Treatment for mild 
disease ineffective, or tender 
mass.  
No overt obstruction.  
CRP raised above the upper limit 
of normal. 
 
Equivalent to a CDAI of >450 
Cachexia (BMI <18) 
Evidence of obstruction or 
abscess. Persistent symptoms 
despite intensive treatment. 
Raised CRP. 
 
Table 6. Clinical grading of Crohn's disease (Adapted from Strange et 
al. (2006) for CDAI score see Table 7. Chapter 1. Introduction 
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In  clinical  studies  or  in  patients  who  are  being  assessed  or  monitored  for 
biological therapy Crohn’s activity is measured more objectively using the Crohn’s 
Disease Activity Index (CDAI), Table 7, or Harvey Bradshaw Index (HBI), Table 8. 
Almost  4  decades  ago  Best  et  al.  (1976)  developed  the  Crohn’s  activity  index 
(CDAI),  they  monitored  18  variables  in  approximately  120  patients  who  they 
consulted for both in- and out-patient treatment. Eight variables were incorporated 
into a rather complex equation to achieve an activity score. Despite the possibility 
that  symptoms  not  due  to active  disease  can  cause  an  increase  in  the  CDAI,  it 
remains the principle index used for trials in Crohn’s, although more recently the 
CRP has been incorporated into the index to reduce the false positive response 
seen by placebo. It is now accepted that CDAI >150 is required for a definition of 
active  disease  and  a  change  >100  points  is  required  to  indicate  a  response  to 
treatment,  although  some  studies  use  different  values  which  complicate 
comparison. 
 
Clinical or laboratory variable  Weighting factor 
Number of liquid or soft stools each day for seven days  x 2 
Abdominal pain (graded from 0-3 on severity) each day for seven days  x 5 
General well being, subjectively assessed from 0 (well) to 4 (terrible) each day for seven days  x 7 
Presence of complications*  x 20 
Taking Lomitil or opiates for diarrhoea  x 30 
Presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite)  x 10 
Absolute deviation of haematocrit from 47% in men and 42% in women  x 6 
Percentage deviation from standard weight  x 1 
*One point each is added for each set of complications; 
  the presence of joint pains (arthralgia) or frank arthritis 
  inflammation of the iris or uveitis 
  presence  of  erythema  nodosum,  pyoderma  gangrenosum,  or  aphthous  ulcers,  anal 
fissures, fistulae or abscesses , other fistulae , 
  Fever (> 100 °F) during the previous week.  
 
Table 7. The Crohn's Disease Activity Index (CDAI).Adapted from Best 
et al. (1976).     Chapter 1. Introduction 
13 
The Harvey Bradshaw Index is a five variable scoring index which is easy to use 
and applicable to the bed side. The first three items are scored for the previous 
day. Remission, mild disease, moderate disease and severe disease are accepted 
as a HBI score of <5, 5-7, 8-16 and >16 respectively. 
 
variable  scores 
General well-being  0 = very well, 1 = slightly below par, 2 = poor, 3 = 
very poor, 4 = terrible  
Abdominal pain  0 = none, 1 = mild, 2 = moderate, 3 = severe 
Number of liquid stools per day.   1x number  
Abdominal mass  0 = none, 1 = dubious, 2 = definite, 3 = definite 
and tender 
Complications: arthralgia, uveitis, erythema 
nodosum, aphthous ulcers, pyoderma 
gangrenosum, anal fissure, new fistula, abscess 
score 1 per item 
Table 8. The Harvey Bradshaw Index (HBI). 
1.1.4.4  Endoscopic activity index 
Endoscopic  activity  is  more  difficult  to  define  for  Crohn’s  than  UC  because 
inflammation  may  be  patchy,  involve  areas  of  the  GI tract  beyond  the  reach  of 
conventional endoscopy and may have overlying normal mucosa in the presence 
of  submucosal  disease.  Despite  the  diagnostic  difficulties,  mucosal  lesions  are 
currently the standard way of measuring disease activity and healing (Daperno et 
al., 2011), and correlate strongly with disease prognosis  (Ardizzone et al., 2004, 
Peyrin-Biroulet  et  al.,  2011).  The  Crohn’s  disease  endoscopic  index  of  severity 
(CDEIS) (Mary and Modigliani, 1989), or the simple endoscopic score for Crohn’s 
disease  (SES-CD)  (Daperno  et  al.,  2004),  Table  9,  are  the  most  widely  used  in 
clinical trials.  Although  in clinical practice, endoscopic activity is graded by the 
presence and appearance of ulcers and / or inflammatory activity in each region 
using the Mayo score, Table 3. 
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  0  1  2  3 
Size of ulcers  None  Aphthous  ulcers 
(Ø 0.1 -0.5cm) 
Large  ulcers  (Ø 
0.5 – 2.0cm) 
Very  large  ulcers 
(Ø >2cm) 
Ulcerated surface  None  <10%  10-30%  >30% 
Affected surface  Unaffected 
segment 
<50%  50-75%  >75% 
Presence  of 
narrowing 
none  Single  and  can  be 
passed 
Multiple,  can  be 
passed 
Cannot be passed 
5 predefined endoscopic segments, the Ileum, right colon (IC valve, caecum and ascending), transverse, 
left colons and the rectum. Each section was given a score of 0-3 from the table above. 
Table 9. The simple endoscopic score for Crohn's disease (SES-CD) 
(Daperno et al., 2004).  
1.1.5  The histopathology of IBD 
Histological  examination  in  IBD  serves  a  number  of  functions;  supporting  the 
diagnosis, differentiating between UC and Crohn’s, assessing disease activity and 
excluding alternative diagnoses or the presence of dysplasia. 
Histology  is  not  a  prerequisite  for  diagnosis  and  by  itself  only  achieves  a 
diagnostic sensitivity of up to 74% for UC and between 18% and 62% for Crohn's 
(Bentley et al., 2002). Differentiation between UC and Crohn's by histology alone is 
also difficult due to the lack of defining histological characteristics. The presence 
of an epithelioid granuloma is specific to Crohn’s although only a feature in 18% of 
patients  and  is  easily  confused  with  peri-cryptic  histiocytic  granuloma  or 
histiocytic reaction around ruptured crypts, both commonly seen in UC and over 
50% of Crohn's depending on disease severity and the source of the tissue (Molnar 
et  al.,  2005).  Besides  epithelioid  granuloma,  patchy  inflammation  is  another 
commonly  used  feature to  differentiate UC  from  Crohn's  although  this  again  is 
common to both diseases depending on biopsy site and treatment regime. 
In circumstances where inflammatory activity is measured, there are four criteria 
which  are  assessed;  architectural  abnormalities,  signs  of  chronic  inflammation, 
signs  of  acute  inflammation  and  epithelial  abnormalities,  these  are  outlined  in 
more detail by Jenkins et al. (1997). These 4 histological criteria are combined in a 
number of different ways to create a histological activity grade, for example the     Chapter 1. Introduction 
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Geboes scale (Geboes et al., 2000) and the Riley index (Riley et al., 1991). Although 
occasionally helpful in UC, for Crohn’s, both diagnosis and disease activity are far 
less dependent on histology and although certain histological features are helpful 
to predict disease activity and progress, there is no expert consensus on using 
these to grade activity (Stange et al., 2006, Mowat et al., 2011). 
Histological activity is rarely used as a grading tool in clinical practice and has not 
yet been used as an endpoint in clinical trials. Mucosal inflammatory activity is 
defined  mainly  on  the  macroscopic  appearance  which  correlates  with  sustained 
remission  as  demonstrated  in  the  landmark  trials,  Activity  in  Ulcerative  Colitis 
Trial  1  and  2  (ACT  1  and  2).  In  this  trial  Rutgeerts  et  al.  (2005)  showed  that 
macroscopic mucosal healing after 8 weeks of anti-TNF-α therapy correlated with a 
4  fold  increase  in  symptomatic  remission  at  30  weeks,  but  did  not  venture  to 
compare microscopic healing. 
In practice the results from histology is most often indeterminate and of little help 
other than ruling out alternative diagnoses and confirming inflammation.   Chapter 1. Introduction 
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1.2  The immune system 
1.2.1  Introduction 
The immune system is a collection of biological structures and processes which 
defend the human body against an almost infinite array of harmful substances
3.  
An effective immune system achieves a balance between a swift and aggressive 
response  to  injurious  substances,  controlled  and  timely  reduction  in  that 
response, a recognition and tolerance to self -antigens and creation of long term 
immunity. A defective immune response has been strongly associated with many 
human diseases including many types of cancer (Ohm and Carbone, 2002), chronic 
inflammatory diseases such as IBD and arthritis  (Baumgart and Carding, 2007) , 
many metabolic diseases including obesity and  nutrient deficiencies (Engstrom et 
al.,  2003) ,  autoimmune  conditions  such  as  diabetes,  thyroid  dysfunction  and 
coeliac disease (Davidson and Diamond, 2001), hypersensitivity reactions such as 
anaphylaxis, immunodeficiency such as HIV and many more (Iborra et al., 2012). 
Our immune system has been evolving for approximately 3 billion years since the 
most  primitive  life  forms  developed  a  defence  against  invasion  by  foreign 
substances. Some features of these primitive defences remain and include the 
defensins and complement cascades, however over time pathogens have evolved 
to circumvent these crude defences, and so our immune system has evolved also. 
The modern human immune system can be subdivided into 3 main mechanisms of 
defence; a physical barrier against invasion, the swift non-specific response of the 
innate immune system against generic pathogenic components and the slower 
adaptive immune system which is capable of providing a targeted response and 
the development of lasting immunity. 
                                              
3 This includes infective pathogens such as microbes, parasites and viruses, autologous substances 
and cells which left unchecked have the potential to become cancerous, and other organic molecules 
and chemicals.     Chapter 1. Introduction 
17 
1.2.2  The barrier 
1.2.2.1  Introduction 
The first line of defence against any pathogen is to prevent its admission into the 
human body. Access is prevented initially by a series of mechanical, chemical and 
biological barriers.  The gastrointestinal tract  has  several cleansing mechanisms 
which  are  commonly  enrolled  to  rid  the  gastrointestinal  tract  of  harmful 
substances  and  pathogens  including  the  actions  of  vomiting  and  diarrhoea.  In 
addition, orally consumed pathogens are met by a hostile environment including 
the  chemical  barriers  of  gastric  acid,  bile  and  pancreatic  secretions  followed 
closely by the biological  inhibition of  foreign bacteria by a balanced growth of 
commensal  flora  in  the  small  bowel.  If  pathogens  manage  to  survive  these 
defences, they are then kept within the lumen of the intestine by a single layer of 
columnar  epithelial  cells  (EC)  coated  with  a  protective  mucus  layer  collectively 
known as the epithelial cell barrier Figure 1. 
1.2.2.2  The epithelial cell barrier 
The function of the epithelial cell barrier can be divided into 2 overlapping areas; 
the first is its role as a physical barrier separating the luminal contents from the 
body and the second are the role it plays in a variety of immune functions. 
The colon contains over 5500 different species of bacteria (Dethlefsen et al., 2008) 
at  a  total  concentration  of  between  10
11  and  10
12  microbial  cells  per  gram  of 
luminal contents. These bacteria perform some crucial metabolic and protective 
roles,  however  some  are  potentially  harmful  pathogens  and  must  be  prevented 
from penetrating through the mucosal barrier (Guarner and Malagelada, 2003). 
Mucus is the first line of defence and lines the entire GI tract. It is thickest in the 
colon, where it serves as a permeable gel through which essential macromolecules 
and nutritional substances can pass but acts as a protective membrane against 
larger  molecules,  e.g.  digestive  enzymes,  toxins  and  bacteria.  Colonic  mucus  is 
composed  of  many  defensive  factors  such  as  antimicrobial  peptides,  defensins 
and the immunoglobulins IgA and IgG. Chapter 1. Introduction 
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The  integrity of the  epithelial  cell  barrier  is  maintained  by  a  layer  of  polarised 
epithelial  cells  which  are  adhered  together  by  cell  to  cell  junctional  proteins, 
Figure 1. These proteins are modulated by a wide range of cytokines and growth 
factors and allow selective passage of macromolecules, nutritional substances and 
specialized dendritic cells (DC). 
Epithelial  cells  function  as  more  than  just  a  physical  barrier,  it  is  becoming 
increasingly recognised that epithelial cells influence the outcome of innate and 
adaptive immune responses through expression of factors such as thymic stromal 
lymphopoietin  (TSLP)  which  influences  DC  function  to  favour  a  T
H2  mediated 
inflammatory response. TSLP is discussed in more depth in Chapter 6. 
Dendritic cells are allowed to bridge the epithelial tight junctions to sample the 
luminal contents. Luminal sampling by DCs promote the development of immunity 
against potentially harmful luminal antigens, whilst developing tolerance to self 
and  innocuous  substances  to  prevent  unrestrained  activation  of  the  immune 
system. 
 
Figure 1.The colonic epithelial cell barrier     Chapter 1. Introduction 
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1.2.3  Innate immune system 
1.2.3.1  Introduction 
In  terms  of  evolution,  the  innate  immune  response  is  the  oldest  part  of  the 
immune system and has evolved to prevent free growth of bacteria. The innate 
immune  system  leads  to  a  fast  but  non-specific  response  against  generic 
components of invading organisms and injured cells. These generic components 
are molecular motifs that create recognisable patterns called pathogen associated 
molecular patterns (PAMPs). 
The major functions of the innate immune system within the GI tract are to: 
1.  Recruit immune cells to the site of invasion or injury. 
2.  Activate the complement cascade. 
3.  Identify and remove foreign substances via phagocytosis. 
4.  Activate the adaptive immune system through antigen presentation and co-
stimulatory signals. Chapter 1. Introduction 
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Figure 2. Dendritic cell sampling of luminal contents. Dendritic cell 
exposure  to  luminal  antigens  occurs  in  4  ways;  Active  luminal 
sampling (1 and 2) and active sampling following bacterial invasion 
through  the  epithelial  barrier  (3  and  4).  1.  DCs  reach  through  the 
epithelial barrier and sample directly from the lumen. 2. M cells are 
specialised  cells  that  mediate  uptake  of  bacteria  in  intestinal 
lymphoid tissue. 3. The bacteria reach the lamina propria by direct 
invasion through the epithelial barrier due to increased permeability. 
4.  Tissue  damage.  After  antigen  encounter,  DCs  travel  in  local 
lymphoid  structures  such  as  Peyer’s  patches  (PP)  and  toward  the 
draining mesenteric lymph nodes (MLN) to initiate or maintain T and 
B lymphocyte cell immune responses. 
The innate immune system consists of many cell types each with their own unique 
characteristics  and  functions.  Mast  cells,  macrophages  and  dendritic  cells  are 
specific types of phagocytic and antigen presenting cells (APC) that reside in their 
inactive state within the interface between the outside world and body tissues, in 
the GI tract this is the lamina propria of the intestinal mucosa. They are constantly 
sampling the local environment for antigens that have breached the epithelial cell 
barrier through increased permeability or injury. In addition, DCs have the unique 
ability to sample the luminal contents of the intestine by extending their dendrites     Chapter 1. Introduction 
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through the epithelial cell barrier whilst maintaining barrier integrity through the 
expression  of  junctional  proteins;  occludin,  claudin  1  and  zonula  occludens  1 
(Rescigno et al., 2001), Figure 2. 
Through the process of luminal sampling the DCs of the innate immune system 
are able to present antigens to the adaptive immune system to develop a specific 
immunity  against  certain  antigens  that  are  potentially  harmful,  and  tolerance 
against  other  antigens  which  are  helpful  to  survival  and  the  maintenance  of 
epithelial  homeostasis.  This  tolerance  prevents  the  unwanted  activation  of  the 
immune response to harmless and / or helpful commensal bacteria. 
1.2.3.2  Pattern recognition receptors 
A vital function of the innate immune system is the ability to distinguish between 
potentially  harmful  antigens  and  products  of  normal  cellular  processes.  The 
molecules responsible for this function are pattern recognition receptors (PRRs), 
which  include;  the  membrane  bound  Toll  like  receptor  (TLR)  family  which 
recognise PAMPs on the cell surface or within extracellular compartments, the Nod 
like  receptor  (NLR)  family  which  recognise  intracellular  PAMPs  and  the  recently 
identified retinoic acid inducible gene 1 (RIG-1) and C-type lectin receptors. 
1.2.3.3  Toll like receptors 
In  1994  the  first  TLR  in  humans  was  reported  (Nomura  et  al.,  1994),  to  date 
another 12 have been identified, TLR1, 2, 4, 5 and 6 are located on the cell surface 
and TLR3, 7, 8, 9,12 (possibly) and 13 are localized to the endosomal / lysosomal 
compartment.  Toll  like  receptors  are  characterised  by  an  extracellular  domain 
which consists of a leucine rich repeat (LRR), a single transmembrane domain and 
a cytoplasmic domain called Toll/interleukin 1 receptor (TIR) domain, Figure 3. 
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Figure  3.  MyD88  mediated  activation  of  the  Toll  like  receptor 
pathway 
The LRR domain is thought to be the ligand sensing motif which is able to identify 
conserved microbial PAMPs or other ligands. TLR4 is perhaps the most best known 
TLR and has been shown to recognise a generic feature of bacterial cell wall, the 
lipopolysaccharide (LPS) (Poltorak et al., 1998). Activation of the TLR4 signalling 
pathway  originates  from  the  cytoplasmic  Toll/IL-1  receptor  (TIR)  domain  that 
associates  with  a  TIR  domain-containing  adaptor,  MyD88.  Upon  stimulation  of 
TLR4  by  LPS,  MyD88  recruits  IL-1  receptor-associated  kinase  (IRAK)  to  TLRs 
through  interaction  of  the  death  domains  of  both  molecules.  IRAK  activated  by 
phosphorylation then associates with TRAF6 leading to activation of JNK and the 
transcription  factor  NF-κβ  and  IFN-γ.  The  final  result  of  the  PRR  pathway  is 
activation of the inflammatory cytokines IL-6, IL-1 and TNF-α. 
Since  the  observation  that  NF-κβ  is  expressed,  although  delayed,  after  TLR4 
stimulation  in  MyD88  deficient  macrophages  (Kawai  et  al.,  1999),  at  least three 
MyD88  independent  pathways  have  been  identified  (Takeda  and  Akira,  2005). 
These  include  other  TIR  domain  containing  adapters,  TIR  domain  containing 
adaptor inducing IFN-γ (Yamamoto et al., 2002, Hoebe et al., 2003), TRIF related     Chapter 1. Introduction 
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adaptor molecules (Yamamoto et al., 2003), and IRF-3 (Kawai et al., 2001). The roles 
of  these  MyD88  independent  pathways  are  likely  to  represent  an  evolutionary 
“redundancy”  measure  to  protect  against  potentially  fatal  consequences  of  a 
defective MyD88 pathway. 
1.2.3.4  NOD like receptors 
 
 
Figure 4. The NLR family and activation of NOD2 
The largest family of intercellular PRRs is the nucleotide-binding oligomerization 
domain  [NOD]  like  receptors  (NLRs).  The  NLRs  include;  NALP(1-14),  NOD  (1-5), 
CIITA, IPAF and NAIP (Martinon and Tschopp, 2005). Three domains characterise 
the  NLRs;  a  LRR  domain  similar  to  TLRs,  which  recognises  PAMPs,  a  NACHT 
domain which is essential for NLR activation, and the N-terminal effector domain. 
Oligomerization of the NACHT domain is essential for the signal mediated by the 
N-terminal  effector  domain  which  is  either  a  pyrin  domain  (PYD),  caspase Chapter 1. Introduction 
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recruitment domain (CARD) or baculovirus  inhibitor of apoptosis  protein repeat 
(BIR) domain. 
 
 
Figure  5.  The  NALP3  inflammasome  is  an  example  of  a  caspase-1 
activating multiprotein complex. Consisting of numerous molecules 
arranged on a central scaffold, the inflammasome is divided into 3 
(or  4  if  AIM2  is  included)  subtypes  defined  by  the  ligand  sensing 
motif which is incorporated into the structure; NALPs, IPAF or NAIPs. 
As well as a ligand sensing motif the inflammasome consists of a 
NACHT  domain  that  drives  oligomerization,  a  PYD  recruitment 
domain and a CARD domain which associates directly with the CARD 
domain of procaspase-1. Caspase-1 is responsible for the activation 
of the pro-inflammatory cytokines; IL-1β, IL-18 and IL-33. Part of this 
figure is adapted from (Ferrero-Miliani et al., 2007). 
The NOD sub family requires recruitment of receptor interacting protein 2 (RIP2) 
kinase through interaction with the caspase recruitment domain (CARD) of NOD1 
or NOD2  (Meylan and Tschopp, 2005),  Figure  4.  The activation of  RIP2 leads to 
increased ubiquinisation of NF-κβ essential modulator (NEMO) and the expression 
of NF-κβ. 
The other NLRs (NALPs and NAIPs) generate IL-1β through cleavage of pro-IL-1β by 
caspase-1 via an inflammatory complex called the inflammasome, of which there 
are a number of types  (Drenth and van der  Meer, 2006, Martinon and Tschopp, 
2007). Figure 5 demonstrates the structure of the NALP3 inflammasome.     Chapter 1. Introduction 
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Figure  6.  The  interaction  of  the  TLR  and  NLR  pathways  and  the 
production of IL-1β, IL-18 and IL-33. 
The  main  functions  of  NLRs  are  to  detect  intracellular  PAMPs  and  trigger  the 
expression of the inflammatory cytokines IL-1β, IL-18 and possibly IL- 33. The most 
potent of the inflammatory cytokines is IL-1β which is an important mediator of 
many immune responses and cellular activities. The expression of IL-1β and IL-18 
is complex and occurs by a slightly different mechanism depending on the NLR 
which  has  been  activated and  the  cell  type  in  which  it  is  occurring.  There  is  a 
common first step; the expression of pro-IL-1β, the inactive precursor molecule of 
IL-1β.  The production of Pro-IL-1β is mediated by NF-κβ through stimulation and 
activation  of  TLRs,  although  the  activation  of  any  PRR  can  produce  NF-κβ,  the Chapter 1. Introduction 
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activation by TLRs has become known as “priming”. The second step depends on 
which NLR is activated, Figure 6. 
The  function  of  TLR  and  NLR  pathways  interact  synergistically.  This  symbiotic 
relationship  protects  against  the  inappropriate  activation  of  inflammatory 
processes by a single pathway, for example, inflammasome activation of caspase-1 
alone without priming (activation of NF-κβ by the TLR pathway) does not lead to 
increased  IL-1β  production  despite  increased  levels  of  active  caspase  1 
(Mariathasan and  Monack,  2007).  However,  there  are  exceptions,  in  a  review  by 
Netea  et  al.  (2008)  it  is  explained  that  under  certain  environmental  situations 
monocytes are capable of releasing active IL-1β upon stimulation of TLR ligands 
alone, in contrast to macrophages which do require TLR and NLR stimulation, an 
adaption that is likely to reflect certain environmental situations. None the less 
combined  TLR  and  NLR  activation  in  monocytes  enhances  cytokine  production 
more than TLR activation alone. 
1.2.4  Adaptive immune system 
1.2.4.1  Introduction 
In  contrast  to  the  swift  but  non-specific  inflammatory  response  of  the  innate 
immune  system,  the  adaptive  immune  system  provides  a  slower  but  targeted 
response to maximise the clearance of specific pathogens from the body. Other 
important  characteristics  of  the  adaptive  immune  system  include  the  ability  to 
differentiate self from non-self and the ability to create immunological memory to 
prevent subsequent infections. 
Adaptive  immunity  is  triggered  through  the  process  of  antigen  presentation. 
Although all nucleated cells are capable of presenting antigen only dendritic cells, 
B lymphocytes and macrophages are termed antigen presenting cells because of 
the  specialised  receptors  that  allow  activation  of  T  lymphocytes.  Antigen 
presenting cells engulf pathogens following recognition of PAMPs by their PRRs; 
this  is  the  immediate  response  of  the  innate  immune  system.  Within  the  APCs 
enzymes split larger pathogens into smaller particles which can then be displayed 
as antigens on the cell surface of the APCs by major histocompatibility complexes     Chapter 1. Introduction 
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(MHCs). Presentation of the antigen / MHC complex on the cell surface of APCs 
then activates the effector cells of the adaptive immune system. Effector cells are 
the T and B lymphocytes. 
1.2.4.2  B Lymphocytes 
The primary role of the B lymphocyte (also known as B cell) is to mastermind the 
humoral response through creation and release into the systemic circulation, and / 
or local environment, specific antibodies (immunoglobulins)  (LeBien and Tedder, 
2008).  Antibodies  bind  to  specific  antigens  which  are  either  targeted  randomly 
through VDJ recombination during B cell maturation or through clonal expansion 
following  B  cell  activation.  The  antigen-antibody  complex  causes  a  number  of 
effects;  disruption  of  the  invading  pathogen  by  interruption  of  its  cell  wall 
integrity, the prevention of pathogen binding to host cells, marking pathogens for 
destruction by the phagocytic cells of the innate immune system, activation of the 
complement cascade and antigen clearance via the spleen or liver. 
Each B cell has a unique receptor protein called the B cell receptor (BCR), this is an 
immunoglobulin  which  an  enormous  degree  of  diversity.  The  immunoglobulin 
contains  a  heavy and  light  domain  split  into  3  sections,  V,  D  and  J.  Through  a 
random, and error prone, process of VDJ recombination in which random changes 
in the antibody gene locus occur during B cell maturation, a unique BCR for each B 
cell clone is created. This process of random BCR creation ensures that B cells are 
able to recognise and process an almost limitless number of antigens. 
Dysfunctional B cells and those displaying self-recognising BCRs are removed at 
an early developmental stage by mechanisms including clonal deletion, receptor 
editing  and  anergy.  Mature  but  naïve  B  cells  which  express  both  IgM  and  IgD 
immunoglobulins are released into the circulation and migrate to the secondary 
lymphoid organs of the periphery. Upon recognition of its cognate antigen by the 
BCR, B cells are able to engulf the pathogen and present processed peptides in the 
cell membrane with both MHC class 1 and 2 complexes. The activated B cell then 
requires  a  further  step  to  produce  antibodies,  this  can  occur  through  a  T 
lymphocyte dependent or independent mechanism (Vale and Schroeder, 2010). Chapter 1. Introduction 
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The typical T lymphocyte (also known as the T cell) activation pathway is T cell 
dependent and mainly occurs in the germinal centres of lymphoid tissues. B cells 
present antigen / MHC complexes on their cell surface to CD4
+ helper T cells (T
H), 
or CD8
+ cytotoxic T cells. Through the production of a cytokine milieu, B cells are 
stimulated to do a number of different things; proliferate in a process called clonal 
expansion,  class  switch  recombination  (a  process  where  the  secreted 
immunoglobulin  is  IgG,  or  IgE  rather  than  IgM),  differentiate  into  short  lived 
plasma  cells  which  release  antibody  or  differentiate  into  long  lived  memory  B 
cells. 
The T cell independent mechanism is critical and allows the B cell to recognise 
antigens that are not recognised by T cells such as DNA or polysaccharides. T cell 
independent  activation  allows  class  switching  and  production  of  IgG 
immunoglobulins independent of the peripheral lymphoid tissues. 
T cells constitute the largest proportion of lymphocytes in the GI tract mucosa, 
with a distribution which is variable along the length of the bowel and between 
layers  and  influenced  by  local  requirements  and  conditions  (Cheroutre  et  al., 
2011). Sub families of T cells have specific roles in the cell mediated response. 
1.2.4.3  T lymphocytes 
The cell-mediated immune response is lead by the T lymphocyte and encompasses 
a highly heterogeneous group of immune cells, Figure 7. T cells are characterised 
by the T cell receptor (TCR). The combination of CD3 and TCR is known as the TCR 
complex, CD3 is a transmembrane protein whose activation is essential for TCR 
signalling. The TCR is responsible for recognising antigen that is bound to MHC 
complexes on the surface of other cells. It is a heterodimer consisting of 2 protein 
chains, in 95% of T cells, this is the α/β chain, in the other 5% it is the γ/δ chain. 
Each  chain  of  the  TCR  is  a  member  of  the  immunoglobulin  superfamily  and 
contains a constant domain, which sits across the cell membrane, and a variable 
domain  which  is  formed  by  VDJ  recombination  during  T  cell  maturation.  The 
randomness  of  VDJ  recombination  ensures  that  the  TCR  recognises  a  great 
diversity of processed and presented antigen.     Chapter 1. Introduction 
29 
The cell mediated immune response involves the activation of cells that directly 
phagocytose and destroy pathogens such as macrophages and natural killer cells, 
and  the  activation  of  cytotoxic  T  cells  which  induce  apoptosis  in  cells  that  are 
displaying  antigen  on  their  surface,  and  the  stimulation  of  cells  to  secrete  a 
variety  of  cytokines  that  themselves  influence  the  defensive  pathways  of  the 
innate and adaptive immune system. 
 
 
Figure 7. The differentiation of precursor cells into the effector cells 
of the adaptive immune system 
Along with the TCR complex the antigen / MHC complex will bind to specific co-
receptors on the surface of T cells, for T helper cells this is the CD4 co-receptor 
specific  to  MHC  class  2  molecules  and  for  cytotoxic  T  cells  it  is  the  CD8  co-
receptor specific for the MHC class 1 molecule. The addition of co-receptor binding 
is  to  enhance  and  activate  a  chain  of  specific  intercellular  cascades.  Other 
important  membrane  proteins  include  CD45  which  has  a  phosphatase  on  its 
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intracellular section which helps to activate pathways within the cytosol and CD28 
which is the receptor for CD80 a protein which is up-regulated on the surface of 
activated APCs, and acts as a failsafe mechanism. Activation of CD28 by CD80 is 
necessary for the T cell to avoid becoming anergic, this ensures the T cell is only 
activating  against  those  foreign  antigens  presented  on  APCs  rather  than  self-
antigens present in the local environment. The role of CD45 is not entirely known 
but conformational changes within the CD45 molecule help to indicate the state of 
T cell activation and maturation, (CD45RA
+ has not been activated, CD45RO
+ has 
been activated). 
1.2.4.3.1  CD4
+ T helper cells 
Included within the T helper cell family are; T
H1, T
H2, and T
H17 lymphocytes, all 
express the surface protein CD4, which during maturation determines the eventual 
affinity to class 2 MHC molecules. T helper cells orchestrate the immune response 
by activating and directing other cells of the immune system, the effect of their 
dysfunction or absence is demonstrated by a number of diseases, many of which 
are  fatal,  the  most  well-known  is  the  Acquired  Immune  Deficiency  Syndrome 
following inactivation of CD4
+ cells by the human immunodeficiency virus. 
When  the  TCR  complex  and  co-receptors  are  activated  the  naïve  T  cell,  T
H0,  is 
capable  of  proliferation  and  clonal  expansion  through  release  of  T  cell  growth 
factor, IL-2 and IL-2R. Depending on the cytokine milieu T
H0 cells then differentiate, 
IFN-γ drives a T
H1 cell proliferation whilst IL-10 and IL-4 inhibit it. On the other 
hand IL-4 drives a T
H2 cell proliferation whilst IFN-γ inhibits it. Determining the 
balance between T
H1 and T
H2 is crucial as the different T cell sub-families generate 
a different pattern of immune response. A T
H1 response maximises the efficacy of 
the  cellular  immune  response  particularly  macrophages  and  CD8
+  cells  and  is 
associated  with  the  production  of  cytokines  INF-γ  and  TNF-α.  A  T
H2  response 
stimulates the B cells into proliferation, class switching and antibody production, 
and is associated with the production of IL-4, IL-5, IL-6, IL-10 and IL-13. 
T
H17 are a distinct sub family of T helper cells, discovered in 2005 (Harrington et 
al., 2005) they are thought to play a vital role  in pro-inflammatory pathways at 
epithelial and mucosal barriers. The differentiation of T
H0 cells into T
H17 cells has     Chapter 1. Introduction 
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been  extensively  studied  (mostly  in  mice)  with  conflicting  results.  In  humans  a 
combination of TGF-β, IL-1 and IL-23 drive the differentiation of T
H0 towards the 
T
H17 cell lineage, where as INF-γ and IL-4 drive the differentiation of T
H0 away from 
T
H17  towards  the  T
H1  and  T
H2  lineages.  An  important  process  shown  in  animal 
models has been the influence of TGF-β and IL-6 on the differentiation of T
H0 cells 
into either regulatory T cells (T
regs) or T
H17 cells, thus influencing either a pro- or 
anti-inflammatory state. Furthermore a cytokine produced by mature T
H17 cells, IL-
21 also drives an IL-23 independent differentiation from T
H0 cell precursors. Once 
differentiated,  IL-23  is  also  associated  with  the  expansion  of  established  T
H17 
populations, perpetuating the inflammatory response. 
Transcription factors that play a role in T
H17 differentiation are STAT3 (Liu et al., 
2008), IRF4  (Huber et al., 2008), RORα and RORγ (Yang  et al., 2008), and RORγt 
(Ivanov  et  al.,  2006).  In  reality  there  are  several  proposed  and  independent 
pathways through which T
H17 cells are differentiated from T
H0 cells or expanded 
and activated. 
The key cytokine product of T
H17 cells is IL-17 which has a number of functions 
including  recruitment  and  activation  of  neutrophils  and  macrophages,  and 
induction of defensins by epithelial cells.  Other effector cytokines  of T
H17 cells 
include,  IL-21,  IL-23,  although  IL-17  is  the  predominant  cytokine.  T
H17  cells, 
through  the  production  of  IL-17,  also  produce  TNF-α,  IL-1β,  IL-6,  G-CSF,  MIP-2, 
CXCL1,  CXCL2  and  CXCL8.  Although  not  directly  involved  in  inflammation,  T
H17 
cells  orchestrate  other  cells  that  are  capable  of  inappropriate  tissue  damage. 
Dysfunction  of  T
H17  cells  is  thought  to  play  a  major  role  in  many  autoimmune 
diseases and immunodeficiency disorders. 
1.2.4.3.2  Regulatory T cells 
Regulatory T cells (T
regs) are characterised by the surface expression of both CD4 
and CD25, and the transcription factor Forkhead box p3 (FoxP3) which is crucial 
for their development and function. Regulatory T cells play an important role in 
suppressing  autoimmunity  and  controlling  inflammation  by  suppressing  the 
proliferation  of  pro-inflammatory  cells  and  the  secretion  of  anti-inflammatory 
cytokines.  Regulatory  T  cell  dysfunction  is  clinically  expressed  in  the  human Chapter 1. Introduction 
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disease  immunodysregulation  polyendocrinopathy  and  enteropathy  X-linked 
syndrome (IPEX) which is a result of a point mutation in the FOXP3 gene leading to 
dysfunctional FoxP3. 
The generation of T
regs from T
H0 cells is driven by TGF-β in a similar way to T
H17 
cells,  however  the  expression  of  the  pro-inflammatory  cytokine  IL-6  appears  to 
inhibit  FoxP3  and  therefore  the  production  of  T
regs  by  driving  differentiation 
towards the T
H17 lineage (Kimura and Kishimoto, 2010). 
Regulatory  T  cells  infer  tolerance  and  inflammatory  suppression  via  2  core 
mechanisms,  bystander  suppression  and  infectious  tolerance.  Bystander 
suppression  is  the  non-specific  suppression  of  activated  effector  cells,  and 
infectious  tolerance  occurs  when  a  new  population  of  T
regs  with  suppressive 
activities  against  a  specific  antigen  are  created.  The  molecular  mechanisms 
through which T
regs exert their influence are complex and increasing in number. In 
a review by Tang et al. (2008), 13 separate molecular mechanisms are reported in 
which T
regs function, they are grouped into; those mechanisms that influence other 
cells, those mechanisms that alter APC activity and those mechanisms that alter 
the secretion of suppressor molecules. The 13 molecular mechanisms included the 
expression of cytokines IL-2, IL-10, IL-35,  TGF-β, IFN-γ, the enzymes  Granzyme B 
and Perforin and receptors CTLA-4 and CD25. 
Central  to  the  functional  effect  of  T
regs  is  the  transcription  factor  FoxP3.  FoxP3 
directly increases CTLA-4 and CD25 and decreases IL-2 expression. Regulatory T 
cells constitutionally express high levels of membrane bound CTLA-4 which acts 
as a negative regulator of the CD80 / CD86 protein on the surface of APCs. The 
inhibition of CD80 / CD86 expression on developing dendritic cells in germinal 
centres  and  the  peripheral  down  regulation  of  CD80  /  CD86  on  mature  DCs 
confers a tolerance to specific antigens. 
Constitutive  expression  of  high  levels  of  CD25  (IL-2  receptor),  and  decreased 
expression of IL-2 ensure that T
regs are highly reliant on exogenous IL-2 production 
for  their  survival.  The  absorption  of  IL-2  depletes  the  local  environment  and 
therefore reduces the availability of the pro-inflammatory cytokine IL-2 to other     Chapter 1. Introduction 
33 
effector cells. Deficiency of IL-2 or CD25 leads to autoimmunity or inflammation 
akin to conditions directly caused by T
reg deficiency. 
Disrupting  T
reg  function  in  experimental  models  can  induce  a  pro-inflammatory 
effect, however translating this into an effective treatment for autoimmune and 
inflammatory conditions by enhancing the suppressive effects of T
regs has not been 
shown, and is hampered by amongst other things, the phenomenon of “plasticity” 
where  by  T  cells  are  able  to  change  their  phenotype,  in  the  case  of  T
regs,  from 
suppressive to pro-inflammatory phenotype depending on the conditions (Zhou et 
al., 2009). 
1.2.4.3.3  CD8
+ cytotoxic T cells 
CD8
+ cytotoxic T cells are a family of T lymphocytes capable of inducing the death 
of infected cells. Along with a TCR they constitutional possess the CD8 membrane 
glycoprotein that binds to the non-variable domain of a MHC class 1 molecule / 
antigen complex. 
Activation of CD8
+ T cells  is  similar to that of CD4
+. Firstly the APC presents a 
processed peptide antigen with a MHC class 1 molecule, this  is recognised and 
bound by the TCR and further stabilised by the addition of the CD8 binding.  The 
co-receptor CD28 then binds with CD80 or CD86 expressed on the surface of the 
APC. Once activated, under the influence of IL-2, the CD8
+ T cell undergoes clonal 
expansion for the specific antigen presented by the APC. 
Activated  CD8
+  T  cells  induce  apoptosis  in  targeted  cells  in  a  number  of  ways, 
although  the  primary  mechanism  is  through  the  initial  release  of  perforins  to 
disrupt  the  cell  membrane  and  allow  the  access  of  various  granzymes  which 
activate the intracellular caspase cascade resulting in apoptosis.    Chapter 1. Introduction 
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1.3  The immune system and IBD 
1.3.1  Introduction 
It is generally accepted that a deregulated immune response lies at the heart of 
IBD,  although  attempts  to  elicit  the  nature  of  this  have  been  hampered  by  the 
complex interplay of causative factors, immune response, disease definition and 
experimental interpretation. 
Over the last 30 years the major advances in IBD have centred on the principle 
that  IBD  is  the  result  of  an  abnormally  polarised  T  cell  response  (Fuss,  2008, 
Neurath  et  al.,  2002).  This  is  encompassed  in  the  “TH1-TH2  paradigm”,  first 
described  by  Mosmann  and  Coffman  (1989)  from  observations  on  experimental 
inflammation. The T
H1-T
H2 paradigm proposes that under certain conditions naïve 
T  cells  are  driven  to  differentiate  either  into  T
H1  or  T
H2  effector  T  cells.  The 
abnormally enhanced proliferation and function of either T
H1 or T
H2 cells will drive 
a distinct pattern of inflammation and cytokine profile which in the case of GI tract 
inflammation produces an inflammatory pattern characteristic for either Crohn’s 
or UC. 
The “T
H1-T
H2 paradigm” describes Crohn’s as a predominantly T
H1 cell mediated 
inflammatory response with the associated excess of cytokines IL-12, IL-23, IFN-γ, 
IL-17 and TNF-α, and UC as a predominantly T
H2 cell response with an excess of 
the cytokines IL-4, IL-5 and IL-13 (Strober et al., 2007, Fuss, 2008). 
The goal of research is to define IBD in terms of a solitary dysfunctional pathway, 
although recently described T cell lineages, such as T
H17, T
H3, T
regs, NK cells, and 
cytokines such as IL-23 and IL-17, also play a crucial role in IBD and do not fit 
comfortably  into  the  T
H1-T
H2  paradigm.  It  is  therefore  likely  that  the  disease 
initiation and perpetuation is the end result of multiple dysfunctional elements of 
numerous pathways, a “multi-hit” idea, a concept that is supported by emerging 
genetic data, see chapter 1.3.7.1. 
Further to the “multi-hit” idea, attempts to find a unifying causative factor have 
been  disappointing,  and  although  specific  cytokine  blocking  agents  (e.g.  TNF-α 
blockers) are now available their long term efficacy is disappointing, reminding us     Chapter 1. Introduction 
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that  IBD  is  almost  certainly  a  multi  factorial  disease  within  an  immune  system 
which is rapidly able to adapt and overcome invasion and external intervention. 
All  aspects  of  the  immune  system  have  been  implicated  in  the  aetiology  and 
perpetuation  of  IBD  although  through  the  use  of  clinical  observation,  animal 
models, engineered cell lines and the limited use of unaltered (either by treatment 
or experimental design) human IBD tissue broad themes are immerging, Table 10. 
 
  mechanism  Notes 
Dysbiosis  Host – microbial 
homeostasis 
Review of treatments which alter commensal bacteria and 
their potential benefit in IBD (Kanauchi et al., 2003) 
Review of trends in the literature in favour of Dysbiosis as 
a cause of IBD (Kaur et al., 2011) 
  Specific antigen 
presentation 
Not known yet 
  Specific infectious 
agents 
None  yet  identified,  no  clinical  benefit  has  been 
demonstrated  following  the  treatment  of  proposed 
infectious agents such as E coli. 
autoimmunity  Loss of tolerance  A review of tolerance in human IBD (Maul and Duchmann, 
2008)  
Barrier 
dysfunction 
Mucus production  Decreased mucus is seen in UC (Cope et al., 1988) 
Muc2-/-  deficiency  in  mice  results  in  spontaneous  colitis 
(Velcich et al., 2002) 
  Epithelial barrier 
dysfunction 
Review  of  barrier  dysfunction  focusing  on  epithelial  cell 
leakiness,  the  multi-functionality  of  tight  junctions  and 
microbiome in IBD (Laukoetter et al., 2008) 
Increasing  attention  to  mucosal  healing  as  an  important 
endpoint in trials and treatment, reviewed by Neurath and 
Travis (2012). 
Increased micro-erosions and epithelial cell permeability in 
IBD seen by confocal laser endomicroscopy (Kiesslich et al., 
2012). 
  Tight junction 
leakiness 
Differential expression of Claudin 2,3 and 4 in IBD (Prasad 
et al., 2005) 
Innate 
immunity 
Dysfunction of 
macrophages 
miR-192 influences the expression of MIP-2α in HT29 cell 
lines (Wu et al., 2008) 
  Dysfunction of 
dendritic cells 
DCs exposed to mucosal epithelial cell microenvironment 
(TGF-β  and  retinoic  acid)  promote  regulatory  T  cell 
differentiation  and  a  tolerogenic  cytokine  environment 
(Iliev et al., 2009) 
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  mechanism  Notes 
Adaptive 
immunity 
Dysfunction of Tregs  Decreased ratio of Tregs : TH17 cells in peripheral blood in 
IBD (Eastaff-Leung et al., 2009) 
Increased in the mucosa during active IBD, but not as much 
as other types of inflammation (Maul et al., 2005) 
Dysfunction  in  experimental  models  leads  to  colitis 
(Asseman et al., 2000) 
  T cell dysfunction   Overall,  total  numbers  of  mucosal  T  cells  is  probably 
raised  in  IBD  compared  with  health  but  probably  not  as 
high as other inflammatory conditions. Results depend on 
experimental method. No imbalance of mucosal CD4 / CD8 
T cells in IBD (Selby et al., 1984) Intraepithelial CD4 : CD8 
ratio  increased  in  UC  but  not  Crohn’s  (Caballero  et  al., 
1995), however it is the cytokine imbalance which is more 
important suggestive of functional imbalance rather than 
total number of cells. 
  Cytokine imbalance  The  cornerstone  of  potential  therapeutic  targets  in  IBD 
with  over  30  therapies  in  development  most  of  which 
target  specific  cytokines  (Danese,  2012).  Review  of 
prominent cytokines by (Sanchez-Munoz et al., 2008).  
IBD  susceptibility  alleles  include  IL-17A  and  IL-23R,  both 
strongly  involved  in  TH17  cell  activation  and  activity  in 
Korean  population  (Kim  et  al.,  2011),  and  multiple  other 
alleles  including  IL-23R,  IL-12B  and  IL-10  identified  by 
GWAS in white populations (Lees et al., 2011). 
Others  miRNAs (see section 
1.4.3 MicroRNA in IBD) 
Seminal  paper  on  the  miRNA  signature  in  the  colonic 
mucosa of patients with UC (Wu et al., 2008) 
Review of miRNA dysfunction in multiple autoimmune and 
inflammatory  conditions,  identifies  30  miRNAs  with 
specific immune functions (Tomankova et al., 2011) 
Table  10.  Multiple  mechanism  through  which  dysfunction  of  the 
immune system is associated with IBD 
1.3.2  Dysbiosis 
1.3.2.1  Host / microbial homeostasis 
There is a symbiotic relationship between man and his microflora that has been 
crucial throughout evolution. In return for a warm home and steady flow of food, 
microflora  assists  us  through  important  metabolic,  trophic  and  protective 
functions  (Guarner  and  Malagelada,  2003,  Tlaskalová-Hogenová  et  al.,  2004). 
Disruption  of  this  relationship  is  associated  with  dysfunction  of  the  immune 
system either through loss of microbial immunological assistance, inappropriate 
activation or direct disruption of the host immune response (Sekirov et al., 2010,     Chapter 1. Introduction 
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Kaur et al., 2011). Imbalance or inappropriate response to microflora is considered 
a major contributor to the pathogenesis of IBD (Maloy and Powrie, 2011). 
Microflora  process  about  20-60g  of  carbohydrate  and  5-20g  protein  daily  from 
substrates  that  would  otherwise  pass  through  and  be  wasted.  Microflora  also 
plays a key role in vitamin and micronutrient absorption as well as the production 
of short chain fatty acids (e.g. butyrate). Many studies have shown that short chain 
fatty  acids  have  a  protective  effect  against  UC  (Tonelli  et  al.,  1995),  possibly 
through actions which include increased epithelial cell proliferation (Alam et al., 
1994) and differentiation (Gordon et al., 1997). A healthy balance of microflora also 
prevents proliferation of single organisms through competition for nutrition and 
other factors. 
A feature of IBD is that microflora biodiversity appears restricted. Scanlan et al. 
(2006)  compared  the  levels  and  stability  of  Clostridium  spp,  bacteroides  spp, 
bifidobacteria  and  lactic  acid  bacteria  in  the  faeces  of  healthy  individuals  and 
patients with Crohn’s and showed that the floral community in Crohn’s is more 
restricted and less stable over time, both of which were correlated, but not causal 
to, inflammatory activity. A stable and well balanced population of luminal flora is 
necessary for epithelial homeostasis. 
Manipulation of the luminal microflora can be achieved through use of probiotics, 
antibiotics  or  faecal  stream  diversion.  VSL#3,  a  probiotic,  has  achieved  some 
favour as a safe option to treat active UC, pouchitis (Bibiloni et al., 2005, Pham et 
al., 2008) and prevent relapse of UC, although there is no clear evidence for its use 
in Crohn’s. Ciprofloxacin and metronidazole are used in the treatment of pouchitis 
and fistulating perianal Crohn’s (Sartor, 2004) and faecal stream diversion with an 
ileostomy  prevents  post-operative  neoterminal  ileum  recurrence  in  Crohn’s 
(Rutgeerts et al., 1991). 
1.3.2.2  Is there a causative agent? 
The microbiome between individuals varies greatly, and within an individual can 
fluctuate rapidly. Many factors contribute to floral composition including birthing 
method, weaning regime, diet, exposure to antibiotics and environmental factors. Chapter 1. Introduction 
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Recently  host  genotype  has  been  shown  to  have  a  prevailing  influence  over 
environmental factors for luminal composition (Zoetendal et al., 2001). A healthy 
GI tract flora is composed of over 5000 different species of which up to 10% are 
aerobes. A small  number of aerobes are potentially pathogenic, but are kept in 
check  by  mechanisms  discussed  earlier.  In  active  Crohn’s  the  balance  is  tipped 
towards a higher percentage of aerobic bacteria compared with quiescent IBD or 
active UC (Giaffer et al., 1991). 
Many organisms have been implicated in the aetiology of IBD and experimental 
colitis  although  results  have  been  too  inconsistent  to  draw  conclusions. 
Experimental models have shown some benefit from the eradication of individual 
pathogens  (Videla  et  al.,  1994),  but  this  benefit  has  not  proven  to  be  clinically 
beneficial  in  IBD.  Two  specific  exceptions  are  the  use  of  ciprofloxacin  and 
metronidazole for the treatment of perianal Crohn’s and pouchitis, a phenomenon 
which may allude to distinct aetiological pathway in these 2 specific phenotypes. 
Organisms  implicated  in  the  aetiology  of  IBD  include;  Salmonella,  Shigella, 
Yersinia,  Listeria  monocytogenes  (Subramanian  et  al.,  2006),  Escherichia  coli, 
Bacteroides  spp,  Clostridium  spp,  Bifidobacteria  spp,  Mycobacteria  spp, 
Campylobacter, Table 11. 
Invasive bacteria are potentially of much greater  significance. Patients  with IBD 
have increased numbers of bacteria attached to their epithelial surfaces and an 
increased  bacterial  load  in  the  intercellular  and  intracellular  compartments 
compared  with  healthy  individuals  (Swidsinski  et  al.,  2002).  Although  no  single 
agent has been singled out, Table 11. 
Despite  experimental  evidence  of  a  strong  link  between  the  microbiome  and 
inflammation, in practice a causal link remains elusive, and manipulation of the 
microbiome  is  only partially beneficial  in a  distinct group of patients. It is  still 
likely  however  that  the  luminal  flora  plays  a  crucial  role  in  the  activation  or 
perpetuation of IBD. 
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Pathogen  Technique used    Ref. 
Mycobacteria spp  Biopsy wash culture  Not detected  1 
Mycobacterium 
tuberculosis 
RT-qPCR  Not detected in biopsies CD 
or UC 
2 
Mycobacterium avium  RT-qPCR  Not detected in biopsies CD 
or UC 
2 
Mycobacterium 
paratuberculosis 
RT-qPCR  Not detected in biopsies CD 
or UC 
2 
PCR (resection 
specimens) 
MP present in 65.0% (CD) vs. 
4.3% (UC) vs. 12.5% normal 
3 
Bacteroids spp  Biopsy wash culture  Main anaerobe in IBD and 
control, significantly higher 
count in CD and UC vs. 
control 
1 
Biopsy RT-qPCR  Present in 16% UC, 30% CD, 
11% non IBD inflammation, 
and 0% controls 
1 
Bacteroids vulgatus  RT-qPCR  100% (CD and UC) vs. 50% 
controls 
2 
Stool culture  No difference CD vs. UC vs. 
control 
4 
Enterobacter spp  Biopsy wash culture  Main aerobe in IBD and 
control, significantly higher 
count in CD and UC vs. 
control 
1 
Escherichia coli  RT-qPCR  Biopsies 63% ( CD), 55% (UC) 
vs. 22% controls 
2 
Biopsy RT-qPCR  Present in 21% UC, 20% CD, 
27% non IBD inflammation 
and 5% controls 
1 
Stool culture  Increase in total numbers in 
active CD vs. quiescent CD, 
UC and controls 
4 
Klebsiella  Stool culture  No difference CD vs. control  4 
Proteus spp  Stool culture  No difference CD vs. control  4 
Streptococcus 
viridans 
Stool culture  No difference CD vs. control  4 
Enterococcus faecalis  Stool culture  Decreased in active CD vs. 
quiescent CD, UC and 
controls 
4 
Diphtheroid bacilli  Stool culture  Increased in active CD vs. 
quiescent CD 
4 
Lactobacillus  Stool culture  Lower count in CD  4 
Bifido bacteria  Stool culture  Lower in CD vs. UC and 
controls 
4 
Clostridium spp  Stool culture  No difference CD vs. UC vs. 
control 
4 
Listeria  Biopsy wash culture  Not detected  1 
pseudomonas  Biopsy wash culture  Not detected  1 
Table 11. A summary of infectious agents and their association with 
IBD. 1 (Swidsinski et al., 2002), 2 (Fujita et al., 2002), 3 (Sanderson et 
al., 1992), 4 (Giaffer et al., 1991). Chapter 1. Introduction 
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1.3.3  Barrier dysfunction in IBD 
Dysfunction of the barrier can be divided into 3 overlapping areas; a decreased 
mucus barrier, altered mucus constituents and a leaky epithelial cell barrier. 
Both  human  and  rodent  models  have  shown  that  a  decreased  mucus  barrier  is 
associated with colitis. A decreased mucus barrier is seen in patients with inactive 
UC compared with healthy individuals (Cope et al., 1988), and induced deficiency 
of mucus in Muc2
-/-, the major constituent of mucus, in rodent models increases 
the rate of spontaneous colitis (Velcich et al., 2002). Together this suggests that a 
reduced  mucus  barrier  predisposes  to  IBD.  Interestingly,  helminth  therapy  has 
been shown to successfully treat otherwise  resistant forms of UC by a process 
which stimulates mucus production through the increased expression of IL-22, and 
GM-CSF has also been shown to improve IBD by mechanisms which may include 
increasing DC and macrophage secretion of IL-23 which up-regulates IL-22. 
Immunoglobulins  and  antimicrobial  peptides  are  important  constituents  of 
intestinal mucus which prevent microbes from invasion. In healthy individuals the 
intestinal mucus is rich in IgA and antimicrobial peptides such as the defensins, 
lysozymes  and  cathelicidins.  In  mucosal  washings  from  patients  with  IBD  the 
concentration of IgG which can trigger inflammatory cascades, is 200-300 times 
higher  compared  with  controls  (Macpherson  et  al.,  1996).  Enhanced  bacterial 
survival and invasion is encouraged by decreased mucosal defensin concentration. 
Reduced  concentration  of  α-defensin  is  seen  in  the  mucosa  of  patients  with 
Crohn’s, and is particularly marked in Ileal Crohn’s associated with mutations of 
NOD2 (Wehkamp et al., 2004) and defective Paneth cell function (Lala et al., 2003). 
There is growing evidence that there is a strong association between increased 
epithelial barrier permeability and IBD  (Clayburgh et al., 2004, Laukoetter et al., 
2008). Older studies report an increased permeability to normally unabsorbable 
carbohydrates in active UC (Nejdfors et al., 1998) and Crohn's (Jenkins et al., 1987) 
but draw their conclusions from a comparison  with healthy individuals, making 
the inference that the increased permeability is due to the IBD diagnosis rather 
than  the  increased  permeability  normally  seen  in  an  inflamed  epithelium.  More 
recent  observational  studies  however  have  shown  an  increased  epithelial     Chapter 1. Introduction 
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permeability in a specific subset of high risk individuals who have not yet been 
diagnosed  with  Crohn's  (May  et  al.,  1993)  and  20%  of  patients  prior  to  a  flare 
(Wyatt  et  al.,  1993).  Both  populations  had  no  signs  of  active  inflammation 
suggesting  a  causal  relationship  to  IBD.  On  a  molecular  level,  both  active  and 
inactive IBD have a differential expression of junctional proteins compared with 
healthy  colon  and  that  these  proteins  can  be  disrupted  in  vitro  by  the 
inflammatory cytokines commonly increased in IBD; TNF-α, INF-γ and IL-13 (Prasad 
et al., 2005). Also, in clinical practice, a feature of successful rescue therapy with 
TNF-α inhibitors is the decreased epithelial permeability, although this appears to 
be  through  a  reduction  in  epithelial  cell  apoptosis  rather  than  an  influence  on 
junctional proteins (Zeissig et al., 2004). 
1.3.4  Dysfunction of the innate immune system in IBD 
Inflammatory  Bowel  Disease  has  long  been  thought  to  be  a  disorder  of  T  cell 
function,  however  the  genetic  association  between  specific  Crohn’s  phenotypes 
and  the  NOD2/CARD15  gene  has  brought  abnormalities  of  the  innate  immune 
system to the fore. 
1.3.4.1  NOD2/CARD15 mutations  
NOD2  is  an  intracellular  PRR  that  is  constitutively  expressed  in  macrophages, 
neutrophils  and  dendritic  cells  (Ogura  et  al.,  2001b),  as  well  as  Paneth  and 
epithelial  cells  (Ogura  et  al.,  2003).  NOD2  is  essential  for  NF-κβ  activation  and 
down-stream  inflammatory  cytokines  production  by  antigens  which  contain  a 
muramyl dipeptide (MDP) moiety. The consequences of loss of function of NOD2 
are  seen  in  the  genetically  inherited  Blau  syndrome  which  is  characterised  by 
multisystem  granulomata.  30%  of  patients  with  Blau  syndrome  suffer  a 
granulomatous colitis akin to Crohn’s. 
Recognition of NOD2 mutations in Crohn’s were first reported in 2001 by Ogura 
et.al. (2001a) and are seen in between 20% and 40% of patients with Crohn’s, these 
patients  tend  to  present  at  an  earlier  age,  follow  a  different  disease  activity 
phenotype and require high rates of surgery (Alvarez-Lobos et al., 2005). Chapter 1. Introduction 
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Three specific NOD2 mutations; Arg702Trp, Gly908Arg and Leu1007fsinsC account 
for 82% of those seen in Crohn’s in Western populations. 90% of the mutations are 
located in the LRR domain of the NLR and  confer a 2-4 fold  risk  of developing 
Crohn’s in heterozygotes and 20-40 fold risk in homozygote carriers (Cuthbert et 
al., 2002). The 3 mutations are however commonly seen in the healthy population 
with  frequencies  of  4.3%,  1.2%  and  2.3%  respectively  (Hugot  et  al.,  2007),  this 
indicates  that  genetic  penetrance  is  low  and  although  associated  with  IBD, 
causation is through an interaction with other unknown risk factors. 
Loss of function mutations of NOD2 can lead to; decreased defensins expression, 
decreased antigen recognition, decreased TCR binding by APCs through decreased 
CD80  and  CD86  expression,  reduced  cytokine  expression  by  leukocytes  and 
decreased  neutrophil  migration  and  function  (Yamamoto-Furusho  and  Korzenik, 
2006)  as  well  as  a  diminished  response  of  macrophages  to  invasion  through 
decreased IL-8 and neutrophil recruitment (Marks and Segal, 2008) and decreased 
DC  activity  with  reduced  autophagy,  bacterial  killing  and  antigen  presentation 
(Cooney et al., 2010). All of these dysfunctions lead to a relative immunodeficiency 
disorder which allows enhanced bacterial survival and invasion. 
1.3.4.2  Monocyte dysfunction 
Dendritic cells play a crucial role in epithelial homeostasis, tolerance to luminal 
flora,  immune  resistance  to  potentially  harmful  luminal  constituents  and  T  cell 
development and function. 
Dendritic cells are influenced by epithelial cells which secrete numerous factors to 
control their function. When exposed to EC derived TGF-β and retinoic acid, DCs 
confer a suppressive role and promote the differentiation of naïve T cells into the 
FoxP3 T
reg lineage (Iliev et al., 2009). Epithelial cells also express other regulatory 
factors  such  as  TSLP  which,  through  influence  on  DCs,  promote  barrier 
homeostasis and a T
H2 favoured inflammatory response. 
Dysfunctional macrophages have also been implicated with IBD through two broad 
mechanisms;  firstly  through  abnormal  bacterial  handling  a  disorder  linked     Chapter 1. Introduction 
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prominently  with  loss  of  function  mutations  in  NOD2,  and  secondly  through 
increased number and / or function of pro-inflammatory macrophages. 
1.3.4.3  Therapies for the innate immune response 
The  contribution  of  the  innate  immune  system  to  the  pathogenesis  of  IBD  is 
reflected through the therapeutic pathways of several established and more novel 
treatments.  Inhibitors  of  TNF-α  and  corticosteroids  affect  macrophages through 
increased apoptosis of pro-inflammatory macrophages and decreased macrophage 
pro-inflammatory  cytokine  release  respectively.  Macrophage  colony  stimulating 
factor  (GM-CSF)  and  granulocyte  colony  stimulating  factor  (G-CSF)  are  growth 
factors  that  enhance  important  functions  in  the  epithelial  and  phagocytic 
components of the innate immune system. Initial studies of recombinant GM-CSF 
(Sargramostim) in moderate to severe Crohn's achieved a remission rate of 53% at 
8  weeks  (Dieckgraefe  and  Korzenik,  2002)  and  although  a  larger  randomised 
placebo controlled trial failed to achieve the earlier promising results it did show a 
significant improvement in CDAI score and quality of life measurement (Korzenik 
et al., 2005). Together these observations not only suggest a direct influence of 
the  innate  immune  system  in  the  pathogenesis  of  IBD  but  also  that  therapies 
aimed at improving the innate immune response have exciting potential. 
1.3.5  Dysfunction of the adaptive immune system in IBD 
The hallmark of IBD  is  a polarised  T cell  response driven by abnormal antigen 
processing by APCs. The T cell response in IBD has 2 separate characteristics, the 
first is an increase in the ratio of pro-inflammatory to suppressive T cells subsets 
in the peripheral circulation as well as the intestinal mucosa (Eastaff-Leung et al., 
2009).  The  second  characteristic  is  abnormal  behaviour  of  those  lymphocytes 
resulting in hyper-reactive pro-inflammatory T cells or hypo-reactive suppressive T 
cells (Strober et al., 2007). 
Mucosal lymphocytes were first described in 1847 (cited by Dobbins, 1986 p972) 
and have been studied closely in IBD for over 40 years (Selby et al., 1981, Selby et 
al., 1984, Caballero et al., 1995). Over recent years numerous distinct T cell subsets 
have  been  identified,  many  of  which  have  abnormalities  of  number  or  function Chapter 1. Introduction 
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associated with IBD. The T cells which have been most prominently linked to the 
aetiology  of  IBD  include  the  CD4
+  helper  T  cells;  T
H1,  T
H2,  T
H17  and  T
regs.  Other 
lymphocyte subsets also increasingly implicated are the NK cells, CD8
+, B cells and 
CD5
+ cells. 
The  T  cell  population  is  increased  in  active IBD  by  2-3  fold  compared  with  the 
mucosa of healthy individuals, although the balance of CD4
+ to CD8
+ is unaltered. 
In both normal mucosa and that of inflamed IBD, CD4
+ T cells predominate in the 
lamina propria, and CD8
+ cytotoxic cells predominate in the intraepithelial layer 
(Selby et al., 1984, Caballero et al., 1995).  
The increased T cell population seen in IBD is a result of either sequestration of 
lymphocytes  from  the  periphery  under  the  control  of  chemotaxic  factors  or 
increased central or peripheral differentiation of effector cells from naïve T cells, 
these issues along  with functional changes in the cells of the adaptive immune 
system are discussed separately for the individual T cell subsets. 
1.3.5.1  Regulatory T cell 
Regulatory T cells play a crucial role in the maintenance of immune homeostasis. 
In mouse models they have been shown to prevent or reverse inducible colitis and 
in  humans  an  imbalance  of  T
reg  numbers  and/or  function  is  associated  with  a 
number  of  autoimmune  conditions,  transplant  rejection,  inability  to  develop 
tolerance and the exaggerated pro-inflammatory response characteristic for IBD. 
In  the  actively  inflamed  mucosa  of  individuals  with  IBD  the  number  of  T
regs  is 
increased,  coinciding  with  a  decrease  in  the  number  of  T
regs  in  the  peripheral 
circulation (Maul et al., 2005, Eastaff-Leung et al., 2009, Holmen et al., 2006). In 
non-IBD colitis the increase in mucosal T
regs is even greater and coincides with an 
increase  in  the  number  of  peripheral  T
regs  (Maul  et  al.,  2005).  In  non-inflamed 
mucosa  of  both  IBD  patients  and  healthy  individuals  there  are  only  a  small 
numbers  of  T
regs,  but  in  areas  of  inflammation  in  the  same  patients  there  are 
increased numbers of T
regs. Taken together, these results suggest that not only is 
the  T
reg  pool  in  IBD  smaller  than  in  healthy  individuals,  but  there  may  be 
dysfunctional trafficking to areas of inflammation. Potential abnormalities include     Chapter 1. Introduction 
45 
dysfunction  of  production,  decreased  T
reg  stability  and  survival  or  de-
differentiation into other T cell phenotypes. 
T
regs are produced centrally in the thymus or differentiated peripherally from naïve 
T  cell  precursors  (T
H0  cells).  Under  the  influence  of  TGF-β  and  IL-6,  T
H0  cells 
differentiate  into  either  T
regs  or  T
H17  cells  establishing  a  reciprocal  balance 
between  inflammation  and  regulation  (Siddiqui  and  Powrie,  2008,  Kimura  and 
Kishimoto,  2010).  Under  normal  conditions  the  potentially  deleterious  effect  of 
luminal  substances  or  microflora  is  suppressed  through  the  enhanced 
differentiation and function of T
regs by the secretion of TGF-β by dendritic cells (Cai 
et al., 2010) and / or other factors. In the presence of STAT3 mediated signals, IL-6 
(or IL-23) T
H0 cells differentiate into T
H17 cells at the expense of T
regs, allowing the 
inflammatory  response  to  override  T
reg  suppression  and  promote  host  defence. 
Imbalance of T
regs / T
H17 is a feature of IBD although the exact mechanism of this is 
unknown  (Kimura  and  Kishimoto,  2010)  but  may  include  abnormalities  within 
pathways involving IL-6, -21, and IL-23 amongst others (Eastaff-Leung et al., 2009).  
However, central to the differentiation, stability, survival and function of T
regs is the 
transcription factor FoxP3, through which the factors mentioned above function. 
FoxP3 is encoded by the FOXP3 gene, in humans, loss of function mutations result 
in  the  IPEX  (Immunodysregulation,  Polyendocrinopathy,  Enteropathy  X-linked) 
syndrome,  and  in  mice  deficiency  results  in  multisystem  inflammation  and 
autoimmunity and a susceptibility to colitis. FOXP3 mutations are not known in 
IBD although pathways involving the FoxP3 transcription factor and downstream 
pathways are central to the idea of T
reg dysfunction in IBD. 
Increased expression of FoxP3 results in increased number and activity of T
regs, it 
classically  occurs  through  induced  phosphorylation  of  the  SMAD  complex  and 
STAT5  as  a  result  of  TGF-β  and  IL-2.  Recently  the  differential  expression  of  5 
miRNAs  have  been  demonstrated  in  T
regs,  two  of  which,  miR-21  and  miR-31  are 
associated  with  abnormal  FOXP3  expression  (Rouas  et  al.,  2009)  and  are 
differentially  expressed  in  the  mucosa  of  IBD  (Fasseu  et  al.,  2010).  FOXP3 
expression  drives  approximately  13  different  mechanisms  through  which  T
regs 
exert their suppressive function; TGF-β, IL-2, CTLA4, IL-10 and IL-35 expression in Chapter 1. Introduction 
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humans, and in-vitro experiments; Granzyme B, Perforin,  IFN-γ, IL-9, HO-1, cAMP, 
Galectins and adenosine (Tang and Bluestone, 2008). 
Continued  stability  and  function  of  T
regs  requires  TGF-β,  IL-2  and  miRNAs 
(discussed later). The lack of TGF-β and IL-2 stimulation is demonstrated in TGF-β
-/- 
and IL-2
-/- knockdown mice which succumb to fatal inflammation in much the same 
way  as  FOXP3
-/-  mice  do,  transfer  of  T
regs  abrogates  this.  Lack  of  on-going 
stimulation reduces T
reg numbers by either death or dedifferentiation. In adoptive 
transfer models about 10-15% of T
regs lose their expression of FOXP3 resulting in a 
reduced expression of CD25, CTLA-4 and GITR and increased IL-2. 
Decreased  production  of  FoxP3  occurs  as  a  result  of  IL-6,  IL-4,  and  strong  TCR 
signals through STAT6, GATA3, and mTOR, respectively, continued loss of FoxP3 
production  can  lead  to  a  change  of  phenotype  from  T
regs  to  T
H17  cells  with  an 
increased expression of IL-2 and IFNγ, a process known as plasticity (Zhou et al., 
2009).  
1.3.5.2  TH1 / TH2 
Precursor T
H0 lymphocytes differentiate into T
H1, T
H2 or other cell types depending 
on  the  cytokine  milieu;  see  section  1.2.4.3.1  and  Figure  7.  Traditional  theories 
describe Crohn’s as a  T
H1 mediated inflammatory condition  with an  increase  in 
cytokines IL-12, IFN-γ and TNF-α, and UC as a T
H2 mediated inflammatory condition 
with an increase in cytokines IL-4 and IL-13. However rather than being mutually 
exclusive to either UC or Crohn’s, T
H1 and T
H2 responses are exaggerated in both 
diseases along  with a complex  interplay of other inflammatory and/or cytokine 
responses associated with other cell types. 
1.3.5.3  TH17 cells 
There  is  an  established  relationship  between  T
H17  cells,  the  pro-inflammatory 
cytokine  IL-17  and  IBD  (Nielsen  et  al.,  2003).  Total  numbers  of  T
H17  cells  are 
increased in the peripheral blood of individuals with inactive IBD (Eastaff-Leung et 
al.,  2009),  and  IL-17  expression  is  enhanced  in  the  intestinal  mucosa  and 
peripheral blood lymphocytes of Crohn’s (Fina et al., 2008)  and mucosal CD4
+ T 
cells in resected UC (Kobayashi et al., 2008).     Chapter 1. Introduction 
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What drives the increased differentiation and / or effector function of T
H17 cells in 
IBD  is  largely  unknown.  Experimental  models  have  shown  opposing  roles  for 
bacteria  between  the  small  and  large  intestine;  in  the  small  intestine  bacteria 
appear necessary for IL-17 production (Ivanov et al., 2008) through mechanisms 
which include APC derived IL-6, IL-23 and TGF-β (Atarashi et al., 2008), compared 
with  the  large  intestine  in  which  the  absence  of  bacteria  is  associated  with  a 
higher level of IL-17 due to the loss of bacteria derived IL-25 (IL-17E) which would 
normally counter-regulate IL-23 produced by lamina propria macrophages (Zaph et 
al., 2008). 
The  genetic  link  to  dysfunction  of  the  T
H17  cell  lineage  is  underpinned  by  the 
recent discovery of many genetic susceptibility loci which are involved in IL23 / 
T
H17  signalling,  including;  IL23R,  IL12B,  JAK2,  TYK2,  STAT3,  IL10,  IL1R2,  REL, 
CARD9,  NKX2.3,  ICOSLG,  PRDM1,  SMAD3  and  ORMDL3  (Lees  et  al.,  2011).  The 
interplay between these loci and T
H17 / IL-17 imbalance has yet to be determined. 
1.3.6  Loss of tolerance 
Tolerance  is  the  mechanism  that  prevents  the  immune  system  triggering  an 
inflammatory response to antigens that are not harmful. There are 2 aspects of 
tolerance;  the  first  is  tolerance  to  self-antigens,  the  second  is  tolerance  to  the 
commensal luminal flora. 
Tolerance  to  self-antigens  is  created  centrally  in  the  thymus  and  bone  marrow 
during  lymphocyte  development,  and/or  peripherally  through  suppression  of 
active  self-reactive  lymphocytes.  Breakdown  of  these  mechanisms  is  a 
characteristic of autoimmune diseases, and although not a recognised feature IBD 
there  is  an  aspect  of  autoimmunity  that  may  play  a  part  in  IBD.  “Molecular 
mimicry” is a process in which an antigen creates an appropriate response and is 
cleared,  but  due  to  the  similarity  between  it  and  normally  innocuous  luminal 
contents or self-antigens an autoimmune response can ensue and perpetuate the 
initial inflammation (Oldstone, 1998). 
Continuous  exposure  to  commensal  flora  is  essential  for  the  maintenance  of 
epithelial homeostasis and protection against injury (Rakoff-Nahoum et al., 2004). Chapter 1. Introduction 
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Exposure and the development of tolerance to commensal non harmful bacteria is 
achieved through luminal sampling and bacterial translocation, both of which are 
normal processes and result in bacteria or components of bacteria being present 
in the lamina propria (Swidsinski et al., 2002) and regional lymph nodes of healthy 
individuals. 
A feature of IBD is the loss of tolerance to commensal flora. Many different mouse 
models  that  are  rendered  susceptible  to  colitis  through  gene  knockout  have 
shown  that  commensal  bacteria  are  required  to  induce  inflammation;  growth 
under  germ  free  conditions  abrogates  this.  In  humans,  inflammation  can  be 
likewise  avoided  by  removing  commensal  bacteria  by  faecal  stream  diversion 
(Harper et al., 1985). The adaptive immune system in IBD demonstrates increased 
numbers of activated T cells against luminal antigens, and increased levels of IgG 
secretion  in  the  mucus  and  mucosal  epithelium.  Together  this  shows  that  the 
presence  or  abnormal  processing  of  commensal  bacteria  is  required  to  trigger 
inflammation  and  that  the  immune  system  in  IBD  is  hyper-responsive  to 
commensal,  normally  harmless,  bacteria.  Abnormal  bacterial  processing  by 
mutations in NOD2/CARD15 gene have also been suggested mechanisms (Guarner 
and Malagelada, 2003). 
1.3.7  Other  aetiological  associations  with  IBD  and  their 
effects on the immune system 
The following broad areas have all been implicated in the aetiology of IBD. 
1.3.7.1  Influence of genetics 
In  recent years  sub-populations  based on genetic or  immunological phenotypes 
have emerged which, show marked differences in disease outcome  (Targan and 
Karp, 2005). The most obvious indication of the association of genetics and IBD is 
the increased incidence of IBD within families and racial groups. There is a high 
concordance rate between monozygotic twins, for UC it is 10-15% and for Crohn’s 
30-35%.  Certain  racial  groups  have  a  higher  prevalence  rate  of  IBD  including 
northern Europeans and Ashkenazi Jews.     Chapter 1. Introduction 
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Early HLA linkage studies suggest an increased risk of UC and Crohn’s for people 
who carry the HLA-DR2 and HLA-DR1 subtypes respectively, although these links 
are inconsistent (Naom et al., 1996). In 2001, a NOD2 frame shift mutation was 
first reported as a risk factor for Crohn’s (Ogura et al., 2001a). By December 2011 a 
total  of  99  susceptibility  loci  have  now  been  identified  for  IBD,  71  for  Crohn’s 
(Franke et al., 2010) and 47 for UC (Anderson et al., 2011), 30 of which are present 
in both forms of IBD (Lees et al., 2011). 
Between 20% and 40% of Crohn’s have variants in the NOD2 gene and those with 
NOD2  mutations  are  more  likely  to  present  at  an  earlier  age,  have  a  more 
aggressive disease phenotype, 3.6 times more likely to have stricturing disease, 
and  require  surgery  (Alvarez-Lobos  et  al.,  2005).  Other  prominent  gene 
associations with Crohn’s include those that influence bacterial handling; ATG16L1 
and IRGM, both involved with autophagy. In ulcerative colitis the IL12B gene (T
H17 
cell function) is prominent. 
The  influence of genetic variants is  stronger  for Crohn’s than UC,  although the 
incomplete  penetrance  suggests  other  factors  play  a  role.  There  is  also  an 
important  difference  between  racial  groups  with  IBD  and  genetic  variants,  for 
example the NOD2 mutation is less commonly seen in the Asian population with 
Crohn’s compared with whites. 
1.3.7.2  Environment influences 
Inflammatory Bowel Disease was a rare diagnosis in Asia until the 1980s, but the 
incidence is climbing (Ahuja and Tandon, 2010), and although the point prevalence 
remains well below that of western countries, the total numbers of people with 
IBD is rapidly increasing. The general consensus is that this increase is due to a 
western lifestyle and changing environmental influences (Mowat et al., 2011). 
This pattern of increased incidence is also seen within Europe in people who have 
emigrated  from  less  developed  areas  (Barreiro-de  Acosta  et  al.,  2011).  Taken 
together the increasing rates within populations previously thought to have a low 
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suggest that environmental factors related to industrialisation play an important 
role in the aetiology of IBD, particularly UC (Barreiro-de Acosta et al., 2011). 
One  suspected  environmental  factor  is  the  lack  of  exposure  to  environmental 
pathogens  immediately  after  birth  and  in  childhood.  During  development,  the 
immune system is influenced by orally consumed environmental pathogens, lack 
of  exposure  and  the  resulting  decreased  oral  tolerance  is  the  key  idea 
underpinning the “Hygiene hypothesis” (Strachan, 1989). 
Other environmental and childhood factors which alter immune development and 
influence  the  risk  of  subsequently  developing  IBD  include  breast  feeding, 
tonsillectomy,  appendectomy,  immunisation  and  common  childhood  infections 
such  as  measles  and  chicken  pox  (Hansen  et  al.,  2011).  Other  environmental 
influences  include  tobacco  (Silverstein  et  al.,  1989),  pollution,  diet,  oral 
contraceptive pill and non-steroidal anti-inflammatory drugs (Hansen et al., 2011). 
Cigarette  smoke  is  of  particular  interest  due  to  the  strong  protective  effect  of 
cigarette smoke in UC and the opposing increased association with Crohn’s. The 
exact mechanism has not been defined but in their review McGilligan et al. (2007), 
suggest several components of cigarette smoke interfere with various aspects of 
the  immune  system  including  effects  on  epithelial  integrity  and  the  T
H1/T
H2 
balance. 
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1.4  MicroRNA 
1.4.1  Before microRNA 
Although  a  modern  phenomenon  the  story  of  MicroRNA  (miRNA)  can  be  traced 
back over 50 years to the work of Jaques Monad, Andre Lwoff and Francis Jacob 
who  were  awarded  the  1965  Nobel  Prize  for  Medicine  “for  discoveries  into  the 
genetic control of enzyme and virus synthesis”. Their work involved the synthesis 
of a simple sugar (lactose) in bacterium and its control by a gene repressor which 
they believed to be RNA; unfortunately they were only ever able to isolate proteins. 
A quarter of a century later, Professors Altman and Čech received the Nobel Prize 
for Chemistry in 1989 for their independent contributions to the discovery of the 
catalytic  properties  of  RNA
4.  Prior  to  their  discoveries  in  the  early  1980’s  only 
proteins were thought to have catalytic properties and the sole role of RNA was to 
act  as  a  messenger  molecule  between  the  genetic  code  stored  in  DNA  and  the 
cellular mechanism responsible for protein synthesis. 
The discovery that RNA has properties other than those of a messenger has two 
important  implications;  the  first  is  an  explanation  of  how  genetic  code  can  be 
deciphered and proteins synthesised in the absence of enzymes, a fundamental 
question in evolution, the second paved the way to work on RNA as a regulator of 
gene expression. 
In the late 1980s it was noticed that the Lin-4 gene controls the progress of C. 
Elegans from the first larval stage to the second, but what was interesting is that 
Lin-4 does not code for a protein, it codes for a pair of short length RNAs (Ambros, 
1989). It was also noticed that the Lin-4 RNAs had antisense complementarity to 
multiple sites in the 3’ UTR of the Lin-14 gene, and that increased lin-4 expression 
reduced the amount of Lin-14 protein without reducing the level of Lin-14 mRNA. 
Together  this  shows  that  Lin-4  RNAs  pair  to  the  Lin-14  3’UTR  to  specify 
translational repression of the Lin-14 pathway (Lee et al., 1993, Wightman et al., 
1993). 
                                              
4 The Novel Prize in Chemistry 1989 presentation speech given by Professor Bertil Andersson gives a 
succinct account of the background to the work of both Altman and Čech and the origins of RNA as 
enzymes. Available at http://nobelprize.org (accessed 10th Oct 2011). Chapter 1. Introduction 
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The  next  two  breakthroughs  came  in  2000  with  the  identification  of  a  second 
gene, let-7 (Reinhart et al., 2000). Let-7 is again involved in the larval development 
of C. Elegans, but the important discovery is that it is conserved across species, 
including  humans  (Pasquinelli  et  al.,  2000).  Within  one  year  another  30  short 
length RNAs were identified in humans and this abundant class of short length 
RNA was given the name miRNA (Lagos-Quintana et al., 2001, Lau et al., 2001, Lee 
and Ambros, 2001). 
1.4.2  MicroRNA 
MicroRNAs  are  a  family  of  single-stranded  and  short-length  RNA  (19-23nt)  that 
exert  their  effect  on  gene  regulation  and  cell  phenotype  by  preventing  the 
translation of mRNAs into protein (Bartel, 2004). To date 1600 human precursor, 
and 2042 mature miRNA sequences have been registered on miRBase release 19 
(Aug, 2012), these follow nomenclature rules outlined Table 12. 
 
Example miRNA = has-miR-146a-5p 
hsa  Tells us it is human, homo sapian 
miR  Capitalisation  of  the  “R”  infers  that  the  miRNA  is  the  mature 
sequence, opposed to “r” which refers to the miRNA precursor, the 
genomic locus, the primary transcript, or the extended hairpin that 
includes the precursor. 
29  Named sequentially, this miRNA belongs to the 29 family. The same 
number is used for miRNA of different species that are orthologous, 
but conveys no information about functionality.  
b  Paralogous miRNAs that differ in 1 or 2 nt. 
-5p/-3p  the same mature miR originate from opposite arms of the same pre-
miRNA  
Table 12 Mature miRNA terminology, used by miRBase. There are 5 
sections to the nomenclature (Ambros et al., 2003). 
A canonical schematic of miRNA biogenesis is shown in Figure 8, although each 
step  can  be  achieved  through  alternative  pathways  (Winter  et  al.,  2009,  Bartel, 
2004). The majority of miRNA genes are intergenic and transcribed from the DNA 
template independently by RNA polymerase 2. However between 20% and 40% of 
human  miRNA  genes  originate  in  the  introns  of  larger  protein  and  non-protein     Chapter 1. Introduction 
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genes  or  the  exons  of  long  protein  coding  transcripts,  and  are  therefore 
transcribed and regulated along with their host genes. It follows that the highly 
conserved relationship between miRNA and host mRNA is due to the necessity for 
a  coordinated  expression,  although  no  example  exists  in  humans,  mir-7  is  a 
striking example of this phenomenon in insects and lower order mammals (Aravin 
et al., 2003). 
MiRNAs are usually transcribed by RNA polymerase 2 which binds to a promoter 
region within the DNA sequence found near the hairpin loop of the pre-miRNA. The 
stem  loop  sequence  forms  part  of  a  long  polycistronic  miRNA  precursor,  pri-
miRNA,  which  may  contain  up  to  6  miRNA  precursors.  Alternatively  RNA 
polymerase 3 transcribes certain miRNA, especially those with Alu sequences. 
 
 
Figure 8. A schematic of miRNA biogenesis Chapter 1. Introduction 
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The pri-miRNA is recognized by a nuclear protein known as DiGeorge Syndrome 
Critical Region 8 (DGCR8) which associated with the enzyme Drosha. Together the 
Drosha / DGCR8 complex utilises the catalytic component of Drosha, RNase 3, to 
liberate  the  70-80nt  hairpin  structure  termed  pre-miRNA  (precursor-miRNA). 
Importantly,  RNase  3  leaves  a  two-nucleotide  overhang  at  its  3’  end  which  is 
required for nuclear export to the cytoplasm. Alternatively pre-miRNAs are spliced 
directly from introns, bypassing the Drosha / DGCR8 complex, these products are 
known as “Mirtrons” and have recently been found to exist in mammals (Berezikov 
et al., 2007). 
Pre-miRNAs  are  exported  from  the  nucleus  in  a  process  involving  the 
nucleocytoplasmic  shuttle  Exportin-5,  which  recognises  the  two-nucleotide 
overhang left by RNase 3 processing. 
In the cellular cytoplasm the pre-miRNA hairpin is cleaved by the RNase III enzyme 
Dicer. Dicer recognises the 3’ end of the hairpin and cuts away the loop resulting 
in a miRNA:miRNA duplex about 22nt in length. Only one strand is usually then 
incorporated  into  the  RNA-induced  silencing  complex  (RISC)  based  on  its 
thermodynamic stability and strength of base pairing relative to the other strand, 
although either end could potentially act as a functional miRNA 
RISC  is  the  functional  component  of  the  process,  and  contains  multiple 
independent  elements  including  members  of  the  Argonaute  (Ago)  family,  TRBP 
(transactivating  response  RNA  binding  protein),  PACT  (protein  activator  of  the 
interferon induced protein kinase), the SMN complex, fragile X mental retardation 
protein  (FMRP),  and  Tudor  staphylococcal  nuclease-domain-containing  protein 
(Tudor-SN). 
Argonauts are the most important components of RISC. Argonauts bind the mature 
miRNA through two RNA binding domains: a PAZ domain that can bind the single 
stranded 3’ end of the mature miRNA and a PIWI domain which interacts with the 
5’  end  of  mature  miRNA.  Binding  orientates  the  miRNA  for  interaction  with  the 
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Gene silencing  occurs  through  mRNA degradation or by preventing mRNA from 
being translated. 
The  association  between  miRNA  and  the  immune  system  began  in  2004  when 
Chen et al observed the selective expression of miR-142a, miR-181a and miR-223 
in  immune  cells  (Chen  et al.,  2004).  Since  this  initial  observation,  miRNAs  have 
been associated with the maturation, proliferation, differentiation and activation 
of immune cells (Cobb et al., 2005, Cobb et al., 2006). At least 28 miRNAs have 
been established as integral to the proper function of many aspects of the immune 
system including; B cell development (miR-150 and miR-17), granulopoiesis (miR-
223),  immune  function  generally  (miR-155  and  miR-146)  and  B  cell 
lymphoproliferative disorders (miR-155 and miR-17), reviewed by Tili et al. (2008), 
O’Connell  et  al.  (2010)  and  Garzon  and  Croce  (2008).  Many  more  have  been 
associated  with  the  aetiology  of  numerous  autoimmune  and  inflammatory 
conditions. 
1.4.3  MicroRNA in IBD 
MicroRNAs  are  essential  for  the  normal  function  of  inflammatory  cells  and 
immune  homeostasis. Interruption of miRNA biogenesis, using  either Drosha or 
Dicer knockout mice promotes Inflammation of the colon, decreased regulatory T 
cell function and rapidly fatal autoimmunity (Chong et al., 2008, Cobb et al., 2006). 
There  is  growing  evidence  that  specific  miRNAs  play  a  crucial  role  in  immune 
regulation  and  the  aetiology  of  IBD.  There  are  4  prominent  miRNA  expression 
profiles reported in the literature for UC and Crohn’s (Wu et al., 2008, Wu et al., 
2010, Fasseu et al., 2010, Van der Goten et al., 2012). The first group to publish a 
miRNA  profile  for  UC  was  Wu  et  al.  (2008)  who  studied  the  expression  of  553 
miRNAs by array and showed the altered expression of 18 miRNAs, of which 11 
were confirmed with qPCR. More recently Fasseu et al. (2010) have used TaqMan
TM 
MicroRNA Array (Applied Biosystems) to study 321 miRNAs and Van der Goten et 
al. (2012) used the Affymetrix GeneChip® miRNA 2.0 array to study 1105 miRNAs. 
The pooled results show that 72 miRNAs have either an increased or decreased 
expression  in  IBD,  although  only  14  miRNA  are  reported  as  differentially 
expressed by 2 or more of the 4 studies, Table 13 and Table 14. Chapter 1. Introduction 
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Reference  Tissue  phenotype  increased  decreased  comment 
Wu et al. 
(2008) 
Mucosal 
biopsies 
Active 
disease 
miR-16 
miR-21 
miR-23a 
miR-24 
miR-29a 
miR-126 
miR-195 
Let-7f 
miR-192 
miR-375 
miR-422b 
 
Fasseu et al. 
(2010) 
Mucosal 
biopsies 
Active 
disease 
miR-7 
miR-31 
miR-135b 
miR-223 
 
5/8 (63%) patients on a 
disease modifying 
agent. Phenotype 
excluded total colitis. 
Array cut of is fold 
difference >5 or <0.2 
Quiescent 
mucosa in 
patient with 
active UC 
miR-196a   
Histological grade 1 
included as non-
inflamed, therefore 
some signs of 
inflammation present 
microscopically 
Active and 
quiescent 
mucosa 
miR-29a 
miR-29b 
miR-126 
miR-127-3p 
miR-324-3p 
miR-188-5p 
miR-215 
miR-320a 
miR-346 
Those miRNA which 
show a differential 
expression in both 
active and non-active 
inflammation in the 
same colon at the 
same time 
Quiescent UC 
miR-29a 
miR-29b 
miR-30c 
miR-126 
miR-127-3p 
miR-196a 
miR-324-3p 
miR-188-5p 
miR-199a-3p 
miR-199b-5p 
miR-215 
miR-320a 
miR-346 
miR-370 
 
Van der 
Goten et al. 
(2012) 
Mucosal 
colon 
biopsies 
Active 
disease 
let-7i-5p 
miR-21-3p 
miR-21-5p 
miR-27a-5p 
miR-29b-1-5p 
miR-29b-2-5p 
miR-31-5p 
miR-99b-3p 
miR-138-5p  
miR-146a-5p 
miR-146b-3p 
miR-146b-5p 
miR-150-5p 
miR-155-5p 
miR-193-5p 
miR-212-3p 
miR-223-3p 
miR-363-3p 
miR-503 
miR-551b-5p 
miR-584-5p 
miR-650  
miR-665 
miR-708-5p 
miR-1273d 
miR-1972 
miR-10b-3p 
miR-10b-5p 
miR-141-3p 
miR-147b 
miR-192-3p 
miR-192-5p 
miR-194-3p 
miR-194-5p 
miR-196a-5p 
miR-196b-3p 
miR-196b-5p 
miR-200a-3p 
miR-200a-5p 
miR-200b-3p 
miR-200b-5p 
miR-215 
miR-3201 
miR-335-5p 
miR-375 
miR-378-3p 
miR-378-5p 
miR-378c 
miR-422a 
miR-4284 
miR-429  
miR-1973 
Undefined patient 
group 
Table  13.  miRNAs  that  are  differentially  expressed  in  UC.  Three 
studies which use differing microarray techniques to discover which 
miRNAs are differentially expressed in the mucosa in UC.     Chapter 1. Introduction 
57 
Reference  Tissue  phenotype  increased  decreased  comment 
Wu et al., 
(2010) 
Mucosal 
biopsies 
Active  colonic 
CD 
miR-23b 
miR-106 
miR-191 
miR-19b 
miR-629   
Terminal  ileal 
CD 
miR-16 
miR-21 
miR-223 
miR-594 
   
Colon  region 
specific 
differential 
expression 
miR-31 (TI) 
miR-215 (TI) 
miR-22 (TI) 
miR-422b 
(caecum) 
miR-23a 
(sigmoid) 
miR-126 
(transverse 
colon  and 
rectum) 
miR-7d  (TI  and 
sigmoid) 
miR-19b (TI) 
miR-26a 
(caecum and 
transverse 
colon) 
miR-320  (TI 
and rectum) 
 
Fasseu et al., 
(2010) 
Mucosal 
biopsies 
Active disease 
miR-9 
miR-126 
miR-130a 
miR-181c 
miR-375 
Inclusion  criteria 
following  the  array, 
RQ  >5  or  <0.2,  all 
p<0.05 
Non inflamed 
miR-9 
miR-30a 
miR-30c 
miR-223 
Active and non 
inflamed 
miR-26a 
miR-29b 
miR-30b 
miR-34c-5p 
miR-126 
miR-127-3p 
miR-133b 
miR-155 
miR-196a 
miR-324-3p 
miR-21 
miR-22 
miR-29c 
miR-31 
miR-106a 
miR-146a 
miR-146-5p 
miR-158 
Table  14.  miRNAs  that  are  differentially  expressed  in  Crohn’s 
disease. Two studies which use differing microarray techniques to 
discover which miRNAs are differentially expressed in the mucosa in 
UC. 
The  poor  concordance  between  the  studies  is  likely  to  represent  sample 
heterogeneity and differing study design. Interpreting and applying the results are 
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heterogeneity. Characteristics  which are combined  into the same group  include; 
treatment  differences  as  diverse  as  not  treated  versus  steroid  or  biological 
therapy,  phenotype  differences  such  as  distal  verses  extensive  disease,  sample 
differences  taken  from  urgent  colectomy  versus  surveillance  biopsies  or  tissue 
from  the  distal  versus  the  proximal  colon.  To  be  clinically  relevant  the  patient 
characteristics  must  be  homogeneous  and  grouped  into  clinically  relevant  and 
distinguishable groups. 
Studies  into  the  impact  of  differentially  expressed  miRNAs  in  IBD  are  in  their 
infancy,  although  their  influence  on  several  mechanisms  has  been  suggested 
including; crosstalk between epithelial cells and the innate immune system (Biton 
et  al.,  2011)  and  influence  on  the  differentiation  of  T
H1  lymphocytes  and  the 
adaptive immune system (Tili et al., 2007). 
The limited work on IBD is in contrast to the vast number of studies which have 
implicated miRNAs in the development of colitis in experimental models. Although 
induced colitis is an entirely different condition to IBD, interpreted correctly, the 
ideas  and  themes  provided  by  experimental  models  provide  important  clues 
regarding the causes of IBD in humans. 
MiR-155 in particular has been implicated in numerous biochemical pathways that 
regulate  the  immune  response.  In  the  innate  immune  system,  miR-155  is 
expressed by macrophages in response to stimulation by LPS, IFN-γ, TNF-α and IL-
1β.  (Ceppi  et  al.,  2009)  In  dendritic  cells,  miR-155  controls  the  intensity  of  the 
inflammatory response by down regulating IL-1β and IL-6. In the adaptive immune 
system  miR-155  shows  greatly  increased  expression  in  activated  B  and  T  cells. 
(Rodriguez et al., 2007) In miR-155 null mice, CD4
+ cells are biased towards T
H2 
differentiation  (Rodriguez  et  al.,  2007)  and  the  production  of  T
regs  are  greatly 
reduced (Kohlhaas et al., 2009) through the targeting of SOCS1. 
Many miRNAs have been shown to be involved in lymphocyte function in animal 
models (Ceppi et al., 2009, Tsitsiou and Lindsay, 2009), although extrapolation into 
human disease must take into account the poor concordance between mouse and 
human lymphocytes, the differing miRNA signature between lymphocyte subsets     Chapter 1. Introduction 
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(Rossi et al., 2011) and the uncertain functional concordance between miRNAs that 
are given the same numerical name across species. 
A T cell subset of particular interest in IBD is the regulatory T cell. Dysfunction is 
associated  with  experimental  and  human  colitis.  Numerous  miRNAs  have  been 
shown to be differentially expressed  in human T
regs,  Table  15, and  shown to be 
important for T
reg stability (Zhou et al., 2009). 
 
  Differentially expressed miRNA  Tissue type  reference 
T
reg (CD4
+CD25
+) 
Increased 
MiR-491 
miR-21 
miR-425-5p 
miR-586 
miR-181c 
miR-340 
miR-26b 
miR-374 
Human  Umbilical 
cord  blood  using 
TaqMan®  low 
density Array 
Rouas et al (2009) 
Decreased  miR-31 
miR-125a 
Table 15. Differentially expressed miRNA in human T
regs 
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1.5  Aims and Objectives  
It is clear that in health miRNA play an important role in the regulation of many 
inflammatory pathways. Loss of regulation through the abnormal  expression of 
certain miRNAs is associated with many inflammatory processes. It follows that 
the initiation and / or perpetuation of IBD is likely to fall under the influence of a 
number of abnormally expressed miRNAs. 
The aim of this thesis is to demonstrate that there is an altered expression of a 
distinct group of miRNAs in the intestinal mucosa of patients with active UC, and 
to  demonstrate  that  the  altered  expression  of  these  miRNAs  influences  the 
function of immune cells leading to a pro-inflammatory state which predisposes to 
or propagates IBD. 
The objectives are: 
1.  To show that there is the abnormal expression of certain miRNAs  in the 
intestinal mucosa of patients with active sigmoid UC. 
2.  To  demonstrate  the  abnormal  expression  of  miRNAs  in  mucosal 
lymphocytes and mucosal CD4
+ lymphocytes in patients with UC. 
3.  To identify a miRNA target. 
4.  To  demonstrate  that  miRNA  expression  influences  the  expression  of  the 
target gene product.  
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2.1  Equipment and materials 
2.1.1  Capital equipment  
7900HT Fast Real-Time PCR System (Applied Biosystems™, USA) 
MagNA Lyser (Cat # 03358968001, Roche Applied Science, UK) 
DNA Engine, Tetrad™ 2 thermal cycler (Bio-Rad Life Sciences, Ca, USA) 
Spectrophotometer, NanoDrop® ND-1000 (NanoDrop Technologies Inc, DE, USA) 
Centrifuge 5417R (eppendorf, UK) 
  Used to centrifuge 1.5 ml reaction tubes 
Centrifuge 5810R (eppendorf, UK) 
  Used to centrifuge FACS tubes, 15 ml and 50 ml centrifuge tubes 
Centrifuge Sorvall® Legend T (Kendro Laboratory Products, Germany) 
  Used to centrifuge PCR and microarray plates 
Freezing  container,  Nalgene®  Mr  Frosty  (Nalgene,  Cat  #  5100-001,  Thermo 
Scientific, USA) 
Dynatech MR7000 microplate reader (Dynatech Technologies, Billinghurst, UK) 
Magnetic stirrer (Cat # PS6001, Electrothermal Engineering, UK) 
BD FACS Aria I flow cytometer (BD Biosciences, Ca, USA) 
2.1.2  Software  
RQ manager version 1.2, (Applied Biosystems™, USA, copyright 2005). 
ABI  PRISM®  7900HT  Sequence  detection  system  (SDS)  v2.3  software,  (Applied 
Biosystems™, USA, copyright 2005). 
GraphPad  Prism  version  5.00  for  Windows,  (GraphPad  Software,  San  Diego, 
California, USA). www.graphpad.com Chapter 2. Materials and Methods 
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Microplate Manager® Software version 6.1 (Bio-Rad Laboratories, Inc.USA) 
BD FACSDiva™ software v6.0 (BD Biosciences, Ca, USA) 
2.1.3  Reagents and general consumables 
   Product code and manufacturer 
General consumables 
 
48 well culture plate  Cat # 677102, Greiner Bio-one, Germany 
24 well culture plate  P/N 3524, Corning Inc, USA 
50 ml Polypropylene centrifuge tubes  P/N 430290, Corning Inc, USA 
15 ml Polypropylene centrifuge tubes  P/N 430791, Corning Inc, USA 
50 mls Polystyrene multipurpose 
containers 
Cat # 219175, Greiner Bio-One, UK 
Polypropylene reaction tubes (0.5 ml, 1.5 
ml) 
various 
MagNA Lyser tubes (and caps)  Cat # CP5518 (Cat # CP5525B), Alpha laboratories, UK 
cryogenic vials (nalgene®) 
from Aug 2009 – Dec 2011 
Cat # 5000-0020, Nalge Nunc Int. Corp. USA 
cryogenic vials (2 mls) 
Dec 2011 onwards 
P/N 430488, Corning Inc, USA 
RadialJaw™4 2.4 mm biopsy forceps  Cat # 13951621, Boston Scientific, Ma, USA 
cell strainer (100 µm)  Cat # 352360, BD Biosciences, UK 
Cellstar® tissue culture flasks, 25 cm
2  Cat # 690160, Greiner Bio-one, Germany 
Cellstar® tissue culture flasks, 75 cm
2  Cat # 658170, Greiner Bio-one, Germany 
Stir bar   
Media  
 
DMEM AQmedia™ 
4500mg/l glucose 
L-alanyl-glutamine 
NaHCO3 
P/N D0819, Sigma®, UK 
HBSS w/o Ca or Mg  Cat # BE10-543F, Lonza, UK 
RPMI 1640 AQmedia™ 
L-alanyl-glutamine 
NaHCO3 
P/N R2405, Sigma®, UK 
RPMI 1640 
L-alanyl-glutamine 
NaHCO3 
P/N R8758, Sigma®, UK 
DEPC treated water  Cat # PIM9906, Lot # 1009021, Invitrogen, Ca, USA 
Bovine Foetal Calf Serum (FBS)  Cat # 10500, Gibco®, UK 
PBS w/o Ca or Mg  Cat #. BE17-516F , Lonza 
PBS (x10) w/o Ca or Mg  Cat # 70011-036, Gibco®, UK 
DMEM  
4500mg/l glucose 
pyridoxine 
NaHCO 
P/N D5671, Sigma®, UK 
DPBS  Cat # 14190240, Gibco®, UK 
Cell Culture 
 
Gentamycin (Cidomycin®) 
40 mg/ml 
Sanofi Aventis 
Penicillin / Streptomycin solution, 5000u 
/ 5 mg strep per ml 
Cat # DE17-60BE, Lot # OMB206, Lonza 
Amphotericin B (Fungizone™) 
50 mg / 50,000 u 
E.R. Squibb and sons Ltd, UK 
Phytohaemagglutinin (PHA)  P/N 19017, Sigma-Aldrich® 
RT-qPCR (TaqMan™) 
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   Product code and manufacturer 
100 mM dNTPs (with dTTP)  Lot # 1003037, P/N 4367381, Applied Biosystems™, USA 
MultiScribe™ Reverse Transcriptase, 50 
U/µL 
Lot # 1011098, P/N 4308228, Applied Biosystems™, USA 
10x Reverse Transcription Buffer  Lot # 1004081, P/N 4319981, Applied Biosystems™, USA 
RNase Inhibitor, 20 U/µL  Lot # P02429, P/N 4308224, Applied Biosystems™, USA 
TaqMan® Universal Master Mix, 
AmpErase® UNG, (x2) 
contains; AmpliTaq Gold DNA 
Polymerase, AmpErase UNG, dNTPs 
with dUTP, Passive Reference, and 
optimized buffer 
P/N 4304437, Applied Biosystems™, USA 
Random hexomers  Lot # N12470, P/N 58002113-a , Applied Biosystems™, USA 
Hsa-miR-155  P/N 4427975, assay id 002623, Applied Biosystems™, USA 
RNU44   P/N 4427975, assay id 001094, Applied Biosystems™, USA 
has-miR-194  P/N 4427975, assay id 000493, Applied Biosystems™, USA 
hsa-miR-31  P/N 4427975, assay id 002279, Applied Biosystems™, USA 
hsa-miR-223  P/N 4427975, assay id 002295, Applied Biosystems™, USA 
hsa-miR-146b-5p  P/N 4427975, assay id 001097, Applied Biosystems™, USA 
hsa-miR-200b  P/N 4427975, assay id 002251, Applied Biosystems™, USA 
hsa-miR-375  P/N 4427975, assay id 000564, Applied Biosystems™, USA 
hsa-miR-422a  P/N 4427975, assay id 002297, Applied Biosystems™, USA 
MicroAmp™ Optical 384 well reaction 
plate 
P/N 4309849, Applied Biosystems™, USA 
ABI PRISM® Optical Adhesive Covers  P/N 4311971, Applied Biosystems™, USA 
TSLP  Cat # 4331182, P/N Hs00263639_m1, Applied Biosystems™, 
USA 
GAPDH  P/N 4352934, Applied Biosystems™, USA 
β-Actin  P/N 4352667, Applied Biosystems™, USA 
RT-qPCR (SYBR®Green) 
 
RT nanoscript kit  
Oligo d(T) primer Random 
nonamer primer  
qScript enzyme  
qScript 10X reaction buffer  
RNAse/DNAse free water  
dNTP mix (10mM) 
DTT (100mM) 
Cat # RT nanoscript, Primer Design Ltd, UK 
Power SYBR® Green PCR master mix 
contains; DMSO, Glycerin, Tris-HCl, 
Sodium Azide 
Lot # 1108294, P/N 4367659, Applied Biosystems™, USA 
miRNA array 
 
TaqMan® Universal Master Mix, No 
AmpErase® UNG, (x2) 
P/N 4324018, Applied Biosystems™, USA 
Megaplex™ RT Primers, Human pool A 
v2.1 
P/N 4399966, Applied Biosystems™, USA 
TaqMan® Array Human MiRNA A Cards 
v2.0 (4 pack) 
P/N 4398977, Applied Biosystems™, USA 
TaqMan® Array Human MiRNA A Cards 
v2.0 (4 pack) 
P/N 4398965, Applied Biosystems™, USA 
RNA extraction (TRIzol®) 
 
TRIzol® Reagent solution  Cat # 15596018, Invitrogen, Ca, USA 
Ceramic beads (1.4mm)  QBZ-58A , Quackenbush company 
Glycogen, stock concentration 20 mg/ml,   P/N 10901393001, Roche 
QIAzol® lysis reagent  Cat # 79306, QIAGEN sciences, USA 
Chloroform  Cat # C2432, Sigma®, UK 
isopropanol  Cat # 19516, Sigma®, UK 
RNA extraction (RNeasy) 
 
RNeasy plus mini kit  Cat # 74134, QIAGEN sciences Chapter 2. Materials and Methods 
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   Product code and manufacturer 
Mouse experiments 
 
TNBS (1M)  Cat # 92823, Sigma-Aldrich®, UK 
Oxazolone  Cat # 862207, Sigma-Aldrich®, UK 
DSS salt (36–50 x10
4 Daltons)  Cat # 0216011080, MP Biomedicals 
Hypnorm  Vm21757/4000, VetaPharma Ltd 
Heparin (5000 iu/ml)  P/N 45774, PC pharmaceuticals 
Sno202  Cat # 4427975, assay id 001232, Applied Biosystems™, USA 
mus-miR-155  Cat # 4427975, assay id 002571, Applied Biosystems™, USA 
mus-miR-125  Cat # 4427975, assay id 002508, Applied Biosystems™, USA 
Lymphocyte isolation 
 
EDTA  Cat # E0511, Melford, UK 
Percoll®  P1644, Sigma®, UK 
Ficoll-Paque  Cat # 17-1440-03, GE Healthcare 
Trypan blue  T8154, Sigma®,UK 
Collagenase 2  Cat # C6885, Sigma-Aldrich®, UK 
Collagenase 4 (280u/mg)  P/N 41C12537, Worthington, UK 
Lithium Heparin BD Vacutainer®  Ref 367377, LH PST2, 8 mls 
DMSO  Cat # D8418, Batch # 056K01731, Sigma-Aldrich®, UK 
Trypsin  Cat # BE02-007E , Lonza 
Transfection 
 
INTERFERin™ siRNA transfection reagent  Cat # 409-10, Lot # 05INF2309F , Polyplus transfection 
Anti-miR™ miRNA inhibitor Negative 
Control #1 
Cat # 17010, Ambion® 
has-miR-31 Anti-miR™ miRNA inhibitor (5 
nM) 
Cat # AM17000, ID # AM11465, Ambion® 
ELISA 
 
Human TSLP Immunoassay kit 
TSLP Microplate 
TSLP Conjugate 
TSLP Standard 
Diluent RD1X  
Calibrator Diluent RD6-10 
Wash Buffer Concentrate 
Colour Reagent A 
Colour Reagent B 
Stop Solution 
Plate Covers 
Cat # DTSLP0, R&D Systems Inc, USA 
P/N 893574 
P/N 893575 
P/N 893576 
P/N 895121 
P/N 895468 
P/N 895003 
P/N 895000 
P/N 895001 
P/N 895032 
FACS (surface antibody staining) 
 
FACS tubes. 5 ml polystyrene round 
bottom tube  
ref 352054, BD Falcon™ 
PE conjugated anti-human CD3  Cat # 21270034, Immunotools 
Pacific blue conjugated anti-human CD4 
Clone OKT4 
Cat # 11-0048-73, eBioscience 
Allophycocyanin conjugated Anti-human 
CD3, Clone UCHT1 
Cat # 17-0038-71, eBioscience 
PE conjugated anti-human CD25 
Clone BC96  
Cat # 12-0259-42, eBioscience 
PE conjugated anti human CD3  Cat # 21270034, Immunotools 
FACS (FoxP3, intracellular  staining) 
 
FITC conjugated FoxP3, clone 236A/E7  Cat # 11-4777-73, eBioscience 
IC Fixation Buffer   Cat # 00-8222-49, eBioscience 
Permeabilization Buffer (10X)  Cat # 00-8333-56, eBioscience 
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2.1.4  Media receipts 
Unless indicated otherwise the following media receipts are used. 
1mM EDTA 
Additives  strength  volume  Final 
concentration 
Ca
2+ and Mg
2+ free HBSS    485 mls   
Penicillin / Streptomycin  5000 u/ml, 5 mg/ml  10 ml  1000 u/ml, 100 µg/ml 
Gentamycin  40 mg/ml  1.25 ml  100 µg/ml 
Amphotericin  250 µg/ml  2 ml  1.0 µg/ml 
EDTA  0.5 mM, pH 7.4  1 ml  1 mM 
HBSS 
Additives  strength  volume  Final 
concentration 
Ca
2+ and Mg
2+ free HBSS    485 mls   
Penicillin / Streptomycin  5000 u/ml, 5 mg/ml  10 ml  1000 u/ml, 100 µg/ml 
Gentamycin  40 mg/ml  1.25 ml  100 µg/ml 
Amphotericin  250 µg/ml  2 ml  1.0 µg/ml 
RPMI 
Additives  strength  volume  Final 
concentration 
RPMI 1640 
L-glutamine 
Sodium bicarbonate 
  435 mls   
Penicillin / Streptomycin  5000 u/ml, 5 mg/ml  10 ml  100 u/ml, 100 µg/ml 
Gentamycin  40 mg/ml  1.25 ml  100 µg/ml 
Amphotericin  250 µg/ml  2 ml  1.0 µg/ml 
FBS    50 mls  10% 
RPMI 1640 AQmedia™ 
Additives  strength  volume  Final 
concentration 
RPMI 1640 AQmedia™ 
L-alanyl-glutamine 
Sodium bicarbonate 
  440 mls   
Penicillin / Streptomycin  5000 u / 5mg per ml  10 ml  100 u/ml, 100 µg/ml 
FBS    50 mls  10% 
DMEM AQmedia™ 
Additives  strength  volume  Final 
concentration 
DMEM AQmedia™ 
4500mg/l glucose 
L-alanyl-glutamine 
Sodium bicarbonate 
  440 mls   
Penicillin / Streptomycin  5000 u / 5 mg per ml  10 ml  100 u/ml, 100 µg/ml 
FBS    50 mls  10% 
Percoll gradient 
Percoll 
gradient  volume  Ingredients 
100%  25 mls  22.5 mls Percoll + 2.05 mls PBS (x10) +0.45 mls CMF-HBSS 
60%  10 mls  6 mls 100% Percoll + 4 mls CMF- HBSS 
40%  10 mls  4 mls 100% Percoll + 6 mls CMF-HBSS Chapter 2. Materials and Methods 
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2.2  Samples 
2.2.1  Patient selection 
Patients were recruited from the endoscopy department of the University Hospital 
Southampton (UHS), UK
1. Peripheral blood and intestinal biopsies were obtained 
from consenting patients aged 18 years or older who had an established diagnosis 
of either UC or Crohn’s using standard criteria (Mowat et al., 2011). 
Patients  were  excluded  if  they  had  comorbidity  requiring  the  use  of 
immunosuppressive or immune altering medication, excluding inhaled therapy for 
asthma. Patients with PSC or other undiagnosed liver abnormalities were excluded. 
No  surgical  samples  were  used  as  patients  undergoing  resection  represent  a 
distinct phenotype, which are likely to have immunological differences from those 
patients undergoing endoscopy. 
Control samples  were  obtained  from  healthy individuals  with a macroscopically 
and histologically normal intestine. Control subjects were attending endoscopy for 
investigation of intestinal bleeding, abdominal pain, polyp surveillance or elective 
surveillance following cancer resection. 
2.2.2  Clinical scoring 
Prior  to  endoscopy  peripheral  blood  was  taken  for;  Full  Blood  Count  which 
includes  the  Haemoglobin  (Hb)  and  haematocrit  (Hct),  urea,  creatinine  (Cr)  and 
serum electrolytes, liver function, which locally includes serum albumin, aspartate 
transaminase, total protein, alkaline phosphatase and bilirubin, C reactive protein 
(CRP) and erythrocyte sedimentation rate (ESR). Biochemical and haematology tests 
were performed by the pathology laboratory at UHS, and results processed and 
recorded in the patient notes for use in clinical management. Clinical parameters 
including; pulse and temperature were recorded as part of routine nursing care. 
The clinical severity of UC was scored using the Truelove and Witts criteria (Table 
2, page 7) and the Mayo score (Table 3, page 8). The clinical severity of Crohn’s 
                                              
1  UHS  is  a  800  bed  tertiary  referral  inner  city  university  hospital  with  a  gastroenterology  service 
catering  for  approximately  600,000  population,  with  an  estimated  3400  patients  with  IBD.  SGH 
performed 2991 colonoscopies between 1
st January and 31
st December 2011 inclusive.     Chapter 2. Materials and Methods 
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was scored using the CDAI (Table 7, page 12) and Harvey Bradshaw Index (Table 8, 
page 13). Scores were calculated by the author using Microsoft Office Excel 2007, 
Microsoft Corporation, USA. 
2.2.3  Endoscopic scoring 
The  absence  of  macroscopic  inflammation,  (endoscopic  healing)  is  rapidly 
becoming the desired outcome for both clinical trials and clinical treatment. The 
degree  of  endoscopic  activity  either  at  diagnosis  or  following  treatment  is 
associated  with  disease  prognosis,  treatment  failure  and  need  for  surgery. 
However many of the scoring systems are complex, impractical, not widely used 
and because of adaption and/or methodology difficult to compare across studies, 
see the SES-CD, Table 9, page 14. 
The  definition  of  normal  and  inflamed  mucosa  differs  between  studies  making 
comparison  difficult.  This  thesis  uses  the  following  definitions:  Active 
inflammation  is  defined  as  macroscopic  inflammation  at  the  site  of  biopsy. 
Inactive UC or inactive Crohn’s is defined as an established diagnosis of UC or 
Crohn’s in the region of the intestine from which the biopsy is taken but there is 
no macroscopic or microscopic (see section 2.2.4) evidence of inflammation at the 
site  of  biopsy,  or  anywhere  within  the  colon,  at  the  time  of  biopsy.  Unaffected 
mucosa is defined as a biopsy taken from an area of normal mucosa at a time 
when there is actively inflamed mucosa elsewhere within the intestine. The reason 
for making  these distinctions  is that IBD  is  a systemic disease  with a systemic 
cytokine response, so even if the mucosa is macroscopically normal at the site of 
biopsy it is being influenced by a milieu of systemic inflammatory cytokines, so 
cannot be considered to be in a non-inflammatory environment. 
Endoscopic appearance and activity was scored by myself using the Baron score 
(Baron et al., 1964) for both UC and Crohn’s. For Crohn’s the absence or presence 
of ulceration at the site of biopsy was also noted. 
2.2.4  Microscopic scoring 
Histological analysis was performed in a separate paired mucosal biopsy sample 
sent to the histology department at UHS. The histology samples were scored using Chapter 2. Materials and Methods 
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Geboes score 0 - 5 (Geboes et al., 2000). A Geboes score of 0 was deemed to be 
normal or without features of current inflammatory activity. 
2.2.5  Sample collection 
Biopsies  were  taken  using  2.4  mm  bite  biopsy  forceps  (RadialJaw™4  biopsy 
forceps, Boston Scientific, USA). Biopsies were either placed in cryogenic vials and 
immediately  frozen  in  liquid  nitrogen  prior  to  storage  at  -80°C,  or  placed  in 
processing media as described for individual experiments.       Chapter 2. Materials and Methods 
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2.3  Lymphocyte extraction 
Together  lymphocytes  of  the  villous  epithelium  and  lamina  propria  are  called 
mucosal  lymphocytes.  Within each biopsy there  will  be two distinct lymphocyte 
subsets,  the  intraepithelial  lymphocyte  and  the  lamina  propria  lymphocyte.  In 
health  CD8
+  T  cells  predominate  in  the  epithelial  layer  and  CD4
+  in  the  lamina 
propria (Selby et al., 1981), in IBD the total number of T cells increases but the 
ratio of CD4
+ : CD8
+ remains the same (Selby et al., 1984). 
Inflammatory bowel disease is a condition of the mucosa, so for the purposes of 
this thesis lymphocytes of the epithelium and lamina propria were extracted from 
biopsies and combined. 
2.3.1  Extraction of mucosal lymphocytes from biopsies 
Firstly,  the  following  media  is  prepared;  1mM  EDTA,  HBSS,  RPMI  and  Percoll® 
gradients as outlined in section 2.1.4. 
Between 6 and 8 biopsies are immediately placed into a multipurpose container 
with 20 mls of 1 mM EDTA and gently stirred at 37°C for 25 minutes. Taking care 
not to decant visible tissue, the media is decanted into a 50 ml centrifuge tube and 
diluted  1:1  with  HBSS and  kept on  ice  whilst  another  20  mls  of  1  mM  EDTA  is 
added to the biopsies and stirred again at  37°C for 25 minutes. This process is 
repeated 3 times in total. The decanted media (x3) are centrifuged at 1500 rpm at 
18°C  for  10  minutes.  The  supernatant  is  discarded  and  the  pellets  are  re-
suspended in 10 mls of HBSS, passed through a cell strainer, and pooled together. 
The solution is made up to 40 mls with HBSS and placed on ice. To the remaining 
biopsy  tissue  add  20  mls  RPMI,  supplemented  with  10%  FBS  and  1  mg/ml 
collagenase type 4, stir at 37°C. After 30 minutes add 20 mls of HBSS and pass the 
solution through a cell strainer. The resulting solution, along with the solutions 
previously pooled together, are centrifuged at 1500 rpm at 18°C for 10 minutes. 
Supernatants are discarded, and the 2 separate pellets are combined and dissolved 
in 4 mls 40% Percoll. 
A  Percoll  gradient  of  3  discontinuous  layers  consisting  of  100%,  60%  and  40% 
Percoll respectively is created by careful layering 2 mls of each concentration in 2 Chapter 2. Materials and Methods 
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separate 15 ml centrifuge tubes, Figure 9. The 40% Percoll contains the mucosal 
lymphocytes.  The  Percoll  gradients  are  centrifuged  at  1500  rpm  at  18°C  for  25 
minutes,  to  achieve  isopycnic  banding  of  cells  between  the  layers  of  Percoll. 
Collect and combine the lymphocyte layers and mix with 10 mls HBSS. Centrifuge 
at 1500 rpm at 4°C for 10 minutes. Discard the supernatant and add 10 mls of 
HBSS. Centrifuge at 1500 rpm at 4°C for a further 10 minutes. After discarding the 
supernatant re-suspend the pellet in 1 ml of RPMI + 10% FBS. 
Lymphocytes can be counted (section 2.3.3, p73), frozen for storage (section 2.3.4, 
p73) or used directly. 
 
 
Figure 9. Percoll® gradient for lymphocyte extraction from biopsies. 
(a)  A  schematic  showing  the  isopynic  layering  of  cells  after 
centrifuging  the  Percoll®  gradient,  (b)  the  Percoll®  gradient  before 
centrifuging,  the  40%  Percoll®  (top  layer)  is  cloudy  due  to  the 
suspended lymphocytes, debris and other cells. 
2.3.2  The extraction of PBMCs from whole blood 
Blood is taken directly into a 8 ml Lithium Heparin vacutainer to prevent thrombin 
formation.  When  ready,  dilute  blood  in  an  equal  volume  of  PBS  at  room 
temperature. Place 15 mls  Ficoll-Paque  in a 50 ml centrifuge tube and carefully 
layer 15 mls of the blood / PBS mixture onto the top. Centrifuge at 2000 rpm at 
18°C  for  20  minutes.  Remove  the  resulting  serum  layer  and  transfer  the  white     Chapter 2. Materials and Methods 
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cloudy PBMC layer into a sterile 15 ml centrifuge tube. Add twice the volume (≈10 
mls)  of  PBS  and  centrifuge  at  1500  rpm  at  18°C  for  15  minutes.  Discard  the 
supernatant. Add a further 10 mls PBS and centrifuge at 1500 rpm at 18°C for 15 
minutes. Discard the supernatant, and re-suspended the pellet in RPMI + 10% FBS, 
aim for a cell concentration of 0.5 - 1.0 x 10
6 cells per ml. 
PBMCs can be counted (section 2.3.3, p73), frozen for storage (section 2.3.4, p73) 
or used directly. 
In health PBMCs consist of approximately 75% T cells, 10% Monocytes, 10-15 % B 
cells, and about 1-2 % Dendritic cells (Autissier et al., 2010). The proportion of cell 
subset is donor and disease specific. 
2.3.3  Cell count and viability analysis 
Combine 50 µl of trypan blue suspension (0.4%) with 50 µl of cell solution. Live 
cells are impermeable to Trypan blue and thus can be differentiated from dead 
cells. Cells in the resulting solution can be counted using a haemocytometer. The 
mean of two separate counts are used. 
Cell viability is calculated using the following equation; 
 
Number of viable cells 
x 100 = viability (%) 
Total number of cells 
 
2.3.4  Cell and Lymphocyte storage 
Firstly  prepare  the  freezing  media;  Combine  9.5  mls  FBS  with  0.5  mls  DMSO at 
room temperature in a 15 ml centrifuge tube. 
After counting with the haemocytometer, centrifuge the cell solutions at 1500 rpm 
at  18˚C  for  5  minutes  to  form  a  pellet.  The  pellet  is  re-suspended  in  freezing 
media at a concentration of 5.0 – 10.0 x 10
6 cells per ml. After allowing 15 minutes 
for the media to enter the cells, place cell solutions in cooled cryogenic vials, and 
then  into  a  freezing  container  containing  100%  isopropyl  alcohol.  Place  the 
freezing  container  into  a  -80°C  freezer.  The  freezing  container  ensures  that the Chapter 2. Materials and Methods 
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cells  are  cooled  slowly  at  1°C  per  minute  to  minimise  cell  damage.  On  the 
following day, transfer cryogenic vials to liquid nitrogen for permanent storage. 
       Chapter 2. Materials and Methods 
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2.4  RNA extraction 
Total RNA was extracted from both cell solutions and whole biopsies using either 
TRIzol®  reagent  or  the  RNeasy™  plus  mini  kit.  These  are  examples  of  a  liquid-
liquid and column (silica) based extraction techniques respectively. Both methods 
use guanidine isothiocyanate (GITC) to lyse cells and denature proteins, RNases 
and DNases. 
The TRIzol® protocol relies on the phase separation between nucleic acids which 
are dissolved in the upper aqueous phase, and proteins (dissolved in phenol) and 
lipids (dissolved in chloroform) which are dissolved in the organic phase. Under 
acidic conditions DNA is dissolved in the interphase or lower phase. RNA is then 
precipitated out of the aqueous phase using isopropanol. 
The RNeasy™ protocol relies on the properties of RNA binding to silica at differing 
salt and buffer conditions.  Although  more expensive an advantage of a  column 
based  techniques  is  the  absence  of  chloroform  and  phenol  which  can  be 
potentially hazardous and unpleasant. 
2.4.1  RNA extraction using TRIzol® 
Whole  biopsies  require  to  be  homogenised  initially.  First  place  whole  biopsies 
straight from frozen into a MagNA Lyser tube containing 1 ml TRIzol® reagent and 
1  g  ceramic  beads.  Homogenize  twice  using  MagNA  Lyser  at  6300  rpm  for  40 
seconds, cool on ice between steps. Place the resulting homogenate into 1.5 ml 
reaction tubes. 
Cell solutions are first pelleted by centrifuging at 1500 rpm at 18°C for 5 minutes. 
Decant the supernatant and add the pellet to 1 ml TRIzol® in a 1.5 ml reaction 
tube. Stand at room temperature for 30 minutes. 
To each TRIzol® / sample mixture add 0.2 mls chloroform (≈20% by volume) and 
vortex  for  15  seconds.  Leave  to  settle.  Centrifuge  at  13,200  rpm  at  4°C  for  40 
minutes. Draw off the clear aqueous phase and place in 1.5 ml reaction tubes. Add 
1 ml isopropanol to each sample and vortex for 10 seconds. Add 5 µl of glycogen 
to each sample and vortex again for 15 seconds. Leave at room temperature for 10 Chapter 2. Materials and Methods 
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minutes. Store the samples at -80°C overnight. The following day, thaw samples on 
ice and centrifuge at 13,200 rpm and 4°C for 30 minutes. Remove the isopropanol 
leaving the glycogen pellet to which add 900 µl of ice cold 75% alcohol. Leave for 
10 minutes. Centrifuge again at 13,200 rpm and 4°C for 30 minutes. Remove the 
alcohol and allow the residual liquid to evaporate, take care not to over dry the 
pellet. Add 50 µl of RNA free water to create the stock RNA solution. 
Store the stock RNA at -80°C until required. 
2.4.2  RNA extraction using RNeasy™ 
The total RNA from the murine models of colitis was extracted using an RNeasy™ 
Plus mini kit, according to manufacturer’s instructions. 
In a MagNA Lyser tube containing 1 g ceramic beads add 20 mg tissue and 600 µl 
RLT Buffer plus (which contains GITC and 6 µl  β-mercaptoethanol). Homogenise 
the mixture using a MagNA Lyser at 6400 rpm for 40 seconds. Cool on ice and 
repeat  previous  step.  Place  the  homogenate  into  1.5  ml  reaction  tubes  and 
centrifuge at 13,200 rpm and 18°C for 3 minutes Apply the supernatant onto the 
gDNA  Eliminator  spin  column  and  centrifuge  at  10,000  rpm  and  18°C  for  30 
seconds. Add an equal volume of 70% ethanol and apply 500 µl of the resulting 
mixture  on  the  RNeasy  spin  column.  The  RNA  is  absorbed  to  the  silica  gel 
membrane  of  the  spin  column  by  centrifuging  at  10,000  rpm  and  18°C  for  15 
seconds. Repeat the step x3 and discard the flow through. Apply wash buffers to 
remove contaminants; to do this first apply 700 µl of Buffer RWI and centrifuge at 
10,000 and 18°C for 20 seconds followed by two applications of the Buffer RPE and 
the  same  process.  The  RNA  is  then  eluted  into  a  new  1.5  ml  reaction  tube  by 
adding  30  µl  nuclease  free  water,  waiting  for  2  minutes  then  centrifuging  at 
10,000 rpm and 18°C for 1 minute. 
The stock RNA is stored at -80°C until required. 
2.4.3  Quantification of RNA  
A  2  µl  aliquot  of  each  RNA  sample  was  analysed  using  a  ND-1000  NanoDrop® 
Spectrophotometer using  manufacturer’s  instructions.  The concentration of RNA     Chapter 2. Materials and Methods 
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was calculated by analysing the absorbance of UV light at a wavelength of 260nm. 
Each reading was performed in duplicate. If duplicates differed by >10% the RNA 
sample was mixed again with a pipette and RNA concentrations re-calculated. The 
260nm / 280nm absorbance ratio  was  used to assess purity and samples used 
only if ratio >1.8. 
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2.5  Reverse Transcription - quantitative PCR 
2.5.1  Introduction 
Reverse Transcription – quantitative PCR (RT - qPCR) is a highly sensitive method 
of quantifying gene expression by measuring the expression of mRNA in a sample. 
It  is  a  2  step  process  involving  first  reverse  transcription  (RT)  of  RNA  into 
complementary  DNA  (cDNA)  and  then  amplification  and  quantification  of  cDNA 
(qPCR).  The  process  is  done  in  real  time  (real  time  –  qPCR)  which  allows 
quantification of the cDNA and therefore quantification of the original RNA. 
2.5.1.1  Reverse transcription  
Reverse transcription is a process whereby mRNA is reverse transcribed into cDNA 
by reverse transcriptase. The poly (A) tail at the 3’ end of the mRNA attracts the RT 
primer which can either be oligo dTs, random primers or gene specific primers 
each of which have their own characteristics. The RT primer provides the 3’-OH 
group which is necessary for initiation of cDNA synthesis. Triggered by the 3’OH 
group,  reverse  transcriptase  uses  the  mRNA  as  a  template  and  by  adding 
individual nucleotides at the 3’ end builds a single cDNA strand, Figure 10. At this 
stage there is a mRNA:cDNA hybrid, and because RNA contains Uracil in place of 
Thymine, the original mRNA strand must be replaced to create the desired double 
stranded cDNA (ds cDNA). The mRNA strand is digested using the enzyme RNase, 
followed by DNA Polymerase which builds the other strand of the ds cDNA using 
the remaining mRNA pieces on the mRNA:cDNA hybrid as the template. The result 
of reverse transcription is ds cDNA. 
The general principles of reverse transcription need special consideration under 
certain situations. MiRNAs are too short, approx. 17-24nt, for standard quantitative 
PCR which requires a transcript (cDNA) length of more than twice the forward and 
reverse primers, >40nt. miRNAs also do not contain a polyp (A) tail like mRNA. The 
specially designed miRNA stem loop primers overcome these two deficiencies by 
binding to mature miRNA in place of the Poly (A) tail and adding length during the 
RT reaction. Extra length and a higher melting temperature are also provided by a 
“hooked” tail on the forward primer during the qPCR reaction. During the reverse     Chapter 2. Materials and Methods 
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transcription reaction, the RT primer / RNA duplex results in >100 times improved 
efficiency compared with traditional linear RT primers, and greater discrimination 
between similar miRNAs and precursor miRNAs through base stacking and spatial 
constraints (Chen et al., 2005). The Looped RT primer is disrupted by the reverse 
primer during qPCR. 
 
 
Figure  10.  Reverse  Transcription  (RT),  the  initial  step  in  which  a 
mRNA/DNA  hybrid  is  created,  adapted  from  TaqMan™  microRNA 
assays: Protocols (2006). 
2.5.1.2  Real Time – qPCR  
Real  Time  –  qPCR  is  a  process  which  identifies,  amplifies  and  quantifies  DNA 
targets  by  utilising  a  thermostable  DNA  polymerase  to  increase  cDNA  to 
detectable levels.  
Repeatedly raising and then lowering the temperature of the reaction breaks the 
double helix of DNA which allows single stranded primers to anneal to the single 
strands  of  DNA.  As  the  solution  cools  DNA  Polymerase  synthesises  new  DNA 
strands (Polymerization) by adding nucleotides commencing from the primer. Each 
time the process is repeated the number of target DNA sequences doubles so that 
after 40 cycles there are over 1 billion copies of the original sequence. Chapter 2. Materials and Methods 
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DNA  quantification  relies  on  the  activation  and  measurement  of  a  fluorescent 
product. There are 2 ways in which this is achieved; probe based (e.g. TaqMan™) or 
by intercalator / dsDNA binding (e.g. SYBR Green®, Lux® primers and hybridisation 
probes). 
TaqMan™ real time qPCR requires a pair of specific forward and reverse primers 
and  a  specific  MGB  (minor  groove  binder)  probe
1.  The  probe  consists  of  a 
fluorophore reporter (6-carboxyfluorescein, FAM) which is covalently attached  to 
the 5’ end of an oligonucleotide probe, a non-fluorescent quencher (NFQ) and a 
minor  grove  binder  (MGB)  attached  to  the  3’  end  of  the  probe.  The  probe  is 
designed to anneal to the DNA within a region between the forward and reverse 
primers and whilst the whole probe is intact and the NFQ is in close proximity to 
the reporter, fluorescence is suppressed by Förster-type energy transfer.  
During polymerization the Taq polymerase moves from the 5’ end towards the 3’ 
end building the nascent strand by adding nucleotides and extending the primer. 
On reaching the probe the exonuclease activity of the Taq polymerase hydrolyzes 
the  phosphodiester  bonds  releasing  the  probe  from  the  DNA  template  and 
breaking the probe into pieces releasing the reporter, Figure 11.  
Free from the suppression of the NFQ, fluorescence emitted by the reporter can be 
detected and quantified by the PCR cycler. 
The  Intercalator  based  method  utilizes  the  light  absorbance  changes  and 
characteristics of a non-specific DNA binding dye, SYBR Green® as it binds non-
specifically to dsDNA. The main advantage of SYBR® Green is the non-specific RT 
reaction which means the cDNA can be used for multiple gene targets, another 
advantage is the cheaper cost. However, it is less accurate than probe based real 
time PCR which emits fluorescence only after hybridization of the probe with its 
specific target DNA compared SYBR® Green which can report non-specific products 
such as primer dimers.  
                                              
1  TaqMan™  MGB  probes  take  their  name  from  the  thermostable  Taq  Polymerase  and  videogame 
PacMan which was popular at the time that this technique was developed and which shares a common 
action of slicing up the enemy (hydrolyzing the MGB probe in this case). 
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In  this  thesis  I  have  used  both  probe  based  RT-qPCR  (TaqMan™)  and  an 
intercalator  (SYBR  Green®)  methods.  The  protocols  for  miRNA  (TaqMan™)  and 
mRNA  (TaqMan™  and  SYBR  Green®)  differed  and  are  therefore  considered 
separately. 
 
 
Figure 11. Quantifying dsDNA using TaqMan™ MGB probes. (a) The 
TaqMan
TM probe anneals to the RNA between the forward and reverse 
primers. (b)  On reaching the probe the Taq polymerase hydrolyses 
the phosphodiester bonds releasing the probe and reporter. (c) Free 
from the NFQ, the reporter emits fluorescence.  
2.5.1.3  Gene quantification 
PCR reactions for both miRNAs and mRNAs were  ran on the  7900HT Fast Real-
Time PCR System (Applied Biosystems™, USA) and analysed using the ABI PRISM® 
7900HT  Sequence  detection  system  (SDS)  v2.3  software  (Applied  Biosystems™, Chapter 2. Materials and Methods 
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USA, copyright 2005). The threshold was calculated automatically for all samples 
but checked manually to ensure the threshold had been set at an appropriate level 
within  the  exponential  phase  of  the  PCR.  The  cycle  number  at  which  the 
fluorescence  crossed  the  threshold  value  is  called  the  Ct  value.  Samples  were 
analysed in triplicate where possible. Calculations were only performed for those 
samples  with  2  or  more  reliable  Ct  values.  Ct  values  were  ignored  if;  the 
amplification  plot  was  erroneous  or  the  Ct  value  for  duplicate  samples  was  >1 
cycle difference. 
Gene  expression  was  calculated  using  the  comparative  Ct
  (2
-∆∆Ct)  method 
(Schmittgen and Livak, 2008), Figure 12. The comparative method calculates the 
relative difference (fold difference) in gene expression between the sample and a 
control. 
The  first  step  in  the  calculation  is  to  normalise  the  Ct  value  for  the  gene  of 
interest (GOI) within each sample against a constitutively expressed endogenous 
control (the house keeper gene), ∆Ct. This is done to correct for differences in the 
amount of cDNA introduced at the start of the reaction for each sample. The house 
keeper genes used were RNU44, MammU6, β-ACT, sno202 or GAPDH. The second 
step  is  to  calculate  the  ∆∆Ct,  which  is  the  difference  in  the  ∆Ct  between  each 
sample and the average  ∆Ct for all controls.  The  ∆∆Ct is  incorporated into the 
final  calculation,  2
-∆∆Ct,  which  results  in  the  relative  fold  difference,  or  relative 
expression in the GOI between the sample and a control sample. 
 
 
Figure 12. Derivation of the 2
-∆∆Ct calculation 
Fold difference = 2
–∆∆Ct 
∆Ct sample – ∆Ct control = ∆∆Ct 
Ct gene of interest (sample) – Ct house keeper gene (sample) = ∆Ct sample 
Ct gene of interest (control) – Ct house keeper gene (control) = ∆Ct control     Chapter 2. Materials and Methods 
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2.5.2  Probe based miRNA RT-qPCR (TaqMan™) 
TaqMan™ miRNA reverse transcription reaction and RT-qPCR are adaptions of the 
manufacturers protocol (Applied Biosystems, 2006). 
2.5.2.1  Reverse Transcription protocol 
Firstly prepare stock RNA and master mix. Thaw stock RNA and dilute 1 µl with an 
appropriate volume of ice cold RNA free water to achieve a concentration of 10 
ng/µl. To prepare the master mix combine on ice the ingredients outlined in Table 
16.  All  ingredients  were  purchased  from  Applied  Biosystems™  and  volume 
multiplied in each experiment by the number of samples studied. 
 
Master mix  No. Samples x 
(µl) 
Applied Biosystems™ Part 
numbers (unless otherwise 
stated) 
     
100mM dNTPs (with dTTP)*  0.075  4367381 
MultiScribe™  Reverse  Transcriptase,  50 
U/µL* 
0.500  4308228 
10x Reverse Transcription Buffer*  0.750  4319981 
RNase Inhibitor, 20 U/µL*  0.094  4308224 
RNase free water  4.081  Lot # 1009021, Invitrogen 
GOI RT primer  1.500  See Table 17 
House keeper gene RT primer  1.500  See Table 17 
     
Table 16. Master Mix for miRNA Reverse Transcription (* individual 
components of the Taqman® MiRNA Reverse transcription kit part # 
4366596 Applied Biosystems™, USA). GOI = gene of interest.  
After thoroughly mixing the master mix with a pipette, combine 7 µl of master mix 
with 0.5 µl (5 ng) diluted RNA in a 0.5 ml reaction tube. There will be a reaction 
tube for each sample and one for a negative control (0.5 µl H
20) multiplied by the 
number of primers being investigated. The Reverse Transcription reaction is ran 
on a Tetrad™ 2 thermal cycler with the following thermal conditions; 30 minutes at 
16°C, 30 minutes at 42°C then 5 minutes at 85°C. 
The primer assays used for experiments are shown in Table 17. 
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House keeper gene 
   
RNU44 (human)  part # 4427975, assay id 001094 
Sno202 (mouse)  Cat # 4427975, assay id 001232 
   
Gene of interest (GOI)   
   
Hsa-miR-155  part # 4427975, assay id 002623 
has-miR-194  part # 4427975, assay id 000493 
hsa-miR-31  part # 4427975, assay id 002279 
hsa-miR-223  part # 4427975, assay id 002295 
hsa-miR-146b-5p  part # 4427975, assay id 001097 
hsa-miR-200b  part # 4427975, assay id 002251 
hsa-miR-375  part # 4427975, assay id 000564 
hsa-miR-422a  part # 4427975, assay id 002297 
   
mus-miR-155  Cat # 4427975, assay id 002571 
mus-miR-125  Cat # 4427975, assay id 002508 
   
Table 17. TaqMan™ MiRNA assays. Each assay includes one solution 
used in the RT reaction containing a specific miRNA RT primer, and 
one  solution  used  in  the  real  time  PCR  reaction  which  contains  a 
miRNA  specific  forward  primer,  the  same  miRNA  specific  reverse 
primer  and  a  miRNA  specific  TaqMan  MGB  probe.  All  probes 
purchased from Applied Biosystems™, USA. 
2.5.2.2  Real time - qPCR 
Firstly  prepare  master  mixes.  A  master  mix  is  created  for  each  GOI  and 
housekeeper gene with the ingredients in Table 18. 
 
  Product info.  (µl) 
     
TaqMan® Universal PCR 
Master Mix 
Applied Biosystems, USA, 
P/N 4304437  5.0 
Nuclease free water    3.1 
PCR Primers  Table 17  0.5 
     
Table 18. The recipe for miRNA PCR master mix. A separate master 
mix is created for each primer. Each qPCR reaction is performed in 
triplicate  for  the  housekeeper  gene  and  duplicate  for  the  GOI. 
Volumes of reagents are multiplied thrice (or twice for duplicates) 
the number of samples to be analysed      Chapter 2. Materials and Methods 
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Into separate wells of a MicroAmp™ Optical 384 well reaction plate combine 8.6 µl 
of master mix and 1.4 µl of the corresponding cDNA sample. Each PCR reaction is 
ran in triplicate for the housekeeper and duplicate for the GOI. Cover the PCR plate 
with an adhesive cover. Centrifuge at 2000 rpm and 18°C for 5 minutes. 
The  PCR  reaction  is  ran  on  the  7900HT  Fast  Real-Time  PCR  System  using  the 
following thermal cycling conditions; stage 1, 2 minutes at 50°C followed by 10 
minutes at 95°C. Stage 2, 15 seconds at 95°C followed by 1 minute at 60°C. Stage 2 
is repeated for 40 cycles. 
The amplification of GOI is normalised to RNU44 for human samples and sno202 
for  mouse  samples  and  compared  with  control  samples  using    the  ABI  PRISM® 
7900HT Sequence detection system  (SDS) v2.3 software. Relative expressions of 
miRNAs in samples were analysed by the Ct method. 
2.5.3  Probe based mRNA RT-qPCR (TaqMan™) 
2.5.3.1  Reverse Transcription 
Two hundred ng of total RNA is mixed with 1.0  µl Reverse Transcription Buffer 
(10x),  0.4  µl  dNTPs  (100  mM,  with  dTTP),  1.0  µl  random  hexamers,  0.5  µl 
MultiScribe™ Reverse Transcriptase (50 U/µL), 0.5 µl RNase Inhibitor (20 U/µL) and 
made up to 10.0 µl with RNAse / DNAse free water. 
The  RT  reaction  is  ran  on  the  Tetrad™  2  thermal  cycler  with  the  following 
conditions; 25°C for 10 minutes, 37°C for 120 minutes, 85°C for 5 minutes. 
2.5.3.2  Real Time – qPCR 
Firstly; dilute the cDNA to a ratio of 1:10 with nuclease free water and create a PCR 
master mix for each PCR primer. The PCR master mixes contain 2.5  µl TaqMan® 
Universal PCR Master Mix, 1.0 µl nuclease free water and 0.25 µl of the PCR primer. 
The primers used for this type of RT-qPCR are shown in Table 19. 
Each  PCR  reaction  is  performed  by  adding  3.75  µl  of  the  PCR  master  mix  to 
individual wells of a MicroAmp™ Optical 384 well reaction plate and adding 1.25 µl 
of diluted cDNA. Chapter 2. Materials and Methods 
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Each sample is performed in triplicate for the house keeper and duplicate for the 
GOI. Non template controls are ran replacing the primers with nuclease free water. 
Cover the reaction plate with an adhesive cover. 
Centrifuge the reaction plate at 2000 rpm at 18°C for 5 minutes and run the PCR 
reaction on the 7900HT Fast Real-Time PCR System using the following thermal 
cycling  conditions;  stage  1,  2  minutes  at  50°C  followed  by  10  minutes  at  95°C. 
Stage 2, 15 seconds at 95°C followed by 1 minute at 60°C. Stage 2 is repeated for 
40 cycles. 
The amplification of the GOI is normalised to GAPDH and compared with control 
samples  using  the  ABI  PRISM®  7900HT  Sequence  detection  system  (SDS)  v2.3 
software. Relative expressions of the GOI in samples were analysed by the Ct 
method. 
 
House keeper gene 
GAPDH  P/N 402869 
Gene of interest (GOI) 
TSLP  Cat # 4331182 
Table  19.  Primers  used  in  TaqMan  mRNA  RT-qPCR  reactions. 
Purchased from Applied Biosystems unless otherwise stated.  
2.5.4  Intercalator based mRNA RT-qPCR (SYBR® Green) 
2.5.4.1  Reverse Transcription reaction 
Reverse  transcription  is  performed  in  a  two-step  process  using  the  Precision 
qScript
1  Reverse  transcription  kit   and  following  the  manufacturers  protocols 
(Primer Design Ltd, 2005). 
The annealing step of the RT reaction consists of creating a pair of reacti on tubes 
for each RNA sample containing the following ingredients;  1 µl Oligo dT primer, 1 
µl Random nonamer primer and 1 µg of total RNA, each reaction volume is made 
                                              
1 Now known as “nanoscript”     Chapter 2. Materials and Methods 
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up  to  10  µl  with  nuclease  free  water.  The  resulting  mixture  is  placed  in  the 
Tetrad™ 2 thermal cycler (Bio-Rad Life Sciences, USA) for 65°C for 5 minutes, to 
eliminate secondary structure in the RNA that can interfere with cDNA synthesis. 
For the extension step of the RT reaction the following ingredients are added to 
each pair of reaction tubes with (RT+) or without (RT-) the reverse transcriptase 
enzyme (1.0 µl qScript enzyme); 1.0 µl dNTP mix (10 mM), 2.0 µl DTT (100 mM) and 
2.0  µl  qScript  buffer  (10x).  The  reaction  mixtures  are  made  up  to  20  µl  with 
nuclease free water. 
The annealing step is ran on the Tetrad™ 2 thermal cycler at 25°C for 5 minutes 
then at 55°C for 20 minutes followed by heat inactivation of the enzyme at 75°C for 
15 minutes. 
Thus, each RNA sample is either  reverse transcribed  into a single  strand cDNA 
(RT+)  or  subjected  to  the  same  process  but  without  reverse  transcription 
indicating that any cDNA formed is derived from contaminating DNA (RT-). 
2.5.4.2  Quantitative PCR amplification 
The cDNA is diluted to a concentration of 1:10 with nuclease free water. 
For each sample,  into separate  wells of a  MicroAmp™ Optical 384 well reaction 
plate, 2.5 µl aliquots of the diluted RT+ cDNA (x4 wells) and 2.5 µl aliquots of the 
diluted  RT-  cDNA  (x2  wells)  are  combined  with  5.0  µl  Power  SYBR  Green  PCR 
master mix and 2.0 µl of nuclease free water. Into two of the RT+ cDNA reactions 
0.5  µl  of  a  solution  containing  the  GOI  sense  and  antisense  oligonucleotide 
primers (Table 20) are added, and into the other 4 wells, 2 containing RT+ cDNA 
and 2 containing RT- cDNA, 0.5 µl of β-actin sense and antisense oligonucleotide 
primers are added (Table 20). The total reaction volume is 10.0 µl. 
The reaction is therefore performed in duplicate with β-actin RT+ as a control, and 
β-actin RT- as a no RT control. 
Primers were purchased by PrimerDesign Ltd and reconstituted with nuclease free 
water to a stock concentration of 4.5 µM, resulting in a working concentration of Chapter 2. Materials and Methods 
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300 nM. However, due to the formation of primer-dimers the stock primers are 
diluted further as indicated in Table 20, and explain in paragraph 2.5.4.3.2. 
The  real-time  PCR  is  ran  on  the  7900HT  Fast  Real-Time  PCR  System  (Applied 
Biosystems™, USA) using the following thermal cycling conditions;  stage 1, 50°C 
for  2  minutes  followed  by  95°C  for  10  minutes.  Stage  2,  95°C  for  15  seconds 
followed by 60°C for 1 minute, stage 2 is repeated for 40 cycles. 
The amplification of the GOI is normalised to β-actin and the relative expression of 
the GOI compared with control samples using the Ct method. 
 
GENE   
Optimised 
primer 
dilution 
ratio 
Product 
length  Tm  GC%  Sequence 
βACT (house 
keeper)  1:1  Supplied by PrimerDesign Ltd 
IL-4 
Amplicon    111  76.7     
Sense  
1:4 
  57.0  55.0  AACGAGGTCACAGGAGAAGG 
Antisense     57.0  55.0  CACCTTGGAAGCCCTACAGA 
IL-5 
Amplicon    128  74.5     
Sense  
1:1 
  56.9  57.9  ATGGACGCAGGAGGATCAC 
Antisense     56.7  41.7  TTGAAGTTAGATAGGAGCAGGAAG 
IL-10 
Amplicon    100  72.0     
Sense  
1:1 
  57.1  41.7  CATACTGCTAACCGACTCCTTAAT 
Antisense     57.1  52.4  GGGCATCACTTCTACCAGGTA 
FOXP3 
Amplicon    127  79.1     
Sense  
1:6 
  58.5  52.4  AGGACAGACCACACTTACTGC 
Antisense     58.7  63.2  CCAGTGGCAGCAGAAGGTG 
TNF-α 
Amplicon    94  73.7     
Sense  
1:4 
  57.2  50.0  GCCTCCCTCTCATCAGTTCTAT 
Antisense     56.8  52.6  TTTGCTACGACGTGGGCTA 
INF-γ 
Amplicon    128  74.5     
Sense  
1:4 
  58.0  40.0  TGATTACTACCTTCTTCAGCAACAG 
Antisense     57.5  63.2  CTGGTGGACCACTCGGATG 
TGFB1 
Amplicon    113  92.6     
Sense  
1:1 
  55.8  50.5  TGGACACACAGTACAGCAAG 
Antisense     55.5  55.0  GTAGTAGACGATGGGCAGTG 
Table  20.  Primers  used  in  SYBR®  Green  RT-qPCR  reactions.  All 
primers are mus primers purchased from PrimerDesign Ltd.      Chapter 2. Materials and Methods 
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2.5.4.3  Trouble  shooting  Intercalator  based  mRNA  RT-qPCR  (SYBR® 
Green) 
2.5.4.3.1  Contaminating DNA 
Because SYBR® Green is a non specific DNA binding dye, contamination of the PCR 
reaction by DNA will lead to an amplification product in RT- reaction, Figure 13. 
The assumption is that the contaminating DNA is genomic DNA (gDNA) as this is 
often impossible to completely eliminate from preparations. To determine if the 
PCR amplification due  to the gDNA is  sufficiently negligible compared  with the 
cDNA  template  to  include  in  the  analysis,  the  Ct  values  of  the  RT+  and  RT- 
reactions were compared in all experiments using SYBR® Green. Only reactions in 
which the Ct for the control RT- was >10 cycles greater than the Ct for the control 
RT+, are analysed. 
Assuming  100%  efficiency  where  1  Ct  equals  a  2  fold  difference,  a  RT-  control 
sample with a Ct value 10x greater than a RT+ control sample will contain (2
∆Ct) 
1024 fold less of the target sequence, indicating that approximately 0.1% of the 
amplification of the target gene overall is due to contamination. In the example 
depicted  in  Figure  13,  the  amplification  plots  for  the  house  keeper  β-Actin  are 
shown. The contamination of the sample is 0.000002%. 
 
 
(a)  (b) 
Figure 13. Trouble shooting contaminating cDNA in RT-qPCR (a) Fold 
difference  between  Ct  values  (b)  Contaminating  DNA.  β-Actin 
expression in murine colonic mucosa. Ct value for the RT+ is 18.25, 
and for the RT- reaction 37.20. 
Calculations 
RT+ = 18.25 
RT- = 37.20 
∆Ct = 18.95 
Fold difference = 2
∆Ct = 2
18.95 
Fold difference = 5.1 x 10
5 Chapter 2. Materials and Methods 
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In no experiments was the contamination of gDNA > 0.001%, and therefore it was 
unnecessary  to  consider  extracting  and  purifying  RNA  using  an  alternative 
method,  or  was  it  thought  necessary  to  add  a  DNase  treatment  step  into  the 
protocols. 
2.5.4.3.2  Optimising primer concentration 
DNA  binding  dyes  used  during  PCR  lack  specificity  because  they  bind 
indiscriminately to the dsDNA products formed during a PCR reaction which then 
adds to the overall fluorescent signal. Artefacts commonly include primer-dimers 
which are the result of hybridization between primer  pairs, and  less commonly 
spurious  amplification  products.  Melting  curve  analysis  uses  the  melting 
characteristics of DNA to identify unwanted PCR products.  
All primers for SYBR® Green PCR experiments are purchased from Eurogentec at a 
concentration of 250 nM. By performing SYBR® Green real time qPCR with a variety 
of primer dilutions, optimal dilutions are identified in which amplification of the 
desired  products  occurs  but  primer  dimers  did  not  occur  Figure  14.  This  was 
carried out for all primers, Table 20 p88. 
 
 
Figure 14. Primer Dimers. The melting curve of 3 experiments (a-c) in 
which the concentration of TGF-β  primers is 250 nM (a), 62.5 nM (b) 
and 25 nM.        Chapter 2. Materials and Methods 
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2.6  TaqMan® miRNA Array 
2.6.1  Introduction 
The  TaqMan®  Human  MiRNA  array  A  card  is  a  microfluidic  384  well  plate 
containing  dried  TaqMan  primers  and  probes  capable  of  measuring  377  of  the 
most  commonly  expressed  human  miRNAs,  along  with  4  control  genes  and  a 
negative control. 
The reverse transcription reaction and TaqMan® Low Density Array are performed 
following  the  manufacturers  protocols;  Megaplex™  Pools  Protocol,  and  Applied 
Biosystems TaqMan® Low Density Arrays on 7900HT Real-Time PCR Systems. 
For  Practical  reasons  only  Human  Pool  A  was  analysed,  and  the  following 
adaptions to the manufacturers protocol were made; adaption 1. For each array 
card 250 ng of total RNA was taken from 2 samples and combined. Combining RNA 
from  separate  samples  serves  two  functions;  the  first  reduces  the  inter-sample 
variation in miRNA levels, the second reduces the cost of the reaction. Adaption 2. 
Array cards were ran in pairs, a disease and control card. The reason for this is 
that array results were thought to be more reliable when comparisons were made 
between array cards that were ran in close proximity. Adaption 3. Analysis  was 
made using ranking rather than relative fold change, see section 2.6.4. 
2.6.2  Megaplex™ reverse transcription reaction 
The Megaplex™ RT reaction includes 500 ng total RNA mixed with the components 
of  the  TaqMan®  MiRNA  Reverse  Transcription  Kit  and  Megaplex™  RT  Primers, 
Human  pool  A,  v2.1  to  the  ratios  shown  in  Table  21.  The  total  volume  of  the 
reaction is 7.5 µl made up with nuclease free water. 
The  resulting  mixture  was  placed  in  the  Tetrad™  2  thermal  cycler  under  the 
following thermal cycling conditions;  stage 1, 16°C for 2 minutes followed by 42°C 
for 1 minute followed by 50°C for 1 second. Stage 1 was repeated 40 times. Stage 
2, 85°C for 5 minutes. Chapter 2. Materials and Methods 
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RT reaction mix components    (µl) 
     
TaqMan® MiRNA Reverse Transcription Kit   (P/N 4366596)   
 dNTPs with dTTP (100 mM)    0.2 
 MultiScribe™ Reverse Transcriptase (50 U/μL)    1.5 
 10✕ RT Buffer    0.8 
 RNase Inhibitor (20 U/μL)  
 MgCl2 (25 mM) 
  0.1 
0.9 
Megaplex™ RT Primers, Human pool A, v2.1   (P/N 4399822)  0.8 
Nuclease-free water    0.2 
     
  Total  4.5 
Table 21. Megaplex™ RT reaction mix. Components purchased from 
Applied Biosystems unless otherwise stated. 
2.6.3  TaqMan™ low density MiRNA array 
For  the  TaqMan  MiRNA  Array,  combine  6.0  µl  of  cDNA  with  450.0  µl  TaqMan® 
Universal Master Mix, No AmpErase® UNG, (x2). Make up to 900.0 µl with nuclease 
free water. Dispense 100 µl into each port of the TaqMan® Human MiRNA array A 
card, as shown in Figure 15. 
.    
Figure 15. Array card, inserting the master mix. Picture taken from 
manufacturer’s instructions (Applied Biosystems, 2006). 
Seal the card and centrifuge twice at 1200 rpm for 1 minute. The reaction is ran 
using  the  7900HT  Fast  Real-Time  PCR  System  using  the  384  well  TaqMan  Low 
Density Array default thermal-cycling conditions. 
2.6.4  Analysing Arrays 
The  array  cards  were  analysed  using  RQ  manager  version  1.2  and  the 
manufacturer’s protocol, Applied Biosystems 7900HT Fast Real-Time PCR System 
Relative Quantification Using Comparative CT Getting Started Guide.     Chapter 2. Materials and Methods 
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Threshold values for each miRNA were set manually within the exponential slope 
of the amplification plot. Ct ≤35 were considered significant. Raw Ct values were 
exported  to  Microsoft  Excel  2010  and  relative  expression  (2
–∆∆Ct)  calculated.  The 
expression of miRNAs are normalised to the mean MammU6 for each microarray 
card and compared with healthy control. The standard equations outlined in Figure 
12 are used. 
There  is  an  option  of  3  constitutively  expressed  endogenous  controls  for  the 
TaqMan™  low  density  miRNA  array  cards,  RNU44,  RNU48  and  MammU6. 
Mammalian  U6  amplifies  in  4  wells,  retrospective  analysis  of  preliminary 
experiments  shows  that  MammU6  has  a  more  consistent  Ct  value  within  and 
across array cards (3 cards; active sigmoid UC, active sigmoid Crohn’s and healthy 
controls shown in Figure 16.) compared with RNU44 and RNU48. The difference 
between  the  lowest  and  highest  Ct  value  for  MammU6,  RNU44  and  RNU48  is 
0.5034, 0.7143 and 0.6576 respectively. 
 
Figure  16.  TaqMan  low  density  miRNA  array  card  endogenous 
controls. 
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2.7  Bioinformatics:  The  search  for  potential  mRNA  / 
miRNA interactions 
2.7.1  Introduction 
The application of computer science in biology, “Bioinformatics”, has become an 
invaluable tool for miRNA gene detection and miRNA target prediction.  
The first miRNA was reported in 1993 (Lee et al., 1993, Wightman et al., 1993) and 
the  first  human  miRNA  7  years  later  (Pasquinelli  et  al.,  2000).  Based  mainly  on 
evolutionary  conservation  early  predictions  suggested  there  would  be 
approximately  200  human  miRNAs  (Lim  et  al.,  2003)  but  within  a  few  years 
evolutionary non-conservation was included and the predicted number of miRNAs 
increased to approximately 800 (Bentwich et al., 2005). By the middle of the decade 
computational software helped increase the number of predicted miRNA to over 
1000 (Berezikov et al., 2005). 
 
Figure 17. The number of known miRNAs. Adapted from the miRBase 
Sequences database, release 19, August 2012. (red = human, blue = 
all).  
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It is clear that the predicted number and identification of miRNAs is determined by 
the  methodology  used  and  attempts  to  predict  the  number  of  miRNA  is  very 
quickly surpassed by the number of miRNA that are identified, currently there are 
2042  miRNAs  listed  on  the  miRBase  Sequences  database,  release  19  (Griffiths-
Jones et al., 2008), a number which is doubling every few years, Figure 17. There is 
no current consensus at what value this will peak. 
The complete miRBase sequences database now on release 19 (August 2012) and 
available at www.mirbase.org
1, currently contains 21,264 hairpin precursor miRNA 
entries, expressing 25,141 mature miRNAs, in 193 species, and is considered the 
primary repository of miRNA sequences. 
2.7.2  MiRNA target prediction 
MiRNA  target  predictions  show  that  each  miRNA  is  expected  to  have 
approximately  200  gene  targets  (Lewis  et  al.,  2003)  although  this  is  largely 
dependent on the computational program which is used. Mir-31 for example has 
678 conserved targets and another 265 poorly conserved targets using TargetScan 
version 6.0 (Lewis et al., 2003, Garcia et al., 2011), 279 targets using MirTarget2 
(Wang and El Naqa, 2008, Wang, 2008) but only 159 targets that are conserved in 
vertebrates with PicTar (Grun et al., 2005), databases accessed 10
th January 2012.  
Taking into account the overlap between miRNA and their predicted targets it is 
thought that about 1/3 of human protein coding genes, currently between 25,000 
and 30,000, fall under the influence of one or more miRNAs, although to date the 
number of proven associations is measured in the 100s. 
One  of  the  weaknesses  of  bioinformatics  target  prediction  is  the  poor  overlap 
between  computational  programs  because  of  the  different  features  that  each 
algorithm incorporates to calculate potential binding (Min and Yoon, 2010), Table 
22. The features used for the different algorithms fall into a number of categories; 
Base  pairing,  thermodynamic  stability,  comparative  sequence  analysis  and 
presence of multiple target sites. 
                                              
1 Previously the Sanger database (http://miRNA.sanger.ac.uk) Chapter 2. Materials and Methods 
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Name of program  Name of 
algorithm 
features  reference 
TargetScan release 6.0 
(www.targetscan.org) 
TargetScan  An algorithm which calculates a 
“context+” score. See 2.7.3.1. Mainly 
seed region pairing and 
complementary 
(Lewis et al., 
2003) 
PicTar (www.pictar.mdc-
berlin.de) 
PicTar  Thermodynamic stability  (Grun et al., 
2005) 
miRDB 
(www.mirdb.org) 
MirTarget2  Support vector machine (SVM)  (Wang, 2008, 
Wang and El 
Naqa, 2008) 
Microcosm Targets version 5 
(www.ebi.ac.uk)  
(accessed 27
th May 2011) 
miRanda  Formerly miRBase Targets, it is a web 
resource developed by the Enright 
Lab at the EMBL-EBI. Main focus is 
complementary  
 
MiRNA.org (www.miRNA.org)  miRanda  August 2010 release. Complementary.  (Enright et al., 
2003) 
RNAhybrid 
(www.bibiserv.techfak.uni-
bielefeld.de/rnahybrid) 
RNAhybrid  Thermodynamic stability and 
statistical method including minimum 
free energy hybridisation 
 
DIANA microT 
(www.diana.pcbi.upenn.edu/cgi-
bin/micro_t.cgi) 
DIANA 
microT 
Thermodynamic stability   
  MiRanda  Uses a number of steps; the first is 
the miRanda algorithm to identify 
complimentary sites which are scored 
between 0 and 100, where 0 
represents no complementarity and 
100 represents complete 
complementarity. The scoring is 
weighted in favour of 
complementarity at the 5’ end of the 
miRNA. Complete complementarity is 
required in the seed region (bases 2-7 
of the miRNA 5’). The next step is to 
assess secondary structure and 
thermodynamic stability using Vienna 
RNA folding routines, followed by a 
final step to ensure target site 
conservation across at least 2 
species. 
 
Table 22. Computational methods for miRNA target prediction 
2.7.2.1  Base pairing 
The  importance  of base pairing originated from the initial observation that the 
target site of the lin-14 UTR is complementary to the 5’ region of the lin-4 miRNA 
(Lee et al., 1993). Target site prediction programs now categorise, or score, base 
pairing  depending  on  the  pattern  of  predicted  binding  of  which  there  are  a     Chapter 2. Materials and Methods 
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number; 1. 5’ end dominant canonical, i.e. perfect base pairing at the 5’ end of the 
miRNA and extensive base pairing through to the 3’ end, 2. Seed only, i.e. base pair 
matching at the 5’ end of the miRNA but not elsewhere and 3. Compensatory, i.e. 
where  bases  are  not  perfectly  matched  in  the  seed  region  but  are  extensively 
matched through to the 3’ end. 
2.7.2.2  Thermodynamic properties 
The thermodynamic properties of the miRNA:mRNA hybrid is calculated using a 
number of RNA folding programs such as the Vienna, RNAfold or Mfold programs 
which  calculate  the  Gibbs  free  energy  (∆G)  of  the  hybrid  binding.  Despite  this 
approach  being  included  in  a  number  of  algorithms,  notably  the  miRanda 
algorithm, it appears to be insensitive and non-specific because of the low free 
energy involved with miRNA:mRNA hybridization (Watanabe et al., 2007). 
2.7.2.3  Comparative sequence analysis 
This  is the comparison between orthologous 3' UTR sequences  in humans  with 
other  species,  on  the  basis  that  miRNA  and  their  targets  are  highly  conserved. 
Comparative  sequence  analysis  reduces  the  false  positive  results,  but 
unfortunately also increases false negatives. 
2.7.2.4  Presence of multiple target sites 
Approximately  40%  of  miRNA  genes  are  within  the  introns  or  exons  of  protein 
coding  genes  and  are  therefore  co-expressed  and  suspected  to  influence  the 
expression of those genes. Multiple miRNA target sites in the 3’ UTR of the mRNA 
may  influence  target  repression,  and  is  therefore  taken  into  account  in  some 
computational programs. 
2.7.3   Available methods 
There are now several dozen miRNA target prediction programs most of which are 
freely available online. Descriptions are given in Table 22. Chapter 2. Materials and Methods 
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2.7.3.1  Target scan (release 6.0)  
In the initial release of TargetScan it was required to have complete base pairing 
in  the  seed  region  of  the  miRNA,  this  was  followed  by  a  complex  calculation 
including  thermodynamic  properties  of  the  mRNA:miRNA  hybrid  and  finally 
conservation of the miRNA target across species (Lewis et al., 2003). There have 
been many step wise adaptations between the first version of this program and 
the latest version released in November 2011 (version 6.0), the most  prominent 
being  the  change  in  the  accepted  base  pairing  patterns.  The  initial  version 
required perfect complimentary base pairing in the seed region, position 2-8 of the 
5’ end miRNA (denoted as 7mer), from version 4.0 onwards slightly different seed 
region base pairing patterns denoted 8mer, 7mer-m8 and 7mer-1A were included, 
Table 23. The most recent adaptations include seed pairing  stability and target 
site abundance factors which also effect the robustness of miRNA targeting and 
reduce the false negative rate (Garcia et al., 2011). 
 
8mer  An  exact  match  to  positions  2-8  of  the  mature  miRNA  (the 
seed + position 8) followed by an 'A'  
7mer-m8  An  exact  match  to  positions  2-8  of  the  mature  miRNA  (the 
seed + position 8) 
7mer-1A  An  exact  match  to  positions  2-7  of  the  mature  miRNA  (the 
seed) followed by an 'A' 
Table 23. TargetScan base pairing patterns. 
TargetScan now ranks predicted targets using the “context+” score, which is the 
sum of the following features; site-type contribution, 3' pairing contribution, local 
AU  contribution,  position  contribution,  target  site  abundance  contribution  and 
seed-pairing  stability  contribution.  The  calculation  is  complex  but  explained  by 
Garcia  et  al.  (Garcia  et  al.,  2011).  The  relevance  of  the  stepwise  changes  to 
TargetScan  algorithm  is  that  it  is  difficult  to  compare  scores,  or  target  gene 
ranking from one version to the next, and with the addition of new steps to the 
algorithm, the number of predicted target genes is expanding. 
TargetScan (v6.0) analyses 18,393 genes for potential targeting.     Chapter 2. Materials and Methods 
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2.7.3.2  miRDB (version 4.0) 
miRDB  is  a  freely  available  online  resource  for  miRNA  target  prediction  and 
annotation, it tests the miRNAs listed in the miRBase sequences database release 
18  against  the  genes  listed  in  the  PANTHER  (Protein  ANalysis  THrough 
Evolutionary Relationships) database, available at http://www.pantherdb.org.  
MiRNA target predictions are calculated using MirTarget2 algorithm. MirTarget2 is 
based on support vector machines (SVMs) which incorporate novel features that 
are important to target down-regulation. Support vector machines are a statistical 
method  in  which  the  algorithm  is  able  to  categorise  complex  patterns  into 
separate groups by generalizing the information of known examples and creating 
hypothetical differences between them, then placing the new pattern, or miRNA 
sequence,  into  one  of  these  groups.  Support  vector  machines  are  a  form  of 
artificial intelligence, in which the computer algorithm learns to process new data, 
without the need for new programming. 
The MirTarget2 algorithm gives a score between 1 and 100, but states that a score 
>80 is likely to be true and supplementary evidence is needed for those targets 
with scores <60. 
2.7.3.3  Method used 
Bioinformatic searches were performed using a combination of TargetScan version 
5.2 (TargetScan algorithm) and miRDB version 4.0 (MirTarget2 algorithm). There is 
no  universally  accepted  ideal  algorithm,  and  there  are  no  head  to  head  trials. 
These 2 separate bioinformatics tools search for targets in 2 distinctly different 
ways, by using a combination of two separate methods it is envisaged that the 
target  gene  search  will  be  a  more  sensitive  method  for  identifying  potential 
targets. Chapter 2. Materials and Methods 
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2.8  Experimental models of colitis 
2.8.1  Introduction 
All  animals  are  maintained  in  accordance  with  local  and  national  regulations. 
Methods adhered to previously published protocols (Wirtz et al., 2007). 
The method of sedation involved firmly holding the mouse by the scruff of the 
neck between the index finger and thumb and inverting in the palm of the hand. 
Performed correctly the mouse is still, calm and held firm. The mouse is sedated 
with 125 µl intraperitoneal (i.p.) hypnorm, 25 µg fentanyl and 1.25 mg fluanisone 
(Vm21757/4000,  VetaPharma,  UK).  The  mouse  is  then  returned  to the  cage and 
monitored. Depending on absorption, after a short time the mouse is still, does 
not move away when touched and ready to be used. 
 
  Strain  Age  Sex    Model 
AM18  C57 BL/6  8 weeks  F  Oral water  Day 0-6, water 
Day 7, harvest 
AM29  C57 BL/6  8 weeks  F  2.0% TNBS 
Day 0, sensitisation 
Day 4, 2% TNBS 
Day 8, harvest 
AM32  C57 BL/6  8 weeks  F  2.5% TNBS 
Day 0, sensitisation 
Day 4, 2.5% TNBS 
Day 8, harvest 
AM35  C57 BL/6  6.5 
weeks  F  3.0% TNBS 
Day 0, sensitisation 
Day 4, 3% TNBS 
Day 8, harvest 
AM24  C57 BL/6  8 weeks  F  2% Oxazolone 
Day 0, 2% Oxazolone 
Day 3, harvest 
Day 5, harvest 
AM22  C57 BL/6  8 weeks  F  2% DSS  Day 0-6, 2% DSS 
Day 7, harvest 
Table 24. Chemical induced animal models of colitis. 
Insertion of chemicals and / or the carrier ethanol is achieved by inserting a 3.5F 
flexible  plastic  catheter  to  4  cm  proximal  to  the  rectum  whilst  the  mouse  is 
sedated. This is generally easily achieved although care is taken not to injure the 
mouse colon. After infusion the mouse is laid down in a head down position to     Chapter 2. Materials and Methods 
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prevent chemicals from leaking from the rectum. Care is taken to avoid leakage as 
oral ingestion of chemical may lead to tolerance. 
Mice are closely monitored until fully recovered from the sedation. The mice are 
then weighed daily. Animal models are denoted “AM”, the timelines for each of the 
models are listed in Table 24. 
2.8.2  TNBS 
Trinitrobenzene Sulfonic acid (TNBS) is mixed with 50% ethanol. A variety of TNBS 
concentrations are used to induce colitis and compared against 50% ethanol which 
is  used  as  the  control.  Calculations  for  creating  the  TNBS  concentration  for 
insertion are shown in Table 25. 
 
TNBS % 
TNBS (µl) 
(1 M stock 
solution) 
100% ethanol 
(µl)  Water (µl)  Total volume 
(µl) 
control  0.0  37.5  37.5  75 
0.5  1.7  37.5  35.8  75 
1.0  3.4  37.5  31.6  75 
2.0  6.8  37.5  30.7  75 
2.5  8.5  37.5  29.0  75 
3.0  10.2  37.5  27.3  75 
Table 25. TNBS solution calculations. 
On day one, each mouse is sedated then sensitised with a 75 µl dose of 0.5% TNBS 
per rectum, after recovery from the sedation they continue to be housed under the 
standard conditions. 
On  day  five,  each  mouse  is  sedated  with  125  µl  hypnorm  and  a  3.5F  catheter 
inserted 4 cm proximal to the rectum. Either 75 µl of TNBS in 50% ethanol or 75 µl 
of 50% ethanol as control is inserted carefully and the mouse placed head down. 
Samples are harvested 4 days later. Chapter 2. Materials and Methods 
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2.8.3  Oxazolone 
On  day  one,  each  mouse  is  sedated  with  125  µl  hypnorm.  A  3.5  F  catheter  is 
inserted 4 cm proximal to the rectum. Mice are either treated with 100 µl of 2% 
Oxazolone  (Cat  No.  862207,  Sigma-Aldrich®,  UK)  or  100  µl  50%  ethanol  for  the 
control. Mice are placed head down and monitored until fully recovered. 
Samples are harvested 3 and 5 days later. 
2.8.4  DSS 
Two  percent  Dextran  Sulphate  Sodium  (2%  DSS,  Cat.  No.  0216011080,  MP 
Biomedicals, UK) supplemented drinking water is created by mixing 40 g of DSS 
salt in 500 mls drinking water. On day one, normal drinking water is substituted 
for 2% DSS.  The 2% DSS drinking water is renewed on Day 3 and 5. On day 7 the 
2% DSS is changed for normal drinking water and on day 8 samples are harvested. 
Control mice continue to be supplied with normal drinking water. 
2.8.5  Termination and sample harvesting 
The mice are terminated with cervical dislocation and placed immediately supine. 
Using sterile forceps and scissors, the axillary artery is immediately dissected and 
blood collected into 1 ml syringes containing 500 units of heparin. (P/N 45774, PC 
pharmaceuticals, UK).  
Immediately following blood collection the superficial layers of the abdomen are 
dissected  revealing  the  peritoneum.  With  a  26  G  needle  5  mls  of  Dulbecco's 
Phosphate Buffered Saline (DPBS, cat No. 14190240, Gibco®) is  injected into the 
peritoneal  space  and  massaged.  After  45  seconds  the  DPBS  is  aspirated  taking 
care to avoid puncturing the bowel.  
Using sterile forceps and scissors a ventral midline incision is made. The colon is 
exposed and dissected as close to the anus as possible. The colon is measured 
and characteristics such as ischemia and inflammation noted. The distal 4 cm is 
removed and divided so that the central 8mm is placed into neutral buffered 10% 
formalin and stored at 4°C. The proximal 1.6 cm is snap frozen in liquid nitrogen     Chapter 2. Materials and Methods 
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for protein and PCR analysis and the distal 1.6 mm snap frozen for storage and 
Western Blot. 
2.8.6  Determining the degree of inflammatory activity 
 The  degree  of  inflammatory  activity  in  all  models  of  experimental  colitis  was 
measured in 3 ways; the first is by determining the weight change of each mouse 
daily throughout each experiment. The second is by measuring the weight of the 
distal 4 cm of resected colon and the third is by visual analysis of the resected 
colon. 
Measuring daily weights serves two purposes; the first is to measure wasting as a 
pseudo-marker  of  inflammatory  activity  and  thus  use  the  measured  weight  to 
predict  when  the  inflammation  is  maximal  and  the  best  time  to  harvest  tissue 
(Wirtz and Neurath, 2007). The second purpose is to monitor the welfare of the 
mice. Although weight loss alone is a poor predictor of wellbeing (Ray et al., 2010) 
it  is  still  accepted  that  weight  loss  >  20%  is  a  criteria  for  euthanasia  and  an 
indication that the experimental design may be too aggressive. 
Additional  indicators  of  the  degree  of  colonic  inflammation  is  conducted  by  a 
visual  inspection  for  thickening,  strictures,  dilations  and  quality  of  the  stool 
followed  by  measurement  of  the  weight  of  the  distal  4  cm  of  colon  after 
harvesting  and  removal  of  stool.  Together  the  three  measures  of  inflammatory 
activity  ensured  that  the  experiments  were  conducted  at  the  optimal  time 
following chemical induction. 
   Chapter 2. Materials and Methods 
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2.9  Tissue culture and Phytohaemagglutinin stimulation 
2.9.1  Jurkat cell culture 
Jurkat cells are an immortalised line of T Lymphocytes that are commonly used to 
study  T  cell  signalling.  CD4
+  JM22  Jurkat  cells  were  donated  by  Dr  S.  Mansour 
(University of Southampton, UK). 
 
(a)  (b) 
Figure  18.  CD4  surface  staining  of  Jurkat  cells.  (a)  Representative 
sample of cells in Jurkat cell culture, 33.3% of total count are Jurkat 
cells, shown in red. (b) Representative dot blot of CD4
+ and PI
+ Jurkat 
cells. Dot blot demonstrates 99.6% of cells are live CD4
+. 
Jurkat  cells  are  maintained  in  suspension  in  a  75  cm
2  cell  culture  flasks.  The 
culture  media  consists  of;  RPMI  1640  AQmedia™  supplemented  with  L-alanyl-
glutamine, Sodium bicarbonate, 10% FBS, 100 units/ml penicillin and 100 µg/ml 
streptomycin. Cultures are maintained at 37°C humidified air with 5% CO
2. Media is 
replaced every 2 to 3 days to maintain the cell concentration at approximately 5.0 -
10.0 x 10
5 cells per ml. 
2.9.2  THP-1 cell culture 
A  human  acute  monocytic  leukaemia  cell  line.  Physiologically  they  behave  like 
monocytes, and are therefore used to mimic macrophage response.  
Culture conditions are identical to those of Jurkat cells, section 2.9.1. 
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2.9.3  HT29 cell culture 
HT29 are an immortalised intestinal epithelial cell line that behaves like intestinal 
epithelial cells. 
HT29  cells  are  maintained  adhered  to  a  75  cm
2  cell  culture  flasks.  The  culture 
media  consists  of  DMEM  AQmedia™  supplemented  with  4500  mg/L  glucose,  L-
alanyl-glutamine,  Sodium  bicarbonate,  10%  FBS,  100  units/ml  penicillin  and  100 
µg/ml streptomycin. Cultures are maintained at 37°C humidified air with 5% CO
2. 
Media is replaced when the cells become confluent. 
2.9.4  Phytohaemagglutinin 
Phytohaemagglutinin  (PHA)  is  a  plant  lectin,  a  protein  that  is  evolutionarily 
conserved for its action on the animal GI tract. Exposure to PHA causes short term 
disruption  and  functional  impediment  to  the  GI  tract  epithelium  resulting  in 
nausea which discourages animal consumption, giving lectin containing plants a 
survival  advantage.  Interestingly  longer  term  exposure  leads  to  epithelial 
stimulation,  maturation  and  growth  through  mechanisms  including  MAPK 
activation and c-fos mRNA expression (Linderoth et al., 2006, Otte et al., 2001). 
Lectins  are  proteins  that  bind  to  carbohydrate  moieties  on  cell  surface 
glycoproteins, PHA gained its name through the ability to agglutinate and clump 
red blood cells. It functions on immune cells by clustering surface proteins. PHA 
thus stimulates T lymphocytes through cross linking the TCR and CD3, resulting 
in a rapid increase cell signalling and RNA synthesis (Kay, 1968), protein synthesis 
and mitosis (Otte et al., 2001). 
The optimum concentration and culture time for PHA varies between experimental 
conditions and requires optimisation, although studies vary between 0.5 and 10.0 
µg/ml, and 2 hours to 1 month depending on the experimental aims. 
2.9.5  PHA stimulation of PBMCs 
PBMCs  from  the  peripheral  blood  of  3  healthy  individuals  are  extracted  using 
technique described in section 2.3.2. After counting, the PBMCs are diluted in RPMI Chapter 2. Materials and Methods 
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1640 AQmedia™ supplemented with L-alanyl-glutamine, Sodium bicarbonate, 10% 
FBS, 100 units/ml penicillin and 100 µg/ml streptomycin at a concentration of 0.5 
x 10
6 PBMCs per ml. 
Place 0.5 x 10
6 PBMCs into each well of a 48 well plate. Add 0.0, 2.5, 5.0 and 10.0 
µg/ml of PHA to individual wells and culture at 37˚C in humidified air at 5% CO
2. 
At 0, 24 and 48 hours, draw off culture solutions and place in a 1.5 ml reaction 
tube. Centrifuge at 1,500 rpm and 18°C for 15 minutes. Discard the supernatant. 
Wash the pellet by adding 1 ml room temperature PBS and centrifuging again at 
1,500 rpm and 18°C for 15 minutes. Discard the supernatant. Dissolve the pellet in 
1 ml TRIzol® and store at  -80˚C until used for RNA extraction. Experiments are 
done in duplicate, with 2 wells for each sample at each concentration and each 
time period. 
2.9.6  PHA stimulation of HT29 cells 
2.9.6.1  Seeding 
HT29 are maintained as adherent cultures. First remove culture media from the 
flask  and  wash  twice  by  instilling  10  mls  of  warm  PBS,  swilling  the  flask  and 
removing.  To  release  the  cells  from  the  culture  flasks  add  2  mls  Trypsin  and 
incubate at 37°C for 15 minutes. Agitate to release cells from the flask, add 10 mls 
DMEM (plain). Transfer the cell solution to a 15 ml centrifuge tube and centrifuge 
at 1500 rpm and 18°C for 5 minutes. Discard the supernatant and re-suspend the 
pellet  in  10  mls  DMEM  (plain).  Centrifuge  again  at  1500  rpm  and  18°C  for  5 
minutes. The supernatant is discarded and the pellet dissolved in an appropriate 
volume  of  DMEM  AQmedia™  supplemented  with  4500  mg/L  glucose,  L-alanyl-
glutamine, Sodium bicarbonate, 10% FBS, 100 units/ml penicillin and 100 µg/ml 
streptomycin to achieve a concentration of 0.5 x10
6 cells/ml. The resulting HT29 
cell solution can be seeded onto culture plates. 
2.9.6.2  PHA stimulation 
HT29 cells are seeded onto a 24 well plate at a concentration of 0.5 x10
6 cells per 
ml.  Experiments  are  conducted  in  duplicate  on  post  confluent  cells  after  24-48     Chapter 2. Materials and Methods 
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hours incubation at 37°C and 5% CO
2. To half of the wells 2.5 µg/ml PHA is added. 
The cultures are incubated at 37°C and 5% CO
2. 
After 48 hours the supernatants are discarded and 1 ml  TRIzol® added to each 
well. After 10 minutes the mixture is transferred into 1.5 ml reaction tubes and the 
RNA extracted using the method outlined in section 2.4. 
2.9.7  PHA stimulation of THP-1 and Jurkat cells 
2.9.7.1  Seeding 
THP-1 and Jurkat cells are taken from culture flasks and centrifuged at 1500 rpm 
and 18°C for 5 minutes. The supernatant is discarded and the pellet dissolved in 
an  appropriate  volume  of  RPMI  1640  AQmedia™  supplemented  with,  L-alanyl-
glutamine, Sodium bicarbonate, 10% FBS, 100 units/ml penicillin and 100 µg/ml 
streptomycin, to achieve a concentration of 0.5 x 10
6 cells per ml. The resulting 
THP-1 or Jurkat cell solution can now be seeded in a culture plate. 
2.9.7.2  PHA stimulation 
THP-1 or Jurkat cells are seeded into the wells of a 48 well plate at a concentration 
of 0.5 x10
6 cells per ml. Experiments are conducted in duplicate. To half of the 
wells  2.5  µg/ml  PHA,  is  added,  and  the  other  half  left  alone.  The  cultures  are 
incubated at 37°C and 5% CO
2. 
After 48 hours the cell solutions are transferred into 1.5 ml reaction tubes and 
centrifuged at 2000 rpm and 18°C for 5 minutes. The supernatants are discarded 
and pellets re-suspended in 1 ml TRIzol®. After 10 minutes RNA is extracted using 
the method outlined in section 2.4. 
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2.10  Antagomir based knockdown of miR-31 
2.10.1  Introduction 
The  silencing  of  miRNAs  by  synthetically  engineered  oligonucleotides, 
“antagomirs”, is an effective method to investigate the loss of function effect of 
miRNA (Krutzfeldt et al., 2005). 
This technique uses the principles of short interfering RNA (siRNA). Antagomirs 
are siRNA which are perfectly complementary to their target miRNA, in this case 
miR-31  with  addition  of  extra  motifs  to  prevent  degradation  and allow  delivery 
into the target cells / organs. Antagomirs bind irreversibly and efficiently to their 
target thus preventing its function and silencing its effect on downstream factors. 
“Off target” effects can limit antagomir specificity through their binding to targets 
with similar base pair sequences as the intended miRNA, these have been largely 
negated  with  newer  proprietary  transfection  reagents,  such  as  TRANSFERin™ 
which  are  efficient  for  target  miRNAs  at  concentrations  below  that  at  which 
specificity is compromised (Caffrey et al., 2011). 
2.10.2  Method 
Firstly Jurkat cells need to be taken from culture and seeded at a concentration of 
2.0 x 10
5 cells/ml in a 24 well plate as described in section 2.9.7.1. 
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Prepare two master mixes, one for the mir-31 antagomir and the second for the 
control antagomir. Each master mix consists of 93.75 µl RPMI AQmedia™ (plain), 
5.00 µl INTERFERin™ and either 1.25 µl anti-miR-31 (Anti-miR™) or 1.25 µl control 
antagomir (Anti-miR™ miRNA inhibitor negative control). 
Vortex  each  master  mix  for  10  seconds  and  incubate  for  10  minutes  at  room 
temperature. Add 100 µl of the master mix to the appropriate wells. An example of 
an experiment for 4 samples is shown in Figure 19. Culture the plate at 37°C and 
5% CO
2. 
After 24 hours, 2.5 µg of PHA (2.5 µg/ml) is added to the appropriate wells. Culture 
at  37°C  and  5%  CO
2.  After  48  hours  the  cell  solution  is  transferred  to  1.5  ml 
reaction tubes and centrifuged at 1500 rpm and 18°C for 5 minutes. 
The Supernatants are transferred to a separate 1.5 ml reaction tube and stored at -
80°C. The pellet is re-suspended in warm PBS and centrifuged again at 1500 rpm 
and 18°C for 5 minutes. Discard the supernatant. One ml TRIzol™ is added to each 
reaction tube and the sample either used directly, or stored at -80°C until required. 
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2.11  Enzyme Linked Immunosorbent Assay 
2.11.1  Introduction 
Genes come under the influence of many post-transcriptional factors that alter the 
efficiency of gene translation into protein. Some factors increase gene translation 
and protein production such as TLR induced hnRNP U expression which stabilises 
inflammatory cytokine mRNA and increases TNF-α and IL-1β expression (Zhao et 
al.,  2012),  and  some  factors  repress  gene  translation  such  as  miRNAs.  Gene 
expression may therefore not correlate with protein production. 
Two commonly used ways to quantify protein concentration are Western Blot and 
ELISA. Both use binding antibodies but ELISA has a number of advantages over 
Western Blot including increased sensitivity and accuracy. 
A  quantitative  sandwich  enzyme  immunoassay  was  performed  using  the 
manufacturer’s  protocol  (Cat  #  DTSLP0,  ©  2010  R&D  Systems  Inc,  USA).  Minor 
variations, outlined below, are made to the TSLP standards to ensure measurement 
of smaller concentrations of TSLP than would otherwise be possible. 
2.11.2  Methods 
2.11.2.1 Cell culture 
Cell  culture  suspensions  are  collected  into  1.5  ml  polypropylene  tubes  and 
centrifuged at 1500 rpm for 5 minutes at 18°C. The particulate free supernatant for 
each sample is removed and placed in a separate 1.5 ml polypropylene tube. These 
are then stored at -80 °C and thawed immediately prior to the experiment. 
2.11.2.2 Biopsy 
Colonic biopsies are snap frozen in liquid nitrogen and stored at -80°C. Prior to 
protein  extraction  the  samples  are  thawed  on  ice.  The  samples  are  then 
homogenised by four cycles of freeze thawing with liquid nitrogen in 200 µL PBS 
and 8 µL protease inhibitor.  The  samples  are vortexed  for 10 seconds  between 
each cycle.     Chapter 2. Materials and Methods 
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The cell solution is transferred to 1.5 ml polypropylene tubes and centrifuged at 
13200 rpm for 10 minutes at 4°C. The palette is discarded and the  supernatant 
aspirated for analysis. 
2.11.2.3 ELISA 
All reagents are brought to room temperature; the reagents contained within the 
Human TSLP Immunoassay kit are prepared; 
  Wash solution is created by mixing 20 mls of wash buffer concentrate with 
480 mls distilled water. 
  Standard  TSLP  concentrations  are  created,  first  by  reconstituting  TSLP 
standard  with 1.0  ml  distilled  water to create a stock solution of 20,000 
pg/ml.  Then  decreasing  concentrations  of  TSLP  are  created  by  diluting 
appropriate volumes of the TSLP stock solution with the calibrator dilutent 
RD6-10.  The  following  concentrations  of  TSLP  are  prepared;  2000,  1000, 
500, 250, 125, 62.5, 31.25, 15.6 and 7.8 pg per ml. 
Each well of the microplate is precoated with polyclonal antibody against TSLP. To 
each well add 100 µl assay diluent RDX1. Followed by 50 µl of either the different 
concentrations  of  TSLP  standard  to  create  a  dilution  ladder  or  cell  culture 
supernatant. The microplate is then sealed with an adhesive cover and incubated 
at room temperature for 2 hours. 
After incubation the solution in each well is removed and the wells are washed x4, 
filling  each  well  with  wash  buffer  and  removing,  after  the  final  wash  the 
microplate  is  inverted  and  blotted  against  a  paper  towel  to  ensure  complete 
removal of liquid. To each well 200 µl of TSLP conjugate is added, the microplate is 
then resealed with an adhesive cover and incubated for another 2 hours. 
The wash step is then repeated. The colour reagent A and B are mixed together in 
equal  volumes,  and  200  µl  added  to  each  well.  The  microplate  is  sealed  and 
incubated once again for another 30 minutes. 
After incubation 50 µl of stop solution is added to each well turning the colour 
instantly from blue to yellow. Chapter 2. Materials and Methods 
112 
 
Standard concentration
(pg/ml)
A
b
s
o
r
b
a
n
c
e
 
o
f
 
l
i
g
h
t
(
4
5
0
n
m
 
c
o
r
r
e
c
t
e
d
)
0 500 1000 1500 2000
0.0
0.5
1.0
1.5
2.0
r
2 = 0.987
 
Standard concentration
(pg/ml)
A
b
s
o
r
b
a
n
c
e
 
o
f
 
l
i
g
h
t
(
4
5
0
n
m
 
c
o
r
r
e
c
t
e
d
)
1 10 100 1000
0.0
0.5
1.0
1.5
2.0
r
2 = 0.999
 
(a)  (b) 
Figure 20. Analysis of the standard curve for ELISA. (a) analysis using 
linear fit, (b) analysis using 5 parameter logistic regression. Graphs 
and analysis performed using Microplate Manager® Software. 
The optical density of each well is measured at 450 nm with wavelength correction 
set to 540 nm on the microplate reader. Analysis is performed using Microplate 
Manager® Software. 
It was expected that the concentrations of TSLP in cell supernatants would be low 
and therefore a five parameter logistic model was used in preference to the linear 
model to build the standard curve. Its strength is that it more accurately predicts 
the values at the extreme of the curve, Figure 20b. 
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2.12  Flow cytometry 
2.12.1  Introduction 
Density  centrifugation  as  outlined  in  section  2.3.1  is  reported  to  yield  a  cell 
suspension containing between 80-90% T lymphocytes. This mixed population of 
lymphocytes and other tissue debris can be further and more accurately quantified 
and divided using multicolour flow cytometry. Fluorescence activated cell sorting, 
FACS™, is a method that counts and sorts a heterogeneous mixture of cells into 
separate  populations,  it  relies  on  the  light  scattering  characteristics  of  specific 
fluorescent  labelled  antibodies  which  have  been  added  to  and  bind  to  specific 
antigens expressed by cells within the mixture. 
The aim of flow cytometry is to acquire a homogeneous sample of  CD3
+CD4
+ T 
cells from the lymphocyte mixture extracted from tissue by density centrifugation. 
These cells are a mixture of both pro-inflammatory and anti-inflammatory T helper 
cells.  The  anti-inflammatory  subtype  is  the  regulatory  T  cell  which  is  already 
known to express a different profile of miRNAs from non T
reg CD4
+ cells (Rouas et 
al., 2009). Regulatory T cells can be identified by staining for FoxP3; however this 
requires cell permeabilization and intracellular staining which prevents analysis of 
miRNAs. However, it is recognised that the cell surface antigen, CD25, is highly 
expressed on T
regs, and that a majority of T
regs are found in the CD25
high, or brightly 
stained,  population.  The  proportion  of  T
regs  in  a  population  of  CD25
low  or 
CD25
intermediate  cells  is  generally  accepted  as  low  enough  to  make the  assumption 
that the expression of miRNAs from T
regs in these populations would not influence 
the  miRNA  profile  overall,  and  thus  a  population  of  CD4
+CD25
intermediate  is  the 
activated pro-inflammatory CD4
+ subtype. 
For  cell  surface  and  intercellular  staining  a  two  step  process  is  used  which  is 
adapted  from  the  manufacturers  FoxP3  staining  protocol,  “Staining  Intracellular 
Antigens  for  Flow  Cytometry”  (eBioscience,  2010).  The  first  step  involves  cell 
surface antibody staining for CD3, CD4 and CD25, followed by a second step in 
which populations of CD3
+CD4
+CD25
intermediate and CD3
+CD4
+CD25
high are divided for 
miRNA analysis and FoxP3 staining. The process of intercellular staining for FoxP3 Chapter 2. Materials and Methods 
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requires  cell  fixing  to  maintain  structural  integrity  followed  by  cell  membrane 
permeabilization with saponin / detergent. 
2.12.2  Cell surface staining 
Lymphocytes  from  peripheral  blood  and  mucosa  were  extracted  using  density 
centrifugation as outlined in sections 2.3.2 and 2.3.1 respectively. 
For ex vivo surface staining, cells are suspended in 1 ml PBS in FACS tubes. Cells 
are  counted  and  viability  analysed  by  mixing  50  µl  Trypan  blue  with  an  equal 
volume  of  cell  suspension,  as  outlined  in  section  2.3.3.  The  cell  suspension  is 
centrifuged at 1500 rpm and 4°C for 5 minutes, the supernatant is discarded and 
the pellet is re-suspend in 1 ml cold PBS and centrifuged at 1500 rpm and 4°C for 5 
minutes.  The  supernatant  is  again  discarded  and  the  FACS  tube  agitated  to  re-
suspend  the  pellet  in  the  remaining  PBS  (approximately  100  µl).  Fluorochrome 
conjugated CD3, CD4 and CD25 are added, 2 µl for every 1.0 x 10
6 cells. Calibration 
samples are also required; a sample which has no antibodies added and separate 
samples each with a single antibody added. 
All  mixtures  are  protected  from  light  and  incubated  at  4
oC  for  30  minutes. 
Mixtures are washed twice by adding 1 ml cold PBS and centrifuging at 1500 rpm 
and 4
oC for 5 minutes, discarding supernatants between washes. Finally the FACS 
tube is agitated to re-suspend the pellet and PBS is added to make up to 300 µl. 
All cell suspensions are now ready for flow cytometry on the FACS ARIA following 
manufacturer’s instructions. 
2.12.3  Intracellular FoxP3 staining 
The  first  step  is  to  prepare  the  Permeabilization  Buffer  by  diluting  the  10x 
concentrate 1:10 with distilled water to create 4-5 mls of 1x working solution for 
each sample. 
Centrifuge  the  sorted  cells  at  1500  rpm  and  4°  for  5  minutes,  discard  the 
supernatant and agitate to dissociate the pellet. Fix the cells by adding 100 µL of 
IC Fixation Buffer while vortexing the tube. Incubate at room temperature for 20 
minutes in the dark then add 2 mls of 1x Permeabilization Buffer to each tube and     Chapter 2. Materials and Methods 
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centrifuge  at  1500  rpm  and  18°C  for  5  minutes.  Discard  the  supernatant  and 
repeat. 
After  discarding  the  supernatant,  re-suspend  the  cells  in  100  µL  of  1x 
Permeabilization Buffer. Add 2 µl FITC conjugated FoxP3 and incubate in the dark 
at room temperature for 20 minutes. 
When ready add 2 mls 1x Permeabilization Buffer and centrifuge at 1500 rpm and 
18°C for 5 minutes, discard the supernatant and repeat with 2 mls PBS. 
After  discarding  the  supernatant,  agitate  the  tube  to  dissociate  the  pellet  and 
make up to 300 µl by adding approximately 200 µl PBS. Cell solution is now ready 
to proceed to FACS. 
2.12.4  Data acquisition 
Using  the  BD  FACS  Aria  1  flow  cytometer,  unstained  and  single  colour  control 
samples were used to calculate compensations. Based on forward and side scatter 
parameters  a  population  of  lymphocytes  were  first  gated.  CD3,  CD4,  CD25  and 
FOXP3 staining characteristics were analysed using BD FACSDiva™ software v6.0. 
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2.13  Statistical Analysis 
Statistical analysis and graphs were created and presented using GraphPad Prism 
version 5.00 for Windows, (GraphPad Software, San Diego California USA), available 
at www.graphpad.com. Tables were generated using Microsoft Office Excel 2007 
software (Microsoft UK, Reading, UK). 
All variables were considered to be non-parametrically distributed unless sample 
sizes  were  >20  and  the  results  conformed  visually  to  a  Gaussian  distribution. 
Comparisons were made between medians using the Wilcoxon Mann Whitney two 
sample rank sum test, otherwise known as the Mann Whitney U test (MW U). The 
results of the MW U test are displayed as shown in Figure 21, unless MW U values 
and n numbers are shown clearly in the accompanying illustrations, in which case 
statistical relevance is shown in the text using the p value only. 
                                                             
Figure 21. Mann Whitney U test. A non parametric hypothesis test for 
assessing whether one group of observations tend to have a value 
different to the other. The U statistic is a measure of the differences 
between  the  groups  and  defines  if  the  null  hypothesis  can  be 
rejected. The MW test generated two U values which vary between 
zero and (n
1 x n
2), it is usual for the smallest U value to be used. With 
group  sizes  <30  there  is  a  difference  between  the  groups  if;  it  is 
obvious or there is a greater difference between U and ½ (n
1 x n
2). 
Comparisons between groups in which n ≤ 2 was performed using the one tailed 
students  t  test.  The  comparison  of  the  mean  values  for  these  groups  using 
parametric tests is due to the inability of the statistical software to perform non 
parametric analyse between groups of such small n numbers. 
The  association  between  two  variables  is  analysed  using  the  Spearman’s  rank 
order correlation (r
s) and is displayed as shown in Figure 22. 
                                       
Figure 22. Spearman's rank order coefficient (r
s). A measure of the 
association between two non parametrically distributed variables, r
s 
ranges between +1 and -1. The further from zero the value of r
s, the 
stronger is the association between the variables. P  ≤ 0.05 rejects 
the  hypothesis  that the  association  happens  by  chance.  Degree  of 
freedom (df) = number of pairwise cases – number of groups.     Chapter 2. Materials and Methods 
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The  distribution  of  values  within  each  group  is  presented  as  the  inter  quartile 
range (IQR) unless otherwise indicated. 
For all analysis a p value ≤ 0.05 is considered statistically relevant. For consistency 
values are given to 3 decimal places.   Chapter 2. Materials and Methods 
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2.14  Ethics 
Human  tissue  and  blood  were  obtained  using  protocols  approved  by  the 
Southampton and South West Hampshire Regional Ethics Committee (REC) under 
the study titles;  
1.  “MiRNA  coordination  of  inflammation-mediated  changes  in  human  gut 
epithelial  tight  junctions  and  innate  immune  cytokine  expression”.  REC 
reference number 10/H0502/69. 
2.  “The  role  of  proteases  in  gut  inflammation”.  REC  reference  number 
08/H0501/44. 
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3.1  Chapter abstract 
Murine models of colitis are widely used to study the expression and functional 
effects of miRNAs and inflammatory cytokines. MiR-155 has a prominent role in 
multiple  inflammatory  pathways,  its  dysregulation  has  been  implicated  in  the 
aetiology of experimental colitis and its expression is increased in UC (Takagi et 
al., 2010, Van der Goten et al., 2012) and Crohn’s (Fasseu et al., 2010). Experimental 
models have suggested an inverse relationship between the expression of miR-155 
and  miR-125  (Tili  et  al.,  2007),  a  feature  which  drives  an  increased  TNF-α 
expression,  a  pro-inflammatory  cytokine  that  is  thought  to  be  central  in  the 
aetiology of IBD. 
TNBS, Oxazolone and DSS are chemicals commonly used to induce murine colitis. 
The aim of this chapter is to develop a murine model of colitis that mimics the 
expression  of  miR-155,  miR-125  and  the  cytokine  profile  of  UC  and  Crohn’s. 
Traditional theory holds that the pattern of cytokine expressions in Crohn's and 
UC favour a T
H1 or T
H2 profile respectively. 
Mice  were  housed  in  accordance  with  local  protocols  and  colitis  induced  with 
either  TNBS,  Oxazolone  or  DSS  according  to  established  protocols  (Wirtz  et  al., 
2007). 
The expression of miR-155 is increased in variants of all 3 types of induced colitis. 
The expression of miR-155 is increased after administration of 3% TNBS, but not 
2.5% or 2%, it is also increased in the 2% DSS model and increased on day 3 of the 
2% Oxazolone model but not day 5. The expression of miR-125 is increased in the 
3% TNBS model but not significantly altered in other models. 
The largest increase in miR-155 expression was seen following rectal Oxazolone, 
in this model there was an increase in TNF-α, IL-10, IL-17. There was no change in 
INF-γ, IL-4 or TGF-β. 
Changes in the expression of miR-155 are not consistent. Increases seen in the 
TNBS model at 3% may indicate that a threshold stimulus is required to trigger 
miR-155 expression. The increase seen at day 3 but not day 5 of the Oxazolone 
model suggests that the expression of miR-155 is an acute response that fades Chapter 2. Materials and Methods 
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over time. There was no significant change in the expression of miR-125. Cytokine 
profiles  of  all  the  experimental  models  did  not  favour  either  a  T
H1  or  T
H2  type 
response. 
   Chapter 3. Developing a murine model of colitis 
123 
3.2  Chapter introduction 
Human  IBD  provides  a  restrictive  system  for  the  experimental  analysis  of 
inflammatory  pathways  mainly  due  to  the  scarcity  and  biodiversity  of  samples. 
Murine models of colitis, on the other hand, provide a reproducible way to study 
the  expression  and  functional  effects  of  miRNAs  and  inflammatory  cytokines. 
Because IBD does not exist in rodents, the first challenge is to create a murine 
model which mimics the histological appearance, disease distribution and cytokine 
expression profile of IBD closely enough to assume analogy between the model 
and  human  disease.  The  ideal  murine  model  will  express  both  miRNAs  and 
inflammatory cytokines in proportion to those known in IBD. 
Murine  colitis  can  be  induced  using  3  main  techniques;  chemical  induction, 
adoptive  cell  transfer  and  gene  manipulation  (Boismenu  and  Chen,  2000).  The 
logistical ease of chemical induction makes this the most widely used model of 
experimental  colitis.  There  are  two  main  techniques;  the  first  is  through  oral 
intake of dextran sulphate sodium (DSS) polymers which disrupt the integrity of 
the epithelial cell barrier and are directly toxic to epithelial cells. Over a prolonged 
period, usually a number of days, oral intake of DSS will induce an acute colitis 
characterised  by  bloody  diarrhoea,  ulcerations  and  mucosal  infiltration  with 
granulocytes.  The  second  technique  involves  rectal  administration  of  a 
haptenating  substance,  such  as  2,4,6-trinitrobenzene  sulfonic  acid  (TNBS)  or 
Oxazolone,  both  dissolved  in  ethanol.  The  ethanol  serves  two  purposes,  as  a 
dissolvent  and  carrier  for  the  TNBS  or  Oxazolone  and  to  disrupt  the  mucus  / 
epithelial  cell  barrier.  Haptenating  substances  are  a  useful  method  to  study  T 
helper  cell  dependent  immune  responses  including  cytokine  secretion  patterns, 
oral tolerance, cell adhesion and immunotherapy. 
In  experimental  models  the  differential  expression  of  miR-155  is  strongly 
associated  with  the  dysfunction  of  numerous  pro-  and  anti-inflammatory 
mechanisms including T
reg function (Kohlhaas et al., 2009), IL-1β expression (Ceppi 
et  al.,  2009)  and  macrophage  response  (O'Connell  et  al.,  2007).  In  UC,  the 
expression of miR-155 is increased in the actively inflamed mucosa compared with 
healthy  controls  (Takagi  et  al.,  2010),  but  decreased  in  IBD  related  dysplasia Chapter 3. Developing a murine model of colitis 
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compared with active UC (Olaru et al., 2011). The exact role of miR-155 in IBD is 
not known. 
The expression of mir-125 in IBD is less certain. Many studies have not identified 
miR-125 as statistically deregulated (Takagi et al., Wu et al., 2008, Wu et al., 2010, 
Fasseu et al., 2010) although in experimental models using an LPS / TNF-α driven 
immune response it has been shown to be decreased and inversely related to miR-
155 (Tili et al., 2007). 
Ulcerative  colitis  is  considered  to  be  a  T
H2  and  Crohn’s  a  T
H1  mediated 
inflammatory  disease,  although  this  assertion  is  losing  favour  as  discussed 
previously.  However  in  experimental  models  it  is  still  an  important  assumption 
that those models in which the cytokine milieu is balanced in favour T
H2 (IL-4, IL-5 
and IL-13) are mimicking UC and those in which the cytokine milieu is balanced in 
favour  T
H1  (INF-γ,  IL-2  and  TNF-α)  are  mimicking  Crohn’s.  Despite  the  potential 
pitfalls of these assumptions, murine models offer a useful method of measuring 
miRNA and inflammatory cytokine levels under conditions which can be mapped 
into human disease and inflammatory processes. 
In this chapter a variety of murine models are analysed to determine if they mimic 
either UC or Crohn’s as measured by the miRNA and cytokine expression profiles. 
The use of 3 different chemical induction agents are used as previously described, 
TNBS, Oxazolone and DSS with the exact timing of induction and sample harvest 
outlined in section 2.8. 
A number of cytokine profiles are described, they fall into a number of categories; 
those which favour a T
H1 type response (TNF-α and INF-γ), those which favour a 
T
H2 type response (IL-4 and IL-10), T
H17 function (IL-17) and other genes of interest 
including those involved in T
reg function (FOXP3, TGF-β and IL-10). 
The hypothesis is that TNBS, Oxazolone or DSS can be used to induce colitis in 
mice in which the pattern of miRNA and cytokine expression mimics that of IBD. It 
is expected that the colonic mucosal expression of miR-155 is increased and the 
expression of miR-125 is decreased.     Chapter 3. Developing a murine model of colitis 
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3.3  Determining colitis severity 
In all of the experimental models the mice developed significant weight loss with 
a majority of the mice reaching a nadir of -15% weight change between days 2 and 
day 4. In all models the weight of each mouse was significantly reduced from base 
line at the time of harvesting. 
3.3.1  The 2% Oxazolone model 
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(a)  (b) 
Figure 23. Determining inflammatory activity by weight change and 
colon weight in the 2% Oxazolone model. Inflammatory activity was 
measured  in  each  experimental  model  by  analysing  daily  weights, 
and by measuring the weight of the distal 4cm of colon after removal 
of  faeces.  (a)  The  daily  %  weight  change  for  each  group  of  mice, 
control group (n = 8), day 3 harvested mice (n = 6), day 5 harvested 
mice (n = 6) and mice kept under the same laboratory conditions (n = 
6). (b) The weight of the distal 4cm of resected colon . Median values 
and  IQR  are  shown.  Medians  compared  with  the  two  tailed  Mann 
Whitney U test * p < 0.05. 
The example shown in Figure 23a is the daily weight change in the 2% Oxazolone 
model  of  colitis.  In  this  model  the  nadir  of  -16.0%  (IQR  -14.0%  –  -18.0%)  weight 
change  occurs  on  day  2.  The  significant  weight  change  is  still  present  when Chapter 3. Developing a murine model of colitis 
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harvested on day 3 and on day 5, -13.0% (IQR -12.0% - -18.0%) and -10% (IQR -5.0% - 
-12.0%) respectively. 
In the 2% Oxazolone model the weight of the distal 4 cm of colon is significantly 
greater in the day 3 and day 5 models compared with controls, Figure 23b. At day 
3 the colon weighs 0.177 g (IQR 0.167 – 0.182, p < 0.001) and at day 5 the colon 
weighs 0.170 g (IQR 0.159 – 0.176, p < 0.001). 
Visual inspection of the resected colons show the presence of thickening, discrete 
strictures, dilated regions of colon and soft stools when compared with controls. 
3.3.2  The TNBS model 
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Figure 24. Determining inflammatory activity by weight change and 
colon weight in the TNBS model. Colons are harvested 5 days after 
rectal infusion of 2.0% (n = 2), 2.5% (n = 2) and 3.0% (n = 2) TNBS and 
compared  with  controls  (n  =  8).  (a)  Inflammatory  activity  was 
measured  in  each  experimental  model  by  analysing  daily  weights, 
and by (b) measuring the weight of the distal 4 cm of colon after 
removal  of  faeces.  Mean  values  are  compared  with  the  students  t 
test. Values shown are the means and ranges, * p < 0.05 
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The  greatest  weight  change  is  measured  2  days  after  TNBS  infusion  and  is 
greatest  in  the  2.0%  TNBS  model,  19.9%  (range  19.8  –  20.0),  Figure  24.  In  all  3 
variations  of  the  TNBS  model  the  colon  weight  on  the  day  of  harvest  is 
significantly greater than in the control group. 
Visual inspection of the resected colons and faeces show that in all of the TNBS 
treated mice the faeces was looser than in the controls. In one of the 2.5% and one 
of  the  3.0%  colons  there  were  obvious  strictures  and  increase  stiffness.  The 
remaining colons looked macroscopically normal. 
 
3.3.3  The DSS model 
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Figure 25. Determining inflammatory activity by weight change and 
colon weight in the DSS model. Colons are harvested on day 7 after a 
6  day  course  of  DSS  (n  =  2)  and  from  controls  (n  =  4).  (a) 
Inflammatory activity was measured in each experimental model by 
analysing  daily  weights,  and  by  (b)  measuring  the  weight  of  the 
distal  4  cm  of  colon  after  removal  of  faeces.  Mean  values  are 
compared with the students t test. Values shown are the means and 
ranges, * p < 0.05 
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The  greatest  weight  change  is  measured  on  day  6,  -10.0%  (range  -10.0  -  -11.0), 
although chronic administration of DSS results in a change in weight which is less 
aggressive  than  that  seen  in  TNBS  or  Oxazolone,  and  due  to  the  duration  of 
administration appears to have a more prolonged effect on body weight, Figure 25. 
On day 7 the mean change in body weight is -7.5% (range -5.0 - -10.0). 
There  was  no  macroscopic  difference  in  the  appearance  of  the  colons  after 
resection  between  the  DSS  treated  mice  and  controls  although  the  stools  were 
looser in the treatment group. 
The weight of the distal 4 cm of colon is significantly greater in the DSS group, 
0.175  g  (range  0.170  –  0.180)  compared  with  control,  0.095  g  (range  0.086  – 
0.1030), p <0.001. 
     Chapter 3. Developing a murine model of colitis 
129 
3.4  The  expression  of  miR-155  and  miR-125  in  murine 
models of colitis 
3.4.1  The expression of miR-155 is raised following rectal 
administration  of  3.0%  TNBS  but  not  2.5%  or  2.0% 
TNBS 
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Figure  26.  The  expression  of  miR-155  in  a  TNBS  model  of  murine 
colitis.  The  expression  of  miR-155  was  normalised  to  sno202  and 
compared against control (50% ethanol infusion). Comparisons of the 
means were calculated using the one-tailed unpaired students t test. 
The relative expression of miR-155 in the colonic mucosa of mice who received a 
rectal infusion of 3.0% TNBS is significantly increased by 2.470 fold (± 1.267 s.d., p 
=  0.021)  compared  with  control.  There  was  no  significant  difference  in  the 
expression of miR-155 in identical murine models AM29 and AM32 in which 2.0% 
and 2.5% TNBS were infused respectively  Chapter 3. Developing a murine model of colitis 
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3.4.2  The expression of miR-125 is raised following rectal 
administration  of  3.0%  TNBS  but  not  2.5%  or  2.0% 
TNBS. 
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Figure  27.  The  expression  of  miR-125  in  a  TNBS  model  of  murine 
colitis.  The  expression  of  miR-125  was  normalised  to  sno202  and 
compared against control (50% ethanol infusion). Comparisons of the 
means were calculated using the one-tailed unpaired students t test. 
The relative expression of miR-125 is significantly increased in both the 2.5% and 
3.0% TNBS models, but not the 2.0% model when compared against control. In the 
2.5% TNBS model the relative expression of miR-125 is increased by 1.308 fold (± 
0.011 s.d., p < 0.001), and in the 3.0% TNBS model the relative expression of miR-
125 is increased by 1.810 fold (± 0.778 s.d., p = 0.004). There appears to be an 
increasing  expression  of  miR-125  with  increasing  concentration  of  TNBS 
suggesting  a  dose  dependent  response,  although  this  is  not  statistically 
significant, r
s (2), = 1.000, p = 0.083.   Chapter 3. Developing a murine model of colitis 
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3.4.3  The  expressions  of  miR-125  and  miR-155  are 
increased following oral administration of 2% DSS. 
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Figure 28. The expression of miR-125 and miR-155 in a 2% DSS model 
of colitis. The expressions of miR-125 and miR-155 were normalised 
to  sno202  and  compared  against  control  (oral  administration  of 
water). Comparisons of the mean values were calculated using the 
one-tailed unpaired students t test. 
The  expressions  of  miR-125  and  miR-155  are  increased  in  the  colonic  mucosa 
following the oral administration of 2% DSS compared with control. The expression 
of miR-155 is significantly increased by 3.603 fold (± 0.491 s.d., p < 0.001), and the 
expression of miR-125 is increased by 2.305 fold but not significantly (± 1.549 s.d., 
p = 0.063). Chapter 3. Developing a murine model of colitis 
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3.4.4  The  expression  of  miR-155  is  increased  on  day  3 
and day 5 following rectal 2% Oxazolone. 
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Figure 29. The expression of miR-125 and miR-155 in a 2% Oxazolone 
model of colitis at day 3 and day 5.The expressions of miR-125 and 
miR-155 were normalised to sno202 and medians compared with the 
one tailed Mann Whitney U test.  
The expression of miR-155 is increased on day 3 and day 5 compared with control. 
On day 3 the expression of miR-155 is increased by 3.593 fold (IQR = 2.533 – 4.641, 
p < 0.001), and on day 5 the expression of miR-155 is increased by 1.528 fold (IQR 
= 1.333 – 1.689, p < 0.001). 
There is no significant change in the expressions of miR-125 on either day 3 or 
day 5.     Chapter 3. Developing a murine model of colitis 
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3.5  The  expression  of  inflammatory  cytokines  in  murine 
models of colitis 
The hypothesis is that TNBS, Oxazolone or DSS can be used to induce colitis in 
mice and this inflammation mimics the pattern of cytokine mRNA expression in 
IBD. It is expected that the different models of colitis will favour either a T
H1 or T
H2 
type  inflammatory  cytokine  profile  and  thus  provide  a  model  in  which  it  is 
possible to analyse the influence of miRNA expression on these cytokines. 
The aim of this section is to describe the T
H1 (TNF-α and INF-γ), T
H2 (IL-4 and IL-10), 
and  cytokines  of  interest  (FOXP3,  TGF-β  and  IL-17)  expression  profiles  in  the 
Oxazolone and TNBS models of colitis. 
3.5.1  Cytokine expression following rectal administration 
of 2% Oxazolone 
Cytokines  were  measured  on  day  3  (n  =  3)  and  day  5  (n  =  4)  following  rectal 
administration  of  2%  Oxazolone  and  compared  against  controls  (n  =  2).  The 
expression of various cytokine mRNA expressions were analysed by SYBR® Green 
RT-qPCR after RNA extraction from murine colonic resection samples following the 
RNeasy™ protocol outlined in section 2.4.2. 
There is no statistically significant differential expression of TNF-α, INF-γ, IL-4, IL-
10, TGF-β, or FOXP3 in the colonic mucosa using this model of murine colitis. The 
expression of TNF-α appeared to be increased on day 3 following 2% Oxazolone 
administration but this did not reach significance. 
Following the rectal administration of 2% Oxazolone the relative expression of IL-
17 mRNA in the murine colonic mucosa is 3.249 fold (± 0.359 s.d., p = 0.007) when 
compared with control but is not altered on day 5, 1.143 fold. 
During the analysis of IL-4, IL-17 and FOXP3 on day 3 and INF-γ on day 5 one of the 
samples  failed  to  amplify  during  the  PCR  resulting  in  fewer  results  in  these 
experiments.  The  results  shown  in  Figure  30,  take these  reduced  numbers  into 
account. Chapter 3. Developing a murine model of colitis 
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    mean  mean  P value 
(cf control)  mean  P value 
(cf control) 
 
TNF-α  1.026  3.389  0.059  0.918  0.338 
INF-γ  1.025  2.784  0.208  2.866  0.171 
 
IL-4  1.124  2.006  0.308  0.727  0.291 
IL-10  1.006  1.327  0.196  0.831  0.053 
 
IL-17  1.025  3.249  0.007  1.143  0.413 
TGF-β  0.957  0.804  0.316  0.703  0.159 
FOXP3  1.038  2.044  0.331  6.183  0.238 
             
Figure  30.  The  expression  of  cytokine  mRNA  in  murine  colonic 
mucosa  following  administration  of  2%  Oxazolone.  The  cytokine 
expressions  were  analysed  by  RT-qPCR,  normalised  to  β-actin  and 
compared  against  controls.  Comparisons  of  the  means  were 
performed using the one tailed students t test. (* p ≤ 0.05). 
  
 
3.6  Chapter discussion 
Little is known about the mechanisms which predispose, trigger or drive IBD. In 
the  middle  of  the  20
th  century  the  leading  ideas  revolved  around  an  infectious 
aetiology although the inability to find a causative agent and the effectiveness of 
steroid  therapy  has  moved  the  prevailing  ideas  towards  thinking  of  IBD  as  an 
immunological  disease.  Murine  models  play  a  crucial  role  in  studying  and 
advancing  our  understanding  of  immunological  mechanisms  because  of  our 
limited ability to interrogate human disease. Since the 1980s there has been an 
explosion in the number of experimental models of colitis. There are now almost 
limitless models available providing a wide range of pathological, phenotypic and 
/ or immunological characteristics (Boismenu and Chen, 2000, Strober et al., 2002). 
The ideal murine model of colitis would reflect all characteristics of IBD. The ideal 
murine model would have the same phenotypic presentation, disease distribution, 
histological  changes  response  to the  microbiome,  cellular  immune  mechanisms, 
cytokine profile and response to gene dysfunction as that seen in IBD. One of the 
many challenges for murine models of colitis is that although IBD or diseases very 
similar exist in cats, dogs and higher order mammals, it is not known to exist in 
mice, and currently available experimentally induced murine models do not mimic 
all aspects of IBD in one. Experimental models therefore are chosen depending on 
what aspect or mechanism of colitis is being studied. 
The aim of this chapter is to develop a model of colitis in which the miRNA and 
cytokine profiles match those that are seen in either UC or Crohn's with a view to 
investigating the effect of manipulation of miRNA levels on cytokine profiles. The 
logistical ease of chemical induction makes this the most widely used method of 
experimentally  induced  colitis.  Three  chemical  induction  models  are  used 
separately;  oral  DSS,  rectal  TNBS  and  rectal  Oxazolone.  Variations  within  these 
models using different doses and time points were used to optimise responses. 
In 2009 there were approximately 1000 known miRNAs, Figure 17, of which miR-
155 was arguably attracting most interest due to its increasing prominence as a 
factor  in  numerous  inflammatory  pathways  (Teng  and  Papavasiliou,  2009)  and 
diseases (Faraoni et al., 2009), it was and still is generally accepted to have an Chapter 3. Developing a murine model of colitis 
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abnormal expression and important role in the aetiology of IBD. Preliminary data 
produced by our laboratory had shown that miR-155 has an increased expression 
in  resected  human  Crohn's  and  UC,  appendix  8.1.1
9,  and  also  an  increased 
expression in TNBS induced mouse colitis, appendix  8.1.2
10. At the same time 
interest in the control of TNF -α  by  the  influence  of  miR-155  and  miR-125  was 
coming to the fore (Tili et al., 2007, O'Connell et al., 2007). It was therefore decided 
to investigate the expression of miR-125 and miR-155 further. 
Despite the preliminary results and the previously published literature, this study 
revealed an inconsistent expression of miR-155 across the different models and 
their  variants.  One  feature  of  the  inconsistency  is  demonstrated  by  the  TNBS 
model in which there is no increase in miR-155 in the 2% and 2.5% models, but a 
statistically significant increase in the 3% model. This would suggest that there is 
a  threshold  concentration  of  TNBS  that  is  required  to  stimulate  miR-155 
expression. Since the carrier substance, ethanol is unchanged between the groups, 
the  difference  in  miR-155  expression  may  be  explained  by  increased  antigen 
presentation to the mucosal immune system by increased amounts of TNBS. 
A feature of the Oxazolone model is the increased miR-155 at day 3 but not day 5. 
This is consistent with previous studies that have found the expression of miR-
155 to be maximal between 12 and 24 hours after chemical induced colitis (Ceppi 
et al., 2009, O'Connell et al., 2007), with other inflammatory cytokines settling to 
normal over 4 to 5 days. This feature is mirrored in this Oxazolone model in which 
the weight change is beginning to recover after the nadir on day 3. 
There is a significant increase in the expression of miR-155 in the DSS model. The 
expression of miR-125 mirrors that of miR-155 in the TNBS and DSS models, but 
does not show a change in expression in the Oxazolone models contrary to the 
expected opposing changes in miR-155 and miR-125 recently reported (Tili et al., 
2007). A closer examination of the literature reveals that the expression of miR-
155 and miR-125 is less clear then is often quoted. 
                                              
9 Unpublished results, experiments performed by Dr Rebecca Morgan-Walsh. 
10 Unpublished results, experiments performed with Dr Elena Vorobeva   Chapter 3. Developing a murine model of colitis 
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The primary studies associating miR-155 with IBD utilise either murine or in vitro 
experimental models, however, there is little in the way of direct evidence for the 
differential  expression  of  miR-155  in  IBD.  The  expression  of  miR-155  has  been 
reported as increased in the colonic mucosa by Takagi et al., (2010) and by Van der 
Goten  et  al.  (2012)  in  an  abstract  presented  at the  2012 European  Crohn’s  and 
Colitis Organisation annual conference. Although in the earlier study the control 
group  were  not  healthy  individuals  as  stated,  but  were  patients  undergoing 
colorectal cancer resection and the relative increase in miR-155 was not measured 
against a control group, but a single individual result. We know that patients with 
colorectal dysplasia and cancer (Olaru et al., 2011) have differential expressions of 
certain  miRNAs  and  so  comparing  miRNA  profiles  against  these  cannot  be 
considered a “healthy control”. 
Neither Wu et al. (2008) or Fasseu et al. (2010) found an altered expression of miR-
155 between active UC and healthy mucosa, although under-reporting may be a 
feature of the study by Fasseu et al. (2010) due to the stringent 5 fold change in 
expression criteria required for miRNA expression to be considered significant. It 
is already well established that much smaller fold differences for many miRNAs 
result in important biological differences. For Crohn's, despite Fasseu et al. (2010) 
reporting  an  increase  in  the  miR-155  expression  in  active  and  inactive  colonic 
Crohn’s compared with healthy mucosa Wu et al. (2010) did not show a differential 
expression in either terminal ileal or colonic Crohn's. In later chapters the focus 
will  be  on  7  “candidate”  miRNAs  shown  by  microarray  and  RT-qPCR  to  have 
consistently deranged expression in active UC compared with healthy control, miR-
155 and miR-125 do not feature amongst them, however in the microarrays, the 
expression  of  miR-155  is  shown  to  be  2.74  and  1.64  fold  increased  in  active 
mucosal UC and Crohn's respectively. These results are displayed in section 8.3. 
Taken together the expression of miR-155 is raised in UC and Crohn's and using 
this as a surrogate marker of miRNA expression as a whole, a model developed to 
reflect miRNA activity in colitis should also have an increased expression of miR-
155. The expression of miR-125 is less well understood. MiR-125 targets TNF-α and 
is shown to be decreased in circumstances in which TNF-α is increased (Tili et al., 
2007).  The  lack  of  differential  expression  of  miR-125  between  UC  and  healthy Chapter 3. Developing a murine model of colitis 
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mucosa,  but  the  increased  expression  in  experimental  models  focusing  on  the 
macrophage response to LPS / PAMPs would suggest that the inverse relationship 
between miR-155 and miR-125 is a cell specific phenomenon, which may explain 
the findings shown in this chapter. 
Ulcerative  colitis  is  considered  to  be  a  T
H2  and  Crohn’s  a  T
H1  mediated 
inflammatory disease respectively, although this assertion is losing favour due to 
the discovery of other important T helper cell subsets such as T
regs and T
H17 cells 
and the successful use of TNF-α inhibitors for UC in clinical practice. None the less 
it is often helpful to achieve a polarised T
H1 (INF-γ, IL-2 and TNF-α) or T
H2 (IL-4, IL-5 
and IL-13) inflammatory response in murine models to analyse specific immune 
mechanisms. 
Following the results of miR-155 expression it was decided to take the Oxazolone 
model forward to analyse cytokine profiles. The decision was made on the basis 
that Oxazolone is thought to mimic mostly the T
H2 inflammatory response and so 
be  representative  of  UC  (Strober  et  al.,  2002,  Boismenu  and  Chen,  2000).  The 
increased expression of miR-155 at day 3 but not day 5 if reflected in a differential 
cytokine expression may also point to an association between miRNA and cytokine 
expression. 
There were no significant changes in the expressions of TNF-α, INF-γ, IL-4, IL-10, 
TGF-β  or  FOXP3  in  the  Oxazolone  model.  The  cytokine  response  to  Oxazolone 
administration is non-specific in line with previous authors who have also found a 
non specific inflammatory response when measured histologically or with serum 
cytokines (Celinski et al., 2010). 
An interesting finding is the significant increase in IL-17 at day 3 but not day 5 
which  mirrors  the  changes  seen  in  miR-155  in  the  Oxazolone  model  and  the 
increase  seen  in  both  IL-17  (Fujino  et al.,  2003)  and  miR-155  in  active UC.  This 
suggests  a  T
H17  response  at  day  3  that  has  decreased  by  day  5,  although  the 
picture is not entirely clear as the expression of IL-17 is driven in part by changes 
in TGF-β, as well as other cytokines including IL-6, IL-23 and IL-1β (Cosmi et al., 
2008)   Chapter 3. Developing a murine model of colitis 
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The major drawback for murine models is that they often fail to mimic either a T
H1 
or T
H2 inflammatory phenotype, but result in a non-specific inflammatory response 
(Celinski et al., 2010). The reasons for this are multifactorial but revolve around 
precise  experimental  conditions.  Dextran  sulphate  sodium  (DSS)  polymers  are 
directly  toxic  to  epithelial  cells  and  disrupt  the  integrity  of  the  epithelial  cell 
barrier. Taken over a number of days, DSS induces an acute colitis characterised 
by bloody diarrhoea, ulcerations and mucosal infiltration with granulocytes. The 
primary  immunological  response  to  DSS  involves  activation  of  the  macrophage 
response and pro-inflammatory cytokines including a large increase in TNF-α, and 
is therefore thought of primarily as a  T
H1 model in which the adaptive immune 
response does not play a major part (Wirtz and Neurath, 2007). The DSS model is 
therefore  useful  to  study  the  innate  immune  mechanisms  and  epithelial  repair. 
However,  in  a  review  of  murine  models  of  colitis  by  Strober  et  al.  (2002),  it  is 
explained that depending on the conditions, DSS can also stimulate a secondary T 
cell response leading to either a T
H1, T
H2 or mixed helper cell response. 
The  GI  tract  lumen  is  packed  full  of  potentially  immunogenic  antigens,  which 
under normal circumstances do not cause an immunological response. The ethanol 
in the TNBS and Oxazolone models disrupts the epithelial barrier and the TNBS or 
Oxazolone binds to the normally innocuous antigens (haptens). Thus the haptens 
are presented to the immune system by TNBS or Oxazolone through a disrupted 
epithelia barrier. Haptenising substances such as TNBS and Oxazolone are a useful 
method to study T  helper cell dependent immune  responses  including  cytokine 
secretion patterns, oral tolerance, cell adhesion and immunotherapy. The model 
used is determined by which part of the immune response is being studied. Often 
small changes in experimental design lead to changes in the immune response, 
including the degree of exposure to each chemical, genetic variations or even the 
use  of  a  pre-sensitisation  step.  The  method  used  will  also  depend  on  how  you 
want to measure the inflammatory response, i.e. via histology, disease distribution 
or cytokine expression. When measuring cytokines the TNBS models favour a T
H1 
type response, where as other haptenising chemicals such as Oxazolone favour a 
T
H2 type response with a marked increase in IFN-γ, IL-4 and IL-5. The inflammatory Chapter 3. Developing a murine model of colitis 
140 
reaction caused by Oxazolone lasts 4 to 5 days which is less than TNBS suggesting 
TNBS induces a more chronic inflammatory phenotype (Wirtz and Neurath, 2007). 
In summary, although a number of the variations within each model presented in 
this chapter resulted in an increased expression of miR-155, this did not result in 
the  reciprocal  decrease  in  the  expression  of  miR-125.  Also,  none  of  the  murine 
models analysed here demonstrated a cytokine expression profile consistent with 
either a T
H1 or T
H2 response. The inconsistencies shown here are mirrored in the 
literature (Wirtz and Neurath, 2007), although there are a number of limitations 
within  the  experimental  design  which  need  to  be  taken  into  account  when 
interpreting the results. A major obstacle to interpretation is the variability of the 
results  within  certain  groups.  Variability  occurs  as  a  result  of  two  factors; 
technical variability and biological variability. Throughout these experiments there 
are several procedures which minimise technical variability including normalising 
gene expression to an endogenously expressed gene and performing  individual 
samples  in  duplicate.  The  second  factor  is  biological  variability  which  is  a 
recognised feature of miRNAs (Mestdagh et al., 2009) and cytokines. To overcome 
biological variability a large sample number is often required, however in some of 
the experiments reported in this chapter the sample sizes were small, n = 2. It is 
therefore difficult to draw meaningful conclusions from some of the experiments. 
However the purpose of these preliminary experiments was to find if there was a 
consistent  and  clear  experimental  design  which  would  produce  an  appreciable 
increase in miR-155 alongside a polarised T
H1 or T
H2 cytokine response. Additional 
mice  could  have  been  utilised  however,  the  fundamental  ethical  principles 
underpinning  the  mice  experiments  require  using  a  few  mice  as  possible  to 
achieve the purpose of the study (University of Southampton, 2011). Experiments 
were drawn to a close with no additional mice due to inconsistent results and a 
positive move towards human tissue to investigate miRNA profiles in IBD. 
Mice were administered 3 different types of chemical induction and their colons 
were harvested at defined time points, Table 24, in line with published protocols 
(Wirtz  et  al.,  2007).  Methods  of  assessing  inflammatory  activity  at  the  time  of 
harvesting  include  histological,  high  resolution  microscopic  endoscopy,  body 
weight,  colon  weight  or  stool  observations  (Wirtz  et  al.,  2007).  As  a  primary   Chapter 3. Developing a murine model of colitis 
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measure of the effect of the induction agent and measure of inflammatory activity 
the body weight and distal 4 cm of colon weight are shown in Figure 23 to Figure 
25. For each of the models there is a decrease in total body weight and an increase 
in  colon  weight,  also  there  were  visual  features  and  appearances  of  the  faeces 
consistent with active colitis. No histology is shown to directly confirm that each 
model had developed colitis, which is a limitation of this chapter. However, these 
previous features show that each model was harvested at a clinically appropriate 
time and were suffering a clinically significant degree of inflammation. 
The  limitations discussed above  would  suggest that in  hindsight an alternative 
approach may have strengthened the study design. Confirmation of inflammation 
at harvesting by histology and / or using a scoring algorithm (Shinzaki et al., 2012, 
Dohi et al., 2005) would directly confirm colitis and perhaps help reduce biological 
variance  by  dividing  the  effect  of  chemical  induction  by  severity.  Rather  than 
focusing  on  miR-155  and  miR-125  specifically  from  the  outset,  performing 
microarrays may have exposed additional miRNAs of interest. The final important 
alteration  is  the  number  of  mice  used.  The  number  used  is  finely  balanced 
between requiring a large enough number to reach meaningful significance and 
avoiding  outliers  of  biological  variance,  and  adhering  to  ethical  principles. 
Defining  a  larger  number  in  each  group  would  have  given  more  weight  to  the 
results presented. 
When interpreting experimental models generally, there are certain considerations 
which  must  be  taken  into  account.  The  first  is  the  difference  between  induced 
colitis  in  mice  and  IBD  in  humans,  the  second  is  the  difference  in  miRNA 
expression  and  function  between  species,  and  the  third  is  the  difference  in 
cytokine  expression  and  function  between  species.  All  three  factors  can  make 
translation  of  murine  models  to  human  biology  challenging  and  study  results 
misleading. 
Another  obstacle  to  correct  interpretation  of  miRNA  results  generated  by 
experimental colitis is the assumption that miRNA which are named numerically 
similar  between  species  are  identical.  MicroRNA  nomenclature  indicates  an 
orthology but conveys no information about expression and function (Ambros et Chapter 3. Developing a murine model of colitis 
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al., 2003). So although similarly named miRNAs across  species are supposed to 
have  an  identical  nucleotide  sequence,  they  do  not  all  have,  and  although 
conservation  of  genes  between  species  is  meant  to  indicate  an  evolutionary  or 
survival advantage for possession of that gene, a similar function across species 
is again an assumption. 
The further from human disease experiments are performed, the less they can be 
interpreted as significant for that human disease, To define the miRNA profile of 
IBD more accurately, the next step is to perform miRNA profiles on human colonic 
tissue  with  a  view  to  identifying  which  miRNAs  are  most  deregulated  in  active 
disease 
. 
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4.1  Chapter abstract 
There have been in excess of 2000 human miRNAs identified to date, of which over 
70 have been associated with IBD. The functional role of miRNAs in IBD remains 
elusive,  but  with  over  50%  of  protein  coding  genes  predicted  to  fall  under  the 
influence of miRNAs, and experimental models that show a crucial role for miRNAs 
in  many  inflammatory  pathways,  it  stands  to  reason  that  miRNAs  play  an 
important part in the aetiology of IBD. 
Previous  studies  have identified  miRNA signatures for  UC,  but the results  have 
been  inconsistent  and  difficult  to  interpret.  Part  of  the  challenge  of  existing 
studies is their lack of concordance; some reasons for this are the grouping of 
patients with clinically important differences including differing phenotypes and 
patients taking a variety of immune altering treatments. In this study a distinct 
group of miRNAs are shown to be deregulated in the actively inflamed sigmoid 
mucosa of a homogeneous group of treatment naive patients. Potential targets of 
these miRNAs are identified. 
Using  microarray,  seven  candidate  miRNAs  are  identified  to  be  consistently 
deregulated in mucosal biopsies from active UC. The relative expression compared 
with healthy control is analysed by RT-qPCR. The expressions of miR-31, -146b and 
-223 are increased by 10.45, 2.26 and 3.45 fold respectively and the expressions of 
miR-194,  -200b,  -375  and  -422a  are  decreased  by  0.39,  0.46,  0.28  and  0.26  fold 
respectively. 
Subgroup analysis reveals that the expression of miR-31 but not miR-375 is lower 
in patients with both active UC and active Crohn's  who are taking  Azathioprine 
alone compared with patients taking 5-ASA alone, this  suggests that combining 
patients taking  different medication regimes can affect the miRNA signature of 
that group of patients. 
Using  in  silico  analysis  >3000  potential  mRNA  are  identified.  Thymic  Stromal 
Lymphopoietin (TSLP) is identified as a target for 4 of the 7 candidate miRNAs. 
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4.2  Chapter introduction 
To date there are 2042 human miRNAs identified of which 72 have been shown to 
be  either  increased  or  decreased  in  the  mucosa  of  active  IBD  compared  with 
healthy mucosa (Wu et al., 2008, Wu et al., 2010, Fasseu et al., 2010, Van der Goten 
et  al.,  2012).  Of  the  72  deregulated  miRNAs  found  between  the  four  published 
microarray studies of IBD there are 65 that are deregulated in UC, however there 
are only 10 that are identified in 2 or more of the studies. The poor concordance 
between studies may reflect group heterogeneity or pre-existing immunotherapy, 
both of  which  will  impact on the interpretation of the  results and their clinical 
usefulness. 
To overcome the pitfalls of previous studies and to ensure the results reflect a 
clinically  applicable  disease  group  there  are  a  number  of  stringent  sample 
inclusion and exclusion criteria have been used. The first is the distinction that is 
made  between  patients  attending  endoscopy  and  those  undergoing  resection. 
Clinically these two groups represent entirely separate phenotypes with different 
long  term  outcomes  and  potentially  different  aetiological  factors.  Samples  are 
therefore only collected from patients attending endoscopy. The second is sample 
collection  from  a  specific  region  of  the  colon.  There  is  debate  over  regional 
differences in miRNA expression, so to exclude this factor only sigmoid biopsies 
are included. The third inclusion criteria is that patients should be free from the 
immune altering influence of medication, as it stands to reason that medications 
which influence immune function may influence miRNA expression. 
Using microarray and validation of the results with RT-qPCR, the expressions of 
377 of the most prominent miRNAs are investigated primarily in active sigmoid 
UC, and for comparison in active sigmoid Crohn's. Firstly the microarray quantifies 
the relative expression of each of the 377 miRNAs in active UC compared with a 
healthy  control;  this  allows  the  miRNAs  to  be  ranked  in  order  of  relative 
expression for each microarray. Previous studies have suggested that about 5% of 
miRNAs have an expression that is differentially expressed by ± 2 fold compared 
with healthy controls (Wu et al., 2008). Therefore, concentrating on the 20 miRNAs 
which  have  the  greatest  increase  in  expression  and  those  20  miRNAs  with  the   Chapter 4. The miRNA signature of IBD 
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greatest decrease in expression for each microarray reveals that seven “candidate 
miRNAs” are consistently differentiated in UC. 
Following the identification of 7 differentially expressed miRNAs in active UC, in 
silico  analysis  using  several  freely  available  but  entirely  different  target  gene 
prediction algorithms are used to predict potential mRNA targets. 
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4.3  The  search  for  differentially  expressed  microRNA  in 
sigmoid UC by microarray 
The  initial  search  for  differentially  expressed  miRNAs  involves  the  quantitative 
analysis of many hundreds of miRNAs from each sample using  microarray. The 
patient characteristics of microarray experiments conducted in UC and Crohn's are 
shown in Table 26 and Table 27 respectively. 
 
 
  Control 
(n = 6) 
Active UC 
(n = 6) 
MW U value  
(comparison of 
medians) 
Demographics 
Age   55 (44 - 66)  52 (29 - 74)  17 
Sex (F/M)  4/2  2/4   
Ethnicity  6x white European  6x white European   
Smoker / ex smoker
1  0/0  0/0   
Disease 
Months since diagnosis   0 (0 – 0)  17 (9 – 95)   
Concomitant drugs  nil  nil   
Maximum disease extent       
Left sided  0  2   
total  0  4   
Clinical Scores 
Baron score  0 (0 – 0)  3 (3-3)   
Mayo Score  1 (1 – 3)  9 (5 – 12)   
Truelove and Witts  4x normal 
2x severe 
2x moderate 
2x mild 
 
Clinical 
investigation 
Deviation of Hct (%)  1.9 (1.6 – 6.6)  8.1 (6.3 – 10.5)  4 
Weight loss (%)  0.0 (0.0 – 0.0)  0.8 (0.4 – 3.6)  0 
Temperature >37.5°C  nil  nil   
Pulse >90 bpm  nil  nil   
Hb  145 (129 – 145)  121 (104 – 147)  7.5 
ESR  9.0 (8.0-10.0)  36.0 (33.0-39.0)  0 
CRP  2.0 (1.0 – 3.5)  15.5 (4.5-31.8)  2 
Raised Creatinine
2  nil  nil   
  Albumin  45 (41 – 46)  37 (35 – 42)  2 
Table  26.  Patient characteristics  for microarray  experiments  in UC. 
Values  given  as  medians  (IQR),  significance  between  groups 
calculated using the Mann Whitney U test. 
1has not smoked within 3 
months of biopsy, 
2above laboratory reference range. 
The UC microarray experiments included 6 patients in both the active sigmoid UC 
group  and  the  control  group.  Patients  are  matched  for  age  (p  =  0.898)  and 
ethnicity,  although  the  proportion  of  females  is  higher  in  the  control  group 
compared with active UC, 66% versus 33% respectively.   Chapter 4. The miRNA signature of IBD 
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Four  of  the  active  UC  group  had  total  UC;  all  had  Baron  Grade  3  macroscopic 
inflammation at the site of biopsy. Markers of clinical activity that are significantly 
different between active UC and the control group include; deviation of Hct (p = 
0.024), weight loss (p = 0.002), ESR (p = 0.029), CRP (p = 0.038). Markers of clinical 
activity that are not significantly different between active UC and controls include; 
Hb (p = 0.762) and albumin (p = 0.143). 
 
    Control 
(n = 6) 
Active Crohn’s 
disease 
(n = 6) 
MW U value  
(comparison of 
medians) 
Demographics 
Age*   55 (44 - 66)  52 (39 - 60)  14 
Sex (F/M)  4/2  3/3   
Ethnicity  4x white European  4x white European   
Smoker / ex smoker
1  0/0  0/0   
Reason for scope 
3x rectal bleed 
2x change of 
bowel habit 
1x abnormal CT 
2x surveillance 
1x change of 
bowel habit 
1x abdominal pain 
1x flare of 
symptoms 
 
Disease 
Months since diagnosis   0 (0 – 0)  90 (15 – 220)   
Concomitant drugs  nil  nil   
       
Disease phenotype       
Ileocolonic  0  4   
Colonic  0  2   
Unknown  0  0   
Previous operations  0  0   
Clinical Scores 
Harvey Bradshaw Index  1 (0 – 4)  7 (0 – 20)  8 
CDAI  53 (35 - 60)  158 (60 - 255)  7 
Biopsy site  6x normal 
5x ulcers 
1x bleeding but 
no ulcers 
 
Clinical 
investigation 
Deviation of Hct (%)  1.9 (1.6 – 6.6)  4.9 (2.5 – 6.5)  7 
Weight loss (%)  0.0 (0.0 – 0.0)  3.8 (0.0 – 13.7)  12 
Temperature >37.5°C  nil  nil   
Pulse >90 bpm  nil  nil   
Hb  145 (129 – 149  133 (130 – 136)  4 
ESR  6 (3 – 8)  22 (13 – 28)  3 
CRP  2 (1 – 3)  40 (7 - 54)  3 
Raised Creatinine
2  nil  nil   
Albumin  45 (41 - 46)  35 (35 – 38)  1 
Table  27.  Patient  characteristics  for  microarray  experiments  in 
Crohn’s  Disease.  Values  given  as  medians  (IQR), 
1has  not  smoked 
within 3 months of biopsy, 
2above laboratory reference range. 
In  the  Crohn's  microarrays  the  groups  are  matched  for  age  (p  =  0.619)  and 
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with  active  Crohn's,  66%  versus  50%  respectively.  None  of  the  patients  had 
undergone previous resections. 
Although  clinical  activity  scores  tended  to  be  higher  in  patients  with  active 
Crohn's,  there  is  no  statistical  significance  between  active  Crohn's  disease  and 
healthy  control  as  measured  by  the  Harvey  Bradshaw  Index  (p  =  0.128),  or  the 
Crohn's disease Activity Index (p = 0.093). Interestingly although the mucosa is 
ulcerated  at  the  site  of  biopsy  in  5  out  of  the  6  patients  with  Crohn's  and 
haemorrhagic in the other, only 17% (1/6) have HBI >16 and thus categorised as 
severe, and only 50% (3/6) have a CDAI >150. 
Biochemical markers of disease severity include Hb and Alb  which have similar 
values in the active Crohn's and control groups. Although the other markers of 
disease  severity  tend  towards  showing  an  inflammatory  reaction  there  is  no 
statistical  difference  between  active  Crohn's  and  the  healthy  control  groups, 
deviation of Hct (p = 0.091), weight loss (p = 0.454), Hb (p = 0.629), ESR (p = 0.062), 
CRP (p = 0.056) and albumin (p = 0.114). 
4.3.1  The  expression  of  miR-31,  miR-146b  and  miR-223 
are  consistently  increased  in  active  sigmoid 
Ulcerative Colitis. 
For  each  active UC  array card  the  relative  expression  of  individual  miRNAs  are 
normalised  to  MammU6  and  compared  against  the  expression  in  the  healthy 
control microarrays.  The  miRNAs are  ranked in order of  relative expression for 
each array card pair and assigned a rank.  Table 28 shows those miRNAs which 
have  the  greatest  increase  in  relative  expression  in  UC  compared  with  healthy 
controls. 
There are 3 miRNAs which are consistently ranked in the top 20 miRNAs for each 
array  card  pair;  miR-31,  miR-146b  and  miR-223.  There  are  11  others  which  are 
ranked in the top 20 for 2 of the 3 array card pairs, but these are not considered 
further. 
The mean (± s.d., one tailed unpaired students t test) fold change in the expression 
of miR-31, miR-146b and miR-223 compared with healthy control is 35.257 (± 0.782   Chapter 4. The miRNA signature of IBD 
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s.d., p < 0.001), 3.766 (± 1.223 s.d., p = 0.076) and 8.523 (± 2.424 s.d., p = 0.047) 
respectively. 
Of  the  377  miRNA  analysed  using  the  TaqMan™  microarray  card  A  (v2.0),  150 
miRNAs amplified with a CT ≤ 35 in all of the 3 array card pairs, appendix 8.3.1. Of 
those  miRNAs  which  amplified  in  the  microarrays,  13.3%  (20/150)  had  a  mean 
increased expression compared with healthy controls of  ≥ 2.0 fold. This is 5.3% 
(20/377)  of  the  total  number  of  miRNAs  contained  in  the  microarray  card,  and 
consistent with previously published results (Wu et al., 2008). 
 
Array card 
pair 1 
Array card 
pair 2 
Array card 
pair 3   
miRNA  miRNA  miRNA  rank 
miR-31  miR-31  miR-31  1 
miR-486  miR-132  miR-223  2 
miR-223  miR-15b  miR-636  3 
miR-483  miR-223  miR-708  4 
miR-146b  let-7d  miR-135b  5 
miR-449a  let-7b  miR-628  6 
miR-202  miR-135b  miR-193a  7 
miR-155  miR-125b  miR-142-5p  8 
miR-708  miR-181a  miR-331  9 
miR-146a  miR-146b  miR-132  10 
miR-193b  miR-212  miR-18b  11 
miR-150  miR-138  miR-494  12 
miR-454  miR-20a  miR-146b  13 
miR-539  miR-155  miR-483  14 
miR-874  miR-21  miR-142-3p  15 
miR-29b  miR-99a  miR-21  16 
miR-126  miR-142-3p  miR-99a  17 
miR-212  miR-193b  miR-548d  18 
miR-628  miR-152  let-7f  19 
miR-140  miR-126  miR-885  20 
Table 28. Microarray for active UC, top ranked miRNA. The miRNAs 
are  ranked  in  order  of  expression.  miRNA  expressions  are 
normalised  to  mammU6.  Each  array  card  is  compared  against  a 
healthy control array card. This table shows the 20 most increased 
miRNAs in each of the array card pairs. Dark grey = those miRNAs 
which feature in all three of the array card pairs. Light gray = those 
miRNAs which feature in two of the three array card pairs. Chapter 4. The miRNA signature of IBD 
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4.3.2  The expression of miR-194, miR-200b, miR-375 and 
miR-422a  are  consistently  decreased  in  active 
sigmoid Ulcerative Colitis. 
There are 4 miRNAs which are consistently ranked in the 20 miRNAs that have the 
most decreased relative expression for each array card pair; miR-194, miR-200b, 
miR-375 and miR-422a. There are 8 other that are ranked within the 20 miRNAs 
with the most decreased relative expression for 2 of the 3 array card pairs, but 
these are not considered further. 
 
Array card 
pair 1 
Array card 
pair 2 
Array card 
pair 3   
miRNA  miRNA  miRNA  rank 
miR-145  miR-375  miR-422a  1 
miR-492  miR-422a  miR-141  2 
miR-328  let-7a  miR-375  3 
miR-339  miR-200b  miR-429  4 
miR-27b  miR-489  miR-192  5 
miR-127  miR-192  miR-194  6 
miR-451  miR-194  miR-339  7 
miR-375  miR-134  miR-200b  8 
miR-99a  miR-196b  miR-200b  9 
miR-30b  miR-200a  miR-200a  10 
miR-422a  miR-141  miR-370  11 
miR-149  miR-106b  miR-491  12 
miR-133b  miR-9  miR-10b  13 
miR-429  miR-200b  miR-130b  14 
miR-218  miR-339-3p  miR-197  15 
miR-423  miR-339-5p  miR-411  16 
miR-143  miR-191  miR-532  17 
miR-200b  miR-370  miR-376c  18 
miR-194  miR-425  miR-486  19 
miR-103  miR-486  miR-186  20 
Table  29.  Microarray  for  active  UC,  bottom  ranked  miRNA.  The 
miRNAs are ranked in order of expression. miRNA expressions are 
normalised to mammU6. Each UC array card is compared against a 
healthy control array card. This table shows the 20 most decreased 
miRNAs in each of the array card pairs. Dark grey = those miRNAs 
which  feature  in  all  three  of  the  array  experiments.  Light  grey  = 
those miRNAs which feature in two of the three array experiments. 
The mean (± s.d., one tailed unpaired students t test) fold change in the expression 
of  miR-194,  miR-200b,  miR-375  and  miR-422a  compared  with  healthy  control  is   Chapter 4. The miRNA signature of IBD 
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0.213 (± 0.058 s.d., p = 0.020), 0.251 (± 0.124 s.d., p = 0.014), 0.129 (± 0.045 s.d., p = 
0.002) and 0.106 (± 0.005 s.d., p < 0.001) respectively. 
There are 33 miRNA whose expression is more than halved in the sigmoid mucosa 
of  active UC compared  with  healthy  controls,  this  is  22.0%  (33/150)  of  miRNAs 
which amplified or 8.8% (33/377) of the total number of miRNAs contained on the 
microarray card, appendix 8.3.1. 
4.3.3  Candidate miRNA expression in Crohn’s Disease by 
microarray. 
 
Array card 
pair 1 
Array card 
pair 2 
Array card 
pair 3   
miRNA  miRNA  miRNA  rank 
miR-31  miR-31  miR-494  1 
miR-451  miR-202  miR-22  2 
miR-486-5p  miR-142-5p  miR-32  3 
miR-486-3p  miR-494  miR-636  4 
miR-223  miR-636  miR-142-5p  5 
miR-548d-5p  let-7c  miR-579  6 
miR-15a  miR-618  miR-130b  7 
miR-20b  miR-22  miR-15a  8 
miR-18b  miR-486-3p  miR-652  9 
miR-193a-3p  miR-579  miR-487a  10 
miR-331-5p  miR-29b  miR-202  11 
miR-135b  miR-18b  miR-455-5p  12 
miR-16  miR-487a  miR-29b  13 
miR-636  miR-224  miR-34a  14 
miR-32  miR-142-3p  miR-885-5p  15 
miR-21  miR-625  miR-223  16 
miR-518b  miR-135b  miR-452  17 
miR-708  miR-148a  miR-618  18 
miR-142-5p  miR-135a  miR-518b  19 
miR-625  miR-182  miR-370  20 
Table  30.  Microarray  in  Crohn’s  disease,  top  ranked  miRNA.  The 
expressions of the miRNAs are normalised to MammU6. Each active 
sigmoid CD array is compared against a healthy control. Dark grey = 
those miRNAs which feature in the top 20 for all three of the array 
card pairs. Light grey = those miRNAs which feature in two of the 
three  array  card  pairs.  Yellow  =  those  miRNAs  which  are  also 
identified as candidate miRNAs for UC.  
Only miR-142-5p is consistently increased in the top 20 miRNAs for active sigmoid 
Crohn's. Of the three candidate miRNAs that are increased in UC, only miR-31 and Chapter 4. The miRNA signature of IBD 
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miR-223 appear in 2 out of the 3 array card pairs. In the 3
rd array card pair they 
feature  at  ranks  121
st  and  25
th  respectively,  Table  30.  The  mean  relative 
expressions of miR-31 and miR-223 across the array card pairs are 39.288 fold (± 
26.914 s.d., p = 0.109) and 6.001 fold (± 1.504 s.d., p = 0.020) respectively. 
Only miR-1 is identified by microarray to have an expression which is consistently 
decreased across all 3 array card pairs. Of the 4 candidate miRNAs identified to 
have a decreased expression in UC by microarray, only miR-422a is ranked in the 
20 miRNAs with the lowest relative expression in Crohn’s. The miR-422a is ranked 
18
th, 15
th and 35
th with a mean relative expression of 0.700 (± 0.224 s.d., p = 0.120). 
 
Array card 
pair 1 
Array card 
pair 2 
Array card 
pair 3   
miRNA  miRNA  miRNA  rank 
miR-361-5p  miR-204  miR-95  1 
miR-125a-3p  miR-125a-3p  miR-1  2 
miR-487b  miR-489  miR-361-5p  3 
miR-193a-5p  miR-491-5p  miR-671-3p  4 
miR-324-5p  miR-134  miR-323-3p  5 
miR-190  miR-125a-5p  miR-454  6 
miR-338-3p  miR-149  miR-134  7 
miR-335  miR-574-3p  miR-23b  8 
miR-147b  miR-193b  miR-16  9 
miR-133b  miR-331-3p  let-7a  10 
miR-376c  miR-331-5p  miR-125a-5p  11 
miR-10b  miR-376a  miR-628-5p  12 
miR-218  miR-133b  miR-342-3p  13 
miR-1  miR-16  miR-489  14 
miR-885-5p  miR-422a  miR-374b  15 
miR-202  miR-1  miR-365  16 
miR-133a  miR-186  miR-20a  17 
miR-422a  miR-24  miR-204  18 
miR-23b  miR-133a  miR-181c  19 
miR-192  miR-138  miR-301b  20 
Table  31.  Microarray  in  Crohn’s  disease,  bottom  ranked.  The  20 
miRNAs with the most decreased expression in Crohn’s disease. This 
table shows the 20 most decreased miRNAs from each of the 3 array 
card pairs. Dark grey = those miRNAs which feature in all three of 
the array experiments. Light grey = those miRNAs which feature in 
two of the three array experiments. Yellow = those miRNAs which are 
identified as candidate miRNAs in the UC microarray. 
In those candidate miRNAs whose relative expressions are decreased in active UC 
compared with healthy controls, the mean relative expressions for miR-194, miR-  Chapter 4. The miRNA signature of IBD 
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200b and miR-375 across the Crohn's disease array card pairs are 1.588 fold (± 
0.746 s.d., p = 0.234), 1.577 fold (± 0.806 s.d., p = 0.246) and 0.851 fold (± 0.183 
s.d., p = 0.220) respectively. 
 Chapter 4. The miRNA signature of IBD 
156 
4.4  The  expression  of  candidate  miRNAs  in  the  sigmoid 
mucosa  of  treatment  naïve  active  and  inactive 
Ulcerative Colitis. 
In the previous section, microarrays identified seven candidate miRNAs which are 
differentially  expressed  in  active  sigmoid  UC  compared  with  healthy  sigmoid 
mucosa. Reverse Transcription-qPCR was conducted to validate the expression of 
miR-31,  miR-146b,  miR-194,  miR-200b,  miR-223,  miR-375  and  miR-422a  in  active 
and inactive sigmoid UC compared with healthy controls. 
 
    Control  Inactive UC  Active UC 
    (n = 21)  (n = 19) 
(U value, p 
value)  (n = 25) 
(U value, p 
value) 
Demographics 
Age  59 (45 - 75)  55 (49 - 66)  118, p = 0.452  49 (36 – 62)  165.5, p = 0.118 
Sex (F/M)  11/10  7/8    8/13   
Ethnicity (if not 
white) 
  1x Asian    2x Asian   
Smoker / Ex 
Smoker
1 
0/1  0/1    0/6   
Disease 
Months since 
diagnosis 
0 (0 - 0)  156 (125 - 221)    60 (6 – 42)   
Concomitant drugs  21 x nil  19 x nil    25 x nil   
disease extent 
(maximal/today)
2 
         
normal  21/21  0/19    0/0   
Left sided  0/0  10/0    17/14   
total  0/0  9/0    8/11   
Clinical 
Scores 
Baron score  0 (0 – 0)  0 (0 – 0)    3 (3 – 3)   
Mayo Score  1.5 (0 - 9)  1 (0 - 2)    6 (4 – 11)   
Truelove and Witts 
16x normal 
4x mild 
1x moderate 
14x normal 
5x mild   
12x mild 
8x moderate 
5x severe 
 
Clinical 
investigation 
Deviation of Hct (%)  4.0 (3.1 – 9.4)  3.2 (1.4 – 4.9)  44.5, p = 0.255  7.2 (3.9 – 8.3)  110.5, p = 0.422 
Weight loss (%)  0.0 (0.0 – 0.0)  0.0 (0.0 – 0.0)  124.5, p > 0.999  0.0 (0.0 – 2.1)  128, p = 0.089 
Temperature 
>37.5°C 
nil  nil    nil   
Pulse >90 bpm  nil  nil    nil   
Hb  139 128 – 149)  145 (142 - 154)  36, p = 0.092  130 (114 – 147)  115.5, p = 0.534 
ESR  6 (2 – 9)  10 (4 – 16)  40.5, p = 0.580  42 (19 – 45)  16.5, p = 0.029 
CRP  2.0 (1.0 – 3.5)  5.0 (3.3 – 6.8)  14.5, p = 0.062  15 (6 – 34)  31, p = 0.002 
Raised Creatinine
3  nil  nil    nil   
Albumin  41 (38 – 44)  44 (42 – 44)  42, p = 0.363  38 (37 – 42)  84, p = 0.112 
Table  32.  Patient  characteristics  for  the  candidate  miRNA  RT-
qPCR.Values  given  as  medians  (IQR).  Statistical  relevance  of  the 
difference  between  the  median  values  and  the  control  group  are 
calculated  using  the  two  tailed  Mann  Whitney  U  test,  probability 
statistics  are  shown  as  the  (U  value,  p  value). 
1have  not  smoked 
within 3 months of biopsy. 
2maximal distribution of disease known 
before  endoscopy  /  disease  distribution  today. 
3above  laboratory 
reference range.   Chapter 4. The miRNA signature of IBD 
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The characteristics of the control, active UC and inactive UC groups are given in 
Table  32.  The  median  age of the healthy control is  59 years (IQR 45  – 75), the 
median age of the active UC and inactive UC groups are 49 years (IQR 36 – 62) and 
55 years (IQR 49 – 66) respectively. There is no significant difference in the ages 
of the active and inactive UC groups compared with healthy controls. The median 
time since diagnosis for the active UC group is 60 months (IQR 6  – 42) and the 
inactive UC group, 156 months (IQR 125 – 221). 
The  following  traditional  measures  of  disease  activity  are  not  significantly 
different in active UC compared with the healthy controls; haematocrit (p = 0.422), 
weight loss (p = 0.089), haemoglobin (p = 0.534) and albumin (p = 0.112). These 
same measures are also not statistically different between active and inactive UC. 
Traditional measures of activity in which there is a significant difference between 
active UC and healthy controls are the ESR (p = 0.029) and CRP (p = 0.002). Between 
active and inactive UC there is a statistically significant difference in the ESR (p = 
0.042), but not the CRP (p = 0.054). 
4.4.1  The  expressions  of  miR-31  and  miR-223  are 
increased  in  the  sigmoid colon  in  both  active  and 
inactive UC. 
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(a)  (b) 
Figure 31. The relative expressions of miR-31 and miR-223in sigmoid 
UC by RT-qPCR. The relative expression of (a) miR-31 and (b) miR-223 
is increased in both active (n = 25) and inactive (n = 19) sigmoid UC. 
Expression of miRNAs was analysed by RT-qPCR. miRNA expression Chapter 4. The miRNA signature of IBD 
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was normalised to RNU44 and compared to healthy control (n = 21). 
Median values were compared using the two tailed Mann Whitney U 
test. * P < 0.05. 
The  relative  expressions  of  miR-31  and  miR-223  are  increased  in  the  sigmoid 
mucosa  in  both  active  and  inactive  UC  compared  with  healthy  controls.  The 
expression of miR-31 is increased by a median of 2.830 (IQR 1.419 – 5.726) fold in 
inactive  UC  (p  <  0.001)  and  10.970  (IQR  2.214  –  26.110)  fold  in  active  UC  (p  < 
0.001).  The  expression  of  miR-223  is  significantly  increased  by  a  median  2.477 
(IQR 1.377 – 7.801) fold in inactive UC (p < 0.001), and 3.454 (IQR 1.790 – 7.853) 
fold in active UC (p < 0.001). 
There is also a statistically significant difference between the expression of miR-
31 in active versus inactive UC (p = 0.029), but not in the expression of miR-223 
between active and inactive UC (p = 0.546). 
4.4.2  The  expression  of  miR-146b  is  increased  in  the 
sigmoid colon of active but not inactive UC. 
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Figure 32. The relative expression of miR-146b in sigmoid UC by RT-
qPCR. The relative expression of mir-146b is increased in active but 
not inactive sigmoid UC. Expression of miRNA was analysed by RT-
qPCR. miRNA expression was normalised to RNU44 and compared to 
healthy control. Median values were compared using the two tailed 
Mann Whitney U test. * P < 0.05. ns = not significant.   Chapter 4. The miRNA signature of IBD 
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The relative expression of miR-146b is significantly increased by 2.261 (IQR 1.243 -
3.619) fold in the mucosa of active sigmoid UC (p = 0.002). The expression of miR-
146b is not significantly altered in inactive UC compared with healthy control, fold 
increase 1.048 (IQR 0.642 – 2.044, p = 0.678). 
There  is  a  significant  difference  in  the  expression  of  miR-146b  in  active  UC 
compared with inactive UC, p = 0.029. 
4.4.3  The expressions of miR-194, miR-200b, miR-375 and 
miR-422a  are  reduced  in  the  sigmoid  colon  of 
patients with active UC. 
c o n t ro l in a c t iv e a c t iv e
0
1
2
3
4
r
e
l
a
t
i
v
e
 
e
x
p
r
e
s
s
i
o
n
 
o
f
 
m
i
R
-
1
9
4
*
ns
 
c o n t ro l in a c t iv e a c t iv e
0 . 0
0 . 5
1 . 0
1 . 5
2 . 0
2 . 5
r
e
l
a
t
i
v
e
 
e
x
p
r
e
s
s
i
o
n
 
o
f
 
m
i
R
-
2
0
0
b
*
ns
 
(a)  (b) 
c o n t ro l in a c t iv e a c t iv e
0
1
2
3
r
e
l
a
t
i
v
e
 
e
x
p
r
e
s
s
i
o
n
 
o
f
 
m
i
R
-
3
7
5
*
*
 
c o n t ro l in a c t iv e a c t iv e
0
1
2
3
4
r
e
l
a
t
i
v
e
 
e
x
p
r
e
s
s
i
o
n
 
o
f
 
m
i
R
-
4
2
2
a
*
ns
 
(c)  (d) 
Figure  33.  The  relative  expression  of  miR-194,  miR-200b,  miR-375 
and miR-422a is decreased in sigmoid UC The relative expressions of 
(a)  miR-194,  (b)  miR-200b,  (c)  miR-375  and  (d)  miR-422a  are Chapter 4. The miRNA signature of IBD 
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decreased in active sigmoid UC. The relative expression of miR-375 
is also decreased in inactive sigmoid UC. Expression of miRNAs is 
normalised  to  RNU44  and  compared  with  healthy  control.  Median 
values are compared using the two tailed Mann Whitney U test. * P < 
0.05, ns = not significant. 
The  relative  expressions  of  miR-194,  miR-200b,  miR-375  and  miR-422a  are 
significantly decreased in active sigmoid UC compared with healthy controls. 
The relative expression of miR-194 is decreased by a median of 0.392 (IQR 0.247 – 
0.534, p < 0.001) fold in the mucosa of active sigmoid UC compared with healthy 
controls. However there is no statistically significant difference in the expression 
of miR-194 in inactive sigmoid UC compared with healthy controls, fold difference 
1.140 (IQR 0.539 – 1.584, p = 0.937). There is also a significant difference in the 
relative expression of miR-194 in active UC compared with inactive UC, p = 0.011. 
The relative expression of miR-200b is decreased by a median of 0.460 (IQR 0.367 
– 0.588) fold in the mucosa of active sigmoid UC compared with healthy controls 
(p < 0.001). However there is no significant difference in the relative expression of 
miR-200b in the mucosa of inactive sigmoid UC compared with healthy controls, 
fold difference 0.812 (IQR 0.443 – 1.411, p = 0.281) or in the expression of miR-
200b between active and inactive sigmoid UC, p = 0.124. 
The relative expression of miR-375 is decreased in the mucosa of both active and 
inactive sigmoid UC. The expression of miR-375 is significantly decreased by 0.281 
(IQR 0.187  – 0.415, p < 0.001) fold in the mucosa of active sigmoid UC, and by 
0.624 (IQR 0.462  – 1.030, p = 0.021)  fold  in  the mucosa of inactive sigmoid UC 
compared  with  healthy  control.  There  is  a  significant  difference  between  the 
expressions of miR-375 in active and inactive sigmoid UC, p = 0.001, indicating 
that  although  reduced  in  inactive  UC  compared  with  healthy  control  there  is  a 
greater decrease in active UC. 
The relative expression of miR-422a is decreased by a median of 0.261 (IQR 0.196 
– 0.472, p <0.001) fold in the mucosa of active sigmoid UC compared with healthy 
control. However there is no significant difference in the expression of miR-422a 
in  the  mucosa  of  inactive  sigmoid  UC  compared  with  healthy  controls,  fold   Chapter 4. The miRNA signature of IBD 
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difference 0.789 (IQR 0.513 – 2.393, p = 0.731). There is a significant difference 
between the expressions of miR-422a in active and inactive sigmoid UC, p = 0.001. Chapter 4. The microRNA signature of IBD
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4.5  The  differential  expressions  of  certain  miRNAs  are 
dependent on the current treatment regime. 
The interpretation of published studies into the profile and / or the expressions of 
miRNAs in IBD are made difficult by confounding factors and group heterogeneity, 
prominent amongst these is the current treatment. Current therapy for IBD targets 
the immune  response  and since miRNAs have been shown to influence, and be 
influenced  by  many  aspects  of  the  immune  response,  it  stands  to  reason  that 
existing treatments for IBD could influence miRNA expression, function or both. 
Thus  current  treatment  differences  challenge  the  ability  to  interpret  existing 
studies on the subject. 
The  expressions  of  miR-31  and  miR-375  have  been  shown  to  be  increased  and 
decreased  respectively  in  the  mucosa  of  patients  with  active  sigmoid  UC  and 
Crohn’s.  Using  miR-31  and  miR-375  as  representative  of  the  most  differentially 
expressed miRNA in IBD the aim is to compare the miRNA expressions of miR-31 
and miR-375 in the sigmoid mucosa in relation to the current treatment regime. 
4.5.1  The expression  of miR-31 is  significantly different 
in  patients  taking  Azathioprine  compared  with  5-
ASA alone 
In  patients  with  Baron  grade  3  macroscopically  inflamed  active  sigmoid  UC the 
expression of miR-31 in patients taking Azathioprine is significantly lower than 
patients  taking  5-ASA  alone  (p  =  0.005)  and  patients  taking  no  treatment  (p  = 
0.001). There is no difference in the expression of miR-31 between patients on no 
treatment and those taking 5-ASA (p = 0.198), Figure 34 “active". 
In patients who have inactive UC there is a significantly lower expression of miR-
31 in patients on Azathioprine compared with those on 5-ASA alone (p = 0.016) 
although  the  reduced  expression  of  miR-31  in  patients  on  Azathioprine  is  not 
significantly less than patients on no treatment (p = 0.071), Figure 34 “inactive”. 
In  both  active  and  inactive  UC  the  expression  of  miR-31  is  not  significantly 
different in patients taking Infliximab compared with patients taking Azathioprine, 
5-ASA alone or no treatment.   Chapter 4. The miRNA signature of IBD 
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Figure  34.  The  effect  of  treatment  of  miR-31  in  UC.  The  mucosal 
expression of miR-31 is decreased in patients taking Azathioprine in 
both  inactive  and  active  UC  compared  with  patients  on  other 
treatment regimes. The expressions of miR-31 in sigmoid biopsies 
taken from patients with active and inactive UC and taking a variety 
of treatments are compared by RT-qPCR. The expression of miR-31 is 
normalised to RNU44 and presented as relative expression compared 
against patients with inactive UC and taking no treatment (control). 
Median values were compared with the one tailed Mann-Whitney U 
test. * p < 0.05, ns = not significant. U values for each comparison are 
found in appendix 8.6.2. 
In  patients  with  actively  inflamed  sigmoid  Crohn's  the  expression  of  miR-31  is 
significantly  lower  in  patients  taking  Azathioprine  (p  =  0.025)  and  significantly 
increased in patients taking Infliximab alone (p = 0.014) compared with patients 
taking no treatment, Figure 35 “active”. 
In  patients  with  a  previous  history  of  sigmoid  Crohn's  but  no  active  colonic 
inflammation, the expression of miR-31 in the sigmoid is higher in patients taking 
Azathioprine  compared  with  patients  taking  no  treatment  but  this  is  not 
significant (p = 0.062), Figure 35 “inactive”. 
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Figure 35. The effect of treatment on miR-31 in Crohn's disease.  The 
expression  of  miR-31  is  less  in  patients  taking  Azathioprine  with 
active  Crohn’s  compared  with  patients  with  the  same  degree  of 
inflammatory  activity  on  different  treatment  regimes.  The 
expressions of miR-31 in sigmoid biopsies taken from patients with 
active and inactive Crohn’s disease and on a variety of treatments 
are compared by RT-qPCR. The expression of miR-31 is normalised to 
RNU44  and  presented  as  relative  expression  compared  against 
patients  with  inactive  Crohn’s  disease  and  taking  no  treatment 
(control). Median  values  were  compared  with the two tailed Mann-
Whitney U test. * p < 0.05, ns = not significant. 
4.5.2  The  expression  of  miR-375  is  not  significantly 
different in patients taking Azathioprine compared 
with 5-ASA alone 
Although the relative expression of miR-375 is decreased in the sigmoid mucosa 
of patients with inactive and active UC compared to healthy controls, there is no 
significant difference in the expression of miR-375 within either of the inactive or 
active sigmoid UC groups, when divided into treatment groups, Figure 36. 
Neither 5-ASAs, Azathioprine or Infliximab appear to alter the expression of miR-
375. 
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Figure 36. The expression of miR-375 is not altered in patients on 
different treatment regimes for UC. The expressions of miR-375 in 
sigmoid biopsies taken from patients with active and inactive UC and 
on a variety of treatments are compared by RT-qPCR. The expression 
of  miR-375  is  normalised  to  RNU44  and  presented  as  relative 
expression compared against patients with inactive UC and taking no 
treatment (control). Median values are compared with the two tailed 
Mann-Whitney U test. ns = not significant. 
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4.6  Bioinformatic search for microRNA targets 
Bioinformatic searches were conducted using the 2 databases; TargetScan version 
5.2, June 2011 (Lewis et al., 2003, Garcia et al., 2011) and MirTarget2 v4.0 (Wang 
and El Naqa, 2008, Wang, 2008) both accessed through to 28
th Sept 2011. 
TargetScan uses the MiRanda algorithm  which primarily predicts miRNA targets 
through the base pair matching qualities between the seed region of the miRNA 
and the 3’ UTR of the target gene. 
MirTarget2 (available at www.mirdb.org) uses a support vector machine to predict 
targets based on known gene / miRNA interactions. 
 
 
TargetScan 
(conserved targets) 
MirTarget2 
(score >50) 
Total number of 
targets 
% similarity 
(targets predicted by 
both) 
         
miR-31  233  247  411  21 
miR-146b  129  229  323  12 
miR-194  252  333  496  19 
miR-200b  798  844  1302  26 
miR-223  202  240  373  23 
miR-375  141  35  170  4 
miR-422a  13  199  210  1 
         
Table 33. Comparison of the predicted target results for 2 distinct 
bioinformatic  search  algorithms.  (TargetScan  v5.2,  and  MiTarget 
v4.0). 
The number of predicated targets using the 2 algorithms is shown in Table 33. By 
combining 2 distinctly separate methods of identifying gene targets it is hoped 
that there is a decrease in false positive results, and increase the true positive 
results. 
Bioinformatic  searches  are  limited  in  their  ability  to  predict  useful  targets  and 
therefore the results presented are those predicted targets that are ranked in the 
top  20  for  TargetScan  v5.2,  those  with  a  MirTarget2  score  >80  and  those  of 
potential interest after review of all the targets and there known functions.   Chapter 4. The miRNA signature of IBD 
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The aims are to identify potential gene targets for miR-31, miR-146b, miR-194, miR-
200b, miR-223, miR-375 and miR-422a. As well as identify a potential target that is 
targeted by more than one of the candidate miRNAs. 
4.6.1  Targets of interest for miR-31 
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SH2D1A  3  2  0  -0.74  0.49  9  88  Encodes  a  protein  that  inhibits  SLAM  and  modifies  T  cell  signal 
transduction  
PRKCE  6  1  2  -0.66  0.55  28  77  Key role in TLR4 / LPS mediated signaling in activated macrophages 
and possibly INF regulation (Aksoy et al., 2004). 
STARD13  15  1  0  -0.52  0.52  148  59 
Suppresses  cell  growth  in  liver  cancer,  inhibits  activity  of  Raf-1-
ERK1/2-p70S6K. Selectively activates CDC42 and is involved in TGF-β 
pathway 
CD28  107  1  1  -0.27  0.41      required for T cell activation 
PPP3CA  160  1  0  -0.2  0.21 
 
  activates T cells 
NCK2  191  1  0  -0.16  0.21 
 
  involved in the regulation of receptor protein kinases 
TSLP  192  0  1  -0.10  <0.1      TH2 pathways, crosstalk between DCs and macrophages 
IL1R1            87  67  inflammation 
CDC42EP
4            108  64 
CDC42  regulates  signaling  pathways  that  control  diverse  cellular 
functions including cell morphology, migration, endocytosis and cell 
cycle progression. 
SP1            132  61  Involved in TGF-β pathway 
Table 34.Targets of interest for miR-31Using TargetScan v 5.2 and 
MirTarget2 v4.0. Pathways are taken from NCBI Gene database (Pruitt 
et al., 2009). 
Mir-31  potential  targets  numerous  genes  involved  with  aspects  of  the  immune 
response, Table 34. Genes of interest include; PRKCE and SH2D1A. 
PRKCE, (protein kinase Cε) is essential for IL-12 synthesis and therefore involved 
in the T
H1 response. PRKCE plays a role in LPS stimulation of macrophages and 
DCs through the TLR4 receptor pathway (Aksoy et al., 2004, Aksoy et al., 2002) 
SH2D1A  encodes  a  protein  that  inhibits  SLAM  (signaling  lymphocyte-activation 
molecule) by blocking the recruitment of SHP-2 to its docking site; this and other 
surface molecule interactions can modify cell signal transduction in activated T, B 
and NK cells. Mutations in this gene cause lymphoproliferative syndrome X-linked Chapter 4. The microRNA signature of IBD
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type  1  or  Duncan  disease,  a  rare  immunodeficiency  characterized  by  extreme 
susceptibility to infection, suggesting that inhibition of SH2D1A can exaggerate T 
cell signalling and thus inflammation. 
4.6.2  Targets of interest for miR-146b 
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TRAF6  2  1  1  -0.99    2  98 
This protein functions as a signal transducer in the NF-κβ pathway by 
mediating  signals  of  the  TNF  receptor  superfamily,  members  of  the 
Toll/IL-1 family and receptors such as CD40, TNFSF11/RANCE and IL-1. 
This  protein  also  interacts  with  various  protein  kinases  including 
IRAK1/IRAK, SRC and PKCζ,.  
CD80  6  1  0  -0.44    109  61  Macrophages  in  mice  show  increased  expression,  blockade  of  CD80 
reduces colitis 
IRAK1  23  1  0  -0.77    12  87 
This  gene  encodes  the  IL-1  receptor-associated  kinase  1,  one  of  two 
serine/threonine  kinases  that  become  associated  with  IL1R  upon 
stimulation.  This  gene  is  partially  responsible  for  IL1-induced  up-
regulation of the transcription factor NF-κβ. 
CCBP2  27  1  0  -0.56         
Chemokines and their receptor-mediated signal transduction are critical 
for the recruitment of effector immune cells to the inflammation site. 
SMAD4  40  1  0  -0.4    18  82 
SMAD  proteins  are  activated  by  transmembrane  serine-threonine 
receptor kinases in response to TGF-β. The product of this gene forms 
complexes with other activated Smad proteins, which accumulate in the 
nucleus  and  regulate  the  transcription  of  target  genes.  Mutations  or 
deletions in this gene have been shown to result in pancreatic cancer, 
juvenile polyposis syndrome, and hereditary hemorrhagic telangiectasia 
syndrome 
ATG12  46  1  0  -0.38          ATG16 GWAS study 
CARD10  54  1  1  -0.35          GWAS study 
Table 35.Targets of interest for miR-146b Using TargetScan v 5.2 and 
MirTarget2 v4.0. Pathways are taken from NCBI Gene database (Pruitt 
et al., 2009). 
MiR-146b has been shown to have an influence on the TLR / NF-κβ pathways; TRAF 
(particularly  TRAF  6)  protein  family  has  been  extensively  studied  in  mice  and 
peripheral  blood  lymphocytes.  CD80  is  involved  in  the  co-stimulatory  signal 
essential for T-lymphocyte activation. T-cell proliferation and cytokine production 
is induced by the binding of CD28 or CTLA-4 to this receptor. IRAK1 binds to the 
IL-1 receptor, triggering intracellular signalling cascades leading to up-regulation 
and mRNA stabilization.    Chapter 4. The miRNA signature of IBD 
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4.6.3  Targets of interest for miR-194 
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ITPKB  7  1  1  -0.65  0.52  56  76 
Regulates immune cell function and is required for T and B 
cell development. 
ACVR2B  18  2  0  -0.52  0.75  73  74 
ACVR2B  is  an  activin type  2  receptor  and  belongs  to the 
(TGF-β) superfamily.  
MAPK1  56  1  1  -0.41  0.5     
Acts as a transcriptional repressor of INF-γ induced genes. 
Seems to bind to the promoter of CCL5, DMP1, FIH1, IFITM1, 
IRF7,  IRF9,  LAMP3,  OAS1,  OAS2,  OAS3  and  STAT1.  MAPKs 
regulate  a  wide  variety  of  cellular  functions  including; 
signals  from  growth  factors,  differentiation,  proliferation 
and  phosphorylation  of  many  inflammatory  transcription 
factors. 
FOXO1  221  1  0  -0.13  0.41     
A member of the forkhead family. The specific function of 
this  gene  has  not  yet  been  determined;  however,  it  may 
play a role in myogenic growth and differentiation. 
TSLP 
 
0  1  -0.03  <0.1      TH2 pathways 
Table 36.Targets of interest for miR-194 Using TargetScan v 5.2 and 
MirTarget2 v4.0. Pathways are taken from NCBI Gene database (Pruitt 
et al., 2009). 
4.6.4  Targets of interest for miR-200b 
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ZEB2  1  6  0  -2.13  1  100  Interacts  with  receptor-mediated,  activated  SMADs.  Represses 
transcription of E-cadherin 
RECK  10  2  1  -0.95  5  99 
The  expression  is  suppressed  in  many.  In  normal  cells,  this 
membrane glycoprotein may serve as a negative regulator for MMP-
9, a enzyme involved in tumour invasion and metastasis 
ZEB1  29  2  0  -0.79  3  100 
Represses  T  cell  specific  IL2  gene.  Represses  E-cadherin,  and 
induces  an  epithelial-mesenchymal  transition  (EMT)  by  recruiting 
SMARCA4/BRG1. Promotes tumorigenicity by repressing miRNAs 
SULF1  62  1  1  -0.65  56  84 
Acts  as  a  negative  regulator  of  TGF-β,  widely  involved  with 
inflammation. facilitates apoptosis 
PLCG1  311  1  0  -0.36      T cell receptor signalling 
MAP3K1  323  1  0  -0.35      sapk / jnk, activated p38 MAPK, TLR pathways 
TOB1  502  1  0  -0.26 
   
TGF-β signalling 
XIAP  570  1  0  -0.23      Apoptosis 
SMAD2  603  1  0  -0.21 
   
TGF-β signalling 
FYN  614  1  0  -0.2      B cell receptor signalling 
PTEN  622  1  0  -0.2      Inhibitor of apoptosis Chapter 4. The microRNA signature of IBD
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Target gene 
TargetScan  MirTarget2 
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ACVR2B  627  1  1  -0.19      TGF-β signalling 
EP300  666  1  0  -0.17     
TGF-β signalling 
CREBBP  675  1  0  -0.16 
   
TGF-β signalling 
ACVR2A  725  1  0  -0.13      TGF-β signalling 
PRKAB1  753  1  0  -0.12 
   
Autophagy 
SP1  758  1  0  -0.11      TGF-β signalling 
BCL2  782  1  0  -0.05      Inhibitor of apoptosis, autophagy and death receptor signalling 
MEF2D  796  1  0  0.03      Activating p38 MAPK pathways 
Table 37.Targets of interest for miR-200b Using TargetScan v 5.2 and 
MirTarget2 v4.0. Pathways are taken from NCBI Gene database (Pruitt 
et al., 2009). 
4.6.5  Targets of interest for miR-223 
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FBXW7  1  1  1  -1.36  0.86  1  99 
Inactivation  results  in  repression  of  TGF-β  dependent 
transcription 
RHOB  4  1  1  -0.73  0.51  13  87 
Role in heat stress response and increased transcriptional 
activity of NF-κβ 
FOXO1  7  1  2  -0.66  0.55  41  75 
A member of the forkhead family. The specific function of 
this gene has not yet been determined; however, it may play 
a role in myogenic growth and differentiation. 
ACVR2A  41  1  0  -0.43  0.47  11  88  Activins are growth and differentiation factors which belong 
to the TGF-β superfamily. 
CALML4  47  1  0  -0.41  0.47  115  62  Ca binding protein involved in inflammation 
AK2  93  1  2  -0.33  0.62 
   
Gene identified by GWAS. Function in T
H17 cells 
SP1  105  1  0  -0.29  0.46     
regulates  the  expression  of  a  large  number  of  genes 
involved  in  a  variety  of  processes  such  as  cell  growth, 
apoptosis, differentiation and immune responses 
MMP16  170  1  1  -0.16  0.58     
Also targeted by miR-146b in glioma cells. Expressed by T 
cells. 
TSLP            5  89  TH2 pathways 
Table 38.Targets of interest for miR-223 Using TargetScan v 5.2 and 
MirTarget2 v4.0. Pathways are taken from NCBI Gene database (Pruitt 
et al., 2009). 
     Chapter 4. The miRNA signature of IBD 
171 
4.6.6  Targets of interest for miR-375 
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ATG2B  61  1  0  -0.16     
associated  with  gastric  and  colorectal  cancers  through 
autophagy. 
SP1  126  1  0  -0.06     
regulates  the  expression  of  a  large  number  of  genes 
involved  in  a  variety  of  processes  such  as  cell  growth, 
apoptosis,  differentiation  and  immune  responses,  TGF-β 
signalling. 
Table 39.Targets of interest for miR-375 Using TargetScan v 5.2 and 
MirTarget2 v4.0. Pathways are taken from NCBI Gene database (Pruitt 
et al., 2009). 
Although  TSLP  is  not  identified  as  a  target  of  miR-375  by  either  TargetScan  or 
MirTarget2, miR-375 has been shown to play a role in IL-13 induced expression of 
TSLP in HT29 cells (Biton et al., 2011). 
4.6.7  Targets of interest for miR-422a 
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SULF1  3  1  0  -0.41  36  71  Acts  as  a  negative  regulator  of  TGF-β,  widely  involved  with 
inflammation. facilitates apoptosis 
DYRK1A  8  1  1  -0.27     
Increased expression improves  survival in  sepsis, by abrogating 
sepsis induced lymphocyte apoptosis. 
TSLP 
 
0  1  -0.06 
    TH2 pathways 
TRAF6          67  65 
This protein functions as a signal transducer in the NF-κβ pathway 
by mediating signals of the TNF receptor superfamily, members of 
the Toll/IL-1 family and receptors such as CD40, TNFSF11/RANCE 
and IL-1. This protein also interacts with various protein kinases 
including IRAK1/IRAK, SRC and PKCζ,. 
Table 40.Targets of interest for miR-422a Using TargetScan v 5.2 and 
MirTarget2 v4.0. Pathways are taken from NCBI Gene database (Pruitt 
et al., 2009). Chapter 4. The microRNA signature of IBD
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4.6.8  TSLP as a target 
There  are  3285  potential  targets  identified  for  the  7  candidate  miRNAs,  using 
TargetScan and MirTarget2, at least 45 of which have been shown to play a role 
within inflammatory pathways involved in IBD and are shown in Table 34 to Table 
40. A number of genes are potential targets for >1 candidate miRNA. TSLP and SP1 
are targets for 4 miRNAs, and TRAF6, ACVR2B, FOX01, SULF1 and ACVR2A are all 
targets for 2 miRNAs. 
Using  TargetScan v6.0 to predict gene targets for the candidate miRNAs  shows 
that  TSLP  is  a  target  for  miR-31,  miR-194  and  miR-422a.  Base  pair  matching 
between the seed region of the miRNAs and TSLP, and context scores using the 
TargetScan algorithm is shown in Table 41. Predicting which miRNA is most likely 
to  target  TSLP  using  the  same  algorithm  reveals  that  miR-495  has  the  highest 
context score. However miR-495 did not amplify in all microarray experiments for 
UC and therefore does not feature in the miRNA expression tables, Table 28 and 
Table 29. The expression of miR-495 in active Crohn's is 1.547 fold greater than 
healthy control, although is ranked 64
th in order of relative expression compared 
with healthy control, appendix 8.3.3. 
TSLP  is  an  interesting  target  for  miRNAs  in  UC  due  to  its  association  with  T
H2 
inflammation, and its involvement in epithelial homeostasis. TSLP was therefore 
chosen ahead of SP1, a gene which encodes the transcription factor Sp1. Through 
the  regulation  of  a  vast  number  of  genes  Sp1  has  many  functions  including 
differentiation,  proliferation  and  apoptosis.  The  main  role  for  Sp1  is  in 
embryological  development,  although  through  its  effect  on  cell  growth  and 
proliferation deregulation of Sp1 is associated with certain forms of cancer. It is 
not known to have an association with inflammation (Deniaud et al., 2009). 
  
 
 
predicted consequential pairing of 
target region (top) and miRNA 
(bottom) 
seed match 
contribution 
context+ 
score 
context+ 
score 
percentile 
conserved 
branch 
length 
PCT 
site-type   3' 
pairing  
local AU   position   TA   SPS  
Position 1236-1242 of TSLP 3' UTR 
 
hsa-miR-31 
5' ...CUUAAAUCCAUCUUACUUGCCAA.. 
                                        I I I I I I I  
3'     UCGAUACGGUCGUAGAACGGA 
7mer-1A  -0.074  -0.002  -0.009  0.028  0.003  -0.047  -0.10  45  0.324  < 0.1 
Position  587-593  of  TSLP  3'  UTR 
 
hsa-miR-194 
5'  ...CCUGAGAAGUACCUUUGUUACAG... 
                                         I  I  I  I  I  I  
3' AGGUGUACCUCAACGACAAUGU 
7mer-1A  -0.074  0.001  -0.004  0.014  0.000  0.031  -0.03  34  0.545  < 0.1 
Position 1357-1363 of TSLP 3' UTR 
 
hsa-miR-422a 
5'  ...UAAGACUCAGCCUUUGUCCAGAG... 
                                         I  I  I  I  I  |  
3' CGGAAGACUGGGAUUCAGGUCA 
7mer-1A  -0.074  0.001  0.014  0.014  N/A  N/A  -0.05  40  0.011  N/A 
Position  585-591  of  TSLP  3'  UTR 
 
hsa-miR-495 
5'  ...AUCCUGAGAAGUACCUUUGUUAC... 
                                        I  I  I  I  I  I 
3' UUCUUCACGUGGUACAAACAAA 
7mer-1A  -0.074  0.001  0.001  0.014  N/A  N/A  -0.06  27  1.770  N/A 
Position 1555-1561 of TSLP 3' UTR 
 
Hsa-miR-223 
5’  .. TGAACTATGAAAATAAATACACA.. 
                                         I I I I I I  
3’  CGUGUAUUUGACAAGCUGAGUU 
7mer-1A  MirTarget2 score 89 
Table 41. The predicted base pair matching for TSLP and the 3’UTR of candidate miRNAs.TargetScan v6.0 identifies TSLP as a target for 
miR-31, miR-194 and miR-422a. MiR-495 is the highest scoring miRNA for TSLP. MirTarget2 identifies miR-223 to target TSLP. 
 
Figure 37. The position of miR-31, miR-194 and miR-422a base pairing with the 3’UTR of TSLP.TargetScan v6. Chapter 4. The microRNA signature of IBD 
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4.7  Chapter discussion 
Experimental models have shown a crucial role for miRNA in many inflammatory 
pathways  and  suggest  a  fundamental  role  for  miRNA  in  the  aetiology  of  IBD. 
However,  the  currently  available  miRNA  profiles  for  IBD  provide  an  ambiguous 
picture  that  is  difficult  to  interpret.  Interpretation  and  clinical  usefulness  of  a 
miRNA  profile  largely  depends  on  the  sample  phenotype  as  this  relates  to 
treatment  decisions  and  a  range  of  long  term  outcomes.  The  wide  variety  of 
phenotypes is also likely to reflect subtle differences in aetiological factors which 
may influence miRNA expression. 
The lack of consistent evidence requires that the first step is to determine which 
miRNAs are differentially expressed in active IBD in a homogeneous and clinically 
applicable patient group. The focus here is on UC, with a comparison to the miRNA 
signature in Crohn’s. 
One of the important clinical and sample selection criteria revolve around current 
therapy.  Medical  treatments  for  IBD  target  elements  of  the  immune  system, 
traditional  treatments  such  as  steroids  and  thiopurines  act  non-specifically  on 
immune function through multiple pathways. New treatments such as Infliximab 
act  against  specific  targets,  in  this  case  TNF-α,  however  the  effects  of  altered 
TNF-α  function  will  influence  a  multitude  of  other  downstream  pathways.  It 
therefore  stands  to  reason  that  therapy  alters  or  interacts  at  some  level  with 
miRNA expression and/or function.  Therefore patients are only included  in this 
study  if  they  have  not  had  medical  therapy  for  IBD  for    6  months,  termed 
“treatment naive”. In section 4.5 it is shown that patients taking Azathioprine have 
a  decreased  level  of  miR-31  compared  with  macroscopically  matched  patients 
taking no medication or 5-ASA alone. This effect is not seen with miR-375 and may 
represent a miRNA specific phenomenon; however it does indicate that patients on 
heterogeneous  treatment  regimes  should  not  be  grouped  together  for  the 
purposes of measuring miRNA levels. In both the study by Wu et al. (2008) and 
Fasseu et al. (2010) patient groups were heterogeneous and included patients on 
disease modifying agents in 80% and 63% of cases respectively.   Chapter 4. The microRNA signature of IBD 
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There are two other  important features of sample homogeneity; the first is the 
origin  of  the  tissue.  Biopsies  are  collected  from  endoscopy  and  not  surgical 
resections due to the obvious differences in disease phenotype, activity and the 
likely differences in aetiological or propagating factors. The second is the region 
from which the samples were taken. There is debate over regional differences in 
miRNA  expression,  in  particular,  miR-422b  was  one  of  six  miRNAs  to  have  a 
difference in expression between different regions of the colon (Wu et al., 2010). 
Again  this  may  reflect  either  a  functional  role  for  certain  miRNAs  and  /  or  an 
interaction with aspects of the colonic environment, for example the microbiome 
or homeostasis mechanisms, which also have regional differences. For consistency 
biopsies are taken only from the sigmoid colon. 
Inflammatory  activity  is  measured  clinically  in  3  ways,  symptomatically, 
biochemically  and  endoscopically.  In  traditional  clinical  practice  the  logistics  of 
endoscopy  result  in  clinical  activity  being  measured  predominantly  by  a 
combination of symptom activity and biochemical results. However symptoms are 
subjective and correlate poorly with endoscopic activity due to a wide variety of 
confounding  factors,  including  psychosocial  issues  and  coexisting  dietary 
intolerances.  Very  raised  biochemical  marker  levels  are  well  validated  at 
distinguishing severe disease from mild to moderate disease and are independent 
predictors of a poor outcome or the need for colectomy. However despite being 
more  objective  than  symptoms,  biochemical  markers  still  correlate  poorly  with 
endoscopic  activity  (Turner  et  al.,  2011)  or  changes  in  activity  over  time. 
Endoscopic  activity  is  therefore  becoming  the  predominant  factor  in  grading 
disease activity and disease response to treatment both clinically and in clinical 
trials. 
In this study patients were included in the active UC group if they had Baron grade 
3 inflammation at the time of biopsy. Patients with active UC tended towards a 
higher clinical activity score although as Table 32 shows, there are a number of 
interesting points; in both the control group and the inactive UC group there are 
patients  who  report  symptoms  which  score  them  as  having  mild  and  moderate 
disease activity despite no macroscopic inflammation, and in the active UC group Chapter 4. The microRNA signature of IBD 
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only  20%  (5/25)  had  a  “severe”  Truelove  and  Witts  score,  despite  severe 
macroscopic inflammation. 
There  are  a  number  of  clinical  activity  scoring  systems  for  UC  (D'Haens  et  al., 
2007),  all  are  subjective  and  many  open  to  in  inter-observer  variation.  The 
Truelove and Witts score was designed to capture those patients with acute severe 
UC, it is the oldest, arguably the simplest and the most commonly used clinical 
score, thus it is favoured in this study to compare clinical activity between patient 
groups.  However,  the  lack  of  concordance  between  endoscopic  activity  and  the 
Truelove  and  Witts  score  is  explained  by  some  of  its  weaknesses;  its  focus  on 
haematochezia as a required symptom renders it unable to capture those patients 
who  do  not  view  their  stools  or  are  not  passing  frequent  amounts  of  bloody 
stools, and the inclusion of signs and symptoms that are also frequently seen in 
non-IBD pathologies such as haematochezia caused by haemorrhoids or diarrhoea 
predominant Irritable Bowel Syndrome, reduces its specificity. Alternative scoring 
systems are available, but their use is limited in clinical practice. 
Biochemical  markers  compared  in  this  study  include;  haematocrit,  haemoglobin, 
albumin and the inflammatory markers ESR and CRP. Only the CRP and ESR were 
significantly different between active UC and healthy control. The ESR in active UC 
is 42 compared with 6 in healthy controls, p = 0.029. The CRP is also increased, 15 
versus 2 respectively, p= 0.002. Despite the statistical significance between CRP in 
active  disease  and  healthy  control,  approximately  25%  (6/25)  of  the  active  UC 
group had a CRP within the normal range, a sensitivity for active inflammation in 
UC which is consistent with published results (Henriksen et al., 2008). Endoscopic 
activity is the only reliable and objective way of measuring disease activity and 
should be the standard way of measuring disease activity in UC. 
The  strength  of  this  study  is  the  homogeneous  selection  criteria,  based  on  a 
definition of Baron grade 3 active sigmoid UC in patients who are naive to disease 
modifying treatment. 
The number of miRNAs is doubling every 3 years, when last updated there were 
1600  human  miRNA  hairpin  precursors  and  2042  mature  miRNA  sequences   Chapter 4. The microRNA signature of IBD 
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registered  on  the  miRBase  sequences  database  (release  19,  available  at 
www.mirbase.org, assessed 30
th November 2012). 
Rapidly increasing numbers of miRNA make complete miRNA profiling impossible. 
When first performed the TaqMan® Array card v2.0 analysed approximately 40% 
(377) of known miRNAs (miRBase, release 14), at time of writing this is only 20% 
(377/1921). However, the 377 miRNAs included on the array card are considered 
the  “most  highly  characterised”  and  “of  demonstrated  interest  to  the  research 
community” by the manufacturer (Applied Biosystems, 2010), implying that they 
are the most likely miRNAs to play a prominent role in IBD. 
During microarray experiments approximately 50% of miRNAs do not amplify, (Wu 
et  al.,  2010,  Fasseu  et  al.,  2010).  During  these  experiments  only  40%  (150/377) 
miRNAs amplified within the cut off Ct value < 35. There are many factors that 
cause  no  or  poor  amplification  including  loss  of  small  RNA,  <  200  nucleotides, 
during the precipitation step of the TRIzol® extraction, or poor amplification due 
to the complexity of the array card, acknowledged by the manufacturer. Although 
alternative  RNA  extraction  techniques  and  pre-amplification  steps  are  available, 
the relative expression is only compared between the same miRNAs in active IBD 
and control and not between different miRNAs in the same samples; therefore the 
quantification of the quality and efficacy of small RNA extraction is not necessary. 
There  are  two  prominent  methods  that  are  used  to  present  the  expression  of 
miRNAs  in  array  studies;  the  first  is  by  listing  in  order  of  relative  expression 
between the active group and a control (Wu et al., 2008, Wu et al., 2010, Fasseu et 
al.,  2010)  using  the  2
-∆∆Ct  calculation  (Livak  and  Schmittgen,  2001),  the  second 
calculates the relative expression but presents the results in rank order, from the 
miRNA with the greatest increase in relative expression to that with the greatest 
decrease in relative expression. Presenting the relative expression values can be 
misleading as they often differ from the actual relative expression by many fold. 
Validation of microarrays is always necessary because of the inherent variation in 
biological  samples  and  the  inaccuracy  of  microarray  results.  It  is  a  feature  of 
microarrays  that  when  validated  with  RT-qPCR  up  to  50%  of  the  differentially 
expressed miRNAs are no longer significant. Microarray data therefore provides Chapter 4. The microRNA signature of IBD 
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only “candidate miRNAs”. To reduce the error rate firstly a method of “pairwise 
analysis”  was  performed  similar  to that  used  by  Van  der  Goten  et  al.  (2012),  a 
technique which involves the comparison of one active IBD array card versus one 
control array card, this was repeated 3 separate times. For each pair of cards the 
differential expression using the 2
-∆∆Ct was calculated and expressions ranked. 
The 20 miRNAs with the greatest increase or decrease in relative expression from 
each pair were then compared to discover which miRNA are consistently the most 
differentially expressed in UC. The same experiments were performed for Crohn's. 
Focusing  on  UC,  for  logistical  reasons,  seven  miRNAs  have  been  identified  as 
consistently  differentiated  in  the  sigmoid  mucosa  of  active  UC  versus  healthy 
controls. At the time of performing the microarray there are 65 miRNAs that have 
been shown to have a differential expression in the colonic  mucosa of patients 
with UC by array (Wu et al., 2008, Fasseu et al., 2010, Van der Goten et al., 2012), 
see  Table 13. At the time of the experiment only miR-31, miR-223, miR-375 and 
miR-422a  had  been  previously  shown  to  be  increased  in  the  mucosa  of  UC. 
However in a recently published abstract, Van der Goten et al.  (2012) have also 
shown the differential expression of miR-146b, miR-194 and miR-200b in UC. 
MiR-31 is well established to have increased expression in many forms of cancer 
including; lung (Liu et al., 2010b), stomach (Zhang et al., 2010b), colon (Creighton 
et al., 2010) and interestingly UC associated dysplasia but not the background UC 
(Olaru et al., 2011). It has been identified as an up-regulated miRNA in UC in some 
studies (Fasseu et al., 2010, Van der Goten et al., 2012), but not others (Wu et al., 
2008). 
Most of the functional pathways influenced by miR-31 have so far implicated it in 
oncogenesis, these include LATS2 and PPP2R2A (Liu et al., 2010b), which suppress 
pathways involved with lung cancer, and SATB2 in tumour associated fibroblasts 
which reduces the ability of metastases to migrate and invade (Aprelikova et al., 
2010), HIF transcription factors (Liu et al., 2010a), and many others. 
MiR-31 plays an important role in the immune regulation and responses.  TNF-α 
increases miR-31 expression in epithelial cells which then target SELE and ICAM-1   Chapter 4. The microRNA signature of IBD 
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decreasing  neutrophil  binding  (Suarez  et  al.,  2010).  MiR-31  was  also  found  to 
directly  target  the  FOXP3  transcription  factor  and  is  under-expressed  in  T
regs 
compared with other T cell phenotypes (Rouas et al., 2009). The role of miR-31 in 
IBD is yet to be established. 
MiR-146  has  a  well  established  role  in  a  number  of  inflammatory  pathways  in 
which  its  influence  appears  to  be  part  of  a  negative  feedback  regulator.  The 
expression of miR-146 is induced through TLR activation and the NF-κβ pathway, 
whilst its increased expression targets TRAF6 and IRAK1, negatively influencing 
the TLR / NF-κβ pathway (Bhaumik et al., 2008). A negative feedback role is also 
suggested by an increased expression of miR-146 by TNF-α and IL-1β on one hand 
(Nakasa et al., 2008) whilst down regulating TNF-α and IL-1β on the other (Jones et 
al., 2009). 
The pathological relevance of miR-146 has been demonstrated in various cancers 
including breast cancer in which miR-146 has been shown to suppress NF-κβ and 
influence  the  migration  of  breast  cancer  cells  (Bhaumik  et  al.,  2008).  In 
inflammatory conditions miR-146 has been shown to have an increased expression 
including Rheumatoid Arthritis (Nakasa et al., 2008), Osteoarthritis (Jones et al., 
2009) and alveolitis. In the later, rapid induction of IL-1β induces miR-146 which 
negatively  regulates  the  release  of  IL-8  and  CCL5,  factors  crucial  to  the  innate 
immune response, thus again dampening the immune response. 
The expression of  miR-146  is  induced in  THP-1 cells  (Taganov et al., 2006) and 
human  cord  blood  monocytes  (Lederhuber  et  al.,  2011)  by  LPS  stimulation 
suggesting  a  role  in  innate  immune  response  and  a  potential  role  within  the 
response to luminal flora. The influence of miR-146 on intestinal immunology has 
not yet been investigated. 
The expression of miR-194 is increased in the mouse lung after stimulation with 
LPS and  is  associated with  reduced  levels  of  TNF-α,  in  the  lung  miR-194  is  not 
affected by corticosteroids (Moschos et al., 2007). In a caco-2 intestinal epithelial 
cell model, hepatocyte nuclear factor-1α (HNF-1α) induces expression of miR-194, 
therefore  suggesting  an  influence  on  epithelial  cell  differentiation  (Hino  et  al., 
2008). The function of miR-194 has yet to be established. Chapter 4. The microRNA signature of IBD 
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MiR-200 is expressed by epithelial cells and is implicated in many cancers due to 
its  influence  on  epithelial-mesenchymal  transition  which  is  required  for 
metastases (Paterson et al., 2008). Differences in miR-200 expression have been 
associated with enhanced tumorigenesis, significantly correlated with decreased 
survival  and  are  associated  with  resistance  to  several  chemotherapy  drugs; 
docetaxel  in  non-small  cell  cancer  cells,  cisplatin  in  breast  cancer  cells,  and 
gemcitabine in cholangiocarcinoma cells. The role in inflammation and /or IBD has 
yet to be established. 
The influence of miR-223 can be broken down into three broad overlapping areas; 
its  de-regulated  expression  in  solid  organ  cancers,  its  role  in  haematological 
malignancies and its effect on lymphocyte function. 
MiR-223  is  deregulated  in  colorectal  cancer  (Earle  et  al.,  2010),  bladder  cancer 
(Gottardo et al., 2007), ovarian cancer (Laios et al., 2008), increased in oesophageal 
adenocarcinoma (Mathe et al., 2009), oesophageal squamous cell cancer (Zhang et 
al.,  2010a),  small  cell  lung  cancer  (Miko  et  al.,  2009)  and  down  regulated  in 
hepatocellular carcinoma. 
The prominent role for miR-223 is in granulopoiesis. Overall miR-223 negatively 
regulates progenitor proliferation and  granulocyte differentiation and activation 
through interaction with numerous transcription factors which are either targets 
of  miR-223  or  target miR-223  directly  including  mef2c  (Johnnidis  et al.,  2008b), 
stathmin 1(Wong et al., 2008), LMO2 (Malumbres et al., 2009), AML1/ETO, (Fazi et 
al., 2007) and E2F1 (Pulikkan et al., 2010). Abnormalities of miR-223 expression are 
manifested  pathologically  as  lymphoproliferative  disorders  (Bellon  et  al.,  2009), 
polycythemia  vera  mononuclear  cells  (Bruchova  et  al.,  2008),  myelofibrosis, 
essential  thrombocythaemia  (Hussein  et  al.,  2009)  and  most  prominently,  T  cell 
acute lymphoblastic leukaemia (Chiaretti et al., 2010) (Mi et al., 2007). 
As  well  as  tumorigenesis  and  granulopoiesis,  miR-223  also  has  an  important 
influence on inflammation across many different tissues. MiR-223 is increased in 
the  synovial  fluid  (Murata  et  al.,  2010)  and  deregulated  in  peripheral  T 
lymphocytes (Fulci et al., 2010) in Rheumatoid Arthritis. MiR-223 is deregulated in 
muscle  inflammation  and  around  sites  of  spinal  cord  injury  (Nakanishi  et  al.,   Chapter 4. The microRNA signature of IBD 
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2010),  in  hepatic  inflammation  (Yu  et  al.,  2009)  and  reduced  in  the  Systemic 
Inflammatory Response Syndrome, SIRS (Wang et al., 2010). 
Overall, miR-223 appears to function as a regulator of the inflammatory process, 
reduced  levels  of  miR-233  are  associated  with  hypersensitive  neutrophils 
(Johnnidis  et  al.,  2008a),  and  although  decreased  levels  prevents  macrophage 
hyper-activation it primes macrophages for a stronger pro-inflammatory response 
(Li et al., 2010). 
Importantly miR-223 is differentially expressed between monocytes and monocyte 
derived DCs (Cekaite et al., 2010) and may account for some of the characteristics 
of the mature cell types. 
MiR-375 has been shown to be decreased in UC miRNA array by Wu et al. (2008). It 
has  been  implicated  in  breast,  hepatic  and  gastric  cancer.  In  gastric  cancer 
miR-375  is  down-regulated  and  directly  targets  the  apoptosis  pathway  through 
PDK1 (Tsukamoto et al., 2010) or JAK2 (Ding et al., 2010). Interleukin 13 induces 
TSLP expression via a miR-375 dependent pathway in HT29 cells indicating that 
miR-375  plays  a  role  in  the  T
H2  response  and  epithelial  crosstalk  (Biton  et  al., 
2011). 
MiR-422 has been shown to be decreased in UC miRNA array by Wu et al. (2008), 
although has no known functional role in inflammation. Limited literature reveals 
a possible  role  in bile acid synthesis (Song  et al.,  2010) and  bone regeneration 
(Palmieri et al., 2008). 
One of the complexities of predicting miRNA targets by bioinformatic searches is 
the quantity of data that is produced. Using TargetScan v5.2 and MirTarget2 v4.0 
together  generated  3285  potential  targets  for  the  7  miRNAs.  Genes  which  are 
ranked in the top 20 for TargetScan v5.2, or have a score above 80 for MirTarget2 
v4.0 or have a significant known inflammatory function are highlighted in  Table 
34 to Table 40. 
Bioinformatic searches using TargetScan identified Thymic Stromal Lymphopoietin 
(TSLP)  as  a  potential  target  for  miR-31,  miR-194  and  miR-422a,  Table  41.  Using Chapter 4. The microRNA signature of IBD 
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MirTarget2, TSLP is also a predicted target for miR-223, with target score of 89. 
There is little concordance between TargetScan and MirTarget2. 
The  seed  site  base  pairing  pattern  has  been  discussed  in  section  2.7.3.1.  A 
7mer-1A seed match indicates that there is an exact Watson Crick base pairing of 
positions 2-7, followed by an Adenine, of the mature miRNA 5’ end and the 3’UTR 
of TSLP. The 4 miRNAs bind to the positions on the 3’ end of TSLP at the positions 
shown in Table 41. 
The focus on TSLP as a target for 4 of the miRNAs is also fuelled by recent interest 
in TSLP as a mediator of the T
H2 response seen in respiratory diseases. Abnormal 
lymphocyte function is thought to be central to the pathogenesis of IBD with UC 
favouring a T
H2 inflammatory response. Thus TSLP is an interesting target gene to 
investigate further. 
It has so far been demonstrated that there is a differential expression of 7 miRNAs 
in  mucosal  biopsies  taken  from  patients  with  active  UC;  to  date  the  published 
miRNA  profiles  in  UC  have  used  whole  tissue  samples  via  either  biopsies  or 
resection specimens (Wu et al., 2008, Fasseu et al., 2010). A limitation of analysing 
miRNA  expression  and  /  or  function  when  miRNA  profiling  using  whole  tissue 
samples is that they consist of a number of cell types which are likely to express 
different  levels  of  miRNA  depending  on  their  function  and  local  environment 
(Lagos-Quintana et al., 2002). A method of identifying which cell types within the 
mucosa express individual miRNAs, so called “spatial expression patterns” is in 
situ hybridisation, a technique which allows localisation of specific segments of 
nucleic acids within a histological specimen. Using in situ hybridisation, in their 
seminal paper, Wu and colleagues (2008) localised the altered expression of miR-
192 and MIP-2α in active UC to colonic epithelial cells. 
Despite  the  potential  advantages  of  identifying  which  cells  within  the  biopsies 
express the candidate miRNAs, in situ hybridisation has its challenges. Previous 
experience within the laboratory had been unsuccessful in identifying miRNAs by 
in situ hybridisation so the alternative approach of analysing miRNA expression 
directly in cell lines which represent 3 prominent cell types within the mucosa and   Chapter 4. The microRNA signature of IBD 
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which feature as predominant factors in the aetiology of IBD; the epithelial cell 
(HT29), monocyte (THP-1) and lymphocyte (Jurkat), was used. 
Not  localising  miRNA  expression  within  tissue  samples  is  a  weakness  of  this 
study, previous laboratory experience of localising miRNA expression in tissue by 
in  situ  hybridisation  had  been  unsuccessful,  however  newer  refined  techniques 
are proving more sensitive and specific (Thompson et al., 2007, Deo et al., 2006). In 
hindsight  developing  a  successful  technique  and  adding  this  step  to  the  study 
protocol  may  have  led  to  alternative  avenues  of  investigation  and  may  have 
strengthened  the  link  between  miRNA  expression  and  TSLP  in  mucosal 
lymphocytes, a subject discussed in subsequent chapters. 
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5.1  Chapter abstract 
Abnormal lymphocyte function is thought to be central to the pathogenesis of IBD 
with UC favouring a T
H2 inflammatory response. Previous studies have identified 
65  miRNAs  that  have  a  deregulated  expression  in  the  mucosa  of  UC,  however, 
there is a paucity of research into miRNA expressions within individual mucosal 
cell subtypes including mucosal lymphocytes. 
Sigmoid  mucosal  lymphocytes  are  extracted  from  whole  mucosal  biopsies  by 
Percoll centrifugation. The pattern of candidate miRNA expressions when analysed 
with RT-qPCR is similar to that seen in whole mucosal biopsies. Although only the 
differential expression of miR-31, -194, -200b and -223 reach significance with fold 
differences of 2.07, 0.33, 0.41 and 11.41 respectively. 
Pro-inflammatory  CD4
+CD25
intermediate  lymphocytes  were  then  separated  from  the 
lymphocyte  pool  using  surface  antigen  staining  characteristics  and  flow 
cytometry. In the CD4
+CD25
intermediate lymphocyte subset the expressions of miR-31, 
miR-146b  and  miR-223  are  increased  significantly  at  3.69,  155.8  and  6.34  fold 
respectively.  The  altered  expressions  of  the  other  candidate  miRNAs;  miR-194, 
miR-200b, miR-375 and miR-422a did not reach statistical significance. 
The results presented in this chapter show the differential expression of certain 
miRNA  in  mucosal  lymphocytes  and  the  CD4
+CD25
intermediate  pro-inflammatory 
lymphocyte  subset.  A  number  of  the  candidate  miRNAs  are  not  significantly 
altered within these mucosal cell subsets, a finding that agrees with the assertion 
that the expressions of miRNAs are cell type specific. 
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5.2  Chapter introduction 
To date 72 miRNAs have been shown to be either increased or decreased in the 
mucosa of active IBD compared with healthy mucosa, of which 65 are deregulated 
in UC (Wu et al., 2008, Wu et al., 2010, Fasseu et al., 2010, Van der Goten et al., 
2012). These miRNA signatures however are taken from the colonic mucosa of a 
heterogeneous  group  of  patients  and  the  studies  are  poorly  concordant  as 
discussed in previous chapters. In earlier chapters it is shown that in treatment 
naive actively inflamed sigmoid UC there are 7 consistently deregulated miRNAs. 
There is growing evidence that miRNA expression is not only organ specific but 
also cell  specific  (Rouas et al.,  2009, Hezova  et al.,  2009),  for  reasons that may 
include a conserved functionality in specific cell types. With the growing evidence 
that miRNAs play a crucial role in cell functionality and inflammatory pathways 
defining the miRNA expression in specific cell types is crucial to understanding 
the pathogenesis of UC 
The  GI  tract  mucosa  consists  of  numerous  cell  types,  the  imbalance,  abnormal 
interaction and function of which have all been associated with UC. Predominant 
cells of the epithelium are the epithelial cell, dendritic cell and lymphocyte. In this 
chapter the expression of the candidate miRNAs is shown, firstly in an enriched 
suspension  of  mucosal  lymphocytes  and  then  in  the  CD4
+CD25
intermediate  pro-
inflammatory subset. 
The lymphocyte has been chosen for a number of reasons; following the validation 
of 7 candidate miRNA in mucosal biopsies, it has been shown by in-silico analysis 
that TSLP is a target of 4 of the candidate miRNAs. Interestingly TSLP is associated 
with T
H2 disorders of the lung and skin and has been previously associated with 
UC (Tanaka et al., 2010). TSLP is thought to be mainly an epithelial cell derived 
factor  which  influences  dendritic  cells  and  the  function  of  down-stream 
lymphocytes,  conferring  a  non-inflammatory  environment  and  thus  supporting 
epithelial homeostasis.  
Recent  data  reviewed  by  Takai  (2012)  would  suggest  that  TSLP  is  more  widely 
expressed  than  previously  thought,  the  expression  of  TSLP  has  not  been   Chapter 5. MicroRNA in mucosal lymphocytes 
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previously described in lymphocytes, although it has been shown that peripheral 
naive CD4
+ lymphocytes upon activation express the TSLP receptor (Rochman et 
al.,  2007).  Since  abnormal  lymphocyte  function  and  loss  of  the  regulatory 
mechanisms  that  support  epithelial  homeostasis  is  a  hallmark  of  UC,  the 
association between lymphocytes, miRNA expression and TSLP in UC is interesting 
and unknown. 
Initially  mucosal  lymphocytes  are  extracted  from  the  sigmoid  mucosa  using 
density  centrifugation  and  later  CD4
+CD25
intermediate  mucosal  lymphocytes  are 
extracted  from  sigmoid  biopsies  by  density  centrifugation  followed  by  sorting 
from other cell subtypes using surface antigen staining characteristics and flow 
cytometry. The expressions of the candidate miRNAs are analysed with RT-qPCR. 
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5.3  The  expression  of  candidate  miRNA  in  mucosal 
lymphocytes 
There are clear differences in the number and function of mucosal lymphocytes in 
IBD  compared  with  healthy  individuals.  The  association  of  abnormal  miRNA 
expression  and  lymphocyte  function  has  been  clearly  demonstrated  in 
experimental models and peripheral lymphocyte subsets, although not in human 
mucosal biopsies. 
The abnormal expression of a distinct group of miRNA in whole mucosal biopsies 
has been demonstrated. The aim of this section is to demonstrate the expression 
of those previously described candidate miRNAs in mucosal lymphocytes. 
 
 
  Control 
(n = 4) 
Active UC 
(n = 4) 
MW U value  
(comparison of 
medians) 
Demographics 
Age  76 (61 - 89)  53 (46 - 62)  1.5, p = 0.086 
Sex (F/M)  3 / 1  3 / 1  - 
Ethnicity (if not white)  nil  nil  - 
Smoker / ex smoker
1  0 / 0  0 / 0  - 
Disease 
Months since 
diagnosis  0 (0 - 0)  151 (0 - 334)  - 
Concomitant drugs  4 x nil  4 x nil  - 
disease extent 
(maximal/today)
2      - 
normal  4/4  0/0  - 
Left sided  0/0  3/0  - 
total  0/0  1/4  - 
Clinical Scores 
Baron score  0 (0 – 0)  3 (3 – 3)  - 
Mayo Score  2 (1 - 4)  11 (7 - 15)  - 
Truelove and Witts  3x normal 
1x mild 
2x mild 
1x moderate 
1x severe 
- 
Clinical 
investigation 
Deviation of Hct (%)  7.0 (4.5 – 11.8)  4.0 (2.4 – 7.3)  3, p = 0.400 
Weight loss (%)  0.0 (0.0 – 5.0)  0.0 (0.0 – 0.0)  6, p > 0.999 
Temperature >37.5°C  nil  nil  - 
Pulse >90 bpm  nil  nil  - 
Hb  126 (99 – 153)  125 (117 - 131)  6, p > 0.999 
ESR  4 (3 - 5)  29 (12 - 60)  0, p = 0.029 
CRP  5 (1 - 14)  52 (27 – 223)  0, p = 0.029 
Raised Creatinine
3  1  nil  - 
Albumin  41 (27 – 44)  33 (24 - 40)  4, p = 0.371 
Table  42.  Patient  characteristics  for  the  mucosal  lymphocyte 
extraction. Values given as medians (IQR), 
1has not smoked within 3 
months of the biopsy. 
2maximal distribution of disease known before 
endoscopy / disease distribution today.  
3above laboratory reference 
range.  Comparisons  of  the  medians  was  calculated  with  the  two 
tailed Mann Whitney U test, probability statistics are shown as the U 
value and p value.   Chapter 5. MicroRNA in mucosal lymphocytes 
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Lymphocytes were extracted from the sigmoid mucosa using EDTA, collagenase 
and  a  discontinuous  Percoll®  gradient  as  outlined  in  section  2.3.1.  The  relative 
expressions of miRNAs were quantified by RT-qPCR relative to healthy controls. 
In section 5.4, it is shown that Percoll centrifugation results in a suspension in 
which 32.2% of cells stain CD3
+. 
Cell suspensions from healthy mucosa (n = 4) are compared against active UC (n = 
4). Patients were matched for age and sex. All active UC patients had Baron Grade 
3 inflammation at the site of the biopsy, for the full demographical information 
see  Table  42.  Traditional  measures  of  disease  activity  that  are  not  statistically 
different between the groups are deviation of haematocrit (p = 0.400), percentage 
weight loss (p > 0.999), haemoglobin (p > 0.999) and albumin (p = 0.371).  
The inflammatory markers ESR and CRP have significantly higher values in active 
UC compared with healthy controls, p = 0.029 and p = 0.029 respectively. 
The relative expressions of the 7 candidate miRNAs in the cell suspension gained 
from  Percoll  centrifugation  follows  the  same  trend  as  found  in  whole  mucosal 
biopsies.  The  3  miRNAs  that  have  an  increased  expression  in  whole  mucosal 
biopsies  also  have  an  increased  expression  in  the  cell  suspension,  and  the  4 
miRNAs that have a decreased expression in whole mucosal biopsies also have a 
decreased expression in the cell suspension. 
The expression of miR-31 is 2.070 (IQR 1.690 – 2.162) fold and the expression of 
miR-223  is  11.41  (IQR  11.37  –  12.88)  fold  in  active  UC  compared  with  healthy 
controls. Both of these increases are  statistically  significant, p  = 0.029 and p = 
0.029 respectively. 
Although  the  expression  of  miR-146b  is  increased  by  1.269  (IQR  1.137  –  1.665) 
fold, this does not reach significance, p = 0.114. Chapter 5. MicroRNA in mucosal lymphocytes 
192 
r
e
l
a
t
i
v
e
 
e
x
p
r
e
s
s
i
o
n
 
(
2
-
D
D
C
t
)
o
f
 
m
i
R
N
A
 
i
n
 
a
c
t
i
v
e
 
U
C
 
c
o
m
p
a
r
e
d
 
w
i
t
h
 
h
e
a
l
t
h
y
 
c
o
n
t
r
o
l
c
o
n
t
r
o
l
a
c
t
i
v
e
 
U
C
c
o
n
t
r
o
l
a
c
t
i
v
e
 
U
C
c
o
n
t
r
o
l
a
c
t
i
v
e
 
U
C
c
o
n
t
r
o
l
a
c
t
i
v
e
 
U
C
c
o
n
t
r
o
l
a
c
t
i
v
e
 
U
C
c
o
n
t
r
o
l
a
c
t
i
v
e
 
U
C
c
o
n
t
r
o
l
a
c
t
i
v
e
 
U
C
0
1
2
3
8
10
12
14
m
i
R
-
3
1
m
i
R
-
4
2
2
a
m
i
R
-
3
7
5
m
i
R
-
2
2
3
m
i
R
-
2
0
0
b
m
i
R
-
1
9
4
m
i
R
-
1
4
6
b
* *
*
*
ns ns
ns
 
Figure  38.  The  relative  expressions  of  candidate  miRNAs  in  cells 
extracted  from  mucosa  by  Percoll  centrifugation.  The  relative 
expression  of  each  miRNA  was  analysed  by  RT-qPCR.  The  miRNA 
expressions are normalised to RNU44 and compared against healthy 
control. Median values are compared with a two tailed Mann Whitney 
U  test.  Whiskers  =  IQR,  *  p  <0.05,  ns  =  not  significant.  Probability 
statistics are shown in appendix 8.6.3. 
The 4 miRNAs which have a decreased expression in whole mucosal biopsies also 
have a decreased expression in cell suspension. The expressions of miR-194 and 
miR-200b have a median fold decrease of 0.335 (IQR 0.091 – 0.380) and 0.415 (IQR 
0.011 – 0.481) respectively. The decreased expressions of miR-194 and miR-200b 
are statistically significant, p = 0.014 and p = 0.014 respectively. The expressions 
of miR-375 and miR-422a are decreased in the cell  suspension of  patients  with 
active UC compared with healthy controls but do not reach significance. Relative 
expressions of 0.505 (IQR 0.144 – 0.597, p = 0.100) and 0.699 (IQR 0.231 – 0.845, p 
= 0.100) respectively. 
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5.4  The  expression  of  candidate  microRNAs  In 
CD4
+CD25
intermediate mucosal lymphocytes 
The expression of miR-31 in umbilical cord blood CD4
+CD25
- cells is five times that 
of  CD4
+CD25
+,  and  is  thought  to  negatively  regulate  FoxP3  expression,  at  least 
another 9 miRNAs are also differentially expressed between CD25
+ and CD25
- cells 
(Rouas et al., 2009). This gives rise to two important implications; the first is that 
miRNA expression is cell (and probably cell subtype) specific, the second is that 
miRNAs  can  influence  lymphocyte  cell  development  and  /  or  function.  We 
hypothesise that miRNAs play a crucial role in many inflammatory pathways. It is 
therefore  helpful  when  looking  at  lymphocyte  miRNA  profiles  to  differentiate 
between pro-inflammatory and regulatory (T
regs) CD4
+ cells. 
Regulatory T cells are anti-inflammatory CD4
+ cells which are characterised by the 
expression of FoxP3. FoxP3 is an intracellular transcription factor and acts as a 
master regulator of T
reg development and function. Disruption of the T
reg pathway 
has  been  shown  to  predispose  or  worsen  experimental  inflammation  and  in 
humans T
reg absence leads to IPEX syndrome of which colitis is a feature. 
The process of intercellular staining for FoxP3 prohibits the analysis of miRNA. A 
widely used alternative to identify the T
reg subfamily from the total CD4
+ pool is 
the presence of surface CD25. The marker CD25 is expressed on the surface of 
activated CD4
+ T cells. In the peripheral blood, a majority of CD4
+ cells that stain 
highly for CD25 (CD4
+CD25
high) express FoxP3 which is almost absent from CD4
+ 
cells expressing low levels of CD25 (CD4
+CD25
low) (Roncador et al., 2005, Eastaff-
Leung et al., 2009). A method of reducing the FoxP3 population within a CD4
+ pool 
is to separate CD25
low/intermediate from CD25
high. 
5.4.1  Flow cytometry 
Lymphocytes within the cell suspensions are first identified by gating on an area 
of the dot plot which contained the highest density of cells, where lymphocytes 
are expected to be located and which demonstrated maximum CD3
+ fluorescence, 
Figure 39a. This population contained on average 32.2% (13.7 – 43.9) of all cells in 
the  cell  suspension,  the  rest  presumably  being  other  cells  and  cellular  debris. Chapter 5. MicroRNA in mucosal lymphocytes 
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Within this population 54.2% (27.5 – 99.3%) stained for CD3, an example of CD3
+ 
staining characteristics are shown in Figure 39b. 
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Figure 39. The initial stage of flow cytometry. (a) 2x Representative 
examples of a dot plots from healthy control and active UC. In each 
dot plot lymphocytes were separated by gating around populations 
of  cells  which  contained  as  many  of  the  CD3
+  cells  as  possible, 
enclosed  populations.  (b)  An  example  of  the  CD3
+  signal  from  the 
gated population is illustrated in the histogram.   Chapter 5. MicroRNA in mucosal lymphocytes 
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The  lymphocyte  population  was  assessed  for  CD3  and  CD4  characteristics.  For 
each sample a population of CD3
+CD4
+ cells was clearly identified, Figure 40a. The 
mean number of CD3
+ lymphocytes per sample is 889 (range 293 – 2046) of these 
the mean number co-expressing CD4
+ is 397 (range 220 – 1695). Within the CD3
+ 
lymphocyte population a mean of 81% (range 75% – 84%) stained for CD4
+ there 
was no difference in this ratio between UC and control. 
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Figure 40. FACS for lymphocyte sub-populations. (a) Representative 
dot plot diagrams showing gating of lymphocytes into CD4
+ and CD4
- 
subpopulations.  (b)  Representative  dot  plot  diagrams  of  CD4 
according to CD25 staining. CD3
+CD4
+ cells are subdivided into CD25 
staining  characteristics,  the  percentage  of  the  total  CD3
+CD4
+ 
population in low, intermediate and high CD25 staining are 10%, 70% 
and 20% respectively. 
CD3
+CD4
+ cells were further subdivided into CD25
low, CD25
intermediate and CD25
high, with 
the proportions 10%, 70% and 20% respectively, Figure 40b. The mean number of Chapter 5. MicroRNA in mucosal lymphocytes 
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CD4
+CD25
intermediate cells for healthy controls were 528 (range 176 – 1186), and for 
active UC 732 (range 528 – 836). 
 
Figure 41. FoxP3 cell count Intracellular staining performed with a 
FITC  conjugated  FoxP3  antibody.  70.4%  of  the  CD4
+CD25
high  (blue) 
population  and  5.5%  of  the  CD4
+CD25
intermediate  (red)  population  stain 
for FoxP3. 
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median  3.689  155.8  0.985  0.099  6.343  3.588  0.504   
75
th percentile  3.855  159.4  2.367  4.987  7.842  6.818  1.676   
25
th percentile  2.935  21.0  0.509  0.069  5.779  0.113  0.191   
MW U  0  0  7  5  0  5  4   
P value  0.018  0.029  0.500  0.286  0.018  0.286  0.198     Chapter 5. MicroRNA in mucosal lymphocytes 
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Figure  42.  Relative  expression  of  candidate  miRNAs  in 
CD4
+CD25
intermediate mucosal lymphocytes of active UC (n = 3) compared 
with  healthy  controls  (n  =  5).  The  expression  of  miRNAs  was 
normalised to RNU44. Bars represent median values. Whiskers = IQR. 
Median  values  are  compared  with  the  one  tailed  Mann  Whitney  U 
test. * = p ≤0.05. ns = not significant. 
The  percentage  of  FoxP3  within  the  CD4
+CD25
intermediate  and  the  CD4
+CD25
high 
populations was analysed in 2 healthy controls and 1 active UC patient, due to the 
small cell numbers in the other samples. The mean percentage of CD4
+CD25
intermediate 
that stain for FoxP3
+ is 4% (range 0.0 – 9.0), compared with 45% (range 30.5– 70.4) 
in the CD4
+CD25
high population, Figure 41. 
The miRNAs which are raised in the mucosa and mucosal lymphocytes of active UC 
are also all significantly increased in CD4
+CD25
intermediate mucosal lymphocytes. 
The relative expressions of miR-31, miR-146b and miR-223 are increased by 3.689 
(IQR 2.935 – 3.855, p = 0.018) fold, 155.8 (IQR 20.96 – 159.4, p = 0.029) fold and 
6.343  (IQR  5.779  –  7.842,  p  =  0.018)  fold  respectively  compared  with  healthy 
controls. 
The expressions of miR-194, miR-200b, miR-375 and miR-422a are not significantly 
different from healthy controls. 
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5.5  Chapter discussion 
The expression of 7 miRNAs has been shown to be abnormal in whole mucosal 
biopsies.  The  mucosa  consists  of  a  number  of  cell  types  which  are  likely  to 
express  different  levels  of  miRNA  depending  on  their  function  and  local 
environment.  Abnormal  lymphocyte  function  is  thought  to  be  central  to  the 
pathogenesis  of  IBD  with  UC  favouring  a  T
H2  inflammatory  response.  Here  we 
analyse the expression of these 7 miRNAs firstly in a cell suspension derived from 
mucosal  biopsies  by  Percoll  centrifugation,  followed  by  the  CD4
+CD25
intermediate 
lymphocyte subset. 
The pattern of candidate miRNA expression is similar in the cell suspension, which 
is consists of 32.2% lymphocytes, to that found in whole mucosal biopsies. The 
expressions of miR-31, miR-146b and miR-223 are increased in active UC and the 
expressions of miR-194, miR-200b, miR-375 and miR-422a are decreased. There are 
several differences between mucosa and  cell suspension miRNA expression; the 
first  is  that  the  predominant  feature  is  the  11.41  fold  increase  in  miR-223  and 
second  are  that  although  increased  and  decreased  respectively,  the  changes  in 
miR-146b, miR-375 and miR-422a do not reach statistical significance in  the cell 
suspension. 
Can the results of the cell suspension analysis be interpreted as the expression 
profiles  of  “mucosal  lymphocytes”?  The  literature  would  suggest  that  Percoll 
centrifugation will enrich a cell suspension extracted from human colon to  60 - 
70%  lymphocytes  (Zhang  et  al.,  2005).  In  this  study,  the  cell  suspension  only 
yielded  a  viable  CD3
+  lymphocyte  population  of  32.2%  as  measured  by  flow 
cytometry. This may be due to a number of factors including the composition of 
the  cell  solution  loaded  onto  the  gradient,  pipetting,  cell  death  prior  to  flow 
cytometry and / or other technical factors. The presence of other cell types in this 
suspension  limits  the  interpretation  with  regards  to  “lymphocyte”  miRNA 
expression.  However  this  is  a  vastly  enriched  suspension  because  in  health 
lymphocytes account for much < 5 % of the total number of cells  in a mucosal 
biopsy.  Overall,  although  the  result  should  be  interpreted  with  caution,  cell   Chapter 5. MicroRNA in mucosal lymphocytes 
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suspension analysis is a step closer to understanding the miRNA expression on 
specific cell types. 
The  CD4
+CD25
intermediate lymphocyte subset  was considered  for  miRNA profiling  as 
these are active pro-inflammatory T lymphocytes in UC. This subset was extracted 
initially on the basis of identifying a population of CD3 and CD4 staining cells, and 
then separated dependant on the strength of CD25 staining. Thus the population 
of  naive  CD3
+CD4
+CD25
-/low  mucosal  lymphocytes  was  separated  from  activated 
CD25
intermediate/high and discarded. 
Activated CD4
+ lymphocytes consist of both regulatory and pro-inflammatory cells. 
These express both miRNAs and cytokines differently and so require separation. 
The regulatory cells express CD25 brightly resulting in a majority of regulatory T 
cells  staining  within  the  CD25
high  subset.  The  CD25
high  subset  consisted  of  45% 
FoxP3
+ cells compared with the CD25
intermediate subset which is only 4% FoxP3
+. To 
define  low,  intermediate  and  high  staining  CD25  subsets  arbitrary  proportions 
were chosen as there is no consistent division across the literature. By defining 
the CD25
intermediate as only 4% FoxP3
+ regulatory T cells it is assumed that miRNA and 
cytokine profiles will be that of activated pro-inflammatory CD4
+ cells. 
In  CD4
+CD25
intermediate  cells  the  expression  of  miR-31,  miR-146b  and  miR-223  were 
increased with statistical significance. All three of these miRNAs are known to play 
a role in T cell function. Taken together the expression of miR-31 and miR-223 are 
consistently  increased  in  the  mucosa,  cell  suspension  and  CD4
+CD25
intermediate 
mucosal lymphocytes, in active UC. 
There is a paucity of research on lymphocytes extracted from the colon of patients 
with  UC  who  are  not  undergoing  resection,  or  are  not  on  immune  altering 
medication.  Lack  of  research  is  mainly  due  to  the  availability  of  appropriate 
volunteers and / or the difficulty in extracting lymphocytes from small quantities 
of tissue. Lymphocyte research to date has focused on experimental models or cell 
lines, research performed on human tissue has focused on lymphocytes extracted 
from peripheral blood, organs such as lymph nodes and spleen or lymphocytes 
extracted  from  surgical  resection  specimens.  Although  useful  previous  studies 
have relied on certain assumptions to extrapolate  their  results into human IBD, Chapter 5. MicroRNA in mucosal lymphocytes 
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which may be one reason why their conclusions fail to translate well into clinical 
practice. 
Together with the most consistently deregulated miRNA in UC, miR-31, the next 
step is to show the association between miR-31 and TSLP in UC and develop an in 
vitro model to analyse the relationship between miR-31 and TSLP in lymphocytes. 
      
 
Chapter 6.  The association between miR-31 
and TSLP   Chapter 6. The association between miR-31 and TSLP 
203 
6.1  Chapter abstract 
The  expression  of  miR-31  is  consistently  raised  in  the  mucosa,  mucosal 
lymphocytes  and  the  CD4
+CD25
intermediate  lymphocyte  subset  of  active  UC. 
Bioinformatic  searches  predict  that  TSLP  is  a  target  of  miR-31  through  the 
complementary base pairing of the seed region of miR-31 and the 3’ UTR of TSLP. 
Previous studies have failed to show the expression of TSLP in peripheral blood 
lymphocytes. Using RT-qPCR we confirm that peripheral blood mononuclear cells 
do  not  express  TSLP,  however  stimulation  with  PHA  produces  a  measurable 
expression of TSLP in a time dependent manner. We also show that lymphocytes 
extracted  from  the  sigmoid  mucosa  constitutionally  express  TSLP  and  that  the 
expression of TSLP in UC is decreased compared with healthy controls in mucosal 
biopsies, mucosal lymphocytes and CD4
+CD25
intermediate lymphocyte subset. 
Using  an  in  vitro  lymphocyte  cell  model,  the  expression  of  miR-31  by  PHA 
stimulated  Jurkat  cells  is  increased  by  over  500%  with  a  strongly  correlated 
decrease in TSLP mRNA expression of 28% compared with control, co-culture with 
the antagomir of miR-31 abrogates both the increase in miR-31 and the decrease in 
TSLP mRNA. 
The  effect  of  PHA  stimulation  on  TSLP  protein  is  greater  than  TSLP  mRNA 
expression suggesting a post transcriptional effect. In stimulated Jurkat cells TSLP 
protein is decreased by ≈50% which is a twofold greater difference than that seen 
with the mRNA. In stimulated Jurkat cells co-cultured with the antagomir of miR-31 
the expression of TSLP mRNA is the same as control. 
Altered  expressions  of  TSLP  mRNA  and  protein  in  stimulated  Jurkat  cells  are 
abrogated when co-cultured with the antagomir of miR-31 indicating that miR-31 
plays a role in the TSLP pathway in lymphocytes. 
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6.2  Chapter introduction 
Thymic stromal  lymphopoietin (TSLP)  is predicted to be a target for 4 of the 7 
miRNAs  that  have  been  identified  as  having  a  dysregulated  expression  in  UC. 
Thymic stromal lymphopoietin is constitutionally expressed by the epithelial cells 
(ECs) of the GI tract where the most well established actions are to directly alter 
DC function and the down-stream effects on T cells. In mice models it has also 
been  well  established  that  TSLP  exerts  an  effect  on  T  cells  directly,  although 
evidence for the direct effect of TSLP on T cells in humans is limited. 
The influence of TSLP occurs through binding with the cell surface TSLP receptor. 
The  receptor  consists  as  a  heterodimer  of  TSLPR  and  IL-7R.  Once  bound  to  its 
receptor, TSLP exerts it influence by activation of the STAT5, STAT3 (in mice) as 
well as other unknown pathways. 
Epithelial cells and dendritic cells form the first line of defence against luminal 
antigens;  under  normal  conditions  expression  of  TSLP  by  ECs  confers  a  non-
inflammatory environment by promoting  T
H2 maturation and differentiation, IgA 
secretion by B cells, as well as other homeostatic functions such as maintenance 
of tight junction integrity and proliferation of regulatory T cells (Reche et al., 2001, 
Soumelis and Liu, 2004). 
To date the predominant role for TSLP has been in the aetiology of allergic  T
H2 
inflammatory conditions of the respiratory tract where it is seen to be increased in 
Asthma and rhinitis. There is no known role for TSLP in UC although it has been 
observed to be increased in surgically resected UC (Tanaka et al., 2010), and has a 
decreased expression in Crohn’s where it is thought to play a role by the absence 
of the non-inflammatory influence on DCs (Rimoldi et al., 2005). It is the role of 
TSLP in T
H2 mediated inflammation that is potentially interesting for UC. 
Murine  and  human  dendritic  cells  preferentially  promote  T
H2  differentiation  in 
response  to  oral  antigens  (Alpan  et  al.,  2001)  and  during  mucosal  infection 
(Rimoldi  et  al.,  2005).  However  DCs  not  exposed  to  the  epithelium,  monocyte 
derived  DCs  (MoDCs),  do  not  favour  T
H2  differentiation  over  T
H1  suggesting 
something in the mucosal environment drives a T
H2 response (Rimoldi et al., 2005).   Chapter 6. The association between miR-31 and TSLP 
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In  response  to  invasion  by  bacteria  and/or  stimulation  by  various  cytokines, 
epithelial cells increase their expression of TSLP and dendritic cells increase their 
expression of the TSLP receptor and IL-7Rα. This is demonstrated by MoDCs which 
do not constitutionally express functional TSLP receptor but when exposed to the 
supernatants of caco-2 cells they express both IL-7Rα and TSLPR (Rimoldi et al., 
2005). Also culture of caco-2 cells with s. typhimurium increases the expression of 
TSLP by 2-3 fold, and culture of HT29 cells with IL-13 (a T
H2 inflammatory cytokine) 
increases the expression of TSLP >8 fold (Biton et al., 2011). 
Bacteria adhered to the basolateral membrane of the epithelial layer is indicative 
of more serious invasion. Under these circumstances a greater pro-inflammatory 
reaction with features of a T
H1 response is seen, this suggests that the protective 
effect of a less aggressive T
H2 response has been overcome. The loss of a TSLP 
influence indicates a narrow window of effect which may be reflected clinically by 
the undetectable levels of TSLP  found in epithelial cells  in 2/3 of patients  with 
active Crohn’s (Biton et al., 2011) and reduced levels seen in experimental colitis 
(Spadoni et al., 2012). 
In  humans,  TSLP  is  expressed  by  epithelial  cells  which  prime  mucosal  DCs  to 
induce maturation and clonal proliferation of T cells, notably T
regs as well as the 
release  of  T  cell-attracting  chemokines.  In  murine  models,  TSLP  has  additional 
features  including  expression  by  DCs  independently  of  epithelial  cells  and  the 
growth and differentiation of pre–B cells and peripheral CD4
+ T cells including the 
development of T
regs (Spadoni et al., 2012) independently of DCs. Although largely 
confined  to  murine  models  TSLP  may  also  directly  influence  T  cell  function.  In 
humans  activated  peripheral  CD4
+  lymphocytes  show  an  expression  of  TSLP 
receptor that is not seen in naive CD4
+ cells and when activated CD4
+ cells are co-
cultured  with  TSLP  they  show  increased  proliferation  and  sensitivity  to  IL-2 
(Rochman et al., 2007). Differences in TSLP function between murine and human 
disease may in part be because they share only 43% amino acid homology, this 
must be taken into account when interpreting and applying experimental models 
into human results. Chapter 6. The association between miR-31 and TSLP 
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To understand the role of TSLP in UC, the first step is to quantify the expression of 
TSLP in active UC, akin to other T
H2 inflammatory conditions we would expect the 
expression of TSLP to be increased. We have already shown the differential levels 
of miR-31 in active mucosa and mucosal lymphocytes, to study the relationship 
between miR-31 and TSLP further an in vitro model of stimulated lymphocytes is 
developed to simulate mucosal lymphocytes. 
Previously the expression of TSLP has been thought to be largely from epithelial 
cells, this has been driven by the research on TSLP involving skin and respiratory 
pathologies,  recent  reviews  however  have  shed  doubt  on  this  assumption  and 
revealed that TSLP is expressed by numerous cell types (Takai, 2012). Despite the 
TSLP  being  previously  thought  of  as  an  epithelial  derived  factor,  the  increased 
expression of miR-31 in mucosal CD4
+CD25
intermediate lymphocytes, and the targeting 
of TSLP by miR-31 has focused this chapter on TSLP expression by lymphocytes 
specifically. 
Using an in vitro cell model in which Jurkat cells are co-cultured with PHA and an 
antagomir to miR-31  it is demonstrated that the expression of  TSLP  mRNA and 
TSLP protein are influenced by the manipulation of miR-31 expression. 
Manipulation  of  miRNA  expression  can  be  achieved  through  specific  miRNA 
genetic  alteration,  generally  through  alterations  of  the  miRNA  biosynthesis 
pathway, or through miRNA post transcriptional repression. In this study miR-31 
expression is manipulated through the transfection of cells with the antagomir of 
miR-31. Antagomirs exert their effect through the base pair complementarity and 
binding  with  specific  miRNA  which  prevents  integration  of  the  miRNA  into  the 
RISC  complex,  thus  silencing  its  function.  The  antagomir  /  miR-31  molecule  is 
eventually degraded by the normal cellular processes. 
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6.3  The expression  of TSLP mRNA is  decreased  in  active 
UC 
Ulcerative Colitis is still considered a T
H2 type inflammatory response, so in line 
with other T
H2 inflammatory conditions it is expected that TSLP has an increased 
expression  in  the  mucosa  of  active  UC.  However,  the  success  of  various  TNF-α 
antagonists in practice points towards a less polarised aetiology. We hypothesize 
that post transcriptional regulation of TSLP by miR-31 decreases the expression of 
TSLP in UC which may lead to a response which could favour T
H1 characteristics. 
6.3.1  TSLP mRNA expression is decreased in the sigmoid 
mucosa 
    Control  Inactive UC  Active UC 
    (n = 8)  (n = 8) 
(U value, p 
value)  (n = 8) 
(U value, p 
value) 
Demographics 
Age  62 (45 – 76)  59 (51 – 66)  25, p = 0.495  52 (29 - 63)  22.5, p = 0.342 
Sex (F/M)  4/4  3/5    3/5   
Ethnicity (if not 
white) 
         
Smoker / Ex 
Smoker
1 
  1x smoker 
1x ex smoker
1    3x ex smokers
1   
Disease 
Months since 
diagnosis 
0 (0 - 0)  165 (127 - 295)    69 (7 – 1271)   
Concomitant 
drugs 
8 x nil  8 x nil    8 x nil   
disease extent 
(maximal/today) 
         
normal  8/8  0/8    0/0   
Left sided  0/0  6/0    5/4   
total  0/0  2/0    3/4   
Clinical 
Scores 
Baron score  0 (0 – 0)  0 (0 – 0)    3 (3 – 3)   
Mayo Score  0.0 (0.0 – 4.5)  0.0 (0.0 – 0.0)    8.6 (6.0 – 11.5)   
Truelove and 
Witts 
8x normal  8x normal   
2x mild 
3x moderate 
3x severe 
 
Clinical 
investigation 
Deviation on 
Hct (%) 
2.3 (0.7 – 6.6)  0.0 (0.0 – 1.6)  9.5, p = 0.058  6.0 (2.9 – 8.2)  26.5, p = 0.591 
Weight loss (%)  0.0 (0.0 – 0.0)  0.0 (0.0 – 0.0)  28, p = 1.000  0.0 (0.0 – 4.8)  24, p = 0.467 
Temperature 
>37.5°C 
nil  nil    nil   
Pulse >90 bpm  nil  nil    nil   
Hb  130 (128 – 145)  142 (141 - 142)  4.5, p = 0.583  135 (113 – 147)  26.5, p = 0.888 
ESR  9 (5 – 27)  15 (8 – 21)  4.5, p = 1.000  36 (13 – 60)  4, p = 0.167 
CRP  2 (2 – 5)  6 (4 – 7)  1.5, p = 0.238  15 (7 – 34)  3, p = 0.018 
Raised 
Creatinine
2 
nil  nil    nil   
Albumin  41 (37 - 45)  43 (40 – 45)  5, p = 0.694  38 (36 – 42)  19, p = 0.321 
Table  43.  Patient  characteristics  for  the  mucosal  biopsies  used  to 
examine TSLP mRNA expression in UC. Values displayed as medians 
(IQR), 
1has not smoked within 3 months of biopsy, 
2above laboratory 
reference range. Statistical relevance of the difference between the 
median values and the control group are calculated using the two 
tailed Mann Whitney U test, probability statistics are shown as the (U 
value, p value). Chapter 6. The association between miR-31 and TSLP 
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Samples are matched for age, sex and ethnicity, Table 43. All patients in the active 
UC group had Baron grade 3 macroscopic inflammation. In the active UC group, 
clinical severity as measured by the Truelove and Witts criteria varied from mild to 
severe.  Clinical  measures  of  disease  activity  as  measured  by  deviation  of  Hct, 
percentage weight loss, Hb and albumin showed no difference between healthy 
control  and  active  UC.  Although  CRP  was  significantly  higher  in  the  active  UC 
group  compared  with  healthy  control,  p  =  0.018,  there  was  no  significant 
difference in the level of ESR. 
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Figure 43. Relative expression of TSLP mRNA in the sigmoid mucosa. 
The expression of TSLP mRNA in active and inactive sigmoid UC is 
compared against healthy controls using TaqMan
TM probe based RT-
qPCR. TSLP mRNA expression is normalised to GAPDH and compared 
against healthy controls. Median values are compared using a one 
tailed Mann Whitney U test. * p < 0.05, ns = not significant. 
The expression of TSLP mRNA is decreased by 0.612 (IQR 0.456 – 0.830, p = 0.014) 
fold in active sigmoid UC compared with healthy control. 
There is no significant difference in the expression of TSLP in the sigmoid mucosa 
of inactive UC compared with healthy controls, p = 0.198.   Chapter 6. The association between miR-31 and TSLP 
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6.3.2  TSLP protein is decreased in the sigmoid mucosa of 
active and inactive UC
11 
    Control  Inactive UC  Active UC 
    (n = 12  (n = 12) 
(U value, p 
value)  (n = 11) 
(U value, p 
value) 
Demographics 
Age  58 (43 – 70)  55 (48 – 67)  28, p = 0.342  49 (29 - 63)  24, p = 0.167 
Sex (F/M)  6/6  6/6    5/6   
Ethnicity (if not 
white) 
         
Smoker / Ex 
Smoker
1 
  3x ex smoker
1    2x ex smokers
1   
Disease 
Months since 
diagnosis 
0 (0 - 0)  210 (97 - 310)    72 (8 – 1123)   
Concomitant 
drugs 
12 x nil  12 x nil    11 x nil   
disease extent 
(maximal/today) 
         
normal  12/12  0/12    0/0   
Left sided  0/0  4/0    6/5   
total  0/0  8/0    5/6   
Clinical 
Scores 
Baron score  0 (0 – 0)  0 (0 – 0)    3 (3 – 3)   
Mayo Score  0.0 (0.0 – 5)  0.0 (0.0 – 0.0)    9.0 (6.0 – 12.5)   
Truelove and 
Witts 
12x normal  12x normal   
2x mild 
5x moderate 
4x severe 
 
Clinical 
investigation 
Deviation on 
Hct (%) 
4.0 (0.5 – 5.5)  0.0 (0.0 – 2.0)  10, p = 0.167  8.0 (3.2 – 10.0)  20, p = 0.467 
Weight loss (%)  0.0 (0.0 – 0.0)  0.0 (0.0 – 0.0)  20, p = 1.000  0.0 (0.0 – 6.0)  24, p = 0.342 
Temperature 
>37.5°C 
nil  nil    nil   
Pulse >90 bpm  nil  nil    nil   
Hb  129 (125 – 144)  145 (138 - 143)  6, p = 0.467  136 (110 – 145)  24, p = 0.888 
ESR  6 (3 – 15)  18 (4 – 15)  4, p = 0.888  40 (15 – 58)  4, p = 0.018 
CRP  3 (0 – 11)  5 (2 – 8)  3, p = 0.167  19 (8– 33)  3, p = 0.018 
Raised 
Creatinine
2 
nil  nil    nil   
Albumin  40 (36 - 43)  42 (38 – 44)  6, p = 0.467  37 (33 – 43)  12, p = 0.281 
Table  44.  Patient  characteristics  for  the  mucosal  biopsies  used  to 
examine TSLP protein expression in UC. Values displayed as medians 
(IQR), 
1has not smoked within 3 months of biopsy, 
2above laboratory 
reference range. Statistical relevance of the difference between the 
median values and the control group are calculated using the two 
tailed Mann Whitney U test, probability statistics are shown as the (U 
value, p value). 
Samples  were  collected  and  protein  concentration  analysed  with  ELISA  as 
described in Chapter 2. Patients were matched for age and sex. All patients are 
treatment  naive  and  patients  in  the  active  UC  group  all  have  Baron  grade  3 
macroscopic inflammation. 
                                              
11 The sample collection, experiment and analysis for section 6.3.2 was perform by Dr Simon Whiteoak 
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Patient characteristics are outlined in Table 44. There is a significant difference in 
the ESR and CRP between the active UC group and healthy controls in keeping with 
an  inflammatory  process.  In  the  inactive  UC  group  there  is  no  significant 
difference in ESR and CRP indicating the absence of inflammation. 
In  all  three  groups  the  protein  concentration  was  low.  In  healthy  controls  the 
median TSLP protein concentration is 7.8 pg / ml (IQR 5.6 – 12.5). In inactive UC 
the median protein concentration is 2.9 pg / ml (IQR 1.2 – 6.2), and in active UC the 
median protein concentration is 2.6 pg / ml (IQR 1.4 – 5.5). 
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Figure  44.  TSLP  protein  concentration  in  active  and  inactive  UC. 
Mucosal  biopsies  are  homogenised  and  protein  concentration 
analysed  in  the  supernatant  by  ELISA.  TSLP  concentration  was 
measured in healthy controls (n = 12), inactive UC (n = 12) and active 
UC (n = 11). Dotted line shows the protein expression in the control 
group.  Median  values  are  compared  with  the  two  tailed  Mann 
Whitney  U  test.  *  p  <  0.05,  ns  =  not  significant.  Experiment  and 
analysis with ELISA performed by Dr Simon Whiteoak. 
The protein concentration in inactive UC is 37% (p = 0.002) and in active UC 34% (p 
= 0.003) of that in healthy controls.   Chapter 6. The association between miR-31 and TSLP 
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6.3.3  TSLP  mRNA  expression  is  decreased  in  mucosal 
lymphocytes 
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Figure  45.  The  expression  of  TSLP mRNA  in mucosal  lymphocytes. 
Mucosal lymphocytes were extracted using EDTA, collagenase and a 
Percoll®  gradient.  Messenger  RNA  was  isolated  and  analysed  with 
RT-qPCR. The relative expression of TSLP mRNA was normalised to 
GAPDH and compared against healthy controls, * p = <0.05. 
There is expression of TSLP by lymphocytes extracted from healthy mucosa. The 
expression of TSLP mRNA is decreased by 0.388 (IQR 0.308 – 0.600, p = 0.014) fold 
in  mucosal  lymphocytes  extracted  from  the  mucosa  in  active  sigmoid  UC 
compared with healthy controls. Chapter 6. The association between miR-31 and TSLP 
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6.3.4  TSLP  mRNA  expression  is  decreased  in 
CD4
+CD25
intermediate mucosal lymphocytes 
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Figure  46.  The  expression  of  TSLP  in  CD4
+CD25
intermediate  mucosal 
lymphocytes. The relative expression of TSLP mRNA in active UC (n = 
3) is first normalised to GAPDH and compared with healthy controls 
(n  =  5).  Median  values  are  compared  using  the  one  tailed  Mann 
Whitney U test. * = p ≤ 0.05. 
In active UC the expression of TSLP mRNA in mucosal  CD4
+CD25
intermediate is 0.669 
(IQR 0.526 – 0.737, p = 0.036) fold relative to healthy controls. 
6.3.5  TSLP expression in healthy PBMCS 
Healthy  peripheral  PBMCs  do  not  express  TSLP  mRNA.  There  is  a  measurable 
amplification  of  TSLP  mRNA  in  33%  (1/3)  of  samples  although  the  Ct  value  is 
above the threshold cycle considered significant. Peripheral PBMCs activated ex-
vivo  by  co-culture  with  PHA  show  amplification  of  TSLP  mRNA  in  33%  (1/3)  of 
samples after 24 hours and in 66% (2/3) samples after 48 hours culture, Figure 47. 
In 3 of the 9  wells there is measurable amplification of TSLP mRNA during RT-
qPCR. In another 2 wells there is measurable TSLP but with Ct value above that 
considered significant. 
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(a)  (b) 
Figure 47. The expression of TSLP mRNA in healthy PBMCs. PBMCs 
from  3  healthy  controls  were  extracted  from  the  peripheral  blood 
using  Ficoll®.  The  PBMCs  were  divided  into  3  and  stimulated  with 
PHA (2.5 µg/ml) for 0, 24 and 48 hours. RT-qPCR was performed. (a) 
The amplification plot of TSLP mRNA and GAPDH. (b) Comparison of 
ΔCt values for TSLP mRNA amplification in relation to the duration of 
stimulation by PHA. >35 = TSLP mRNA amplified but with a Ct value 
greater than 35. 
In sample #2, there is a measurable quantity of TSLP mRNA in healthy PBMCs, but 
at 0 hours this is above the cut off Ct value. At 24 and 48 hours of co-culture with 
PHA the amplification is significant. In sample #3 there is no amplification at 0 
hours  but  after  24  hours  the  amplification  becomes  measurable,  but  not 
significant, after 48 hours the amplification is measurable, Figure 47b. 
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6.4  Stimulation  of  Jurkat  cells  with  PHA  as  a  mucosal 
lymphocyte model for Ulcerative Colitis. 
The expression of miR-31 is raised in whole mucosal biopsies, lymphocytes and 
CD4
+CD25
intermediate  lymphocytes  extracted  from  active  UC.  A  target  of  miR-31  is 
predicted to be TSLP. The expression of TSLP has been shown to be decreased in 
mucosal biopsies, lymphocytes and CD4
+CD25
intermediate lymphocytes extracted from 
the sigmoid mucosa of active UC. Little is known of the expression and function of 
TSLP  in  UC  and  the  expression  of  TSLP  has  not  been  previously  reported  in 
mucosal  lymphocytes.  The  expression  of  TSLP  has  been  shown  to  be  raised  in 
other  T
H2  inflammatory  disorders  where  it  is  expressed  by  epithelial  cells  as  a 
factor that influences dendritic and lymphocyte cell function. 
The aim of this section is to develop an in-vitro model of colitis that mimics the 
miR-31 and TSLP mRNA expressions previously seen in mucosal samples. 
Three  distinct  cell  types  are  analysed  for  their  expression  of  miR-31  and  TSLP. 
Jurkat,  THP-1  and  HT29  cells  are  immortalised  clones  of  human  lymphocytes, 
monocytes  and  epithelial  cells  respectively.  They  represent  three  distinct  cell 
types which are found within the colonic mucosa and have been implicated in the 
aetiology of UC. 
6.4.1  Optimal  culture  conditions,  the  stimulation  of 
PBMCs with PHA 
Peripheral blood was taken from 3 healthy volunteers, 2 male and 1 female ages 
32, 32, and 35 years. All are on no medication and have no current or previous 
medical history. The PBMCs were stimulated with PHA at 0.0 µg/ml, 2.5 µg/ml, 5.0 
µg/ml and 10.0 µg/ml for 0, 24 and 48 hours as described in section 2.9.5. 
The relative expression of miR-31 compared with unstimulated PBMCs increases 
over time for all concentrations of PHA. The relative expression of miR-31 appears 
to reach a peak at 48 hours with no further significant increase beyond this. 
After  48  hours  culture  with  PHA  the  expression  of  miR-31  in  healthy  PBMCs  is 
increased by a median of 3.099 (IQR 2.666 – 4.134) fold, 3.247 (IQR 2.776 – 4.747)   Chapter 6. The association between miR-31 and TSLP 
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fold and 2.212 (2.093 – 3.744) fold in cultures with 2.5 µg/ml, 5.0 µg/ml and 10.0 
µg/ml  PHA  respectively.  The  relative  expression  of  miR-31  is  significantly 
increased at 48 hours between PBMCs not cultured with PHA and those cultured 
with  2.5  µg/ml  PHA,  p  =  0.050.  However  the  small  increase  of  3.099  to  3.247 
between 2.5 µg/ml and 5.0 µg/ml respectively is not significant. 
These  results  would  indicate  that  the  optimum  culture  conditions  for  the 
expression of miR-31 in PBMCs is 2.5 µg/ml PHA for 48 hours. 
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(a)  (b) 
Figure  48.  The  expression  of  miR-31  in  healthy  PBMCs  following 
culture with PHA.The expression of miR-31 is analysed in PBMCs of 3 
healthy  volunteers  by  RT-qPCR.  The  expression  of  miR-31  was 
normalised to RNU44 and compared against paired samples without 
PHA stimulation. (a) The expression of miR-31 increases over time 
for  all  concentrations  of  PHA,  however  there  is  no  significant 
increase  in  miR-31  expression  beyond  48  hours.  (b)  The  relative 
expression of miR-31 at 48 hours. There is a significant difference in 
the expression of miR-31 at 48 hours after co-culture with 2.5 µg/ml 
PHA. Median values are compared using the one tailed Mann Witney 
U test. * p  0.05. 
6.4.2  Candidate miRNAs in Jurkat cells 
The expressions of miR-31, miR-194, miR-223 and miR-422a are increased in Jurkat 
cells when cultured with 2.5 µg/ml PHA for 48 hours compared with control. Chapter 6. The association between miR-31 and TSLP 
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The expressions of miR-31 and miR-223 in stimulated Jurkat cells mimic that seen 
in  UC.  Despite  the  expressions  of  miR-194  and  miR-422a  being  increased  in 
stimulated Jurkat cells, this is opposite to that found in UC suggesting that Jurkat 
cell  stimulation  with  PHA  is  not  a  good  model  to  mimic  miR-194  or  mir422 
expression and their down-stream influence on gene transcription. 
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Figure  49.  The  relative  expression  of  Candidate  miRNAs  in  PHA 
stimulated Jurkat cells. Jurkat cells were cultured for 48 hours with, 
or  without,  2.5  µg/ml  PHA,  and  a  RT-qPCR  performed.  The 
expressions  of  miRNAs  were  normalised  to  RNU44,  and  the 
expressions  of  miRNAs  were  compared  in  stimulated  versus 
unstimulated  (control)  Jurkat  cells.  Median  values  were  compared 
using  the  one  tailed  Mann  Whitney  U  test.  *  p  ≤  0.05.  ns  =  not 
significant. 
The expression of miR-194 is 1.959 (IQR 0.881  – 1.175, p = 0.029) fold greater in 
stimulated  Jurkat  cells  compared  with  control.  The  expression  of  miR-422a  is 
1.924  (IQR  0.947  –  3.148)  fold greater  in  stimulated Jurkat cells compared  with 
control, although does not reach significance, p = 0.171.   Chapter 6. The association between miR-31 and TSLP 
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The expression of miR-31 is 4.209 (IQR 1.993 – 7.110, p = 0.001) fold greater in 
stimulated Jurkat cells compared with control. The expression of miR-223 is 6.122 
(IQR 2.756 – 9.965, p = 0.014) fold greater in stimulated Jurkat cells compared with 
control. 
Of the 4 miRNAs which are predicted to have TSLP as a target, the expressions of 
miR-31 and miR-223 mimic the expressions in UC. 
6.4.3  The association between miR-31 and TSLP 
Both miR-31 and miR-223 have an increased expression in stimulated Jurkat cells 
and both are predicted to target TSLP. The focus of this section is miR-31 due to 
the  greater  expression  of  miR-31  in  mucosal  biopsies  compared  with  miR-223, 
10.970 versus 3.454 respectively, section 4.4.1. As a target of miR-31 it is expected 
that the expression of TSLP is reduced in stimulated Jurkat cells. In this section 
the  association  between  miR-31  and  TSLP  in  paired  Jurkat  cell  samples  is 
demonstrated. 
The  relative  expressions  of  both  miR-31  and  TSLP  follow  the  same  pattern  in 
stimulated  Jurkat  cells  as  that  seen  in  whole  mucosal  biopsies,  mucosal 
lymphocytes and CD4
+CD25
intermediate lymphocytes in UC, Figure 50a and b. 
The expression of miR-31 is increased by 4.209 fold in stimulated Jurkat cells. The 
expression  of  TSLP  mRNA  is  0.822  (IQR  0.549  –  0.875,  p  <  0.001)  fold  less  in 
stimulated compared with unstimulated Jurkat cells. 
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relative expression of miR-31
in Jurkat cells by RT-qPCR
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Figure  50.  The  association  of  miR-31  and  TSLP  in  PHA  stimulated 
Jurkat cells. The expression of miR-31 and TSLP mRNA are analysed 
using  RT-qPCR.  (a)  The  expression  of  miR-31  in  PHA  stimulated 
Jurkat cells (n = 8) is normalised to RNU44 and compared against 
unstimulated Jurkat cells (n = 7). (b) The expression of TSLP mRNA in 
PHA  stimulated  Jurkat  cells  (n  =  13)  is  normalised  to  GAPDH  and 
compared against unstimulated Jurkat cells (n = 12). For both miR-31 
and  TSLP  there  was  a  significant  difference  between  the  median 
values, MW U = 3 and 15 respectively. (c) Comparison of the relative 
expression  of  miR-31  and  TSLP  in  paired  samples  of  stimulated 
Jurkat cells. (d) The association between the relative expression of 
miR-31  and  TSLP  in  stimulated  Jurkat  cells.  Best  fit  line calculated 
using  one  phase  decay  equation,  [Y=(Y0-plateau)x(-KxX)+plateau], 
(GraphPad Prism v5.04). Spearman’s rank correlation coefficient r
s (6) 
= -0.905, p = 0.002. 
r
s = -0.905   Chapter 6. The association between miR-31 and TSLP 
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The relationships between miR-31 and TSLP mRNA in paired samples are shown in 
Figure 50c. There is a significant inverse relationship between the expression of 
miR-31 and TSLP mRNA, r
s (6) = -0.905, p = 0.002, Figure 50d. It appears that the 
influence  of  miR-31  on  TSLP  expression  has  a  finite  effect.  The  maximum 
inhibitory effect of miR-31 peaks when it’s expression is between 8 and 10 times 
normal, an expression which halves the expression of TSLP. 
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6.5  Antagomir silencing of miR-31 blocks the effect of PHA 
on TSLP mRNA 
We have shown that in human samples the expression of miR-31 is increased and 
the expression of TSLP mRNA is decreased in the mucosa, mucosal lymphocytes 
and  CD4
+CD25
intermediate  lymphocyte  subset  in  active  UC.  We  have  also  shown  the 
same inverse relationship in stimulated Jurkat cells. 
Using PHA stimulated Jurkat cells as an in vitro model to mimic the relationship 
between miR-31 and TSLP in lymphocytes in actively inflamed UC; we aim to show 
an association between the expression of miR-31 and TSLP mRNA and TSLP protein 
by silencing miR-31. 
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(a)  (b) 
Figure  51.  The  relative  expression  of  (a)  miR-31  and  (b)  TSLP  in 
stimulated  Jurkat  cells  co-cultured  with  the  antagomir  of  miR-31. 
Jurkat  cells  were  co-cultured  with  or  without  PHA  and  either  the 
antagomir to miR-31 or a scrambled sequence antagomir for control. 
Results are presented relative to the expression in unstimulated cells 
transfected with scrambled antagomir. All groups n = 6. Medians are 
compared with the one tailed Mann Whitney U test, * P≤0.05. Grey 
area = stimulated cells.   Chapter 6. The association between miR-31 and TSLP 
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Specific silencing of miR-31 decreases the endogenous expression of miR-31 by 
≈50%  (relative  expressions  1.117  vs.  0.490).  As  previously  demonstrated 
stimulation  of  Jurkat  cells  increases  the  relative  expression  of  miR-31,  in  this 
series of experiments  the relative expression of miR-31  was 5.106  (IQR 2.277  – 
21.390,  p  =  0.002)  fold  compared  with  unstimulated  cells.  This  increase  is 
abrogated when stimulated cells are also cultured with miR-31 specific antagomir, 
0.873 (IQR 0.577 – 1.421) fold, a difference which is significant, p = 0.001, Figure 
51a. 
In these same cultures there is an inverse relationship between miR-31 and TSLP. 
The endogenous expression of TSLP mRNA is increased by 1.357 fold when cells 
are  cultured  with  miR-31  specific  antagomir,  although  this  does  not  reach 
significance p = 0.131. 
In Jurkat cells stimulated with PHA, the relative expression of TSLP is 0.717 (IQR 
0.477 – 0.783, p = 0.021) fold compared with unstimulated cells. This difference is 
abrogated  when  stimulated  cells  are  cultured  with  miR-31  specific  antagomir, 
relative expression of TSLP is 0.985 (IQR 0.866 – 1.089) fold, a difference which is 
significant, p = 0.004, Figure 51b. 
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6.6  Silencing of miR-31 blocks the effect of PHA on TSLP 
protein 
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Figure  52.  TSLP  concentration  in  cell  culture  supernatants  from 
Jurkat  cells  transfected  with  the  antagomir  to  miR-31.  Jurkat  cells 
were  co-cultured  with or  without  PHA  and  either the  antagomir to 
miR-31  or  a  scrambled  sequence  antagomir  for  control.  Protein 
quantification was performed by ELISA. All groups n = 6. Dotted line 
shows  the  protein  expression  in  the  control  group.  Medians  are 
compared  with  the  one  tailed  Mann  Whitney  U  test,  *  P≤0.05. 
Whiskers indicate IQR. Grey area = stimulated cells. 
Stimulation of Jurkat cells with PHA decreases the concentration of TSLP by 53.4%, 
p = 0.001. In unstimulated cells the concentration of TSLP is 32.5 pg/ml (IQR 28.1 – 
49.1) and in stimulated cells 15.1 pg/ml (IQR 4.6 – 20.5). Both cell cultures were co 
cultured with a scrambled sequence antagomir. 
In cells  stimulated  with PHA the concentration of TSLP  is 15.1 pg/ml,  when co-
cultured with miR-31 antagomir the concentration of TSLP is 41.5 pg/ml (IQR 23.6 
– 46.3) a significant difference, p = 0.002. 
This indicates that co-culture with the miR-31 antagomir abrogates the negative 
influence  of  PHA  on  TSLP  expression.  Interestingly  the  expression  of  TSLP  in 
unstimulated cells is increased to 56.8 pg/ml (IQR 30.8 – 140.0) if co-cultured with   Chapter 6. The association between miR-31 and TSLP 
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the  miR-31  antagomir,  indicating  that  in  the  absence  of  miR-31  the  basal 
expression of TSLP is greater. 
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6.7  Chapter discussion 
Although identified as being expressed in the healthy intestine in 2000 and absent 
from active Crohn's colon in 2005, it was not until a study by Tanaka et al. (2010) 
that  the  differential  expression  of  TSLP  was  reported  in  the  colonic  mucosa  of 
active UC. The finding of an increased expression of TSLP is consistent with the 
well  documented  increase  in  TSLP  expression  found  in  other  T
H2  mediated 
inflammatory conditions such as allergic respiratory and skin disorders. 
In  health  there  are  several  drivers  for  TSLP  expression  including  infection  and 
response to cytokines. During infection, TSLP has 2 roles, the first is to enhance 
pathogen expulsion, a feature particularly important in helminth infection, and the 
second role is to promote a less destructive inflammatory response and maintain 
epithelial barrier homeostasis through the promotion of T
H2 cytokines including 
IL-4. 
Cytokines  which  drive  TSLP  expression  include  IL-4,  suggesting  a  positive 
feedback mechanism, IL-13 and IL-25 and the T
H1 cytokines TNF-α, IL-1 and INF-γ, 
suggesting an attempt to steer the inflammatory milieu away from a T
H1 response. 
It  is  not  known  if  TSLP  triggers  inflammation  through  the  promotion  of  an 
exaggerated T
H2 inflammation or is triggered during an inflammatory response as 
a control mechanism against a far more destructive T
H1 response. 
We  found  that  the  expression  of  TSLP  mRNA  and  TSLP  protein  is  decreased  in 
whole biopsies taken during endoscopy from active sigmoid UC. This is opposite 
to  the  increase  found  in  UC  by  Tanaka  et  al.  (2012)  and  opposite  to  what  is 
expected if UC is thought to parallel inflammatory respiratory conditions. 
There are a number of features of the study by Tanaka et al. (2010) which make 
direct comparison challenging. Firstly, the study by Tanaka et al. includes a small 
and distinct population of Asian UC patients undergoing resection presumably for 
treatment  resistant  severe  UC  under  which  circumstances  it  is  likely  that  they 
were also on high dose steroids as well as other immune altering medications. It is 
not stated from where the tissue is taken, and the comparison is not with healthy 
individuals as claimed but patients undergoing colorectal cancer resection. These   Chapter 6. The association between miR-31 and TSLP 
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are all important factors given that; 1. There are important aetiological differences 
between Asian and Western IBD patients, not least genetic and environmental risk 
factors, 2. The annual incidence of colectomy is <1%, indicating that the study was 
performed on a highly selected and unique cohort from within the UC family, their 
immunological  milieu  is  likely  to  have  been  altered  by  treatment  including  an 
effect  on  cytokines  that  influence  TSLP  expression,  e.g.  TNF-α,  3.  There  are 
regional differences in TSLP expression throughout the intestine, and 4. Healthy 
colon mucosa has a different expression of factors, particularly miRNAs compared 
with colorectal cancer. 
In inflammation such as that seen in allergy and respiratory inflammation, TSLP 
may be a driver of T
H2 differentiation, proliferation and function and thus causal in 
these non-destructive inflammatory conditions. An alternative role for TSLP could 
be in its expression which is triggered as part of the inflammatory response as an 
attempt to maintain homeostasis and a non-inflammatory environment. In UC, a 
situation akin to more invasive infection and more destructive inflammation, pro-
inflammatory factors come to the fore and drive a more aggressive inflammation 
with features leaning towards a T
H1 response. In practice this is reflected by the 
beneficial effects of Infliximab, a TNF-α inhibitor, on more aggressive forms of UC. 
The  decreased  expression  of  TSLP  in  mucosal  biopsies  reflects  the  combined 
expression  from  all  cells  within  the  mucosa  including;  epithelial  cells, 
lymphocytes,  monocytes  and  various  other  cells.  A  technique  of  analysing  the 
origin of TSLP  protein from  within a sample is  immunohistochemistry, however 
the  study  moved  directly  into  cell  subtype  analysis  and  in  vitro  work  partly 
because  of  logistical  limitations  of  human  sample  collection  and  also  the 
established association and interest in lymphocyte malfunction and UC, and the 
increased expression of miR-31 already shown in lymphocytes. 
We have shown for the first time the expression of TSLP by mucosal lymphocytes 
in  health  and  UC.  Like  previous  studies  we  have  shown  that  peripheral 
lymphocytes  do  not  express  TSLP.  However  we  have  also  indicated  that  when 
stimulated there is a measurable expression of TSLP in 33% of lymphocytes at 24 
hours  and  66%  at  48  hours,  indicating  that  the  expression  of  TSLP  may  be  a Chapter 6. The association between miR-31 and TSLP 
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feature of activated lymphocytes. Lymphocytes extracted from the healthy sigmoid 
mucosa constitutionally express TSLP. This may be because a particular subset of 
lymphocytes is  homed to the GI tract  mucosa, or that exposure to the mucosal 
environment  stimulates  lymphocytes  to  express  TSLP.  The  nature  of  this 
phenomenon remains to be found, but ECs are known to increase TSLP expression 
in response to bacteria, in much the same way as healthy mucosal lymphocytes 
increase TSLP expression when cultured with PHA. 
Two initial studies had shown the expression of miR-31 and TSLP in PBMCs from 
healthy volunteers before and after stimulation with PHA, section 6.4.1 and 6.3.5 
respectively. Further work on the expression and relationship between miR-31 and 
TSLP in lymphocytes however, involved using Jurkat cells as an in vitro cell model. 
This is because gene silencing, which is a key component in the investigation of 
the  effect  of  altering  miR-31  expression  on  TSLP  involves  transfection  with  an 
antagomir to miR-31. Primary lymphocytes are fragile and notoriously difficult to 
transfect, in contrast to Jurkat cells which show > 50% gene silencing in this study, 
Figure  51.  There  are  a  number  of  reasons  why  primary  lymphocytes  are 
challenging  to  transfect,  including  cell  fragility  and  transfection  toxicity  which 
may explain why the manufacturer of INTERFERin™ only lists robust adherent cells 
in its list of successfully transfected primary cell lines (Polyplus Transfection Inc, 
2012). 
Jurkat  cells  are  a  well  established  in  vitro  cell  model  to  analyse  T  lymphocyte 
function. The miR-31 and TSLP change seen with PHA stimulation in Jurkat cells 
mimics that seen in mucosal lymphocytes, Jurkat cells therefore provide a good 
model to infer the effect of miR-31 manipulation on TSLP in lymphocytes. 
Jurkat cells cultured with PHA reveal a number of important findings; the first is 
the  duration  and  concentration  of  PHA  required  for  maximal  stimulation.  It  is 
shown that PHA stimulation in terms of miR-31 expression reaches a plateau at 48 
hours  and  shows  a  peak of  expression  at a  concentration  between  2.5  and  5.0 
µg/ml.  The  activation  of  cells  by  PHA  is  situation  specific,  studies  have  used 
between  0.5  and  >10  µg/ml  to  stimulate  cells,  and  for  durations  up  to  several 
months. Higher doses cause increased cell death amongst certain cell types and   Chapter 6. The association between miR-31 and TSLP 
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greater  proliferation  amongst  others,  longer  durations  are  used  to  achieve  cell 
proliferation rather than activation. 
The expression of miR-31 increases and TSLP decreases in Jurkat cells stimulated 
with PHA. In individual cell cultures the association between the degree of miR-31 
increase and the degree of TSLP decrease is inversely correlated, r
s = 0.905, p = 
0.002. This strong correlation implies that miR-31 plays a role in the TSLP pathway. 
To study the effect of miR-31 “loss of function” on lymphocytes we introduced the 
antagomir of miR-31 into the previously described Jurkat cell model. 
The use of antagomirs is an established method to study the effect of a “loss of 
function” of a particular gene (Krutzfeldt et al., 2005). To transfect the antagomir 
into the target cell it is first complexed with a generic siRNA transfection reagent 
(TRANSFERin™),  this  aids  the  introduction  of  the  antagomir  into  the  target  cell 
during culture. Within the cell the antagomir binds with its complimentary base 
pair combination and prevents miRNA integration into the RISC complex and its 
function. 
The efficiency of antagomir silencing is largely dependent on transfected cell type 
and  technique.  Under  optimal  conditions  transfection  with  TRANSFERin™  can 
achieve over 90% efficiency (Polyplus Transfection Inc, 2012), however, Jurkat cell 
transfection is notoriously difficult with efficiencies ranging from <1% (Choi et al., 
2012)  to  70%  (Jordan  et al.,  2008).  There  are  no  references  to the  efficiency  of 
Jurkat cell transfection with INTERFERin™. Following the manufactures protocol we 
achieved  a  50%  reduction  in  the  expression  of  miR-31  with  no  increase  in  cell 
death between transfected cells and cells grown in parallel culture. 
The expression of TSLP mRNA and concentration of TSLP protein in cell culture 
supernatants  are  decreased  in  Jurkat  cells  stimulated  with  PHA  and  associated 
with  an  increased  expression  of  miR-31.  In  cell  cultures  transfected  with  the 
antagomir to miR-31, there is no increase in miR-31 expression and no reduction in 
TSLP mRNA expression or production of TSLP, indicating a role for miR-31 in the 
TSLP pathway. Chapter 6. The association between miR-31 and TSLP 
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Interestingly the effect on TSLP protein production appears to be approximately 
twice the change seen for TSLP mRNA. In stimulated Jurkat cells transfected with a 
scrambled  sequence  antagomir  the  expression  of  TSLP  mRNA  is  0.71  fold 
compared with control, in the same cultures the concentration of TSLP protein is 
0.46  fold  compared  with  control,  indicating  a  none  linear  relationship  between 
TSLP mRNA expression and protein production. 
The ratio of protein production to mRNA expression is dependent on many factors 
including  mRNA  degradation  rate  and  ribosomal  binding  factors,  the  later  is  a 
feature of miRNAs. Despite the control of gene translation into protein by miRNAs, 
the production of protein could occur freely due to the phenomenon of “miRNA 
escape”. There are 3 variants of the TSLP protein gene, complementary binding of 
miR-31  to  the  3’UTR  of  TSLP  occurs  in  only  one  of  the  three  variants,  NCBI 
Reference  Sequence:  NM_033035.4.  The  3’UTR  of  this  variant  is  2570  bases  in 
length compared with 57 and 719 for the other two. The translational repression 
of  many  protein  coding  genes  occurs  more  frequently  with  those  variants  with 
longer  3’UTRs,  probably  due  to  increased  base  pair  combinations.  Deliberate 
shortening of the 3’UTR of a protein to escape miRNA inhibition is a feature of 
certain  viral  survival  strategies  (De  Francesco  and  Migliaccio,  2005)  and  drug 
resistant cancer pathways (To et al., 2009). What degree of TSLP function depends 
on the three TSLP mRNA variants and therefore fall under the influence of miR-31 
is unknown. 
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7.1  Conclusions 
1.  Seven miRNAs have a consistently deregulated expression in the sigmoid 
mucosa of patients with UC compared with healthy controls. 
a.  The  expressions  of  miR-31,  miR-146b  and  miR-223  have  a 
consistently  increased  expression  in  the  mucosa  of  active  UC 
compared with healthy controls. 
b.  The  expressions  of  miR-31  and  miR-223  are  also  increased  in  the 
sigmoid mucosa of inactive UC compared with healthy controls. 
c.  The expressions of miR-194, miR-200b, miR-375 and miR-422a have a 
consistently  decreased  expression  in  the  mucosa  of  active  UC 
compared with healthy control. 
d.  The expression of miR-375 is also reduced in the sigmoid mucosa of 
inactive UC compared with healthy controls. 
2.  The  expressions  of  miR-31  and  miR-223  are  increased,  and  miR-194  and 
miR-200b decreased in mucosal lymphocytes taken from active sigmoid UC 
compared with healthy control. 
3.  TSLP is identified as a target for 4 of the 7 miRNAs using in silico analysis. 
4.  The  expression  of  TSLP  mRNA  is  39%  less  in  the  mucosa  of  active  UC 
compared with healthy controls. 
5.  The expression of  TSLP  protein  in active UC is 34% of the expression  in 
healthy controls. 
6.  TSLP  is  not  expressed  in  unstimulated  PBMCs,  but  is  expressed  when 
PBMCs are stimulated with PHA. 
7.  There is a constitutional expression of TSLP in mucosal lymphocytes. 
8.  The expression of TSLP mRNA is 61% less in mucosal lymphocytes and 33% 
less in CD4
+CD25
intermediate mucosal lymphocytes of active UC compared with 
healthy control. 
9.  The  expression  of  miR-31  and  TSLP  mRNA  is  inversely  correlated  in 
stimulated Jurkat cells. 
10. Silencing  of  miR-31  abrogates  the  effect  of  PHA  stimulation  on  TSLP  in 
Jurkat cells indicating a role for miR-31 in the TSLP pathway. 
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7.2  Discussion 
7.2.1  Animal models 
The initial hypothesis of this thesis is that in IBD there is a distinct number of 
miRNAs that are differentially expressed compared with healthy individuals and 
that one or all of these miRNAs influence an inflammatory pathway in such a way 
as  to  predispose  to  or  perpetuate  IBD.  Murine  models  are  a  well  established 
method  of  reproducing  inflammatory  conditions  akin  to  that  seen  in  IBD.  We 
started by attempting to develop a murine model which would mimic the features 
of IBD in terms of miRNA and cytokine expression. 
The  initial  experiments  analysed  the  expressions  of  miR-155  and  miR-125  in  3 
widely used models of chemically induced experimental colitis; TNBS, Oxazolone 
and DSS. It was expected that in induced colitis the expression of miR-155 would 
be significantly increased with an inversely related expression of miR -125. At the 
time there was no direct evidence of raised miR-155 in IBD in fact the only miRNA 
profile in human mucosa at the time had not demonstrated an increase in miR-155 
(Wu et al., 2008), however the expected increase was based on the well established 
role of miR-155 in many types of in vitro and animal models of inflammation. The 
inverse relationship between miR-155 and miR-125 had been demonstrated in LPS 
stimulated murine monocytes and thought to be a result of TNF-α driven miRNA 
expression  (Tili  et  al.,  2007).  TNF-α  continues  to  be  the  prominent  pro-
inflammatory cytokine and target for biological therapy in IBD it therefore stands 
to reason that a similar relationship should be seen in humans. 
The increased expression of miR-155 in IBD has since been confirmed (Takagi et 
al., 2010, Van der Goten et al., 2012). The expression of miR-125 does not feature 
as  a  differentially  expressed  miRNA  in  any  of  the  microarray  studies  to  date, 
although tissue used for these are mucosal biopsies, which may indicate that miR-
125 has a cell specific expression e.g. down regulated in healthy  T
regs compared 
with  other  T  cells  (Rouas  et al.,  2009),  and  decreased  in  stimulated  monocytes, 
therefore not applicable to whole biopsy studies.     Chapter 7. Discussion and future work 
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In all three experimental models we demonstrated an increased expression of miR-
155 compared with healthy controls, although the results were not consistent and 
only seen in certain variants of each model; including 3.0% TNBS, but not 2.0% or 
2.5% TNBS, after day 3 but not day 5 of the 2% Oxazolone model, and with the 2% 
DSS model. The expression of miR-125 appeared to follow no pattern across the 
models, with a small but significant increase in both the 2.5% and 3.0% TNBS but 
not the 2.0% model, and no significant difference in the DSS model or in either the 
day 3 or day 5 variant of the Oxazolone model. 
The increase in miR-155 was greatest in the day 3 variant of the 2% Oxazolone 
model, and therefore cytokines were analysed in this model. 
The  premise  of  experimental  models  is  that  the  cytokine  expression  profile 
mimics that of either UC or Crohn’s, i.e. in Crohn’s like colitis the expression of IL-
12, IL-23, IFNγ and TNF-α are increased and in UC the expression of IL-4, IL-5 and 
IL-13 are increased. 
The  results  presented  in  Chapter  3  show  that  2%  Oxazolone  did  not  favour  a 
polarised T cell response. On day 3 there was an increase in TNF-α but not INF-γ, 
and an increased expression of IL-4, IL-17 and IL-10. On day 5 the expression of 
FOXP3 was increased suggesting an increase activity of regulatory T cells with no 
change in the expression of TNF-α, IL-4, IL-17 or IL-10, although TGF-β continued to 
increase. 
Taken together these results demonstrate that under the experimental conditions 
used, the 2% Oxazolone model had a cytokine profile consistent with a generalised 
mucosal inflammation which did not mimic either a Crohn’s like (T
H1) or UC like 
(T
H2)  type  reaction  and  suggests  that  miR-155  is  a  generalised  marker  of 
inflammation rather than specific to a particular disease model. 
Although attempts are made to categorise different models into either a T
H1 or T
H2 
type inflammation, see review by Strober et al. (2002, p 498), the actual immune 
response  as  defined  by  cytokine  pattern,  histology  or  macroscopic  pattern  of 
disease  depends  on  many  factors  including  the  mouse  strain  and  experiment 
conditions. For example with TNBS models of colitis, in SJL/J mice a chronic T
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mediated response is seen, but in INF-γ
-/- Balb/c mice a T
H2 mediated colonic patch 
hypertrophy is seen. Oxazolone is often used to study T
H2 pathways but at lower 
doses a mixed T
H1/T
H2 dependent colitis is seen. 
Dextran  Sulphate  Sodium,  TNBS  and  Oxazolone  are  all  widely  used  to  study 
inflammation within the bowel and often interpreted as mimicking IBD, however 
they only resemble some aspects of human IBD (Wirtz and Neurath, 2007) and it is 
therefore impossible to unambiguously classify the different mouse models into 
UC or Crohn’s type inflammation (Celinski et al., 2010). 
In  an  attempt  to  further  understand  the  miRNA  profile  and  cytokine  targets  in 
human IBD, treatment naive, active sigmoid UC biopsies were used, focusing on 
active UC. 
7.2.2  The miRNA profile of the sigmoid mucosa, mucosal 
lymphocytes  and  CD4
+CD25
intermediate  mucosal 
lymphocytes 
To  date  there  are  a  number  of  published  (Wu  et  al.,  2008,  Fasseu  et  al.,  2010, 
Takagi et al., 2010) and unpublished (Van der Goten et al., 2012) mucosal miRNA 
profiles for UC. Together these have identified 65 miRNAs that have a differential 
expression between active UC and healthy controls. The functional relevance of 
these miRNAs has yet to be demonstrated in humans, although in vitro and animal 
models have suggested multiple pathways through which many of these miRNAs 
could play a role. 
This study has identified 7 miRNAs that have a consistent differential expression 
between biopsies taken from active sigmoid UC and healthy controls. Although all 
7  have  been  previously  identified  by  individual  microarrays  the  concordance 
between studies has been poor, mainly because of differing patient phenotype and 
microarray  methodology.  It  is  also  established  that  cell,  tissue  and  regional 
differences in miRNA expression make comparison across these studies difficult 
(Wu et al., 2010). 
Sample  heterogeneity  challenges  the  interpretation  between  studies  and  also 
limits their clinical relevance. Existing  studies have combined samples collected     Chapter 7. Discussion and future work 
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from  various  sources  including;  resections  and  biopsies,  various  regions  of  the 
colon,  differing  definitions  of  inactive  disease  and  importantly  reported  miRNA 
expression  in  patients  on a variety of  immune  altering  treatments,  including  5-
ASAs,  immunosuppressive  medication  and  biologics.  Heterogeneity  makes 
interpretation of the clinical relevance of miRNAs challenging other than the broad 
theme that potentially large numbers of miRNA are deregulated in IBD. 
The  relevance  of  differentially  expressed  miRNAs  in  disease  is  their  ability  to 
explain disease aetiology and provide possible therapeutic targets. A real strength 
of this work is the homogeneity of the samples used. This study therefore takes 
into  account  several  important  variables  in  sample  selection;  human  versus 
animal,  biopsies  taken  at  endoscopy  rather  than  resection  samples,  colonic 
mucosa rather than blood, sigmoid rather than other colonic regions and samples 
from patients who are not on treatment that could potentially alter disease and / 
or miRNA expression. 
This thesis starts by demonstrating a differential expression of 7 miRNAs in active 
UC compared  with  healthy  controls.  By  comparing  microarrays,  first  by  ranking 
miRNA  expression,  then  by  only  analysing  those  with  consistently  deregulated 
expression,  all  7  miRNAs  are  validated  by  RT-qPCR.  Previous  studies  reporting 
comparative expressions analysed by microarray alone give a false positive rate, 
and can increase the number of differentially expressed  miRNA by up to 200%, 
these studies should be interpreted with caution. 
The expressions of the 7 candidate miRNAs are reported in 3 distinct areas; the 
first  is  in  mucosal  biopsies,  the  second  in  mucosal  lymphocytes  derived  by 
centrifugation  on  a  Percoll  gradient  and  the  second  is  in  CD4
+CD25
intermediate 
lymphocytes derived  initially on a Percoll gradient and then acquired  with flow 
cytometry. 
The miRNA expressions in the mucosa are the most widely reported profiles in 
mucosal UC. This is because of the logistics of tissue collection and quantity. This 
however provides an expression profile for a mixed cell population, with different 
and unknown proportions of each cell type within samples, for example there is 
likely to be a higher proportion of epithelial cells in biopsies of the same size from Chapter 7. Discussion and future work 
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normal  mucosa  compared  with  inflamed  mucosa,  and  alternatively  a  higher 
proportion of inflammatory immune cells in actively inflamed mucosa compared 
with healthy mucosa. The cellular origin of the miRNA is therefore impossible to 
conclude  from  whole  mucosal  biopsies;  however  what  can  be  concluded  is  the 
differential miRNA environment between active UC and health. 
Density  centrifugation  of  digested  biopsy  tissue  achieved  a  cell  suspension  of 
32.2% lymphocytes with ≥90% viability. This again is a mixed population including 
lymphocytes,  but  is  considerably  more  enriched  with  lymphocytes  than  whole 
biopsies.  There  are  no  reported  miRNA  expressions  in  mucosal  lymphocytes 
extracted from biopsies. In this population the expression of 4 of the 7 miRNAs 
continue  to  have  a  significant  differential  expression  compared  with  healthy 
lymphocytes. The expressions of miR-31 and miR-223 are higher, and miR-194 and 
miR-200b are lower in active UC. 
Using  flow  cytometry  and  multicolour  analysis  of  the  lymphocyte  cell  solution 
acquired  through  density  centrifugation,  a  population  of  CD3
+CD4
+  lymphocytes 
was  initially  acquired,  and  then  further  divided  depending  on  their  CD25 
characteristics.  CD25  is  a  cell  surface  antibody  expressed  on  the  surface  of 
activated lymphocytes; these include both pro-inflammatory and regulatory T cells. 
In the periphery  it has already been demonstrated that  T
regs express a different 
miRNA  profile  to  other  CD4
+  cells,  in  part  due  to  the  influence  of  miRNAs  in 
controlling cellular function, particularly the negative influence of miR-31 on FoxP3 
expression (Rouas et al., 2009, Hezova et al., 2009), it is therefore important to 
separate these functionally opposite cell populations. 
Regulatory T cells are characterised by the expression of FoxP3, an intercellular 
transcription  factor.  To  identify  FoxP3  within  cells  requires  fixation  and 
permeabilization, a process which traditionally results in RNA cross linking and 
degradation.  In  some  techniques,  such  as  formalin  fixed  paraffin  embedded 
samples, small RNA escape the effects of permeabilization and can therefore be 
reliably  measured  (Li  et  al.,  2007,  Xi  et  al.,  2007),  however  for  flow  cytometry 
newer techniques which offer a way of measuring certain gene expressions after 
intracellular antigen staining (Yamada et al., 2010), have not yet been applied to     Chapter 7. Discussion and future work 
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the measurement of miRNAs. To date the conventional method of separating T
regs 
from a heterogeneous T cell pool is by surface antigen characteristics. 
Regulatory T cells express high levels of surface CD25. In peripheral blood 80  - 
95% of CD4
+CD25
high cells stain for FoxP3 although the proportion is slightly less in 
IBD (Roncador et al., 2005, Eastaff-Leung et al., 2009), indicating that in health a 
larger  proportion  of  activated  peripheral  CD4
+  cells  are  of  the  regulatory 
phenotype. In the colonic mucosa it is accepted that the number of lymphocytes 
increases with the severity of IBD and that the number of  CD4
+CD25
high are also 
increased  (Holmen  et  al.,  2006),  although  the  proportion  of  T
regs  is  less  in  IBD 
compared with non IBD colitis (Maul et al., 2005). The proportion of CD4
+CD25
high 
that  also  stain  for  FoxP3  in  the  colonic  mucosa  is  not  known  although  FOXP3 
mRNA  expression  is  2  -  5  times  higher  in  colonic  CD4
+CD25
high  compared  with 
CD4
+CD25
low, and CD4
+CD25
high but not CD4
+CD25
low exert a suppressive effect on T 
cell proliferation and cytokine production  (Makita et al., 2004). All this together 
suggests that like blood, most sigmoid T
regs are within the CD4
+CD25
high population. 
Exclusion of 20% of the most brightly stained CD25 lymphocytes (T
regs) and 10% of 
the least brightly stained lymphocytes (naive T cells), leaves the CD4
+CD25
intermediate 
cell  sub  family.  This  was  shown  to  be  only  4%  FoxP3
+,  and  therefore  T
regs,  an 
important finding because the influence of  T
regs miRNA expression on the group 
would be negligible. The expression of miR-31 and miR-223 was again significantly 
increased in CD4
+CD25
intermediate from active UC compared with healthy controls. 
It is clear that certain miRNA have a purposeful influence on biochemical pathways 
beyond coincidental interaction and those influences are finely balanced, probably 
with  many  other  factors,  to  control  expression  and  function  of  many  protein 
coding  genes.  Dysfunction  of  miRNA  regulation  within  distinct  pathways, 
particularly involving inflammation, is likely to influence disease predisposition, 
initiation  and  propagation.  The  expression  of  miRNAs  in  different  cell  types  is 
likely  to  reflect  the  need  to  control  the  expression  of  different  genes  under 
differing circumstances. 
TSLP was identified as a potential target of 4 of the 7 miRNAs by bioinformatic 
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shown  a  consistent  increase  in  expression  in  active  UC  compared  with  healthy 
control. We also show that in association with an increased miR-31 the expression 
of  TSLP  is  reduced  in  the  mucosa,  mucosal  lymphocytes  and  mucosal 
CD4
+CD25
intermediate lymphocytes of active UC. 
7.2.3  TSLP in IBD and regulation by miR-31 
It  is  almost  20  years  since  the  biological  function  of  TSLP  was  first  described 
(Friend et al., 1994) and although well documented in disorders of the skin and 
lung it was not until 2000 that murine studies identified TSLP in the ileum (Sims et 
al., 2000). It has since been shown that TSLP is constitutionally expressed by the 
human colonic mucosa (Rimoldi et al., 2005). 
Much  of  what  we  know  about  human  TSLP  comes  from  work  on  T
H2  mediated 
inflammatory disorders of the skin and lung in which the expression of TSLP is 
increased.  Murine  studies  also  contribute  towards  our  knowledge  of  TSLP  but 
must be interpreted with caution because of the inter-species differences in the 
origin, expression and action of TSLP. In the human TSPL is thought to originate 
only  from  epithelial  cells  and  keratinocytes  at  barrier  surfaces  in  response  to 
antigens  or  bacterial  invasion,  in  mice  TSLP  is  expressed  by  other  cells, 
predominantly  dendritic  cells,  independently  of  epithelial  cells.  The  action  of 
Human TSLP is through the STAT5 pathway, in mice TSLP works also through the 
STAT3  pathway.  Differences  may  be  due  to  poor  sequence  homology  between 
humans  and  mice,  only  43%,  which  could  also  result  in  other  subtle,  as  yet 
unknown, differences of function. 
Little  is  known  of  the  role  of  TSLP  in  the  intestine.  Although  current  evidence 
suggests that it is expressed by epithelial cells at the barrier surface in response 
to  the  luminal  flora  and  /  or  invasive  pathogens.  In  vitro  studies  have  also 
demonstrated TSLP expression is also driven by TLR ligands, viruses and a variety 
of  cytokines  including  TNF-α  and  IL-4  (Tanaka  et  al.,  2010),  reviewed  by  Takai 
(2012). 
In  response  to  commensal  flora  TSLP  aids  in  the  maintenance  of  mucosal 
homeostasis, by maintaining immune hypo-responsiveness through the promotion     Chapter 7. Discussion and future work 
239 
of  T
H2  cell  maturation  and  proliferation.  When  challenged  by  certain  pathogens 
particularly Helminths, TSLP is critical in developing the defensive  T
H2 mediated 
cytokine  response  and  pathogen  expulsion.  Abnormal  TSLP  expression  is  also 
found in other infections such as H Pylori in human gastric cell lines (Kido et al., 
2010) and Rhinovirus in human bronchus epithelial cells (Kato et al., 2007) In the 
GI tract there are regional differences in TSLP expression which may be explained 
by the regional differences in the microbiome (Taylor et al., 2009). 
TSLP is multifunctional cytokine with an important role in Dendritic cell activation, 
T cell maturation and T
H2 cell proliferation (Reche et al., 2001, Soumelis and Liu, 
2004).  
In health epithelial cells constitutionally express TSLP but little is known about 
TSLP in IBD. It is commonly suggested that TSLP is not expressed in the colon of 
active Crohn’s (Biton et al., 2011) although this is not a complete statement and 
misleading. In the original study by Rimoldi et al. (2005), the analysis of TSLP by 
qPCR  is  from  unaffected  mucosa  (region  not  described)  of  patients  undergoing 
resection for Crohn’s (phenotype not described). There is undetectable expression 
of  TSLP  mRNA  in 6 of the 9 Crohn’s  samples, and of  note is  the reduced  TSLP 
mRNA expression in 2 out of the 3 controls. No other study confirms or refutes 
this finding. 
It is suggested that the increased expression of TSLP in T
H2 disorders indicates a 
“cycles of amplification” (Takai, 2012), in which TSLP expression is triggered and 
inappropriately exaggerated leading to the inflammatory response seen. Ulcerative 
colitis has traditional thought of as a T
H2 mediated inflammatory condition, and it 
stands  to  reason  that  TSLP  should  be  increased  in  the  mucosa.  It  has  been 
reported  that  TSLP  expression  is  raised  in  UC,  although  in  the  original  study 
Tanaka  et  al.  (2010)  compared  surgical  resections  of  UC  against  patients 
undergoing colorectal cancer treatment, this is a unique UC phenotype who are 
probably  on  steroids  compared  with  colorectal  cancer  patients  who  are  not 
“healthy  controls”  and  potentially  have  a  differential  expression  of  miRNAs  of 
their own. Chapter 7. Discussion and future work 
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The  findings  of  Tanaka  et  al.  (2010)  fit  with  the  theory  of  raised  TSLP  in  T
H2 
mediated  inflammation.  However,  we  have  shown  that  TSLP  has  a  decreased 
expression in UC. The explanation for this dichotomy may be due to a number of 
factors  including;  the  differences  in  disease  aetiology  between  allergic  lung 
inflammation and UC which  is a disordered  and often destructive inflammatory 
reaction with features of a T
H1 mediated response. The opposing results of Tanaka 
et al. May be explained by differences in sample population, disease phenotype 
and treatment regimes, which are known to alter the factors which influence TSLP 
expression. It is interesting also that cigarette smoking, a therapy that can protect 
against UC, can induce TSLP production in ECs (Nakamura et al., 2008) something 
that would only help if a decreased TSLP expression was part of the aetiological 
milieu of UC. 
Human studies have been unable to identify TSLP expression from peripheral or GI 
tract lymphocytes. The mechanism of action of TSLP on lymphocytes is through 
the  influence  of  TSLP  on  DCs  which  then  drive  T
H2  lymphocyte  responses, 
although recently the TSLP receptor has been shown to be expressed by peripheral 
lymphocytes  activated  in  vitro,  whilst  not  expressed  by  naive  peripheral  CD4
+ 
lymphocytes.  In-vitro  activation  of  naive  peripheral  lymphocytes  with  anti-CD3
+ 
and  co-culture  with  TSLP,  results  in  increased  proliferation  and  increased 
sensitivity  of  lymphocytes  to  CD2  (Rochman  et  al.,  2007),  suggesting  that  like 
mice,  TSLP  can  act  directly  on  lymphocytes  and  increase  their  inflammatory 
response. 
The connection between miRNA and TSLP has not been shown in IBD beyond the 
predicted  targeting  in  4  of  the  7  miRNAs.  In  Dicer
∆gut  mice  which  have  reduced 
levels  of  miRNA,  a  reduced  expression  of  TSLP  is  found  (Biton  et  al.,  2011) 
suggesting miRNA are necessary for TSLP expression. We show that in the three 
aspects of active UC; mucosa, mucosal lymphocytes and CD4
+CD25
intermediate mucosal 
lymphocytes the expression of miR-31 is increased and TSLP is decreased. Using 
an  in  vitro  lymphocyte  model  we  have  demonstrated  an  inverse  relationship 
between  miR-31  and  TSLP,  and  confirmed  the  ex  vivo  finding  in  extracted 
lymphocytes that stimulation increases miR-31 and decreases TSLP expression.     Chapter 7. Discussion and future work 
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Furthermore, in Jurkat cells cultured with the antagomir of miR-31 not only is the 
increase  in  miR-31  negated  in  stimulated  cells  but  also  the  effect  on  TSLP  is 
prevented, indicating an effect of miR-31 on the TSLP pathway. 
Although CD4
+ T cells have been shown to express the TSLP receptor, this is the 
first  study  to  identify  TSLP  expression  in  lymphocytes.  It  is  possible  that  both 
TSLP  and  TSLP  receptor  expression  form  a  feedback  loop  to  maintain  immune 
homeostasis through prevention of an over aggressive immune response. 
The  complexity  of  the  immunological  milieu  and  heterogeneity  of  disease 
phenotypes has confounded attempts to discover the aetiology of IBD. We have 
shown  that  the  expression  of  certain  miRNAs  in  UC  is  increased  and  certain 
miRNAs  are  decreased.  We  have  demonstrated  that  miR-31  is  associated  with  a 
decreased level of TSLP and that manipulating miR-31 expression directly effects 
TSLP expression. 
Both miR-31 and miR-223 have an increased  expression in the sigmoid colon of 
patients  who  have  no  macroscopic  inflammation  at  the  time  of  endoscopy 
indicating that these miRNAs have a greater expression in the mucosa of patients 
with UC than healthy controls even in the absence of inflammatory activity. These 
miRNAs are potential diagnostic markers for UC, suggesting they could potentially 
be used as a marker for diagnosis in the absence of macroscopic disease. 
There is no doubt that UC is a complex disease that has failed to be explained by a 
single unifying theory. This is reflected in the difficulty in diagnosis, management 
and outcomes. On one hand UC tends towards a T
H2 inflammatory pattern but on 
the other there are strong  features of  T
H1 pattern as  well as many others.  The 
finding  of  a  decreased  TSLP  expression  in  UC  is  important  because  it  links 
together and provides a mechanism for several disordered features of UC such as; 
the disordered response to luminal antigens, the breakdown of regulation of the 
epithelial barrier, and the predominance of T
H1 type responses in more severe UC 
phenotypes. Understanding the role of TSLP in acquired immunity and regulation 
of T helper cell responses is not only diagnostically helpful but could also provide 
possible therapeutic options.   Chapter 7. Discussion and future work 
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7.3  Future work 
Despite  the  growing  evidence  that  miRNAs  have  a  crucial  influence  on  human 
disease our understanding of these processes are in their infancy. What the total 
number of miRNAs will reach is unknown, although it is clear that many of them 
play  a  pivotal  role  individually,  or  in  combination,  in  many  distinct  and  /  or 
generalised  inflammatory  pathways.  In  this  study  we  have  focused  on  the 
influence of miR-31 on TSLP in UC. 
The use of miRNAs as a novel screening tool in IBD as well as other illnesses is 
receiving growing attention (Iborra et al., 2012). In chapter 4 it is shown that the 
expression of miR-31 is increased in mucosa biopsies of inactive and active UC 
compared with health. There are also 6 miRNAs that are identified as consistently 
deregulated in active UC. Alone or in combination with other miRNAs, miR-31 has 
promise  as  a  useful  diagnostic  or  screening  tool,  however  miR-31  and  the 
expressions  of  other  miRNAs  are  not  UC  specific  (Sonkoly  and  Pivarcsi,  2009), 
requiring further  studies to compare miRNA profiles of UC with other forms of 
colitis and the relationship between mucosal and peripheral expression. 
In  chapter  5,  it  has  been  shown  that  miR-31  has  an  increased  expression  in 
CD4
+CD25
intermediate mucosal lymphocytes. MiR-31 is expressed from a wide variety of 
cell types (Valastyan and Weinberg, 2010) and it stands to reason that other cell 
types contained within the mucosal biopsies such as epithelial cells, monocytes or 
other lymphocyte subsets are also likely to contribute to the miR-31 expression in 
the mucosa. This thesis did not extract other cell subsets from the mucosa, partly 
due to logistical issues, but also because the focus was centred on lymphocytes. 
To understand the functional significance of miR-31 and effect on other prominent 
factors  associated  in  the  aetiology  of  IBD  understanding  the  spatial  expression 
pattern of miR-31 within the colonic mucosal would be helpful. 
In  chapter  6  it  is  shown  that  there  is  a  decreased  expression  of  TSLP  in  the 
mucosa,  mucosal  lymphocytes  and  mucosal  CD4
+CD25
intermediate cell  population.  To 
date,  studies  suggest  that  TSLP  expression  drives  certain  disease  conditions. 
However, in these situations a raised TSLP may be physiologically normal, part of 
the  bodies  attempt  to  steer  inflammation  away  from  more  destructive  type  of     Chapter 7. Discussion and future work 
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inflammation  and  thus  regulate  immunity.  A  decreased  TSLP  expression  may 
therefore  indicate  an  inability  to  regulate  inflammation  and  thus  cause  or 
potentiate  disease.  Whether  or  not  TSLP  drives  inflammation  or  is  part  of  a 
regulatory process, the expression of TSLP and its function may well be influenced 
by many other yet unknown factors such as time from insult, degree of insult and 
the therapeutic range of expression and influence.  
It has already been shown that activated peripheral lymphocytes express the TSLP 
receptor  (Rochman  et  al.,  2007),  but  the  expression  of  TSLP  directly  has  not 
previously been shown. The expression of TSLP by an increasing number of cell 
types would suggest that it has a functional significance beyond the traditional 
role of an epithelial derived factor that influences lymphocytes through a dendritic 
cell  pathway.  Autocrine  signalling  is  a  potential  positive  feedback  mechanism 
through which TSLP regulates an inflammatory response in activated lymphocytes, 
the lack of expression of both TSLP receptor and TSLP in naive lymphocytes may 
allow these naive lymphocytes to respond more rapidly to external factors, before 
the regulatory mechanism of TSLP is engaged.  
The functional significance of TSLP in lymphocytes has yet to be explored and is 
not addressed in this thesis. The function of TSLP is traditionally thought to be 
through STAT5 signalling (Rochman et al., 2007), however Takai (2012) and Taylor 
(2009)  review  multiple  mechanisms  which  are  potentially  involved  in  the 
expression and function of TSLP and suggests there are many other factors which 
are yet unknown, possibly cell specific and yet to be explored.  
Questions raised by this study include;  
1.  If  Jurkat  cells  and  primary  lymphocytes  express  TSLP  in  response  to 
activation  do  they  also  express  the  TSLP  receptor  and  provide  the 
hypothesized positive feedback mechanism?  
2.  Through  what mechanism does TSLP exert its effect? Does lymphocyte / 
Jurkat cell stimulation activate the STAT5 pathway or an alternate pathway? 
3.  What is the functional significance of TSLP? 
i.  Does TSLP alter the lymphocyte phenotype? Chapter 7. Discussion and future work 
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ii.  Does TSLP play a role in lymphocyte proliferation, maturation 
and migration? 
4.  Does  TSLP  play  a  differing  role  in  different  types  or  degrees  of 
inflammation? 
It is yet to be revealed if miR-31 or TSLP alone are sufficient to influence mucosal 
immune  responses.  We have shown that miR-31 provides a mechanism through 
which  TSLP  mRNA  can  be  manipulated;  however  there  are  many  other  factors 
which  influence  its  expression  and  function  and  need  to  be  explored.  We  have 
identified constitutional expression of TSLP by mucosal lymphocytes, along with 
TSLP receptor expression in activated lymphocytes this offers a potential insight 
into an as yet unexplored positive feedback mechanism. 
Like so many other potentially exciting therapies for UC, the efficacy of therapy 
between individuals differs for unexplained reasons and declines over time. The 
relevance  of  protein  variants  and  “miRNA  escape”  mechanisms  are  becoming 
increasing recognised in viral pathways, and could be relevant in UC and explain 
differences in disease patterns between otherwise identical patients. 
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8.1  Preliminary data 
8.1.1  miR-155 expression in IBD (unpublished results) 
 
Figure 53. The differential expression on miR-155 in IBD, preliminary 
results. The expression of miR-155 in mucosal resection specimens 
from  patients  with  Crohn's  (n  =  5)  and  UC  (n  =  5)  are  compared 
against  the  expression  of  miR-155  in  the  mucosa  of  patients 
undergoing colectomy for colorectal cancer (n = 5) using  RT-qPCR. 
Results  reproduced  courtesy  of  Dr  Rebecca  Morgan-Walsh.  Mean 
values of each group are compared with the two tailed student’s t 
test. 
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8.1.2  miR-155 expression in a 3% TNBS model of colitis 
 
Figure  54.  The  differential  expression  on  miR-155  in  a  3%  TNBS 
model of colitis, preliminary results. The expression of miR-155 in 
the mucosa of mice is compared 4 days after rectal infusion of either 
3% TNBS (n = 4), or control/ETOH (n = 4) using RT-qPCR. Experiments 
performed  by  Dr  Elena  Vorobeva.  Mean  values  of  each  group  are 
compared with the two tailed students t test. 
   
0.0 
0.5 
1.0 
1.5 
2.0 
2.5 
3.0 
3.5 
4.0 
4.5 
f
o
l
d
 
d
i
f
f
e
r
e
n
c
e
 
(
2
-
Δ
Δ
C
t
)
 
p=0.042 
ETOH  3% 
TNBS     Chapter 8. Appendix 
249 
8.2  Patient data collection sheet 
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8.3  Microarray data 
8.3.1  Expression of miRNA in active UC 
  mean  ±sd  t test 
miR-31  35.257  0.782  <0.001 
miR-223  8.523  2.424  0.047 
miR-486-3p  4.588  1.440  0.076 
miR-708  3.960  0.586  0.062 
miR-146b-5p  3.766  1.223  0.076 
miR-483-5p  3.742  0.490  0.018 
miR-628-5p  3.292  1.587  0.152 
miR-132  2.985  2.164  0.230 
miR-142-3p  2.809  1.675  0.198 
miR-155  2.715  1.310  0.166 
miR-18b  2.562  1.849  0.252 
miR-150  2.500  0.805  0.106 
miR-135b  2.489  1.927  0.284 
miR-539  2.488  1.986  0.358 
miR-146a  2.471  1.033  0.146 
miR-126  2.350  1.046  0.163 
miR-331-5p  2.154  0.656  0.233 
miR-21  2.085  1.233  0.253 
miR-501-5p  2.044  1.101  0.223 
miR-125b  2.040  1.376  0.266 
miR-193b  1.921  0.236  0.040 
miR-148b  1.881  1.038  0.243 
miR-494  1.714  1.431  0.377 
let-7f  1.674  1.349  0.343 
miR-140-3p  1.633  0.494  0.164 
let-7c  1.628  1.190  0.337 
miR-99a  1.590  1.461  0.380 
miR-202  1.555  0.776  0.405 
miR-454  1.525  0.761  0.379 
miR-23b  1.523  1.288  0.406 
miR-15a  1.489  0.029  0.433 
miR-134  1.412  0.447  0.328 
miR-34a  1.361  0.775  0.381 
miR-212  1.343  0.086  0.033 
miR-652  1.343  0.955  0.409 
miR-222  1.341  0.599  0.314 
miR-224  1.338  0.954  0.379 
miR-455-5p  1.337  0.278  0.252 
miR-365  1.326  1.191  0.405 
miR-140-5p  1.289  0.824  0.384 
miR-342-3p  1.261  0.388  0.312 
miR-214  1.230  0.067  0.351 
miR-181a  1.226  0.738  0.398 
miR-16  1.225  0.109  0.129 
let-7a  1.174  0.931  0.445 
miR-100  1.148  0.909  0.451 
miR-138  1.117  0.283  0.370 
let-7b  1.097  0.699  0.457 
miR-29b  1.094  0.227  0.493 
miR-25  1.094  0.948  0.465 
miR-99b  1.088  0.877  0.485 
miR-28-5p  1.062  0.489  0.460 
miR-15b  1.051  0.922  0.499 
miR-29a  1.038  0.563  0.485 
miR-744  1.031  0.560  0.484 
miR-27a  1.025  0.631  0.486 
miR-484  1.018  0.269  0.485 
miR-331-3p  1.015  0.320  0.495 
miR-24  1.000  0.404  0.490 
let-7d  0.989  0.741  0.490 
miR-130a  0.973  0.582  0.451 
miR-362-5p  0.948  0.729  0.475 
miR-221  0.939  0.518  0.454 
miR-148a  0.916  0.660  0.455 
miR-185  0.875  0.336  0.374 
miR-451  0.865  0.757  0.423 
miR-339-5p  0.845  0.769  0.425 
miR-590-5p  0.817  0.344  0.327 
miR-152  0.812  0.013  0.132 
miR-518d-3p  0.807  0.434  0.316 
miR-374a  0.782  0.461  0.342 
miR-19a  0.778  0.541  0.361 
miR-376a  0.767  0.367  0.313 
miR-338-3p  0.758  0.464  0.328 
miR-17  0.754  0.447  0.319 
miR-143  0.753  0.565  0.345 
let-7g  0.752  0.472  0.326 
  mean  ±sd  t test 
miR-106b  0.752  0.346  0.282 
miR-487a  0.748  0.389  0.300 
miR-125a-5p  0.747  0.104  0.137 
miR-196b  0.745  0.187  0.232 
miR-320  0.737  0.012  0.010 
miR-195  0.727  0.537  0.330 
miR-411  0.725  0.079  0.238 
miR-452  0.712  0.006  0.192 
miR-18a  0.702  0.258  0.262 
miR-106a  0.699  0.371  0.251 
let-7e  0.699  0.558  0.321 
miR-199a-3p  0.688  0.403  0.260 
miR-374b  0.667  0.356  0.224 
miR-95  0.653  0.235  0.139 
miR-191  0.643  0.112  0.076 
miR-20b  0.643  0.452  0.261 
miR-139-5p  0.633  0.320  0.205 
miR-93  0.632  0.356  0.216 
miR-29c  0.620  0.258  0.206 
miR-660  0.614  0.454  0.242 
miR-133b  0.609  0.521  0.270 
miR-210  0.607  0.007  0.228 
miR-574-3p  0.595  0.136  0.054 
miR-26b  0.594  0.415  0.216 
miR-886-5p  0.592  0.044  0.156 
miR-186  0.578  0.016  0.001 
miR-193a-5p  0.576  0.550  0.262 
miR-337-5p  0.564  0.142  0.243 
miR-19b  0.563  0.404  0.197 
miR-20a  0.543  0.396  0.184 
miR-133a  0.523  0.259  0.104 
miR-103  0.517  0.370  0.162 
miR-149  0.514  0.365  0.195 
miR-491-5p  0.508  0.055  0.044 
miR-127-3p  0.506  0.386  0.214 
miR-218  0.505  0.311  0.188 
miR-370  0.504  0.060  0.034 
miR-130b  0.503  0.029  0.028 
miR-28-3p  0.502  0.297  0.118 
miR-10a  0.502  0.279  0.139 
miR-345  0.493  0.134  0.034 
miR-339-3p  0.482  0.155  0.040 
miR-26a  0.476  0.340  0.133 
miR-425  0.474  0.128  0.030 
miR-532-3p  0.461  0.182  0.096 
miR-203  0.460  0.182  0.066 
miR-92a  0.450  0.262  0.110 
miR-145  0.440  0.378  0.157 
miR-324-3p  0.423  0.121  0.033 
miR-486-5p  0.423  0.184  0.050 
miR-101  0.418  0.334  0.121 
miR-376c  0.416  0.142  0.027 
miR-10b  0.415  0.379  0.194 
miR-30b  0.413  0.327  0.110 
miR-328  0.411  0.336  0.135 
miR-886-3p  0.406  0.189  0.050 
miR-27b  0.400  0.320  0.108 
miR-30c  0.399  0.249  0.072 
miR-1  0.383  0.018  <0.001 
miR-197  0.381  0.247  0.076 
miR-200b  0.331  0.080  0.031 
miR-340  0.327  0.200  0.103 
miR-215  0.323  0.077  0.125 
miR-532-5p  0.322  0.159  0.042 
miR-200a  0.309  0.059  0.004 
miR-379  0.283  0.092  0.024 
miR-200b  0.251  0.124  0.014 
miR-194  0.213  0.058  0.020 
miR-141  0.212  0.042  0.002 
miR-192  0.199  0.056  0.004 
miR-429  0.178  0.077  0.011 
miR-375  0.129  0.045  0.002 
miR-422a  0.106  0.005  <0.001 
 
Table  45.  miRNAs  differentially  expressed  in  active  sigmoid  UC. 
Microarray  was  performed  using  TaqMan®  Array  Human  MiRNA  A 
Cards v2.0. 150 miRNA had an expression below the threshold CT ≤ 
35  in  all  array  card  pairs.  miRNA  expression  was  normalised  to 
MammU6 and compared against healthy control. Microarray data is     Chapter 8. Appendix 
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presented as mean fold difference of active UC and analysed using 
the one tailed unpaired students t test. 
8.3.2  Non expressed miRNA in active sigmoid UC 
miRNA 
miR-105  miR-219-5p  miR-372  miR-501-3p  miR-520d-5p  miR-615-5p 
miR-107  miR-219-a  miR-373  miR-502-3p  miR-520e  miR-616 
miR-122  miR-219-b  miR-376b  miR-502-5p  miR-520f  miR-618 
miR-124  miR-22  miR-377  miR-503  miR-520g  miR-624 
miR-125a-3p  miR-220  miR-380  miR-504  miR-521  miR-625 
miR-127-5p  miR-220b  miR-381  miR-505  miR-522  miR-627 
miR-128  miR-220c  miR-382  miR-506  miR-523  miR-629 
miR-129-3p  miR-23a  miR-383  miR-507  miR-524-5p  miR-636 
miR-129-5p  miR-296-3p  miR-384  miR-508-3p  miR-525-3p  miR-642 
miR-135a  miR-296-5p  miR-409-5p  miR-508-5p  miR-525-5p  miR-651 
miR-136  miR-298  miR-410  miR-509-3p  miR-526b  miR-653 
miR-137  miR-299-3p  miR-412  miR-509-5p  miR-541  miR-654-3p 
miR-139-3p  miR-299-5p  miR-423-5p  miR-510  miR-542-3p  miR-654-5p 
miR-142-5p  miR-301a  miR-424  miR-511  miR-542-5p  miR-655 
miR-146b-3p  miR-301b  miR-431  miR-512-3p  miR-544  miR-671-3p 
miR-147  miR-302a  miR-433  miR-512-5p  miR-545  miR-672 
miR-147b  miR-302b  miR-448  miR-513-5p  miR-548a-3p  miR-674 
miR-153  miR-302c  miR-449a  miR-515-3p  miR-548a-5p  miR-758 
miR-154  miR-32  miR-449b  miR-515-5p  miR-548b-3p  miR-871 
miR-181c  miR-323-3p  miR-450a  miR-516a-5p  miR-548b-5p  miR-872 
miR-182  miR-324-5p  miR-450b-3p  miR-516b  miR-548c-3p  miR-873 
miR-183  miR-325  miR-450b-5p  miR-517a  miR-548c-5p  miR-874 
miR-184  miR-326  miR-453  miR-517b  miR-548d-3p  miR-875-3p 
miR-187  miR-329  miR-455-3p  miR-517c  miR-548d-5p  miR-876-3p 
miR-188-3p  miR-330-3p  miR-485-3p  miR-518a-3p  miR-551b  miR-876-5p 
miR-190  miR-330-5p  miR-485-5p  miR-518a-5p  miR-556-3p  miR-885-3p 
miR-193a-3p  miR-335  miR-487b  miR-518b  miR-556-5p  miR-885-5p 
miR-198  miR-33b  miR-488  miR-518c  miR-561  miR-887 
miR-199a-5p  miR-342-5p  miR-489  miR-518d-5p  miR-570  miR-888 
miR-199b-5p  miR-346  miR-490-3p  miR-518e  miR-576-3p  miR-889 
miR-204  miR-34c-5p  miR-491-3p  miR-518f  miR-576-5p  miR-890 
miR-205  miR-361-5p  miR-492  miR-519a  miR-579  miR-891a 
miR-208  miR-362-3p  miR-493  miR-519c-3p  miR-582-3p  miR-891b 
miR-208b  miR-363  miR-495  miR-519d  miR-582-5p  miR-892a 
miR-211  miR-367  miR-496  miR-519e  miR-589  miR-9 
miR-216a  miR-369-3p  miR-499-3p  miR-520a-3p  miR-597  miR-96 
miR-216b  miR-369-5p  miR-499-5p  miR-520a-5p  miR-598  miR-98 
miR-217  miR-371-3p  miR-500  miR-520b  miR-615-3p   
 
Table  46.  miRNA  that  are  not  expressed  in  active  sigmoid  UC. 
Microarray  data  of  none  expressed  miRNA  including  those  miRNA 
which are amplified above the threshold CT ≥35. 217 miRNAs are not 
expressed in the microarray, a further 10 are expressed in ≤2 arrays. 
8.3.3  Expression  of  miRNA  in  active  sigmoid  Crohn’s 
disease 
 
mean  ±sd  t test 
miR-31  39.288  26.914  0.109 
miR-494  26.268  24.374  0.171 
miR-22  15.472  13.029  0.156 
miR-142-5p  14.714  12.959  0.166 
miR-202  13.134  14.433  0.217 
miR-636  9.684  5.712  0.120 
miR-451  8.653  10.015  0.233 
miR-579  8.329  1.292  0.037 
miR-618  7.375  5.726  0.161 
let-7c  7.356  6.577  0.185 
miR-32  7.074  3.988  0.135 
miR-486-3p  6.860  3.907  0.102 
miR-223  6.001  1.504  0.020 
miR-18b  5.434  2.073  0.052 
miR-29b  5.109  2.876  0.112 
miR-135a  5.075  0.527  0.011 
miR-15a  4.930  1.006  0.025 
miR-130b  4.723  2.039  0.070 
miR-487a  4.683  2.523  0.106 
miR-135b  4.399  1.120  0.029 
miR-224  4.190  1.701  0.066 
 
mean  ±sd  t test 
miR-548d-5p  4.169  1.257  0.042 
miR-518b  4.105  0.887  0.024 
miR-34a  4.077  1.247  0.041 
miR-486-5p  3.899  4.142  0.250 
miR-148a  3.468  1.843  0.119 
miR-370  3.453  0.884  0.029 
miR-20b  3.364  0.642  0.015 
miR-625  3.357  2.070  0.152 
miR-142-3p  3.271  2.200  0.171 
miR-21  3.251  0.192  0.003 
miR-455-5p  3.231  1.652  0.122 
miR-652  3.196  2.203  0.182 
miR-181a  3.180  1.450  0.100 
miR-452  3.174  1.397  0.100 
miR-18a  3.064  0.958  0.062 
miR-185  2.940  0.471  0.013 
miR-106b  2.902  1.305  0.106 
let-7d  2.602  1.844  0.207 
miR-19a  2.595  1.000  0.090 
miR-182  2.538  2.064  0.240 
miR-483-5p  2.533  0.361  0.012 Chapter 8. Appendix 
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mean  ±sd  t test 
miR-152  2.509  0.881  0.080 
miR-193a-3p  2.488  1.078  0.206 
miR-27a  2.438  1.061  0.117 
miR-28-5p  2.399  0.749  0.113 
miR-29a  2.379  1.330  0.173 
miR-140-5p  2.355  0.702  0.065 
miR-143  2.249  1.352  0.210 
miR-99a  2.223  0.940  0.142 
miR-886-3p  2.209  1.265  0.187 
miR-885-5p  2.173  2.051  0.292 
miR-147b  2.170  1.624  0.280 
miR-125b  2.166  1.214  0.187 
miR-331-5p  2.144  1.143  0.237 
miR-410  2.143  0.100  0.062 
miR-19b  2.136  0.731  0.095 
miR-132  2.131  0.327  0.050 
miR-93  2.128  0.248  0.011 
miR-27b  2.121  0.849  0.124 
let-7b  2.106  1.345  0.219 
miR-660  2.093  0.927  0.143 
miR-708  2.090  0.626  0.218 
miR-146a  2.086  0.159  0.003 
miR-296-5p  2.028  1.563  0.262 
miR-576-3p  2.016  0.863  0.172 
miR-886-5p  2.006  1.028  0.202 
miR-215  2.002  1.094  0.224 
miR-193a-5p  1.975  1.509  0.273 
miR-501-5p  1.963  0.225  0.010 
miR-511  1.898  1.103  0.223 
miR-148b  1.890  1.529  0.285 
miR-150  1.876  0.486  0.079 
miR-340  1.855  1.124  0.252 
miR-424  1.850  0.464  0.105 
miR-492  1.849  1.451  0.284 
miR-361-5p  1.787  2.274  0.366 
miR-339-5p  1.785  0.039  0.005 
miR-10b  1.746  1.175  0.284 
miR-433  1.742  0.543  0.157 
miR-103  1.728  0.793  0.195 
miR-100  1.728  0.635  0.163 
miR-20a  1.709  1.087  0.263 
miR-324-3p  1.704  0.867  0.223 
miR-320  1.698  0.873  0.223 
let-7g  1.682  0.702  0.185 
miR-146b-5p  1.669  0.277  0.042 
miR-127-3p  1.654  0.679  0.237 
miR-425  1.646  0.608  0.165 
miR-532-5p  1.645  0.242  0.043 
miR-155  1.637  0.357  0.094 
miR-25  1.636  0.607  0.167 
miR-362-5p  1.625  0.992  0.270 
miR-642  1.623  0.563  0.227 
miR-590-5p  1.616  0.517  0.145 
miR-429  1.607  0.778  0.230 
miR-99b  1.604  0.608  0.215 
miR-106a  1.603  0.245  0.037 
miR-194  1.588  0.746  0.234 
miR-92a  1.580  0.618  0.203 
miR-628-5p  1.578  0.801  0.279 
miR-200b  1.577  0.806  0.246 
let-7a  1.567  1.211  0.332 
miR-126  1.561  0.063  0.002 
miR-744  1.559  0.190  0.112 
miR-145  1.552  0.809  0.270 
miR-210  1.547  0.421  0.296 
miR-495  1.547  0.631  0.273 
miR-17  1.531  0.206  0.042 
miR-140-3p  1.529  0.136  0.012 
miR-200a  1.519  0.539  0.185 
miR-10a  1.515  0.446  0.175 
miR-24  1.506  0.842  0.286 
miR-141  1.489  0.535  0.195 
miR-411  1.483  0.651  0.287 
miR-212  1.471  0.075  0.017 
 
mean  ±sd  t test 
miR-101  1.455  0.545  0.223 
miR-16  1.434  1.203  0.362 
miR-15b  1.417  0.562  0.280 
miR-345  1.410  0.655  0.272 
miR-181c  1.408  0.798  0.337 
let-7e  1.389  0.953  0.355 
miR-133b  1.381  1.256  0.387 
let-7f  1.364  0.052  0.170 
miR-500  1.361  0.212  0.104 
miR-323-3p  1.349  0.956  0.377 
miR-149  1.343  0.977  0.391 
miR-491-5p  1.341  1.184  0.388 
miR-195  1.338  0.547  0.286 
miR-221  1.320  0.694  0.334 
miR-196b  1.312  0.527  0.312 
miR-192  1.298  0.680  0.332 
miR-532-3p  1.278  0.425  0.299 
miR-214  1.258  0.455  0.369 
miR-379  1.242  0.253  0.219 
miR-218  1.241  0.914  0.436 
miR-29c  1.234  0.541  0.389 
miR-374a  1.229  0.352  0.263 
miR-26b  1.194  0.623  0.378 
miR-133a  1.186  0.865  0.415 
miR-365  1.153  0.768  0.421 
miR-191  1.152  0.415  0.365 
miR-301a  1.151  0.810  0.426 
miR-324-5p  1.150  0.664  0.439 
miR-539  1.145  0.182  0.390 
miR-222  1.139  0.117  0.145 
miR-454  1.124  0.542  0.480 
miR-28-3p  1.120  0.383  0.377 
miR-335  1.118  0.862  0.477 
miR-199a-3p  1.106  0.356  0.383 
miR-200b  1.080  0.132  0.339 
miR-193b  1.031  0.304  0.476 
miR-130a  1.025  0.402  0.490 
miR-342-3p  1.025  0.476  0.492 
miR-139-5p  1.023  0.365  0.497 
miR-598  1.020  0.369  0.418 
miR-484  1.018  0.066  0.447 
miR-328  1.009  0.258  0.479 
miR-671-3p  1.002  0.739  0.470 
miR-376c  1.002  0.549  0.499 
miR-330-3p  1.001  0.328  0.387 
miR-30b  1.001  0.370  0.499 
miR-545  0.998  0.519  0.476 
miR-339-3p  0.993  0.349  0.492 
miR-376a  0.963  0.546  0.424 
miR-203  0.941  0.125  0.342 
miR-9  0.935  0.368  0.423 
miR-186  0.914  0.200  0.336 
miR-301b  0.911  0.276  0.380 
miR-487b  0.900  0.593  0.430 
miR-197  0.876  0.434  0.384 
miR-26a  0.862  0.264  0.304 
miR-375  0.851  0.183  0.220 
miR-331-3p  0.842  0.187  0.235 
miR-30c  0.821  0.228  0.233 
miR-338-3p  0.766  0.473  0.335 
miR-374b  0.757  0.218  0.155 
miR-190  0.748  0.324  0.237 
miR-422a  0.700  0.224  0.120 
miR-138  0.644  0.099  0.017 
miR-23b  0.626  0.254  0.160 
miR-574-3p  0.596  0.043  0.002 
miR-125a-5p  0.585  0.126  0.034 
miR-134  0.584  0.228  0.122 
miR-95  0.528  0.257  0.069 
miR-125a-3p  0.463  0.458  0.158 
miR-1  0.446  0.196  0.027 
miR-489  0.376  0.144  0.060 
miR-204  0.348  0.245  0.084 
Table 47. miRNAs differentially expressed in active sigmoid Crohn’s 
disease.  Microarray  was  performed  using  TaqMan®  Array  Human 
MiRNA  A  Cards  v2.0.  188  miRNA  had  an  expression  below  the 
threshold  CT  ≤  35  in  all  array  card  pairs.  miRNA  expression  was 
normalised  to  MammU6  and  compared  against  healthy  control. 
Microarray  data  is  presented  as  mean  fold  difference  of  active 
Crohn’s disease and analysed using the one tailed unpaired students 
t test.     Chapter 8. Appendix 
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8.3.4  Non  expressed  miRNA  in  active  sigmoid  Crohn’s 
disease 
miRNA 
miR-105  miR-219b  miR-380  miR-505  miR-520b  miR-589 
miR-107  miR-220  miR-381  miR-506  miR-520d-5p  miR-597 
miR-122  miR-220b  miR-382  miR-507  miR-520e  miR-615-3p 
miR-124  miR-220c  miR-383  miR-508-3p  miR-520f  miR-615-5p 
miR-127-5p  miR-23a  miR-384  miR-508-5p  miR-520g  miR-616 
miR-128  miR-296-3p  miR-409-5p  miR-509-5p  miR-521  miR-624 
miR-129-3p  miR-298  miR-412  miR-509a  miR-522  miR-627 
miR-129-5p  miR-299-3p  miR-423-5p  miR-510  miR-523  miR-629 
miR-136  miR-299-5p  miR-431  miR-512-3p  miR-524-5p  miR-651 
miR-137  miR-302a  miR-448  miR-512-5p  miR-525-3p  miR-653 
miR-139-3p  miR-302b  miR-449a  miR-513-5p  miR-525-5p  miR-654-3p 
miR-146b-3p  miR-302c  miR-449b  miR-515-3p  miR-526b  miR-654-5p 
miR-147  miR-325  miR-450a  miR-515-5p  miR-541  miR-655 
miR-153  miR-326  miR-450b-3p  miR-516a-5p  miR-542-3p  miR-672 
miR-154  miR-329  miR-450b-5p  miR-516b  miR-542-5p  miR-674 
miR-183  miR-330-5p  miR-453  miR-517a  miR-544  miR-758 
miR-184  miR-337-5p  miR-455-3p  miR-517b  miR-548a-3p  miR-871 
miR-187  miR-33b  miR-485-3p  miR-517c  miR-548a-5p  miR-872 
miR-188-3p  miR-342-5p  miR-485-5p  miR-518a-3p  miR-548b-3p  miR-873 
miR-198  miR-346  miR-488  miR-518a-5p  miR-548b-5p  miR-874 
miR-199a-5p  miR-34c-5p  miR-490-3p  miR-518c  miR-548c-3p  miR-875-3p 
miR-199b-5p  miR-362-3p  miR-491-3p  miR-518d-3p  miR-548c-5p  miR-876-3p 
miR-205  miR-363  miR-493  miR-518d-5p  miR-548d-3p  miR-876-5p 
miR-208  miR-367  miR-496  miR-518e  miR-551b  miR-885-3p 
miR-208b  miR-369-3p  miR-499-3p  miR-518f  miR-556-3p  miR-887 
miR-211  miR-369-5p  miR-499-5p  miR-519a  miR-556-5p  miR-888 
miR-216a  miR-371-3p  miR-501-3p  miR-519c-3p  miR-561  miR-889 
miR-216b  miR-372  miR-502-3p  miR-519d  miR-570  miR-890 
miR-217  miR-373  miR-502-5p  miR-519e  miR-576-5p  miR-891a 
miR-219-5p  miR-376b  miR-503  miR-520a-3p  miR-582-3p  miR-891b 
miR-219a  miR-377  miR-504  miR-520a-5p  miR-582-5p  miR-892a 
          miR-96 
          miR-98 
Table 48. Non expressed miRNA in active Crohn's disease microarray. 
There are 188 non expressed miRNA including those which have no 
amplification  and  /  or  those  with  an  amplification  above  the 
threshold CT ≤ 35.  
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8.4  MicroRNA target prediction 
The  following  tables  contain  a  list  of  predicted  gene  targets  for  the  individual 
miRNAs. Bioinformatic searches are limited in their ability to predict useful targets 
and therefore the results presented are those predicted targets that are ranked in 
the top 20 for TargetScan v5.2, those with a MirTarget2 score >80 and those of 
potential interest after review of all the targets and their known functions. 
8.4.1  Predicted targets for miR-31 
T
a
r
g
e
t
 
g
e
n
e
  Target scan  MirTarget2 
pathway 
r
a
n
k
 
c
o
n
s
e
r
v
e
d
 
s
i
t
e
s
 
t
o
t
a
l
 
p
o
o
r
l
y
 
c
o
n
s
e
r
v
e
d
 
s
i
t
e
s
 
t
o
t
a
l
 
T
o
t
a
l
 
c
o
n
t
e
x
t
 
s
c
o
r
e
 
A
g
g
r
e
g
a
t
e
 
P
C
T
 
r
a
n
k
 
t
a
r
g
e
t
 
s
c
o
r
e
 
RSBN1  1  2  3  -0.98  0.5  1  100  Transcription of haploid germ cells 
NR5A2  2  1  2  -0.81  0.58      Role in cholesterol and bile acid homeostasis 
SH2D1A  3  2  0  -0.74  0.49  9  88 
Encodes a protein that plays a major role in the stimulation of T and 
B  cells.  The  protein  contains  a  SH2  domain  which  associates  and 
inhibits  the  signaling  lymphocyte-activation  molecule.  This  protein 
can also bind to other related surface molecules that are expressed 
on activated T, B and NK cells, thereby modifying signal transduction 
pathways.  Mutations  in  this  gene  cause  Duncan  disease,  a  rare 
immunodeficiency  characterized  by  extreme  susceptibility  to 
infection with Epstein-Barr virus. 
SLC1A2  4  2  2  -0.72  0.67  128  61  Clears excessive glutamate from neuronal synapses 
PIK3C2A  5  2  0  -0.69  0.4  13  84  Key role in signaling pathways, proliferation, survival and migration 
PRKCE  6  1  2  -0.66  0.55  28  77 
Key  role  in  TLR4  /  LPS  mediated  signaling  and  INF  regulation  in 
activated macrophages (Aksoy et al., 2004). 
PEX5  7  1  1  -0.6  0.32  202  52  Essential role in peroxismal protein import. 
RHOBTB1  8  1  1  -0.59  0.6  35  76  Actin and other proteins 
SATB2  9  2  0  -0.58  0.54  73  69  Transcriptional  regulation  and  chromatin  remodeling,  implicated  in 
cleft palette, and other craniofacial defects in mice. 
PPP1R9A  10  1  0  -0.56  0.58  47  73  No information. 
DCBLD2  11  1  1  -0.54  0.31  32  77  No information. 
CAMK2D  12  1  0  -0.53  0.57     
Some studies in myocardial failing and endothelial barrier (in cardiac 
context)  dysfunction,  Ca  signaling.  Calmodulin  involved  in  TGF-β 
pathway 
HIF1AN  13  1  3  -0.53  0.63  88  67 
miR-31  contributes  to  head  and  neck  cancer  by  impeding  HIF1AN 
activation (Liu et al., 2010a). Major contributor to O
2 homeostasis. 
SLC6A6  14  1  1  -0.52  0.59  37  76  Taurine homeostasis. 
STARD13  15  1  0  -0.52  0.52  148  59 
Suppresses  cell  growth  (liver  cancer),  inhibits  activity  of  Raf-1-
ERK1/2-p70S6K.  Selectively  activates  CDC42  involved  in  TGF-β 
pathway. 
DKFZp66
7G2110 
16  1  0  -0.5  0.29 
 
  No information. 
PAX9  17  1  0  -0.5  0.29  22  79  Mainly maxillofacial dysmorphias. 
SLC5A3  18  1  2  -0.5  0.37  97  66  Mainly in coronary heart disease and diabetes observational studies. 
FGF7  19  1  1  -0.49  0.4 
 
  Release  from  fibroblasts  increased  by  IL-1β  and  platelet  derived 
growth factor together but not individually. 
C2orf67  20  1  0  -0.48  0.24      No information. 
CREG1  37  1  0  -0.42  0.41  12  84 
Expression  inhibits  cardiac  inflammation,  hypertrophy  and  fibrosis 
(Bian et al., 2009). 
SOX11  46  2  1  -0.4  0.36      Associated with lymphoproliferative disease. 
CLASP2  47  1  0  -0.39  0.45  107  64  No information. 
LATS2  59  1  0  -0.38  0.39  14  83  Lots of references to tumour suppression. 
CD28  107  1  1  -0.27  0.41      Required for T cell activation. 
PPP2R2A  111  1  0  -0.27  0.21  27  78  Implicated in the negative control of cell growth and division. 
VAV3  149  1  0  -0.21  0.21 
 
  T cell signaling. 
PPP3CA  160  1  0  -0.2  0.21      T cell activator. 
NCK2  191  1  0  -0.16  0.21      Bind  and  recruit  various  proteins  involved  in  the  regulation  of 
receptor protein kinases. 
TSLP  192  0  1  -0.10  <0.1      T
H2 pathways, crosstalk between DCs and macrophages. 
CAMK2D            41  74 
Some studies in myocardial failing and endothelial barrier (in cardiac 
context)  dysfunction,  Ca  signaling.  Calmodulin  involved  in  TGF-β 
pathway.     Chapter 8. Appendix 
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CDC42EP
4            108  64 
CDC42  is  a  small  GTPase  of  the  Rho-subfamily,  which  regulates 
signaling pathways that control diverse cellular functions including 
cell morphology, migration, endocytosis and cell cycle progression. 
CDC42SE
1   
        119  63  As above. 
HSD17B6            8  88 
Oxidative  and  reductive  activity,  various  effects  on  endogenous 
steroids. 
IL1R1            87  67  Inflammation. 
KIAA1967            16  82  Multiple random pathways. 
LOC7280
54            2  100  None known. 
LOC7284
17            5  90  None known. 
MYO5A 
 
        15  83  Involved  in  cytoplasmic  vesicular  transport,  implicated  in  several 
cancers 
NSF 
 
        7  89  Lots of observational studies. 
PARP1            141  60  Induces apoptosis. 
PDZD2            17  81 
Possible involvement in intracellular signaling. The protein encoded 
by  this  gene  contains  six  PDZ  domains  and  shares  sequence 
similarity  with  pro-IL-16.  The  encoded  protein  localizes  to  the 
endoplasmic reticulum and is thought to be cleaved by a caspase to 
produce a secreted peptide containing two PDZ domains. This gene is 
up-regulated in prostate tumors. 
PEX26            6  90  Interacts with PEX-1,-6 and SUFU. 
SP1            132  61  TGF-β pathway. 
TRIM67            10  86  Zink finger domain, one of many that play a role in ubiquinisation. 
VPS53            3  97  Vesicle trafficking in late Golgi. 
ZNF74 
 
        4  92  Observational study with schizophrenia. 
Table  49.Predicted  targets  for  miR-31Using  TargetScan  v  5.2  and 
MirTarget2 v4.0. Pathways are taken from NCBI Gene database (Pruitt 
et  al.,  2009).  Genes  and  pathways  of  particular  interest  are 
highlighted in red. 
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ZNF826  1  1  2  -1.19    1  99  Possible role in transcription regulation.. 
TRAF6  2  1  1  -0.99    2  98 
This protein functions as a signal transducer in the NF-κβ pathway by 
mediating  signals  of  the  TNF  receptor  superfamily,  members  of  the 
Toll/IL-1 family and receptors such as CD40, TNFSF11/RANCE and IL-1. 
This  protein  also  interacts  with  various  protein  kinases  including 
IRAK1/IRAK, SRC and PKCζ,. 
NOVA1  3  2  0  -0.61    3  98 
A neuron-specific RNA-binding protein, a member of the Nova family of 
paraneoplastic disease antigens, which are recognized and inhibited by 
paraneoplastic  antibodies.  These  antibodies  are  found  in  the  sera  of 
patients with breast cancer and small cell lung cancer. 
ZNRF3  4  2  0  -0.49          None known. 
SIAH2  5  1  0  -0.45         
Encodes a protein involved in ubiquinisation and proteasome-mediated 
degradation of proteins. Implicated in regulating response to hypoxia 
CD80  6  1  0  -0.44    109  61  Macrophages  in  mice  show  increased  expression,  blockade  of  CD80 
reduces colitis. 
LRP2  7  1  0  -0.43    194  53  Expression is induced by PPAR,  
NRAS  8  1  0  -0.43    103  62  Activated in HL60 promyelocytic leukemia. 
GOSR1  9  1  1  -0.38          Trafficking protein among the endoplastic reticulum and Golgi. 
USP47  10  1  1  -0.35    65  68  Has a possible role in blocking ubiquitin. viral or tumour inflammation. Chapter 8. Appendix 
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GRID1  11  1  1  -0.34          Key  role  in  synaptic  plasticity,  and  Ca  transport  in  the  glutamate 
receptor ligand gated channel. 
SRrp35  12  1  0  -0.29    210  52  Contains RNA recognition motif, has a number of functions. 
ZNF148  13  1  1  -0.25          Interacts with PTRF (pauses transcription) and p53. 
PPM1M  14  1  1  -0.25          A phosphoprotein phosphatase with unknown function. 
MMP16  15  1  1  -0.22          Activates MMP2. 
SNX21  16  1  0  -0.22          None known. 
ROBO1  17  1  0  -0.18          Involved in central nervous system structure. 
BAG1  18  1  0  -0.17         
Oncogene BCL2 is a membrane protein that blocks a step in a pathway 
leading to apoptosis or programmed cell death. The protein encoded by 
BAG1 binds to BCL2 and enhances the anti-apoptotic effects of BCL2. 
BNC1  19  1  0  -0.15          Found in germ cells of testes and ovaries. 
IRAK1  23  1  0  -0.77    12  87 
This  gene  encodes  the  IL-1  receptor-associated  kinase  1,  one  of  two 
putative  serine/threonine  kinases  that  become  associated  with  IL1R 
upon stimulation. This gene is partially responsible for IL1-induced up-
regulation of the transcription factor NF-κβ. 
CCBP2  27  1  0  -0.56         
Chemokines and their receptor-mediated signal transduction are critical 
for the recruitment of effector immune cells to inflammation. 
EIF4G2  36  1  0  -0.42    14  86  A repressor of translation by forming inactive complexes. 
SMAD4  40  1  0  -0.4    18  82 
SMAD proteins are activated in response to TGF-β. The product of this 
gene  forms  complexes  with  other  activated  Smad  proteins,  which 
regulate the transcription of target genes. Mutations or deletions in this 
gene have been shown to result in pancreatic cancer, juvenile polyposis 
syndrome, and hereditary hemorrhagic telangiectasia syndrome 
ATG12  46  1  0  -0.38          ATG16 GWAS study 
STRBP  52  1  0  -0.37    9  89  None known. 
FBXL10  53  1  0  -0.36    11  88  None known. 
CARD10  54  1  1  -0.35          GWAS study. 
WWC2  61  1  0  -0.32    15  86  Involved with targeting proteins to cell membranes. 
CDC42BPA 111  1  0  -0.09          Role in regulation of cell migration. 
AMPH              197  53  Muscle function. 
BHLHB3              115  61  TGF-β signaling. 
CREBL2              45  72  Apoptosis. 
ITCH              19  81  The protein encoded by this gene interacts with atrophin-1. 
MRS2              8  89  Major  transport  protein  for  Mg
+  uptake  into  mitochondria.  Protein 
expression is essential for respiratory complex I and cell viability. 
PTAR1              16  86  None known. 
RHOBTB3              7  89  Member of the subfamily of Rho GTPases. 
SFRS6              4  91  Involved in mRNA splicing. 
TIMELESS              5  91  Involved in the progression of S phase and cell survival after damage. 
ZNF253              6  90  Transcriptional repression activity. 
ZNF506              13  86  may be involved in transcription. 
ZNF90              10  88  may be involved in transcription. 
Table 50.Predicted targets for miR-146b Using TargetScan v 5.2 and 
MirTarget2 v4.0. Pathways are taken from NCBI Gene database (Pruitt 
et  al.,  2009).  Genes  and  pathways  of  particular  interest  are 
highlighted in red.  
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FBXW2  1  1  2  -0.83  0.41  6  90  Degradation of cellular regulatory proteins. 
DISC1  2  1  1  -0.76  <0.1  46  79 
Neurite outgrowth and cortical development, disruption of 
gene leads to psychiatric disorders. 
TMED5  3  1  1  -0.75  0.43  23  85  None known.     Chapter 8. Appendix 
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DCUN1D4  4  1  4  -0.74  0.36  1  94  None known. 
CNTNAP2  5  1  3  -0.72  0.38  48  79 
Functions  on  the  nervous  system  as  a  cell  adhesion 
molecule.. 
BTBD7  6  2  1  -0.7  0.68  86  72  None known. 
ITPKB  7  1  1  -0.65  0.52  56  76 
Regulates immune cell function and is required for T and B 
cell development. 
HBEGF  8  2  0  -0.65  0.69  8  89  It has been shown to play a role in wound healing, cardiac 
hypertrophy and heart development and function. 
BNIP2  9  1  1  -0.62  0.17  121  66  Plays a role with BCL-2, also an apoptotic protector. 
ZFAND5  10  1  1  -0.6  0.47  146  64  None known. 
MITF  11  1  2  -0.57  0.3  174  61  Role in melanocyte and osteoblast development. 
FAM63B  12  1  1  -0.56  0.46      None known. 
CUL4B  13  1  2  -0.54  0.48  93  71  The  protein  interacts  with  a  ring  finger  protein,  and  is 
required for DNA replication. 
CHD1  14  1  0  -0.54  0.2  92  71 
CHD  genes  alter  gene  expression  by  modification  of 
chromatin  structure..  Associates  with  HDACS  and  RNA 
splicing proteins. 
CROP  15  1  1  -0.54  0.51  81  73  Could be involved in the formation of splicesome via the 
RE and RS domains. 
KHDRBS2  16  1  0  -0.53  0.18  84  73  Member  of  the  QKI  family  of  genes  implicated  in 
schizophrenia, known as STAR, signal transduction of RNA. 
ATP6V1H  17  1  0  -0.53  0.41  49  78 
Encodes a component of vacuolar ATPase, a enzyme that 
mediates acidification of intracellular organelles. 
ACVR2B  18  2  0  -0.52  0.75  73  74  An activin type 2 receptor. Belong to the TGF-β superfamily. 
SETD5  19  1  1  -0.52  0.52  7  89  None known. 
EPC2  20  2  0  -0.51  0.55  22  85  None known. 
C7orf60  23  1  2  -0.5  0.4  10  88  ADHD genetic studies. 
C14orf43  24  1  0  -0.5  0.54  14  87  None known. 
C21orf91  28  1  0  -0.49  0.49  34  81  None known. 
MAPK1  56  1  1  -0.41  0.5     
Acts  as  a  repressor  of  INF-γ  induced  genes.  Binds  the 
promoter of CCL5, DMP1, FIH1, IFITM1, IRF7, IRF9, LAMP3, 
OAS1,  OAS2,  OAS3  and  STAT1.  MAPKs  regulate  growth 
factors,  differentiation,  proliferation  and  phosphorylation 
of many inflammatory transcription factors. Dysregulation 
of  MAPK  kinase  pathways  has  been  associated  with 
various diseases including inflammation (p38). 
SLTM  59  1  0  -0.41  0.53  36  81 
When  overexpressed,  acts  as  a  general  inhibitor  of 
transcription that eventually leads to apoptosis. 
BCAT1  67  1  2  -0.38  0.34      Essential for cell growth.. 
SUMO2  73  1  0  -0.38  0.53  16  86 
Encodes a protein that is a member of the small ubiquitin-
like  modifier  family.  This  protein  is  involved  in  nuclear 
transport, transcription, apoptosis, and protein stability. 
LPHN2  162  1  0  -0.2  0.41  24  85 
This gene encodes a member of the latrophilin subfamily 
of  G-protein  coupled  receptors  (GPCR).  Latrophilins  may 
function in both cell adhesion and signal transduction. 
FOXO1  221  1  0  -0.13  0.41      Apoptosis. 
BMP1  250  1  0  -0.02  0.36      Formation of cartilage. 
CASP7            171  62  Apoptosis. 
TSLP    0  1  -0.03  <0.1      T
H2 pathways 
CNR1 
 
        32  82  Neurotransmitter release. 
MAP2            25  84  None known. 
MLST8                TGF-β signaling. 
Table 51.Predicted targets for miR-194 Using TargetScan v 5.2 and 
MirTarget2 v4.0. Pathways are taken from NCBI Gene database (Pruitt 
et  al.,  2009).  Genes  and  pathways  of  particular  interest  are 
highlighted in red. Chapter 8. Appendix 
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8.4.4  Predicted targets for miR-200b 
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ZEB2  1  6  0  -2.13  1  100 
Interacts  with  receptor-mediated,  activated  SMADs.  Represses 
transcription of E-cadherin. 
VASH2  2  1  4  -1.5  2  100  Angiogenesis inhibitor. 
LEPR  3  1  4  -1.23  52  85 
LEP-R  functions  as  a  receptor  for  the  fat  cell-specific  hormone 
leptin.  
GPM6A  4  2  2  -1.06  16  96  Part of cellular wall and/ or plasma membrane. 
RPS6KB1  5  1  4  -1.05  13  97 
The kinase activity of this protein leads to an increase in protein 
synthesis and cell proliferation. Over expressed in breast cancer. 
WIPF1  6  3  0  -1.04  24  93  Part of the cytoskeleton. Mutated in Wiskott-Aldrich syndrome, an 
X-linked recessive disorder. 
MCFD2  7  1  2  -0.96  36  90  Mutations cause the combined deficiency of factor V and VIII.. 
ELL2  8  1  1  -0.95  4  99  The extension of an RNA molecule after transcription. 
MAP2  9  1  3  -0.95  14  97  Involved in microtubule assembly, neurogenesis. 
RECK  10  2  1  -0.95  5  99 
Metastasis suppressor. The protein is suppressed in many tumours 
and cells transformed by various kinds of oncogenes. Serves as a 
negative regulator for MMP-9. 
TRIM33  11  1  3  -0.94  6  99  A transcriptional corepressor. Interacts with TRIM24. 
C16orf72  12  2  2  -0.9  17  96  Potentially down regulates transcription. 
C7orf58  13  1  2  -0.89      None known. 
MSN  14  2  1  -0.88  51  85 
A  member  of  the  ERM  protein  family.  ERM  proteins  cross  link 
plasma membranes and actin cytoskeletons. Important for cell-cell 
recognition and signalling and for cell movement / adhesion. 
LRP1B  15  1  1  -0.88  9  98  Belongs to the LDL receptor family, play a wide variety of roles in 
normal cell function and development. 
CCNJ  16  2  1  -0.87  7  99  Control the progression through the cell cycle by activating cyclin-
dependent kinase enzymes. Function of this cyclin is unknown. 
GLT8D3  17  1  3  -0.87  81  81  None known. 
FAM8A1  18  1  4  -0.86  38  89  None known. 
NR5A2  19  2  1  -0.85  49  86  Plays a critical role in the regulation of development, cholesterol 
transport, bile acid homeostasis and steroidogenesis. 
WDR91  20  1  2  -0.85  29  92 
Possibly  plays  a  role  in  conversion  of  one  or  more  primary  RNA 
transcripts into one or more mature RNA molecules 
FAT3  21  2  2  -0.83  74  81  Plays  a  role  in  organ  size  through  the  regulation  of  cell 
proliferation and apoptosis. 
SEC23A  22  1  1  -0.83  22  94  Involved in anterograde vesicle transport from ER to Golgi, Sec23 is 
involved in vesicle transport. 
DZIP1  23  2  2  -0.83  67  83  Spermatogenesis via its interaction with DAZ. 
ZNF532  24  3  0  -0.81  41  88  Transcriptional regulation. 
SYNJ1  25  2  0  -0.8  27  92  Synaptic transmission and membrane trafficking. 
JHDM1D  27  3  1  -0.79  75  81  Histone demethylase required for brain development. 
RAB11FIP2  28  1  4  -0.79  55  84 
A Rab11 effector protein acting in the regulation of the transport of 
vesicles  from the  endosomal  recycling compartment (ERC)  to the 
plasma membrane. 
ZEB1  29  2  0  -0.79  3  100 
Represses  T  cell  specific  IL2  gene.  Represses  E-cadherin,  and 
induces  an  epithelial-mesenchymal  transition  (EMT)  by  recruiting 
SMARCA4/BRG1. Promotes tumorigenicity by repressing miRNAs 
ZC3H6  30  1  4  -0.79  31  92  None known. 
MKLN1  31  1  5  -0.78  25  93 
Mediator  of  cell  spreading  and  cytoskeleton  responses  to  the 
extracellular matrix component thrombospondin 1. 
LHFP  32  1  1  -0.78  21  95  Mutations result in deafness. 
RNF2  33  1  2  -0.78  45  87 
Transcription repression of various genes involved in development 
and cell proliferation. 
MARCKS  34  1  1  -0.77  26  93  The  protein  is  a  substrate  for  protein  kinase  C.  Involved  in  cell 
motility, phagocytosis, membrane trafficking and mitogenesis. 
ZFPM2  36  2  1  -0.77  82  81  Modulates activity of GATA, important for cardiac formation. 
TFAP2A  37  2  1  -0.76  83  81  Large spectrum of important biological functions including proper 
eye, face, body wall, limb and neural tube development. 
KDR  39  1  1  -0.74  76  81  Vascular endothelial growth factor. 
ERRFI1  42  2  1  -0.73  8  99  Plays a role in uterine and keratinocyte cell growth. 
FEZ2  43  2  0  -0.72  70  82  Involved in axonal outgrowth and fasciculation. 
GTF2E1  44  1  1  -0.72  20  95 
Recruits  TFIIH  to  the  initiation  complex  and  stimulates  the  RNA 
polymerase II. 
CFL2  46  1  2  -0.71  43  87  Involved in the regulation of actin-filament dynamics. 
PTPN21  50  2  0  -0.69  28  92 
Member of the tyrosine phosphatase family, known to be signalling 
molecules  that  regulate  cell growth,  differentiation,  mitotic cycle, 
and oncogenic transformation.  Increases  the  activation of  STAT3, 
but not STAT2. Studies in mice suggested the possible roles of this 
PTP in liver regeneration and spermatogenesis. 
PCTK2  51  1  1  -0.69  10  98  May play a role in terminally differentiated neurons.     Chapter 8. Appendix 
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WAPAL  52  2  1  -0.69  72  82  Chromosome partitioning and DNA repair 
PALM2  54  2  0  -0.68  59  83  None known. 
SESN1  57  1  1  -0.67  11  98  Inhibition of cell growth by activating AMP-activated protein kinase. 
PHC3  60  1  4  -0.66  86  80  Role in transcriptional repression. 
OSTM1  61  1  2  -0.65  30  92  Required for osteoclast and melanocyte maturation and function. 
SULF1  62  1  1  -0.65  56  84  Acts  as  a  negative  regulator  of  TGF-β,  widely  involved  with 
inflammation. facilitates apoptosis. 
ZNF652  64  1  2  -0.65  60  83  Functions as a transcriptional repressor. 
SMCR7L  66  2  3  -0.65  15  97  None known. 
SFRS1  69  1  3  -0.64  53  85 
Member of the arginine / serine-rich splicing factor protein family, 
and  functions  in  pre-mRNA  splicing  by  binding  to  pre-mRNA 
transcripts and components of the spliceosome. 
NOVA1  71  2  0  -0.63  33  91 
A  neuron-specific  RNA-binding  protein,  a  member  of  the  Nova 
family of paraneoplastic disease antigens, which are inhibited by 
paraneoplastic antibodies. These antibodies are found in the sera 
of patients with breast cancer and small cell lung cancer. 
YWHAG  72  1  1  -0.63  12  98  Important role for this protein in muscle tissue. It has been shown 
to interact with RAF1 and protein kinase C. 
ADAMTS3  74  1  1  -0.62  61  83 
The protein is the major procollagen II N-propeptidase. A deficiency 
of this protein may be responsible for dermatosparaxis, a genetic 
defect of connective tissues. 
MMD  78  1  1  -0.61  77  81 
This  protein  is  expressed  by  in  vitro  differentiated  macrophages 
but not freshly isolated monocytes. 
TSGA14  80  2  1  -0.61  87  80  Cell cycle. 
MED13  81  2  1  -0.61  46  87 
A  transcriptional  coactivator  complex  thought  to  be  required  for 
the expression of almost all genes. 
APOO  89  1  1  -0.58  54  85  Involved in the transport and metabolism of lipids. 
LAMC1  94  2  0  -0.57  37  90  Embryonic development. 
C3orf23  98  1  0  -0.56  62  83  None known. 
INTS8  99  1  0  -0.56  88  80  U1 and U2 transcription. 
SLC6A1  101  1  0  -0.56  34  90  Terminates the action of GABA. 
RANBP10  107  3  0  -0.56  19  96  Haemostasis. 
TMEM188  114  2  0  -0.55  63  83  Indirect role in intracellular lipid composition. 
HRNBP3  117  1  0  -0.54  71  82  Regulates alternative splicing events. 
ELAVL2  130  1  1  -0.53  47  87  RNA binding protein. 
KIAA0101  136  1  0  -0.52  78  81  None known. 
EGLN1  139  1  0  -0.51  57  84  Hypoxia influenced events, catalyses HIF proteins. 
FBXO33  140  1  0  -0.51  39  88  Protein degradation. 
GIT2  141  1  0  -0.51  50  86  GTPase-activating protein. 
ERBB4  215  1  2  -0.44  73  82  Many cellular responses to ligand binding. 
PLCG1  311  1  0  -0.36      T cell receptor signalling. 
MAP3K1  323  1  0  -0.35 
   
sapk / jnk, activated p38 MAPK, TLR pathways. 
TOB1  502  1  0  -0.26      TGF-β signalling. 
XIAP  570  1  0  -0.23      Apoptosis. 
SMAD2  603  1  0  -0.21      TGF-β signalling. 
FYN  614  1  0  -0.2      B cell receptor signalling. 
PTEN  622  1  0  -0.2      Inhibitor of apoptosis. 
ACVR2B  627  1  1  -0.19      TGF-β signalling. 
EP300  666  1  0  -0.17      TGF-β signalling. 
CREBBP  675  1  0  -0.16 
    TGF-β signalling. 
ACVR2A  725  1  0  -0.13      TGF-β signalling. 
PRKAB1  753  1  0  -0.12      Autophagy. 
SP1  758  1  0  -0.11 
    TGF-β signalling. 
BCL2  782  1  0  -0.05 
   
Inhibitor of apoptosis, autophagy and death receptor signalling. 
MEF2D  796  1  0  0.03      Activating p38 MAPK pathways. 
Table 52.Predicted targets for miR-200b Using TargetScan v 5.2 and 
MirTarget2 v4.0. Pathways are taken from NCBI Gene database (Pruitt 
et  al.,  2009).  Genes  and  pathways  of  particular  interest  are 
highlighted in red. Chapter 8. Appendix 
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8.4.5  Predicted targets for miR-223 
Target gene 
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FBXW7  1  1  1  -1.36  0.86  1  99 
Inactivation  results  in  repression  of  TGF-β  dependent 
transcription. 
MYO5B  2  1  3  -0.85  0.56      Mutations involved in microvillous disease. 
APC 
(adenomatous 
polyposis coli) 
3  1  1  -0.78  0.28  9  88 
Encodes  a  protein  that  acts  as  an  antagonist  of  the  Wnt 
signalling  pathway.  It  is  also  involved  in  cell  migration, 
adhesion, transcriptional activation, and apoptosis. Defects 
in this gene cause familial adenomatous polyposis. 
RHOB  4  1  1  -0.73  0.51  13  87 
Role in heat stress response and increased transcriptional 
activity of NF-κβ. 
PURB  5  1  1  -0.7  0.57  56  72  Implicated in leukaemia. 
SLC4A4  6  1  1  -0.69  0.45  8  89  Control of intracellular acid base balance. 
FOXO1  7  1  2  -0.66  0.55  41  75  Apoptosis pathway. 
ADCY7  8  1  2  -0.66  0.46  7  89  cAMP pathway 
KPNA1  9  1  1  -0.65  0.41  34  77  Binds to RAG1, although outcome uncertain 
ECT2  10  1  1  -0.65  0.29  22  81  Cell proliferation mainly S and M phase. 
RIBC1  11  1  1  -0.64  0.43  51  72  None known. 
SEPT6  12  1  1  -0.64  0.51  205  52  None known. 
SLC8A1  13  1  1  -0.62  0.57  138  59  Involved in Ca channel activation. 
SPTLC2  14  1  1  -0.6  0.51  118  62  None known. 
SETBP1  15  1  1  -0.59  0.51  169  56  Associated with Schinzel-Giedion syndrome. 
SORBS1  16  1  1  -0.59  0.54  6  89 
Associated  with  Alzheimer’s,  cholesterol,  blood  and 
endocrine  disorders.  Proposed  pathways  include  adherens 
junctions, insulin signalling pathways and PPAR signalling. 
MYST3  17  1  1  -0.59  0.35  67  69  Transcriptional co-activator. 
ATP7A  18  1  1  -0.56  0.55  40  75  Menkes syndrome. 
SEPT10  19  1  0  -0.55  0.45  23  81  Cell cycle and division. 
INPP5B  20  1  0  -0.5  0.52  105  64  Associated with disease of eye lens, and proposed function 
in inositol-polyphosphate 5- phosphatase activity 
MEF2C  21  1  1  -0.5  0.42      Cardiac morphogenesis. 
FAM46A  23  1  0  -0.48  0.39  81  67  None known. 
ZNF772  24  1  0  -0.48  0.33  124  60  Response to pheromone. 
ACSL3  25  1  0  -0.48  0.51  37  76  Expressed in brain. Fatty acid metabolism. 
FBXO8  26  1  0  -0.48  0.47  2  91  Deletion results in growth retardation in mice. 
PKNOX1  27  1  0  -0.48  0.47  39  75  Associated with Down’s syndrome. 
ARMCX1  28  1  0  -0.47  0.35  208  52  Tumour suppression. 
SYAP1  29  1  0  -0.47  0.47 
   
Possible involvement in liver cancer. 
CENPN  30  1  1  -0.47  0.44  202  53  None known. 
RRAS2  31  1  0  -0.46  0.46  30  78 
The protein may function as a signal transducer. Also plays 
a  role  in  activating  signal  transduction  pathways  that 
control  cell  proliferation.  Mutations  in  this  gene  are 
associated with the growth of certain tumours. 
PSIP1  32  1  1  -0.46  0.48      None known. 
PARP1  34  1  0  -0.45  0.43  151  58  Differentiation, proliferation, and tumour transformation 
LAYN  35  1  0  -0.45  0.4      None known. 
ZXDC  36  2  0  -0.45  0.49      None known. 
NUP210  37  1  0  -0.45  0.5  62  71 
A  structure  that  regulates  the  flow  of  macromolecules 
between the nucleus and the cytoplasm. 
SP3  39  1  0  -0.44  0.47  63  70  Regulate transcription by binding to consensus GC- and GT-
box regulatory elements in target genes.  
ACVR2A  41  1  0  -0.43  0.47  11  88 
Encodes  activin  A  type  II  receptor.  Belong  to  the  TGF-β 
superfamily. 
ULK2  42  1  0  -0.43  0.35  80  67  The  gene  is  located  within  the  Smith-Magenis  syndrome 
region on chromosome 17 
PSCDBP  43  1  0  -0.43  0.45 
   
Expressed  weakly  in  resting  NK  and  T  cells.  The  protein 
modulates  the  activation  of  ARF  genes.  This  protein 
interacts  with  CYTH1  and  SNX27  proteins  and  may  act to 
sequester CYTH1 protein in the cytoplasm 
CALML4  47  1  0  -0.41  0.47  115  62  T cell receptor signalling. 
NFIA  52  1  0  -0.4  0.48  166  56  Transcription and replication. 
LMO2  60  1  0  -0.39  0.47  3  90  Red cell development. 
HSP90B1  65  1  0  -0.39  0.22  16  85  Processing and transport of proteins. 
NFIB  72  1  0  -0.37  0.24      Transcription and replication. 
AK2  93  1  2  -0.33  0.62      Gene identified in GWAS T
H17 cells. 
MEF2D  96  1  0  -0.32  0.23 
   
Transcriptional activator in neurones and muscle. 
SP1  105  1  0  -0.29  0.46     
Regulates a large number of genes involved in a variety of 
processes  such  as  cell  growth,  apoptosis,  differentiation 
and immune responses. TGF-β signalling. 
VAMP2  149  1  0  -0.2  0.46      Associated with Crohn’s disease in GWAS.     Chapter 8. Appendix 
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MMP16  170  1  1  -0.16  0.58 
   
Also targeted by miR-146b in glioma cells. Expressed by T 
cells. 
PLA2G6  197  1  0  -0.08  0.36 
   
Role in phospholipid remodelling, arachidonic acid release, 
leukotriene  and  prostaglandin  synthesis.  PLA2G2E  = 
association found with UC in GWAS studies 
CREB1            87  66  Inhibition of apoptosis. 
GALNTL4 
         
21  82  Oligosaccharide biosynthesis. 
IL6ST            18  84  Forms subunit of IL-6 receptor, pro-inflammatory receptor. 
LOC728709            12  87  None known. 
MAP4 
         
160  57  P38 signalling. 
MPP7            10  88  Epithelial cell polarity and junction formation. 
MYO5B            6  90  Possible vesicular trafficking. 
PAX6 
         
4  90  P38 signalling. 
PKP4 
         
15  85  Rho activity. 
PRDM1            20  82  Maturation of B cells. 
SLC7A8            14  85  Protein reabsorption in the kidney. 
SLMO2 
         
17  84  None known. 
STAT1            133  60  P38 signalling. 
UBR1            19  84  Pancreatic homeostasis. 
TSLP            5  89  TH2 pathways. 
Table 53.Predicted targets for miR-223 Using TargetScan v 5.2 and 
MirTarget2 v4.0. Pathways are taken from NCBI Gene database (Pruitt 
et  al.,  2009).  Genes  and  pathways  of  particular  interest  are 
highlighted in red. 
8.4.6  Predicted targets for miR-375 
Target gene 
TargetScan  MirTarget2 
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SLC16A2  1  1  1  -0.69  19  59  A membrane protein transporter of thyroid hormone. 
ELAVL4  2  1  0  -0.50  10  67  Neuronal cells. 
SHOX2  3  1  1  -0.46  13  62  Implicated  in  development  of  nervous,  cardiovascular  and 
skeletal systems. To do with hypoxic stress. 
HNF1B  4  1  0  -0.39  25  56 
Mutations are associated with diabetes, kidney and genital 
tract abnormalities, hypomagnesaemia, gout, deranged liver 
function and pancreas atrophy. 
RASD1  5  1  0  -0.38      Interacts with rennin transcription, and signal transduction. 
BAHCC1  6  1  0  -0.37  9  69  Transcriptional silencing and the remodelling of chromatin. 
PTPN4  7  1  0  -0.37     
A  member  of  the  protein  tyrosine  phosphatase  family, 
known to regulate cell growth, differentiation, mitotic cycle, 
and oncogenic transformation. 
GREM2  8  1  1  -0.36      Inhibits the activity of BMP, a role in organogenesis. 
ZFP36L2  9  2  0  -0.36 
   
Possible regulation of growth factors. 
SYNCRIP  10  1  0  -0.35      None known. 
HOXB3  11  1  1  -0.35      Involved in development and associated with AML. 
ISL2  12  1  0  -0.34 
   
Insulin. Foetal development. 
FOXF1  13  1  1  -0.34      None known. 
PLXNA4  14  1  1  -0.30 
   
Forms  a  receptor  complex  with  neuropilin-1  and  can 
propagate  semaphorin-3A  elicited  inhibitory  signals  into 
cells and neurons. 
C15orf41  15  1  1  -0.30      None known. 
BMPR1B  17  1  1  -0.28      Organogenesis. 
ARL4C  37  1  0  -0.19 
   
A role in cholesterol transport. 
PAX6  47  1  0  -0.18      Involved in development of eyes and nervous system. 
SKI  57  1  0  -0.16      TGF-β signalling. Chapter 8. Appendix 
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ATG2B  61  1  0  -0.16     
Associated  with  gastric  and  colorectal  cancers  through 
autophagy. 
NFIX  63  1  1  -0.15      None known. 
SP1  126  1  0  -0.06 
   
Regulates a large number of genes involved in a variety of 
processes  such  as  cell  growth,  apoptosis,  differentiation 
and immune responses. TGF-β signalling. 
ZNF471          1  83  None known. 
Table 54.Predicted targets for miR-375 Using TargetScan v 5.2 and 
MirTarget2 v4.0. Pathways are taken from NCBI Gene database (Pruitt 
et  al.,  2009).  Genes  and  pathways  of  particular  interest  are 
highlighted in red.      Chapter 8. Appendix 
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8.4.7  Predicted targets for miR-422a 
Target gene 
TargetScan  MirTarget2 
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PHC3  1  1  1  -0.41  93  62  Some references to osteosarcoma and bones. 
RBMS3  2  1  0  -0.41      Liver fibrosis. 
SULF1  3  1  0  -0.41  36  71 
Involved  in  cell  signalling.  Heparan  sulphate  6-O-endosulfatases, 
such as SULF1 activity modulates the effects of heparan sulphate 
by  altering  binding  sites  for  signalling  molecules.  Acts  as  a 
negative  regulator  of  TGF-β,  widely  involved  with  inflammation. 
Facilitates apoptosis. 
VANGL1  4  1  2  -0.37  13  81  Membrane proteins, neural tube defects. 
PLEKHG2  5  1  0  -0.34      Associated with leukaemia. 
GOLT1A  6  1  0  -0.31 
   
Associated with hepatoblastomas. Hypertension. 
SLC39A9  7  1  0  -0.3     
Membrane transport protein, 1 of 400 in family to do with metal 
transport. 
DYRK1A  8  1  1  -0.27     
Increased expression improves  survival in  sepsis, by abrogating 
sepsis induced lymphocyte apoptosis. 
PAX8  9  1  0  -0.24     
Transcription  factor  for  the  thyroid-specific  expression  of  the 
genes exclusively expressed in the thyroid cell type, maintaining 
the functional differentiation of such cells. 
SFRS3  10  1  0  -0.2 
   
May  be  involved  in  RNA  processing  in  relation  with  cellular 
proliferation and/or maturation. 
GLS  11  1  0  -0.17     
Catalyzes the first reaction in the primary pathway for the renal 
catabolism of glutamine. 
BCL2L2  12  1  1  -0.12      Apoptosis. 
TSLP    0  1  -0.06      TH2 pathways 
DSCAM          10  83  Neuronal development. 
ELAC1          3  89  tRNA maturation. 
FOXG1 
       
6  87  Brain development. 
ITPRIPL2          4  89  None known. 
KDSR          12  81  Catalyst. 
LOC10012817
8          5  87  None known. 
MGC13057          1  92  None known. 
NKX3-1          7  87  Transcriptional repressor. Prostate development. 
NR2C2 
       
11  82  Transcription. 
PAPOLA          2  91  Polymerase. 
RPN2          8  84  N-oligosaccharyl transferase enzyme. 
SLC7A6 
       
15  81  Neural amino acids. 
TRAF6          67  65  TLR pathway. 
UHRF1          9  84  Transcriptional regulation. 
Table 55.Predicted targets for miR-422a Using TargetScan v 5.2 and 
MirTarget2 v4.0. Pathways are taken from NCBI Gene database (Pruitt 
et  al.,  2009).  Genes  and  pathways  of  particular  interest  are 
highlighted in red.    Chapter 8. Appendix 
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8.5  Centrifuge calculations 
Experimental procedures were carried out and described using the rpm settings 
on all centrifuges. The table below gives the approximate conversion as calculated 
using  the  manufacturers  technical  data,  (Eppendorf,  2012,  Kendro  laboratory 
products, 2001). 
  Rotations per minute 
(rpm) 
Gravitational force 
(g) 
Centrifuge 5417R, FA-45-
24-11, (eppendorf, UK) 
13,000  15,600 
2,000  370 
1,500  200 
Centrifuge 5810R, A-4-62, 
(eppendorf, UK) 
1,500  450 
2,000  800 
Centrifuge Sorvall® 
Legend T (Kendro 
Laboratory Products, 
Germany) 
2,000  800 
1,500  400 
       Chapter 8. Appendix 
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8.6  Statistical calculations 
8.6.1  Mann Whitney calculations for section 4.4 
 
 
Control 
(n) 
Active UC 
(n) 
Inactive 
(n) 
Active vs 
control 
(U value) 
Inactive UC vs 
control 
(U value) 
miR-31  21  25  19  55  42 
miR-146b  21  25  19  39  74 
miR-194  21  20  11  49  113 
miR-200b  19  25  19  49  71 
miR-223  21  25  19  47  34 
miR-375  21  25  19  38  151 
miR-422a  21  25  19  30  96 
 
8.6.2  Mann Whitney calculations for section 4.5.1 
8.6.2.1  miR-31 in Ulcerative Colitis 
Statistical  differences  between  median  values  calculated  with  two  tailed  Mann 
Whitney and shown as U values, p values 
Active UC 
  5-ASA 
(n = 7) 
Azathioprine 
(n = 10) 
Infliximab 
(n = 2) 
No treatment 
(n = 10)  20, p = 0.198  8, p = 0.001  7, p = 0.711 
5-ASA 
(n = 7)  -  9, p = 0.005  6, p = 0.889 
Azathioprine 
(n = 10)  -  -  1, p = 0.061 
 
Inactive UC 
  5-ASA 
(n = 10) 
Azathioprine 
(n = 10) 
Infliximab 
(n = 2) 
No treament / 
control 
(n = 8) 
34, p = 0.317  12, p = 0.071  6, p = 0.711 
5-ASA 
(n = 10)  -  10, p = 0.016  9, p = 0.909 
Azathioprine 
(n = 10)  -  -  1, p = 0.143 
 Chapter 8. Appendix 
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8.6.2.2  miR-31 in Crohn's disease 
Statistical  differences  between  median  values  calculated  with  two  tailed  Mann 
Whitney and shown as U values, p values 
Active Crohn's Disease 
    Azathioprine 
(n = 4) 
Infliximab 
(n = 4) 
No treament 
(n = 3)    0, p = 0.025  0, p = 0.014 
 
Inactive Crohn's Disease 
  Azathioprine 
(n = 5) 
No treament / 
control 
(n = 3) 
3, p = 0.062 
8.6.3  Mann Whitney calculations for section 5.3 
Statistical  differences  between  median  values  calculated  with  two  tailed  Mann 
Whitney and shown as U values, p values 
Mucosal lymphocytes 
 
Control 
(n) 
Active UC 
(n) 
Active vs control 
(U value, p value) 
miR-31  4  4  1, p = 0.029 
miR-146b  4  4  2, p = 0.114 
miR-194  4  4  0, p = 0.014 
miR-200b  4  4  0, p = 0.014 
miR-223  4  4  0, p = 0.029 
miR-375  4  4  3, p = 0.100 
miR-422a  4  4  3, p = 0.100 
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8.7  The effect of PHA on cell lymphocyte culture 
Stimulation with PHA has a differential effect on leukocyte subtypes. In a mixed 
leukocyte  sample,  monocytes  and  granulocytes  decline  over  time,  CD3
+  cells 
increase, and CD4
+ and CD8
+ cells decrease until a nadir on day 1, then normalise 
by day 2 and proliferate thereafter (O'Donovan et al., 1995). 
Short term cell disruption and possible death may contribute to the miR-31 and 
TSLP expression levels; therefore cell death was quantified by staining cells with 
Trypan blue. 
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Figure  55.  Lymphocyte  viability  following  PHA  culture.  (a)  % 
lymphocyte viability measured by trypan blue staining. (b) The effect 
of PHA stimulation on well conditions after 48 hours culture. HT29 
cells  were  cultured  at  0.5  x  10
6  cells  per  well.  Median  values  are 
compared with one tailed Mann Whitney U test.* p ≤ 0.05. Whiskers 
are IQR. 
After 48 hours incubation, visual inspection of the culture media showed that in 
the stimulated wells (labelled in Figure 55b as numbers 7, 8 and 9) the media had 
turned yellow indicating a reduced pH. The two causes of a reduced pH; metabolic 
activity  and  cell  death  are  differentiated  by  counting  viable  cells.  The  median 
number of viable lymphocytes is 60.2% to 49.0% in unstimulated and stimulated 
cells respectively, p = 0.020. However despite this reduction in cell viability the 
house keeper gene in the RT-qPCR was similar between the groups, maintaining 
good Ct values (17 to 19), indicating preservation of gene transcription. Chapter 8. Appendix 
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Despite the 11% reduction in cell viability, gene levels did not match this change, 
with  an  increased  miR-31  expression  of  510%  and  a  decreased  TSLP  mRNA 
expression of 29%. 
The purpose of this section is to show how culture affected well conditions and 
the necessity to change culture medium regularly. It also indicates the increased 
cell activity in the stimulated wells. 
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